

UNAIDS DATA 2021

CONTENTS

Global and regional data	04
Combination HIV prevention	16
Testing and treatment	26
Ending paediatric AIDS and eliminating vertical transmission	32
Gender equality	34
Removing punitive laws and policies	37
Investments to end AIDS	38
Eastern and southern Africa	44
Country tables	56
Western and central Africa	98
Country tables	110
Asia and the Pacific	160
Country tables	174
Latin America	226
Country tables	238
Caribbean	272
Country tables	286
Middle East and North Africa	308
Country tables	320
Eastern Europe and central Asia	352
Country tables	362
Western and central Europe and North America	390
Country tables	398
Annex on methods	442

The 90-90-90 targets were missed, but not by much. At the end of 2020, 84% of people living with HIV knew their HIV status, 87% of people living with HIV who knew their HIV status were accessing antiretroviral therapy, and 90% of people on treatment were virally suppressed.

GLOBAL AND REGIONAL DATA

Building on two decades of progress against AIDS

Forty years have passed since the human immunodeficiency virus (HIV) was first detected and isolated and within a decade acquired immunodeficiency syndrome (AIDS) was killing millions around the world. In 2001 the United Nations (UN) General Assembly convened its first-ever special session on HIV to set a common agenda that propelled global efforts to reverse the pandemic's course. Despite the huge progress achieved in the past 20 years, the immense scale of the AIDS pandemic remains as world leaders at the 2021 United Nations High Level Meeting on AIDS adopted a new Political Declaration pledging urgent, transformative action to end the global AIDS epidemic by 2030.

Antiretroviral medicines that were once deemed too expensive and too complicated for low-resource settings were being taken by an estimated 27.5 million [26.5 million–27.7 million] people living with HIV globally at the end of 2020.




and prevents the further spread of the virus. Derided by some as an aspirational fantasy when they were first proposed by UNAIDS in 2014, the 90–90–90 targets were adopted by the UN General Assembly two years later as a global target for 2020. At the deadline, at least eight countries in a variety of geographic, epidemic and socioeconomic settings had fully achieved the targets, and another 11 had reached 73% viral load suppression among all people living with HIV. The average performance in eastern and southern Africa, the region most affected by HIV, nearly achieved the targets, and 74% of people living with HIV in western and central Europe and North America had suppressed viral loads.

GLOBAL SUMMARY OF THE AIDS EPIDEMIC, 2020

Number of people living with HIV			[30.2 million–45.1 million] [28.9 million–43.2 million] [15.5 million–23.1 million] [1.2 million–2.2 million]
People newly infected with HIV in 2020			[1.0 million–2.0 million] [910 000–1.8 million] [450 000–920 000] [100 000–240 000]
AIDS-related deaths in 2020	Total Adults Women (15+ years) Children (<15 years)	680 000 580 000 240 000 99 000	[480 000–1.0 million] [400 000–850 000] [170 000–360 000] [68 000–160 000]

Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).

HIV TESTING AND TREATMENT CASCADE, GLOBAL, 2020



Source: UNAIDS special analysis, 2021.

At the global level, however, these targets were missed, although not by a wide margin: at the end of 2020, 84% [67–>98%] of people living with HIV knew their HIV status, 87% [67–>98%] of people living with HIV who knew their HIV status were accessing antiretroviral therapy, and 90% [70–>98%] of people on treatment were virally suppressed. These seemingly small gaps add up to leave more than one quarter (27%) of people living with HIV globally not on treatment, and roughly one third with unsuppressed viral loads (Figure above). These gaps are even larger within subpopulations, including children, young people and men.

The global roll-out of HIV treatment has saved millions of lives: an estimated 16.6 million [11.7 million–24.2 million] AIDS-related deaths have been averted over the last two decades, including a 47% decline in AIDS-related mortality since 2010.

Efforts to prevent HIV infections have been less successful. The annual number of new infections among adults globally has hardly changed over the past four years, and total new infections have declined by just 31% since 2010, far short of the 75% target for 2020 that was set by the UN General Assembly in 2016. Too many countries have failed to put in place the combination of structural, behavioural and biomedical approaches to HIV prevention focused on those at greatest risk that experience shows has the maximum impact. Consistent condom use, although possible, has proved difficult to achieve among all populations: women in many countries, for example, need greater agency and support to negotiate consistent condom use. Coverage of pre-exposure prophylaxis (PrEP) and voluntary medical male circumcision (VMMC) in 2020 also were well below the targets set five years earlier.


Reductions in new infections were strongest in sub-Saharan Africa and the Caribbean, but no region achieved the 75% declines that were agreed by the UN General Assembly in 2016 (Figure below). Epidemics in large parts of eastern Europe and central Asia expanded in the face of serious legal and policy barriers and inadequate attention to the needs of people who inject drugs and gay men and other men who have sex with men. The annual number of new HIV infections also climbed in the Middle East and North Africa, and Latin America did not achieve any reduction in infections over the course of the last decade.

EVERY DAY THERE ARE 4000 NEW HIV INFECTIONS (ADULTS AND CHILDREN), 2020

- 60% are in sub-Saharan Africa
- 10% are among children under 15 years of age
- 90% are among adults aged 15 years and older, of whom:
 - 51% are among women
 - 31% are among young people (15–24)
 - 20% are among young women (15–24)


 $Source: UNAIDS\ epidemiological\ estimates,\ 2021\ (https://aidsinfo.unaids.org/).$

AIDS-RELATED DEATHS, GLOBAL, 2000-2020, AND 2020 AND 2025 TARGETS




Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).

NEW HIV INFECTIONS, GLOBAL, 2000-2020, AND 2020 AND 2025 TARGETS



Note: Please see the Annex on Methods for a description of how these estimates are calculated. Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).

CHANGE IN NEW HIV INFECTIONS AND AIDS-RELATED DEATHS, BY REGION AND GLOBAL, 2010–2020



Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).

REGIONAL HIV AND AIDS STATISTICS AND FEATURES, 2020

	Adults and children living with HIV	Adults and children newly infected with HIV	Adult and child deaths due to AIDS
Eastern and southern Africa	20.6 million [16.8 million–24.4 million]	670 000 [470 000–930 000]	310 000 [220 000–470 000]
Western and central Africa	4.7 million [3.9 million–5.8 million]	200 000 [130 000–330 000]	150 000 [100 000–210 000]
Middle East and North Africa	230 000 [190 000–310 000]	16 000 [12 000–28 000]	7900 [6000–13 000]
Asia and the Pacific	5.8 million [4.3 million–7.0 million]	240 000 [170 000–310 000]	130 000 [87 000–200 000]
Latin America	2.1 million [1.4 million–2.7 million]	100 000 [66 000–150 000]	31 000 [20 000–46 000]
Caribbean	330 000 [280 000–390 000]	13 000 [8700–18 000]	6000 [4300–8500]
Eastern Europe and central Asia	1.6 million [1.5 million–1.8 million]	140 000 [120 000–160 000]	35 000 [28 000–43 000]
Western and central Europe and North America	2.2 million [1.9 million–2.6 million]	67 000 [53 000–81 000]	13 000 [9200–17 000]
GLOBAL	37.7 million [30.2 million–45.1 million]	1.5 million [1.0 million–2.0 million]	680 000 [480 000–1.0 million]

Note: The ranges around the estimates in this table define the boundaries within which the actual numbers lie, based on the best available information.

Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).

Nearly two thirds of children not on treatment are aged 5 to 14 years—children who cannot be found through HIV testing during postnatal care visits.


Children being left behind

New HIV infections among children declined by more than half (54%) from 2010 to 2020, due mainly to the increased provision of antiretroviral therapy to pregnant and breastfeeding women living with HIV. However, that momentum has slowed considerably, leaving particularly large gaps in western and central Africa, which is home to more than half of pregnant women living with HIV who are not on treatment.

Eliminating vertical HIV transmission requires improvements across the continuum of efforts to provide women with services as they become sexually active, plan families and go through pregnancy, childbirth and breastfeeding. Programmes need to become better at empowering women to protect themselves from HIV infection, and at finding women who acquire HIV and quickly providing them with antiretroviral therapy in order for them to achieve viral suppression.

Gaps in the testing of infants and children exposed to HIV have left more than two fifths of children living with HIV undiagnosed. The number of children on treatment globally has declined since 2019, leaving almost 800 000 children (aged 0 to 14 years) living with HIV not on antiretroviral therapy in 2020. Just 40% of children living with HIV had suppressed viral loads, compared to 67% of adults (Figure below). Nearly two thirds of children not on treatment are aged 5 to 14 years—children who cannot be found through HIV testing during post-natal care visits. A priority for the next five years is to expand rights-based index, family and household testing and to optimize paediatric treatment in order to diagnose these children, link them to treatment and retain them in life-long care.

PROPORTION OF ADULTS (AGED 15+ YEARS) AND CHILDREN (AGED 0–14 YEARS) WITH SUPPRESSED VIRAL LOAD AMONG PEOPLE LIVING WITH HIV, GLOBAL, 2015–2020



Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).

Criminalization of key populations slowing HIV responses

In every region of the world, there are key populations who are particularly vulnerable to HIV infection. People who inject drugs are at 35 times greater risk of acquiring HIV infection than people who do not inject drugs; transgender women are at 34 times greater risk of acquiring HIV than other adults; female sex workers are at 26 times greater risk of acquiring HIV than other adult women; and gay men and other men who have sex with men are at 25 times greater risk of acquiring HIV than heterosexual adult men. Overall, key populations and their sexual partners accounted for 65% of HIV infections worldwide in 2020 and 93% of infections outside of sub-Saharan Africa.

Key populations continue to be marginalized and criminalized for their gender identities and expression, sexual orientation and livelihoods. An ecological analysis led by Georgetown University's O'Neill Institute for National and Global Health has reinforced smaller-scale studies showing that the criminalization of key populations has a negative effect on HIV outcomes (1). Where same-sex sexual relationships, sex work and drug use were criminalized, levels of HIV status knowledge and viral suppression among people living with HIV were significantly lower than in countries that opted not to criminalize them. Conversely, there was a positive correlation between better HIV outcomes and the adoption of laws that advance nondiscrimination, the existence of human rights institutions and responses to gender-based violence (1).





The risk for key populations to acquire HIV infection in 2020 was:

Gay men and other men who have sex with men: **25 times greater risk** than heterosexual men.

Female sex workers: **26 times greater risk** than women in the general population.

Transgender women: **34 times greater risk** than other adults.

People who inject drugs: **35 times greater risk** than people who do not inject drugs.


A transgender woman speaks at a UN-supported photo exhibition in Peru. Credit: UNAIDS

Key populations continue to be marginalized and criminalized for their gender identities and expression, sexual orientation and livelihoods

Across countries and regions, important HIV prevention services for key populations are unevenly accessible or entirely absent. Harm reduction services for people who inject drugs, for example, are seldom provided on a meaningful scale across all regions. Similarly, coverage of prevention programmes for gay men and other men who have sex with men is still low, including among many high-income countries. Coverage of prevention programmes for transgender people is meagre in all but a handful of countries. Coverage of prevention programmes among sex workers in eastern and southern Africa is still low. People in prisons and other closed settings are often not provided HIV services, despite the relative ease of reaching them.

DISTRIBUTION OF HIV INFECTIONS, BY POPULATION, GLOBAL, SUB-SAHARAN AFRICA AND REST OF WORLD, 2020





Source: UNAIDS special analysis, 2021 (see Annex on Methods).

Women, men and young people face different challenges

Gender inequality and discrimination robs women and girls of their fundamental human rights, including the right to education, health and economic opportunities. The resulting disempowerment also denies women and girls sexual autonomy, decision-making power, dignity and safety. Gender-based violence is among the most egregious manifestations of gender inequality: it has been shown to increase the risk of acquiring HIV infection for women and girls, and among women living with HIV, it can lead to reduced access and adherence to treatment (2, 3). These impacts are most pronounced in sub-Saharan Africa, where adolescent girls and young women (aged 15 to 24 years) accounted for 25% of HIV infections in 2020, despite representing just 10% of the population.

Sexual and reproductive health and rights are the foundation of the ability of women and girls to prevent the acquisition of HIV. The UN General Assembly has committed to ensuring that 95% of women and girls of reproductive age have their HIV and sexual and reproductive health service needs met by 2025, but very few low- and middle-income countries are currently within reach of that target.

There is evidence that completing secondary education can help protect girls against acquiring HIV infection in places where HIV is common, in addition to its broader social and economic benefits (4). In many countries, however, girls are less likely to complete secondary education than boys, and the quality of their education suffers due to discrimination in schools. Several comprehensive prevention projects are being implemented for adolescent girls and young women in settings with a high incidence of HIV infections. However, the totality of these efforts still lacks the required scale, leaving many women and girls in settings with high HIV burden at substantial risk of infection.


Outside of sub-Saharan Africa, men and boys accounted for 58% of HIV infections in 2020, in part because there are more men than women within key populations and among their sexual partners globally. Across nearly all regions, men are less likely to access HIV services, and men living with HIV consistently fare worse than women across the HIV testing and treatment continuum. Compared to women living with HIV, there are 1 million more men living with HIV who do not know their HIV status, 1.8 million more men who know their status but are not on treatment and 1.6 million more men who are not virally suppressed.

Gender norms that prize male strength and stoicism may partly explain why many men delay seeking care, but other factors are also at play (5). Primary health-care services in eastern and southern Africa place a great deal of focus on women of reproductive age, and reproductive, maternal and child health services offer ideal entry points for HIV services. Similar entry points for men are not commonplace (6, 7). Focused efforts to reach men with HIV services—including through workplace-based interventions and greater use of self-testing approaches, and by providing services at outpatient


Sexual and reproductive health and rights are the foundation of the ability of women and girls to prevent the acquisition of HIV.

DISTRIBUTION OF NEW HIV INFECTIONS AND OF THE POPULATION, BY AGE AND SEX, GLOBAL, SUB-SAHARAN AFRICA AND OUTSIDE SUB-SAHARAN AFRICA, 2020


New HIV infections, sub-Saharan Africa




Population distribution, sub-Saharan Africa




New HIV infections, outside sub-Saharan Africa




Population distribution, outside sub-Saharan Africa



New HIV infections, global



Population distribution, global



Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/). Note: Due to rounding, the percentages do not add up to 100%.

departments—will improve their health outcomes and also help prevent transmission of HIV to their sexual partners.

Young people, including young people within key populations, accounted for 27% of HIV infections in 2020. Young people face parental consent barriers to HIV and sexual and reproductive health services. They also have insufficient access to quality and age-appropriate comprehensive sexuality education, leaving them vulnerable to myths and misinformation about sex and sexuality. Students who receive comprehensive sexuality education are empowered to take responsibility for their own decisions and behaviours, and the ways in which they may affect others. Comprehensive sexuality education also plays a role in preventing gender-based violence, increasing the use of contraception, decreasing the number of sexual partners and delaying the initiation of sexual intercourse.

Young people face parental consent barriers to HIV and sexual and reproductive health services. They also have insufficient access to quality and age-appropriate comprehensive sexuality education, leaving them vulnerable to myths and misinformation about sex and sexuality.



Credit: U-Report

COMBINATION HIV PREVENTION

Condoms a critical part of combination prevention


When used correctly and consistently, male and female condoms and lubricant offer very high protection against HIV, sexually transmitted infections (STIs) and unintended pregnancy. Condom use has had an enormous impact on the global AIDS pandemic: model simulations show that increased condom use since 1990 has averted an estimated 117 million new infections, close to half (47%) of them in sub-Saharan Africa and more than one third (37%) in Asia and the Pacific (8).

Condom programmes are among the most cost-effective interventions in the HIV response (9). Assuming an average cost of about US\$ 0.18 for each male condom distributed, each averted HIV infection during 1990–2019 cost approximately US\$ 230 (8). In recent years, however, condom social marketing programmes and condom demand generation have declined. Data from population-based surveys conducted after 2015 also suggest that condom use has declined among young people in several countries in sub-Saharan Africa.

Consistent condom use, although possible, has proved difficult to achieve among all populations. Women in many countries, for example, need greater agency and support to negotiate consistent condom use. Condoms alone, therefore, are not sufficient to control HIV epidemics: if condom use rates are increased to reach the 2025 target of 95% of higher risk sex acts and all other prevention interventions remain at 2019 coverage levels, about one third of the required reductions in HIV infections will be achieved. Full achievement of the 2025 targets requires combining increases in condom availability and use with a full range of prevention choices (8).




NEW HIV INFECTIONS WITH AND WITHOUT SCALE-UP OF CONDOM USE, GLOBAL, 1990-2019



Source: Stover J, Teng Y. The impact of condom use on the HIV epidemic [version 1]. Gates Open Res. 2021;5:91. doi: 10.12688/gatesopenres.13278.1

THE IMPACT OF CONDOM USE ON NEW HIV INFECTIONS IN THE FUTURE UNDER THREE SCENARIOS, GLOBAL, 2019–2030 $\,$



Source: Stover J, Teng Y. The impact of condom use on the HIV epidemic [version 1]. Gates Open Res. 2021;5:91. doi: 10.12688/gatesopenres.13278.1


All interventions scale-up to UNAIDS 2025 targets

HIV prevention for adolescent girls and young women lacks scale and impact

Gender inequality, underpinned by harmful gender norms, restricts women's access to HIV and sexual and reproductive health services. There were 260 000 [150 000–390 000] HIV infections among adolescent girls and young women globally in 2020, far shy of the 2025 target of 50 000. Eighty-three per cent of these infections occurred in sub-Saharan Africa, where adolescent girls and young women (aged 15 to 24 years) account for 25% of HIV infections, despite representing just 10% of the population.

Despite several comprehensive prevention projects being implemented for adolescent girls and young women through the United States President's Emergency Plan for AIDS Relief (PEPFAR) DREAMS partnership, the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), the United Nations Children's Fund (UNICEF) and national programmes such as South Africa's She Conquers, the response in settings with high HIV incidence still lacks in scale and impact. Out of the 38 countries in sub-Saharan Africa with subnational HIV incidence data, 20 countries had a total of 555 subnational locations of high, very high or extremely high HIV incidence. Out of those subnational locations, just 30% (200) had dedicated HIV programmes for adolescent girls and young women in 2020.

HIV INCIDENCE AMONG ADOLESCENT GIRLS AND YOUNG WOMEN (AGED 15-24 YEARS), SUBNATIONAL LEVELS, **SUB-SAHARAN AFRICA,** 2020



Women often denied sexual and reproductive health and rights

Sexual and reproductive health and rights are the foundation of women and girls' ability to prevent the acquisition of HIV. The UN General Assembly has committed to ensuring that 95% of women and girls of reproductive age have their HIV and sexual and reproductive health service needs met by 2025, but very few low- and middle-income countries are currently within reach of that target. Family planning services are an important component of sexual and reproductive health and rights, but the availability of these services varies widely. Across 32 countries with available data between 2015 and 2020, the percentage of women aged 15 to 49 years who had their demand for family planning satisfied by modern methods ranged from about 6% in Albania to 87% in Colombia.


Fulfilment of family planning needs varies by background characteristics. Women were more likely to have their demand for family planning satisfied using modern methods if they were living in urban areas compared to rural areas (in 19 of 32 countries), or if they had secondary or higher education compared to no formal or only primary education (in 21 of 32 countries). That percentage also tended to be higher for older women compared to younger women, and for women in the highest wealth quintile compared with their peers in the lowest quintile. In 17 of the 32 countries, that disparity was not very large (<10%) or not present at all, but it was very wide (>25%) in several others (Angola, Cameroon, Guinea, Mali, Nigeria, Papua New Guinea and Uganda).

Family planning services are an important component of sexual and reproductive health and rights, but the availability of these services varies widely.




WOMEN (15–49 YEARS) WHO HAVE THEIR DEMAND FOR FAMILY PLANNING SATISFIED BY MODERN METHODS, BY AGE, EDUCATION LEVEL, PLACE OF RESIDENCE AND WEALTH QUINTILE, COUNTRIES WITH AVAILABLE DATA, 2015–2020






Source: Demographic and Health Surveys, 2015–2020.

PLACE OF RESIDENCE



Source: Demographic and Health Surveys, 2015–2020.


EDUCATION LEVEL



- No education or primary education
- Secondary education or higher

Source: Demographic and Health Surveys, 2015–2020.

HOUSEHOLD WEALTH




Source: Demographic and Health Surveys, 2015–2020.

Comprehensive sexuality education empowers young people

Comprehensive sexuality education plays a vital role in promoting health, well-being and critical thinking skills among young people and in strengthening responsible citizenship. When it comes to sex and sexuality, young people are vulnerable to myths and misinformation. Students who receive comprehensive sexuality education, however, are empowered to take responsibility for their own decisions and behaviours, and the ways in which their actions may affect others. This helps them make healthier sexual choices and better equips them to seek help when it is needed.

EDUCATION POLICIES THAT GUIDE THE DELIVERY OF LIFE SKILLS-BASED HIV AND SEXUALITY EDUCATION, ACCORDING TO INTERNATIONAL STANDARDS, BY COUNTRY, 2017–2021 Gender-transformative, age- and culturally-appropriate comprehensive sexuality education—both in and outside of school—is a key component of HIV and STI prevention for adolescents and young people. It also plays a role in preventing gender-based violence, increasing the use of contraception, decreasing the number of sexual partners and delaying the initiation of sexual intercourse. Among the 137 countries that have reported data to UNAIDS between 2017 and 2021, 85 (63%) reported having education policies that guide the delivery of life skills-based HIV and sexuality education according to international standards in primary schools, and 111 (81%) reported having such policies in secondary schools. Overall, 84 (62%) reported having such policies for both primary and secondary schools.




Source: UNAIDS National Commitments and Policy Instrument, 2017–2021.

Male circumcisions disrupted by COVID-19, fall short of the 2020 target

In areas with high HIV prevalence and low rates of male circumcision, VMMC can greatly contribute to HIV prevention. Despite this, there was a steep drop in the number of VMMCs performed in the 15 priority countries in 2020, due mainly to service disruptions caused by the COVID-19 pandemic: approximately 2.8 million procedures were performed in 2020, compared with 4.1 million in 2019. Several countries suspended their programmes when the pandemic took hold, including South Africa, where service coverage has been declining since 2018. Despite this, programmes in some countries proved resilient enough to recover quickly and expand during the rest of 2020—notably in Rwanda and Zambia, where programme coverage grew by about 15%. In these countries, adjustments for the safe continuation of VMMC services during COVID-19 included changes in promotion and demand generation, client transportation, service delivery at a health facility or in the community, and post-procedure follow-up appointments. For example, personal protective equipment was provided to VMMC community mobilizers, clients and staff.

A total of about 18 million VMMCs were performed in 2016–2020, far shy of the 2020 target of 25 million. As well as COVID-19, an additional setback in 2015 and 2016 was the detection of tetanus cases in Uganda, which led to activities being scaled back in that country.

ANNUAL NUMBER OF VOLUNTARY MEDICAL MALE CIRCUMCISIONS, 15 PRIORITY COUNTRIES, EASTERN AND SOUTHERN AFRICA, 2008–2020



Source: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/).


The focus of VMMC services should be on sexually active adolescent boys and adult men at higher risk of HIV infection.

Adolescent boys and young men increasingly reached with VMMC

In areas of low prevalence of circumcision and high HIV burden, the focus of VMMC services should be on providing services to sexually active adolescents 15 years and older and to adult men at higher risk of HIV infection in order to make an immediate impact on HIV incidence (10). In areas where the prevalence of circumcision among sexually active men is already high, a focus on sustaining and expanding VMMC services for adolescent boys over 15 years of age is needed to maintain these high coverage levels and reap the health benefits of the services.

Several priority countries are increasing their VMMC focus on young men, in line with recommendations in the 2020 World Health Organization (WHO) guidance on the subject (10). This has led to a steady increase in the percentage of procedures conducted among young men aged 15 years and older in several countries, but in a number of other countries—including Eswatini, Lesotho, Mozambique and Zimbabwe—at least 30% of VMMCs in 2020 were among males younger than 15 years.

PROPORTION OF VOLUNTARY MEDICAL MALE CIRCUMCISIONS, BY AGE GROUP, 10 COUNTRIES WITH AVAILABLE DATA, 2018–2020



Source: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/).


Note: The countries with available data are: Botswana, Eswatini, Kenya, Lesotho, Mozambique, Rwanda, South Sudan, United Republic of Tanzania, Zambia and Zimbabwe.

Pre-exposure prophylaxis use expands, but not fast enough

It has been more than a decade since the first evidence of the efficacy of daily oral PrEP was published. PrEP is now a valuable additional option for people who are at higher risk of acquiring HIV, and its global uptake has continued to increase, despite the COVID-19 pandemic: country data show that approximately 845 000 people in at least 54 countries received PrEP in 2020—a 43% increase since 2019, and a 182% increase since 2018. Much of the PrEP scale-up is still highly concentrated in a fairly small number of countries, notably the United States and in eastern and southern Africa, where Kenya and South Africa accounted for 158 630 (19%) of people who received PrEP at least once during 2020 in the region.

There continue to be substantial gaps in the availability of PrEP, however: the total number of people using this prevention option in 2020 was just 28% of the target of 3 million in low- and middle-income countries, which represents only 8% of the new global 2025 target. Access is still poor in much of western and central Africa and Asia and the Pacific, and 20 of 48 countries in Europe still lacked systematic provision of PrEP in 2020 (11). Even in countries with widespread PrEP availability, such as the United States, inequalities are apparent in the divergent rates of PrEP uptake along racial, ethnic, socioeconomic, geographic, age and self-identity lines (12).

NUMBER OF PEOPLE WHO RECEIVED PRE-EXPOSURE PROPHYLAXIS AT LEAST ONCE DURING THE REPORTING PERIOD, GLOBAL, 2016–2020, AND 2020 TARGET



Source: UNAIDS Global AIDS Monitoring, 2017–2021 (https://aidsinfo.unaids.org/); Country Updates. In: PrEPWatch [Internet]. AVAC; c2020 (https://www.prepwatch.org/ in-practice/country-updates/); and country documents and meeting reports (available on request).


More people living with HIV than ever know their HIV status, are accessing antiretroviral therapy and are achieving the viral suppression required to stay healthy and prevent onward transmission of the virus.

TESTING AND TREATMENT

Gaps narrow across the cascade

Progress across the HIV testing and treatment cascade has included an increase in the proportion of people living with HIV who are virally suppressed, and a narrowing in the proportions of people who are unaware that they are living with HIV and those who know they are living with HIV but have not started treatment or whose treatment was interrupted, suggesting global improvements have been made in HIV testing, linkage to care and retention in care. Reductions in the percentages of people newly infected and those on treatment who are not virally suppressed have been more modest.

PEOPLE LIVING WITH HIV, PEOPLE NEWLY INFECTED IN THE PAST SIX MONTHS, AND HIV TESTING AND TREATMENT CASCADE, ADULTS (AGED 15+ YEARS), GLOBAL, 2016–2020



- People living with HIV who were infected in the past six months
- People living with HIV who don't know their status and were infected more than six months ago
- People living with HIV who know their status but are not on treatment
- People living with HIV who are on treatment but are not virally suppressed
- People living with HIV who are on treatment and are virally suppressed

Source: UNAIDS special analysis, 2021.

A diversity of countries achieve 90-90-90

At least eight countries fully achieved the 90–90–90 targets by the end of 2020, and another 11 reached an equivalent 73% viral load suppression among all people living with HIV. The diversity of these 19 countries demonstrates that these ambitious targets can be achieved across income levels, epidemic settings and sociocultural norms.

COUNTRIES REACHING THE HIV TREATMENT CASCADE TARGETS, 2020

	90–90–90 value (all)	90–90–90 value (children aged 0–14 years)	90–90–90 value (women aged 15+ years)	90–90–90 value (men aged 15+ years)	Viral suppression level (all)
Eswatini	>98->98-95	>98->98-91	>98->98-95	94->98-94	97
Switzerland ^a	93–>98–96				88
Rwanda	93–>98–96	54->98-89	96->98-96	93–>98–96	89
Qatar ^a	93->98-96		>98->98-81	90–97–>98	86
Botswana	91–95–>98	62->98-94	94.5->98->98	88–87–97	85
Slovenia	90–97–96				85
Uganda	91–>98–90	63->98-78	96->98-92	88–97–89	85
Malawi	91–94–94	73->98-73	94–94.9–95	90–92–94	85
Zimbabwe	93->98-89	72->98-72	96->98-91	92->98-88	82
Kenya	96–89–94	84->98-86	>98–92–94	91–83–94	81
Namibia	89.9–98–91	81–92–80	92->98-93	86–94–89	80
Cambodia	84->98-97	60->98-88	82->98-98	86->98-97	81
Lesotho	94–87–97	83->98-92	94.6–92–97	93–79–97	80
Burundi	89->98-89.7	31->98-70	>98->98-91	85–96–89	79
Uruguay					79
Norway					79
Thailand	94–84–97	>98–76–87	92–86–97	96–81–97	77
Zambia	86–95–93	58->98-84	89–94–94	84–95–93	76
Croatia	84–88–>98		80–92–>98	84–87–>98	73

- Reached the 90–90–90 targets
- Reached only the 73% viral load suppression target
- Not reached the 90–90–90 target
- Data not available

Source: UNAIDS special analysis, 2021.

^aData are not available on testing and treatment coverage for children. However, because children living with HIV represent less than 1% of the total people living with HIV, adult data were used.

Note: In the 2020 Global AIDS Update, Seizing the moment: tackling entrenched inequalities to end epidemics, Australia, Namibia and the Netherlands were among the countries reaching the 90–90–90 targets in 2019. Based on the 2020 data, however, Namibia has fallen short of the targets, mainly because of children falling behind. Australia and the Netherlands did not have full estimates on the cascade this year. In the same report, Ireland and Spain were among the countries reaching their viral suppression target at all population levels. This year, however, there was no viral suppression data available for either country.

Note: The UNAIDS models estimated that in the region of western and central Europe and North America, more than 73% of people living with HIV had suppressed viral loads in 2020.

Note: Countries have been assessed as reaching the 90–90–90 targets if coverage is >= 90.0. Thus coverage of 89.9 is not considered as reaching the target. Please see the Annex on Methods for a description of how regional estimates of the testing and treatment targets are calculated.


Note: In Eswatini, viral load suppression among all people living with HIV is estimated to be slightly higher than the proportion virally suppressed among people on treatment due to the uncertainty in the number of people on treatment and the number of people living with HIV.

Missing men living with HIV

Globally, the 90–90–90 targets were almost reached among adult women (15 years and older) living with HIV, and they were achieved in eastern and southern Africa and in western and central Europe and North America. Men living with HIV, however, are consistently faring worse than women across the HIV testing and treatment continuum. Compared to women living with HIV, there are 1 million more men living with HIV who do not know their HIV status, 1.8 million more men who know their status but are not on treatment, and 1.6 million more men who are not virally suppressed.

While gender norms that prize male strength and stoicism may partly explain why many men delay seeking care, other factors are also at play (13). Primary health-care services in eastern and southern Africa place a great deal of focus on women of reproductive age, and reproductive, maternal and child health services offer ideal entry points for HIV services; similar entry points for men are not commonplace (14, 15). Interventions to reach and include men more successfully in HIV testing and treatment services are increasing—including through workplace-based interventions and greater use of self-testing approaches, and by providing services at outpatient departments—but a more finely-tuned understanding of why men's use of HIV services continues to lag can help shape additional ways to close this gap (16, 17).


HIV TESTING AND TREATMENT CASCADE, WOMEN (AGED 15+ YEARS) COMPARED TO MEN (AGED 15+ YEARS), GLOBAL, 2020




Testing and treatment gaps for key populations

Reaching key populations living with HIV with HIV testing and treatment services has been a challenge across regions. Even HIV programmes that generally are performing well—such as in South Africa—can struggle on that front. HIV testing and treatment data from three mainly urban South African districts show that female sex workers living with HIV were consistently less likely to know their HIV status than adult women overall. In two of the districts, HIV-positive sex workers were also significantly less likely to be receiving HIV treatment and to be virally suppressed (18, 19).

Gay men and other men who have sex with men living with HIV were similarly much less likely to know their HIV status compared with the overall adult male population living with HIV. Strikingly, however, the data from Pretoria and eThekwini districts suggest that, when HIV-positive gay men and other men who have sex with men did know their HIV status, they were more likely than other HIV-positive men to receive antiretroviral therapy and be virally suppressed (18, 19). The variations emphasize the importance of tailoring HIV testing and treatment services at the local level to the challenges and needs of key populations living in the area.



KNOWLEDGE OF STATUS, TREATMENT AND VIRAL SUPPRESSION GAPS AMONG ADULT WOMEN AND FEMALE SEX WORKERS IN SOUTH AFRICA, SELECT DISTRICTS, 2018



KNOWLEDGE OF STATUS, TREATMENT AND VIRAL SUPPRESSION GAPS AMONG GAY MEN AND OTHER MEN WHO HAVE SEX WITH MEN IN SOUTH AFRICA, SELECT DISTRICTS, 2018

- People living with HIV who don't know their status
- People living with HIV who know their status but are not on treatment
- People living with HIV who know their status, are on treatment but are not virally suppressed
- People living with HIV who know their status, are on treatment and are virally suppressed

Source: South African Health Monitoring Survey, 2018; South Africa District HIV Estimates, 2017 (https://www.hivdata.org.za/).


Tuberculosis remains the leading cause of death among people living with HIV.

Reductions in tuberculosis cases among people living with HIV

Tuberculosis is a preventable and treatable disease—yet it continues to claim millions of lives each year and remains the leading cause of death among people living with HIV (20).

Progress has been achieved in recent years. There has been a steady decline in the estimated number of incident tuberculosis cases among people living with HIV, and a gradual increase in the number of tuberculosis patients living with HIV who are on antiretroviral therapy. However, just 55% of the estimated 815 000 [729 000–906 000] incident cases of tuberculosis globally among people living with HIV in 2019 were diagnosed and notified. Fully 88% of those people living with HIV with diagnosed and notified tuberculosis cases were linked to antiretroviral therapy (20).

NOTIFIED NEW AND RELAPSE TUBERCULOSIS CASES KNOWN TO BE HIV-POSITIVE, NUMBER ON ANTIRETROVIRAL THERAPY AND ESTIMATED NUMBER OF INCIDENT TUBERCULOSIS CASES AMONG PEOPLE LIVING WITH HIV, 2004–2019



Source: UNAIDS Global AIDS Monitoring, 2020 (https://aidsinfo.unaids.org/); Global tuberculosis report. Geneva: World Health Organization; 2020.


Tuberculosis deaths fall by more than half

There were an estimated 210 000 [177 000–242 000] tuberculosis-related deaths in 2019 among people living with HIV, a 63% reduction since 2010, when tuberculosis claimed the lives of 570 000 [470 000–680 000] people living with HIV. The 2021 Political Declaration on AIDS requires an 80% reduction by 2025 (compared to a 2010 baseline).

The biggest reductions in tuberculosis deaths among people living with HIV have been in India (a 83% reduction since 2010), Kenya (a 70% reduction), South Africa (a 77% reduction) and the United Republic of Tanzania (a 71% reduction). Those achievements represent tens of thousands of averted deaths. In South Africa, for example, an estimated 36 000 people living with HIV died of tuberculosis in 2019, compared with almost 160 000 deaths in 2010.

Progress is much slower in Cameroon, the Democratic Republic of the Congo, Uganda and Zambia. They are among the 30 countries that accounted for 88% of all tuberculosis-related deaths among people living with HIV in 2019.

NUMBER OF TUBERCULOSIS-RELATED DEATHS AMONG PEOPLE LIVING WITH HIV, GLOBAL, 2000–2019 AND TARGETS FOR 2020 AND 2025



Source: Global tuberculosis report. Geneva: World Health Organization; 2020. Note: The 2025 target was set by the General Assembly in the 2021 Political Declaration on AIDS.


ENDING PAEDIATRIC AIDS AND ELIMINATING VERTICAL TRANSMISSION

Fewer children on treatment


The number of children receiving antiretroviral therapy declined in 2020, leaving almost 800 000 children (aged 0-14 years) living with HIV not on life-saving treatment. Almost two thirds (63%) of those children were aged 5 years and older. Finding undiagnosed older children and adolescents requires an expansion of self-testing, and of rights-based index, family and household testing.

Treatment coverage among children living with HIV (aged 0–14 years) remains far lower than it is among adults (aged 15 years and older): 54% [37–69%] versus 74% [57–90%] in 2020. The health outcomes of children who receive HIV treatment are also worse than those of adults, partly due to suboptimal paediatric HIV medicines and challenges in retaining the children in care. A mere 40% [29–51%] of children living with HIV were virally suppressed in 2020. Children living with HIV require a continuum of treatment, care and social protection that is proven to improve health outcomes as they grow and progress through youth into adulthood.

NUMBER OF CHILDREN LIVING WITH HIV AND THOSE RECEIVING ANTIRETROVIRAL THERAPY, GLOBAL, 2010–2020




CHILDREN LIVING WITH HIV NOT RECEIVING TREATMENT, BY AGE GROUP, 2020



Almost two thirds of children living with HIV not on treatment were aged 5 years or older.

Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).

HIV TESTING AND TREATMENT CASCADE, CHILDREN (AGED 0-14 YEARS) COMPARED TO ADULTS (AGED 15 YEARS AND OLDER), GLOBAL, 2020



Source: UNAIDS special analysis, 2021.

GENDER EQUALITY

Gender-based violence remains common

Interventions and services to prevent sexual and gender-based violence—and to support survivors of violence—are urgently needed.

Globally, more than one in 10 (13%) ever-married or partnered women (aged 15 to 49 years) have experienced physical and/or sexual violence by an intimate partner in the previous 12 months (21). Only seven of 43 countries with data available between 2015 and 2020 met the 2025 target of less than 10%. Two of those seven countries—the Philippines and Senegal—have conducted multiple surveys over the years that suggest a steady decline in recent intimate partner violence.¹


A 2013 World Health Organization (WHO) study on the health burden associated with violence against women found that, in some regions, women who had experienced intimate partner violence were 1.5 times more likely to acquire HIV, compared to women who had not experienced partner violence (22). Similarly, more recent studies from Togo and Uganda—and analysis of population-based survey data in Zambia—have found a higher risk of HIV infection among women reporting various forms of intimate partner violence (23, 24). Women who inject drugs face high levels of physical and sexual violence, which contributes to their high risk of HIV, but they are often ignored by harm reduction programmes because the vast majority of people who inject drugs globally are men (25).

Deeply entrenched stigma and prejudice against LGBTI people—and discriminatory laws and regulations that foster a climate where hate speech, violence and discrimination are condoned—perpetuate high levels of violence against LGBTI communities. Acts of violence range from daily exclusion and discrimination to torture and arbitrary killings. There are no comprehensive and systematic data on the number of victims of violence, but a UN-appointed Independent Expert has estimated that there are millions every year (26). In Virginia, in the United States of America, as many as 45% of transgender individuals experience some form of gender-based victimization, including: physical or sexual violence; social, workplace or housing discrimination; or rejection in family, social or media contexts (27–30). These experiences have been associated with depression and anxiety, substance use and suicide risk (31–33).

Intimate partners are an alarmingly common source of violence towards transgender people. A 2020 systematic review of 74 quantitative data sets on intimate partner violence in transgender populations found a median lifetime prevalence of physical intimate partner violence among transgender individuals of 37.5% (34). Lifetime prevalence of sexual intimate partner violence was 25.0%, past-year physical intimate partner violence was 16.7%, and past-year sexual intimate partner violence was 10.8% (34). In Lima, Peru, a cross-sectional study among 576 gay men and other men who have sex with men and transgender women found that 7.9% of gay men and other men who have sex with men and 15.0% of transgender women reported experiences of intimate partner violence with at least one of their last three partners (35).

¹ Data are from population-based surveys: 2008, 2013 and 2017 in the Philippines, and 2017, 2018 and 2019 in Senegal.

PERCENTAGE OF EVER-MARRIED OR PARTNERED WOMEN (AGED 15–49 YEARS) WHO EXPERIENCED PHYSICAL AND/OR SEXUAL VIOLENCE BY AN INTIMATE PARTNER IN THE PAST 12 MONTHS, COUNTRIES WITH AVAILABLE DATA, BY REGION, 2015–2020



2025 target

Source: Population-based surveys, 2015–2020.


Violence negatively impacts children

Experiences of violence too often occur early in life. Violence in childhood has been linked to increased risks of: HIV and other sexually transmitted infections (STIs); mental health problems; delayed cognitive development; poor school performance and dropout; early pregnancy; reproductive health problems; communicable and noncommunicable diseases; and injury (36).

Among the 11 countries with available data between 2016 and 2020, violence (physical, sexual and/or emotional) experienced within the last 12 months by children (aged 13 to 17 years) ranged from 19.2% in the Republic of Moldova and Zimbabwe to 65.4% in Uganda among males, and from 17.7% in the Republic of Moldova to 57.5% in Uganda among females.

The percentage of young people (aged 18 to 24 years) who experienced one or more types of violence during childhood (before the age of 18) is high across all 11 countries with available data between 2016 and 2020, ranging from 26.3% in Zimbabwe to 75.6% in Uganda among males, and from 26.5% in Zimbabwe to 75.3% in Uganda among females.

CHILDREN (AGED 13–17 YEARS) AND YOUNG PEOPLE (AGED 18–24 YEARS) WHO EXPERIENCED ONE OR MORE TYPES OF VIOLENCE IN CHILDHOOD, COUNTRIES WITH AVAILABLE DATA, 2016–2020



- Male young people (aged 18–24 years) who experienced one or more types of violence before the age of 18
- Male children (aged 13–17 years) who experienced one or more types of violence in the past 12 months
- Female young people (aged 18–24 years) who experienced one or more types of violence before the age of 18
- Female children (aged 13–17 years) who experienced one or more types of violence in the past 12 months

Source: Violence against children surveys, 2015–2020.

REMOVING PUNITIVE LAWS AND POLICIES


Parental consent laws leave adolescents vulnerable to HIV

Sexual activity often starts during adolescence. Many countries have age of consent laws in relation to sexual activity that are inconsistent with minimum age laws for accessing sexual and reproductive health information and services without parental permission. This means that adolescents may legally have sex before they can legally access any information or services relating to safer sex practices or contraception, leaving them at greater risk of HIV, other STIs and unwanted pregnancy (37).

The removal of laws that require parental permission to access services for sexual and reproductive health and HIV prevention, testing and treatment has been shown to improve health-seeking behaviours (38). That effect is even stronger when schools can provide age-appropriate comprehensive sexuality education to young people so they can protect themselves from HIV, STIs, unwanted pregnancy, and gender-based and sexual violence.

Forty countries reported to UNAIDS in 2021 that they have laws requiring parental/guardian consent for adolescents to access hormonal or long-lasting contraceptives, 108 reported that this consent is required for an HIV test, 43 for HIV self-testing, 92 for HIV treatment and 22 for PrEP. Among these countries, some provide exceptions based on demonstrated maturity: 10 for hormonal or long-lasting contraceptives, 15 for HIV testing, eight for self-testing and nine for HIV treatment. The age cut-off of parental consent laws varied by service. The majority of countries that reported having requirements for parental/guardian consent had an age cut-off of 18 years, with exceptions in a few countries where adolescents as young as 14 years could access a service without parental/guardian consent, which varied by service.

COUNTRIES WITH REQUIREMENTS FOR PARENTAL/GUARDIAN CONSENT FOR ADOLESCENTS (UNDER AGE 18) TO ACCESS SERVICES, GLOBAL, 2021



Source: UNAIDS National Commitments and Policy Instrument, 2017–2021.

INVESTMENTS TO END AIDS

Stronger and smarter investments needed to end AIDS


Ending AIDS will require substantial additional domestic investments, reinvigorated international contributions, more efficient allocation of available resources and creative solutions to the reductions in fiscal space caused by the COVID-19 pandemic.

Under-investment in the HIV responses of low- and middle-income countries was a major reason why global targets for 2020 were missed. Financial resource availability during the last five years was consistently below the resources needed, and in 2020, it was 29% less than the US\$ 26 billion target for that year (in constant 2016 US dollars). Domestic funding (public and private), which had been the main source of investment growth for HIV responses in low- and middle-income countries over the last decade, has plateaued and begun to decline. International contributions have fluctuated for 10 years; in 2020, they were at the same level as in 2010. When domestic and donor resource trends are combined, there have been three straight years of decline in total resource availability.

The failure to achieve programmatic and impact targets has translated to more people living with HIV and more people at risk of HIV infection who are in need of services. Higher levels of resources are now needed to get the AIDS pandemic response back on track towards the global goal of ending AIDS by 2030. Annual HIV investments in low- and middle-income countries need to rise from the US\$ 21.5 billion (in constant 2019 US dollars) in resources available in 2020 to reach the 2025 target set within the 2021 Political Declaration on AIDS: US\$ 29 billion (in constant 2019 dollars) for low-and middle-income countries, which in 2020–2021 included countries formerly classified as high-income (Figure below).

² The group of low- and middle-income countries included in the resource availability and needs estimates of this chapter follow the World Bank's country income-level classification for 2020–2021.

RESOURCE AVAILABILITY FOR HIV IN LOW- AND MIDDLE-INCOME COUNTRIES, 2000–2020 AND 2025 TARGET



Source: UNAIDS financial estimates and projections, 2021 (http://hivfinancial.unaids.org/hivfinancialdashboards.html).

Note: The resource estimates are presented in constant 2019 US dollars. The countries included are those that were classified by the World Bank in 2020 as being low- and middle-income.

³ The percentage shortfall compared to the 2020 target uses a 2020 resource availability estimate (US\$ 18.5 billion) measured in 2016 US dollars to match the resource targets in the 2016 Political Declaration on Ending AIDS. The other resource availability and needs estimates in this chapter are measured in 2019 US dollars, consistent with the resource targets in the 2021 Political Declaration on AIDS.

Reaching the global price tag for the AIDS response is just part of the challenge—where funds come from, where they go and how they are spent also require close attention.

Eastern and southern Africa, the region with the highest burden of HIV, accounts for 29% of the estimated resource needs among all low- and middle-income countries for 2025. Asia and the Pacific's substantial share (32%) of total resource needs is due mainly to HIV prevention efforts for its much larger population, as well as higher unit costs in some countries. Higher unit costs also contribute to the relatively high per capita resource needs in Latin America and eastern Europe and central Asia.

Regional patterns in resource availability demonstrate that greater impact is achieved where sufficient funds are invested and used wisely. In eastern and southern Africa, for instance, a combination of domestic and international investments has fuelled the rapid expansion of HIV prevention, testing and treatment in areas with a high burden of HIV, resulting in strong and steady reductions in the rate of HIV infections and AIDS-related mortality. Even though the per capita amounts of resources available in eastern and southern Africa and the Caribbean in 2020 met or even surpassed 2025 investment targets, reductions in infections and deaths are not on track to achieve the 2025 impact targets, reflecting the need for greater efficiency in resource allocation and use within several countries in the region. This pattern is more pronounced in Latin America, where relatively high levels of spending per person living with HIV have been maintained, and HIV prevention efforts have stalled at relatively low incidence (0.16 HIV infections per 1000 population).


Under-investment in the HIV responses of low- and middleincome countries was a major reason why global targets for 2020 were missed.



The Global AIDS
Strategy calls for a
doubling of domestic
and international
funding for primary
HIV prevention
interventions, such as
condoms, PrEP and
VMMC.

The resources allocated to effective combinations of HIV prevention services for populations at higher risk of HIV infection are insufficient across most regions. The Global AIDS Strategy 2021–2026 calls for a doubling of domestic and international funding for primary HIV prevention interventions, such as condoms, PrEP and VMMC, increasing from the US\$ 5.2 billion in estimated total expenditures in low- and middle-income countries in 2019 to about US\$ 9.5 billion in 2025. A substantial share of these additional resources for HIV prevention should be focused on key populations in all regions, and on adolescent girls and young women in areas in sub-Saharan Africa with high HIV burden.

Much of the gap between 2020 resource availability and 2025 resource needs for HIV responses is in upper-middle-income countries that generally have more fiscal space to increase domestic resource allocations. By contrast, low-income countries remain heavily reliant on donor resources, in part because some of the countries spend a substantial proportion of their tax revenues on servicing debt. Deficit spending related to the COVID-19 pandemic in countries across all income levels threatens to impact funding availability for HIV responses in the coming years.



TOTAL HIV RESOURCE AVAILABILITY PER PERSON LIVING WITH HIV, HIV INCIDENCE AND AIDS-RELATED MORTALITY RATES, LOW- AND MIDDLE-INCOME COUNTRIES, 2010-2020 AND 2025 TARGET



0.01

2025

1000

2013

2014 2015 2016 2017 2018 2019

Source: Analysis based on UNAIDS epidemiological and financial estimates and projections, 2021.

Incidence per 1000 population

Mortality per 1000 population

References

- Kavanagh M, Agbla SC, Pillinger M, Joy M, Case A, Erondu N et al. Law, criminalization and HIV in the world: have countries that criminalize achieved more or less successful AIDS pandemic responses? O'Neill Institute for National and Global Health pre-print white paper; 2021 (https://www.hivpolicylab.org/documents/reports/hlm/PRE-PRINT%20 WHITE%20PAPER-Kavanagh%20et%20al-Law%20Criminalization%20%26%20HIV%20in%20the%20World-2021.pdf).
- 2. Global and regional estimates of violence against women: prevalence and health effects of intimate partner violence and non-partner sexual violence. Geneva: WHO; 2013.
- Hatcher AM, Smout EM, Turan JM, Christofides N, Stöckl H. Intimate partner violence and engagement in HIV care and treatment among women: a systematic review and meta-analysis. AIDS. 2015;29(16):2183-94.
- 4. De Neve JW, Fink G, Subramanian SV, Moyo S, Bor J. Length of secondary schooling and risk of HIV infection in Botswana: evidence from a natural experiment. Lancet Glob Health. 2015;3(8):e470-e477.
- 5. Dovel K, Dworkin SL, Cornell M, Coates TJ, Yeatman S. Gendered health institutions: examining the organization of health services and men's use of HIV testing in Malawi. J Int AIDS Soc. 2020;23:e25517.
- 6. Cornell M, Majola M, Johnson LF, Dubula-Majola V. HIV services in sub-Saharan Africa: the greatest gap is men. Lancet. 2021;397(10290):2130-2.
- 7. Tanser FC, Kim HY, Mathenjwa T, Shahmanesh M, Seeley J, Matthews P et al. Home-based Intervention to Test and Start (HITS): a community-randomized controlled trial to increase HIV testing uptake among men in rural South Africa. J Int AIDS Soc. 2021;24(2):e25665.
- 8. Stover J, Teng Y. The impact of condom use on the HIV epidemic [version 1]. Gates Open Res. 2021;5:91. doi: 10.12688/gatesopenres.13278.1.
- 9. Smith B, Mann C, Jones C, Miller N, Longfield K, Gesuale S. Challenges and recommendations for reaching "FastTrack" Targets for condom use. Mann Global Health; 2019.
- Preventing HIV through safe voluntary medical male circumcision for adolescent boys and men in generalized HIV epidemics: recommendations and key considerations. WHO: Geneva; 2020 (https://apps.who.int/iris/rest/bitstreams/1296029/retrieve).
- The EACS European standard of care meetings 2020–202: report and summary of workshops. Tbilisi: European AIDS Clinical Society; 2020 (https://www.eacsociety.org/files/eacs_soc_2020-21_report.pdf?utm_source=conference+newsenglish&utm_medium=email&utm_campaign=2021-04-14).
- 12. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2019. HIV Surveillance Supplemental Report 2021; 26 (No. 2). May 2021 (http://www.cdc.gov/hiv/library/reports/ hiv-surveillance.html).
- 13. Blind spot—reaching out to men and boys. Geneva: UNAIDS; 2017.
- Dovel K, Dworkin SL, Cornell M, Coates TJ, Yeatman S. Gendered health institutions: examining the organization of health services and men's use of HIV testing in Malawi. J Int AIDS Soc. 2020;23:e25517.
- Cornell M, Majola M, Johnson LF, Dubula-Majola V. HIV services in sub-Saharan Africa: the greatest gap is men. Lancet. 2021;397(10290):2130-2.
- Tanser FC, Kim HY, Mathenjwa T, Shahmanesh M, Seeley J, Matthews P et al. Home-based Intervention to Test and Start (HITS): a community-randomized controlled trial to increase HIV testing uptake among men in rural South Africa. J Int AIDS Soc. 2021;24(2):e25665.
- 17. Dovel K, Shaba F, Offorjebe OA, Balakasi K, Myirenda M, Phiri K et al. Effect of facility-based HIV self-testing on uptake of testing among outpatients in Malawi: a cluster-randomised trial. Lancet Glob Health. 2020;8:e276-e287.
- 18. South African Health Monitoring Survey, 2018.
- 19. South Africa District HIV Estimates, 2017 (https://www.hivdata.org.za/).
- 20. Global tuberculosis report 2020. Geneva: WHO; 2020.
- 21. Violence against women prevalence estimates, 2018. Global, regional and national prevalence estimates for intimate partner violence against women and global and regional prevalence estimates for non-partner sexual violence against women. Geneva: WHO; 2021.
- 22. Global and regional estimates of violence against women: prevalence and health effects of intimate partner violence and non-partner sexual violence. Geneva: WHO; 2013.

- 23. Burgos-Soto J, Orne-Gliemann J, Encrenaz G, Patassi A, Woronowski A, Kariyiare B et al. Intimate partner sexual and physical violence among women in Togo, West Africa: prevalence, associated factors, and the specific role of HIV infection. Glob Health Action. 2014;7:23456.
- 24. Sileo KM, Kintu M, Kiene SM. The intersection of intimate partner violence and HIV risk among women engaging in transactional sex in Ugandan fishing villages. AIDS Care. 2018;30(4):444-52.
- 25. Iversen J, Page K, Madden A, Maher L. HIV, HCV, and health-related harms among women who inject drugs: implications for prevention and treatment. J Acquir Immune Defic Syndr. 2015;69 Suppl 2(0 1):S176-S181.
- Report of the Independent Expert on protection against violence and discrimination based on sexual orientation and gender identity. A/HRC/38/43. 11 May 2018 (https://undocs.org/A/HRC/38/43).
- 27. Barboza GE, Dominguez S, Chace E. Physical victimization, gender identity and suicide risk among transgender men and women. Prev Med Rep.2016;4:385-90.
- 28. Bradford J, Reisner SL, Honnold JA, Xavier J. Experiences of transgender-related discrimination and implications for health: results from the Virginia transgender health initiative study. Am J Pub Health. 2013;103(10):1820-9.
- 29. Goldblum P, Testa RJ, Pflum S, Hendricks ML, Bradford J, Bongar B. The relationship between gender-based victimization and suicide attempts in transgender people. Prof Psychol Res Pr. 2012;43(5):468-75.
- 30. McNeil J, Ellis SJ, Eccles FJR. Suicide in trans populations: a systematic review of prevalence and correlates. Psychol Sex Orientat Gend Divers. 2017;4(3):341-53.
- 31. Tebbe EA, Moradi B. Suicide risk in trans populations: an application of minority stress theory. J Couns Psychol. 2016;63(5):520-33.
- 32. Klein A, Golub SA. Family rejection as a predictor of suicide attempts and substance misuse among transgender and gender nonconforming adults. LGBT Health. 2016;3(3):193-9.
- 33. Wolford-Clevenger C, Frantell K, Smith PN, Flores LY, Stuart GL. Correlates of suicide ideation and behaviors among transgender people: a systematic review guided by ideation-to-action theory. Clin Psychol Rev. 2018;63:93-105.
- 34. Peitzmeier SM, Malik M, Kattari SK, Marrow E, Stephenson R, Agénor M et al. Intimate partner violence in transgender populations: systematic review and meta-analysis of prevalence and correlates. Am J Public Health. 2020;110(9):e1-e14.
- 35. Passaro RC, Segura ER, Gonzales-Saavedra W, Lake JE, Perez-Brumer A, Shoptaw S et al. Sexual partnership-level correlates of intimate partner violence among men who have sex with men and transgender women in Lima, Peru. Arch Sex Behav. 2020 Oct;49(7):2703-13.
- 36. INSPIRE: seven strategies for ending violence against children. Geneva: World Health Organization; 2016 (https://apps.who.int/iris/rest/bitstreams/920857/retrieve).
- 37. My body Is my own. New York: UNFPA; 2021 https://www.unfpa.org/sites/default/files/pub-pdf/SoWP2021_Report_-_EN_web.3.21_0.pdf).
- 38. McKinnon B, Vandermorris A. National age-of-consent laws and adolescent HIV testing in sub-Saharan Africa: a propensity-score matched study. Bull World Health Organ. 2019;97(1):42-50.

EASTERN AND SOUTHERN AFRICA



astern and southern Africa remains the region most heavily affected by HIV, accounting for approximately 55% of all people—and two thirds of all children—living with HIV. It is also the region that has made the strongest progress against the HIV epidemic since 2010: new HIV infections declined by 43% overall from 2010 to 2020, and by 64% among children (aged 0 to 14 years), the sharpest reductions in any region.

As a whole, the region came very close to achieving 2020 targets for testing and treatment—a remarkable achievement given the high burden of HIV in the region. Countries such as Eswatini, Namibia and Zambia have shown tremendous leadership in advancing towards the 90–90–90 targets, with Eswatini already reaching the 95–95–95 targets. Overall, there were 50% fewer deaths due to AIDS-related causes in 2020 compared with a decade earlier.

Such is the scale of the region's epidemic, however, that it still claimed 310 000 [220 000–470 000] lives in 2020, and 670 000 [470 000–930 000] people acquired HIV in the same period. An estimated 58% of those infections were among women and girls, against a background of entrenched gender inequalities and prevalent gender-based violence. Key populations and their sexual partners accounted for 32% of new infections in 2020.

Testing and treatment coverage for men continues to be significantly lower than for women, a trend that jeopardizes the health and lives of men and their partners. Children have experienced much slower progress across the testing and treatment cascade than adults.


Political commitment remains strong across the region: most countries have adopted ambitious targets for programme expansion and increased domestic funding for their HIV responses. The extensive involvement of community-led organizations and networks in HIV activities is a hallmark of the regional response. Their efforts helped limit disruptions and delays to HIV services caused by the COVID-19 pandemic.

Efforts to improve sexual and reproductive health and rights—including the expansion of comprehensive sexuality education and programmes to reduce gender-based violence, gender inequality, harmful practices and child marriage—are also gathering pace in many countries.

PRIORITY ACTIONS FOR ENDING AIDS


- Expand high-impact combination HIV prevention for key populations, adolescent girls and young women, and young men in all their diversity.
- Preserve gains in testing, treatment and care during the COVID-19 pandemic, and address geographicand populationspecific service coverage gaps that are particularly affecting priority subpopulations.
- Ensure the sustainability of the HIV response, including through greater domestic funding and service integration.
- Address social and structural barriers, including harmful gender and social norms and genderbased violence.
- Empower communities and place them at the centre of national and subnational HIV responses. Strive to tailor HIV and sexual and reproductive health and rights services to the needs of young people in all their diversity, thus ensuring higher service uptake.

ANTIRETROVIRAL TREATMENT COVERAGE AMONG MEN (AGED 20–24 YEARS), SUBNATIONAL LEVEL, EASTERN AND SOUTHERN AFRICA, 2020



Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).


PERCENTAGE OF YOUNG WOMEN (AGED 15–24) WHO REPORT HAVING EXPERIENCED SEXUAL VIOLENCE, SELECTED COUNTRIES, EASTERN AND SOUTHERN AFRICA, 2015–2018



Source: Demographic and Health Surveys, 2015–2018.


STATE OF THE PANDEMIC

NUMBER OF NEW HIV INFECTIONS AND AIDS-RELATED DEATHS, EASTERN AND SOUTHERN AFRICA, 2000–2020




Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).

DISTRIBUTION OF NEW HIV INFECTIONS BY POPULATION GROUP AND SEX (AGED 15–49 YEARS), EASTERN AND SOUTHERN AFRICA, 2020



Sources: UNAIDS special analysis, 2021 (see methods annex).

HIV PREVALENCE AMONG KEY POPULATIONS, REPORTING COUNTRIES IN EASTERN AND SOUTHERN AFRICA, 2016–2020




- Sex workers (n = 14)

 Gay men and other men who have sex with men (n = 11)
- People who inject drugs (n = 6)Transgender people (n = 6)
- Prisoners (n = 9)

Source: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/). Note: (n = number of countries). Total number of reporting countries = 21.

How to read this chart



REPORTED ESTIMATED SIZE OF KEY POPULATIONS, EASTERN AND SOUTHERN AFRICA, 2018–2020

	National adult population (aged 15–49 years) in 2020 or relevant year	Sex workers	Sex workers as per cent of adult population (aged 15-49 years)	Gay men and other men who have sex with men	Gay men and other men who have sex with men as per cent of adult population (aged 15–49 years)	People who inject drugs	People who inject drugs as per cent of adult population (aged 15–49 years)	Transgender people	Transgender people as per cent of adult population (aged 15–49 years)	Prisoners	Prisoners as per cent of adult population (aged 15-49 years)
Comoros	430 000										
Eswatini	608 000									46 800	7.70%
Kenya	25 000 000										
Lesotho	1 150 000	7500		6100							
Madagascar	13 600 000										
Malawi	9 277 000	36 100	0.39%							14 200	
Namibia	1 311 000										
Rwanda	6 448 000	13 700	0.21%	5900							
Seychelles	47 000									300	0.64%
South Africa	31 700 000	24 000		310 000	0.98%					166 000	0.53%
South Sudan	5 395 000	8400									
Uganda	21 364 000										
United Republic of Tanzania	28 264 000										
Zambia	8 901 000									20 800	0.23%
Zimbabwe	8 000 000			23 300						20 900	0.26%
Estimated regional proportion as per cadult population (aged 15–49 years)	cent of		0.29%		0.73%		0.30%		0.16%		-

National population size estimateLocal population size estimate

Insufficient data

No data

Sources: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/); Spectrum Demproj module, 2021; World Population Prospects 2019 [Internet]. New York: United Nations Department of Economic and Social Affairs; c2020 (https://population.un.org/wpp/)(custom data acquired via website).

Note 1: Estimates shown are government-provided estimates reported for 2018–2020. Additional and alternative estimates may be available from different sources, including the Key Populations Atlas (https://kpatlas.unaids.org/), academic publications or institutional documents. Note 2: The regions covered by the local population size estimate are as follows:

Lesotho: Butha Buthe, Leribè, Mafeteng and Maseru.

Malawi: Blantyre, Chikwawa, Chitipa, Dedza, Karonga, Kasungu, Lilongwe, Mangochi, Mulanje, Mzimba, Mzuzu, Nkhata Bay, Nkhotakota, Ntcheu, Ntchisi, Nsanje, Rumphi, Thyolo and Zomba.

Rwanda: Kigali.

South Africa: Cape Town Metro, Durban Metro and Johannesburg Metro.

South Sudan: Wau and Yambio. Zimbabwe: Bulawayo and Harare.


Note 3: The reported values for gay men and other men who have sex with men are presented as a per cent of the adult population (aged 15–49 years) for consistency across key populations. The percentage of this population out of the adult male population (aged 15–49 years) will be approximately twice the values shown.

^a Quick Start Guide for Spectrum, 2020. Geneva: UNAIDS; 2020 (https://www.unaids.org/sites/default/files/media_asset/QuickStartGuide_Spectrum_en.pdf).

^b Technical brief: recommended population size estimates of men who have sex with men. Geneva: WHO, UNAIDS; 2020.


HIV SERVICES

PEOPLE LIVING WITH HIV, PEOPLE NEWLY INFECTED IN THE PAST SIX MONTHS, AND HIV TESTING AND TREATMENT CASCADE, ADULTS (AGED 15+ YEARS), EASTERN AND SOUTHERN AFRICA, 2016–2020



Source: UNAIDS special analysis, 2021.

PERCENTAGE OF YOUNG WOMEN (AGED 15–24 YEARS) WITH UNMET NEED FOR FAMILY PLANNING AND ALL PREGNANT WOMEN LIVING WITH HIV WHO ARE AGED 15 TO 24 YEARS, SELECTED COUNTRIES, EASTERN AND SOUTHERN AFRICA, 2015–2018




- Young women (aged 15–24 years) with unmet need for family planning
- Percentage of all pregnant women living with HIV who are aged 15 to 24 years


Source: Demographic and Health Surveys, 2015–2018; UNAIDS epidemiological estimates, 2021.

HIV TESTING AND TREATMENT CASCADE, CHILDREN (AGED 0-14 YEARS) COMPARED TO ADULTS (AGED 15 YEARS AND OLDER), EASTERN AND SOUTHERN AFRICA, 2020

Children (aged 0-14 years) living with HIV





Adults (aged 15 years and older) living with HIV




Source: UNAIDS special analysis, 2021.

HIV TESTING AND TREATMENT CASCADE, WOMEN (AGED 15+ YEARS) COMPARED TO MEN (AGED 15+ YEARS), EASTERN AND SOUTHERN AFRICA, 2020





Men (aged 15+ years) living with HIV



Source: UNAIDS special analysis, 2021.

LAWS AND POLICIES

PUNITIVE AND DISCRIMINATORY LAWS, EASTERN AND SOUTHERN AFRICA, 2021

POLICIES	Criminalization of transgender people	Criminalization of sex work	Criminalization of same-sex sexual acts	Law allows for possession of a certain limited amount of drugs for personal use	Parental consent for adolescents to access HIV testing	Laws criminalizing the transmission of, non-disclosure of or exposure to HIV transmission	Laws or policies restricting the entry, stay and residence of people living with HIV	Mandatory HIV testing for marriage, work or residence permits or for certain groups
Angola	2	4	1	1		23		2
Botswana	2		1					2
Comoros	1		10	1	1	1		1
Eritrea		5	11			24		1
Eswatini	2	6				1		1
Ethiopia	3							1
Kenya	1		12	1	1			1
Lesotho	2		1			2		2
Madagascar	1		1					1
Malawi	1							1
Mauritius	2		13			2		2
Mozambique	2	2	2			2		2
Namibia	2					1		1
Rwanda	3	9	11					2
Seychelles	2		2		2	2		2
South Africa	1		1					1
South Sudan	2				2			2
Uganda	1		14			1		1
United Republic of Tanzania	1					1		1
Zambia	1							1
Zimbabwe	1	1	15	1	1	1		1

Criminalization of transgender people

- Criminalized and prosecuted
- Neither criminalized nor prosecuted
- Data not available

Criminalization of sex work

- Any criminalization or punitive regulation of sex work
- Sex work is not subject to punitive regulations or is not criminalized
- Issue is determined/differs at the subnational level
- Data not available

Criminalization of same-sex sexual acts

- Death penalty
- Imprisonment (14 years-life, up to 14 years) or no penalty specified
- Laws penalizing same-sex sexual acts have been decriminalized or never existed, or no specific legislation
- Data not available

Law allows for possession of a certain limited amount of drugs for personal use

- No
- Data not available

Parental consent for adolescents to access HIV testing

- Yes, for adolescents younger than 18
- Yes, for adolescents younger than 14 or 16
- Yes, for adolescents younger than 12
- No
- Data not available

Laws criminalizing the transmission of, non-disclosure of or exposure to HIV transmission

- No, but prosecutions exist based on general criminal laws
- No
- Data not available

Laws or policies restricting the entry, stay and residence of people living with HIV

- Deport, prohibit short and/or long stay and require HIV testing or disclosure for some permits
- Prohibit short and/or long stay and require HIV testing or disclosure for some permits
- Require HIV testing or disclosure for some permits
- No restrictions
- Data not available

Mandatory HIV testing for marriage, work or residence permits or for certain groups

- Yes
- No
- Data not available

Sources


- 1. UNAIDS National Commitments and Policy Instrument, 2021 (see http://lawsandpolicies.unaids.org/).
- 2. UNAIDS National Commitments and Policy Instrument, 2019 (see http://lawsandpolicies.unaids.org/).
- 3. UNAIDS National Commitments and Policy Instrument, 2017 (see http://lawsandpolicies.unaids.org/).
- 4. Angola. Codigo Penal. Article 189 (https://governo.gov.ao/fotos/frontend_1/gov_documentos/novo_codigo_penal_905151145fad02b10cd11.pdf).
- 5. Eritrea. Penal Code. Article 314 (https://www.refworld.org/pdfid/55a51ccc4.pdf).
- 6. Eswatini. The Crimes Act, 61 of 1889. Article 49 (http://www.osall.org.za/docs/2011/03/SwazilandCrimes-Act-61-of-1889.pdf); Eswatini. Sexual Offences and Domestic Violence Act, 2018. Articles 13–18.
- 7. Ethiopia. Penal Code (https://www.refworld.org/docid/49216b572.html%22%3Ehttp://www.refworld.org/docid/49216b572.html%3C/a&qt).
- 8. Namibia. Combating of Immoral Practices. Act 21 of 1980 (https://laws.parliament.na/cms_documents/combating-of-immoral-practices-2c85487772.pdf).
- 9. Rwanda. Organic Law Instituting the Penal Code. Section 4 (https://sherloc.unodc.org/res/cld/document/rwa/1999/penal-code-of-rwanda_html/Penal_Code_of_Rwanda.pdf).
- 10. Comoros. Code Penal 2020. Article 300 (https://www.droit-afrique.com/uploads/Comores-Code-2020-penal.pdf).
- 11. Mendos LR. State-sponsored homophobia, 2020. Geneva: International Lesbian, Gay, Bisexual, Trans and Intersex Association; December 2020 (https://ilga.org/downloads/ILGA_State_Sponsored_Homophobia_2019_light.pdf).
- 12. Kenya. Penal Code. Section 163–165 (http://kenyalaw.org:8181/exist/kenyalex/actview.xql?actid=CAP.%2063)
- 13. Mauritius. Criminal Code Act. Article 250 (https://www.icac.mu/wp-content/uploads/2015/06/140318-Criminal-Code-Act.pdf).
- 14. Uganda. The Penal Code Act. Section 145 (https://www.refworld.org/docid/59ca2bf44.html).
- 15. Zimbabwe. The Criminal Law (Codification and Reform) Act (Act No. 23) (2004). Article 73 (1) (https://zimlii.org/zw/legislation/num-act/2004/23/Criminal%20Law%20%28Codification%20and%20Reform%29%20Act%20%5BChapter%209-23%5D.pdf).
- 16. Angola. Protocolo Servicos de Testagem para o VIH, 2017 (https://pdf.usaid.gov/pdf_docs/PA00MV73.pdf).
- 17. Eswatini. The Children's Protection and Welfare Act, 2012. Sections 240–243 (https://osall.org.za/docs/2011/03/Swaziland-Childrens-Protection-and-Welfare-Act-6-of-2012-Part-7.pdf).
- 18. Ethiopia. HIV Testing Guidelines, 2007 (https://www.who.int/hiv/topics/vct/ETH_HCT_guidelinesJune26_clean.pdf).
- 19. Lesotho. Children's Protection and Welfare Act, 2011. Section 233 (http://jafbase.fr/docAfrique/ Lesotho/children%20act%20 lesotho.pdf).
- 20. Mozambique. Law 19/2014 Lei de Proteccao da Pessoa, do Trabalhador e do Candidato a Emprego vivendo con HIV e SIDA. Article 26 (http://www.ilo.org/aids/legislation/WCMS_361981/lang--en/index.htm).
- 21. Namibia. National Guidelines for Antiretroviral Therapy, 2016.
- 22. National Guidelines for prevention and management of HIV and STIs. Edition 2016. Rwanda Biomedical Centre, Republic of Rwanda Ministry of Health; 2016 (https://aidsfree.usaid.gov/sites/default/files/rw_national_guidelines_hiv.pdf).
- 23. Angola. Lei n°8/04 sobre o Vírus da İmunodeficiência Humana (VIH) e a Síndroma de Imunodeficiência Adquirida (SIDA) (https://www.ilo.org/wcmsp5/groups/public/---ed_protect/---protrav/---ilo_aids/documents/legaldocument/wcms_125156.pdf).
- 24. Global HIV Criminalisation Database [database]. Amsterdam: HIV Justice Network (https://www.hivjustice.net/global-hiv-criminalisation-database/).
- 25. Still not welcome: HIV-related travel restrictions. Geneva: UNAIDS, UNDP; 2019 (https://www.unaids.org/sites/default/files/media_asset/hiv-related-travel-restrictions-explainer_en.pdf).

Note: A country is considered to have criminalized transgender persons if it uses the law to punish transgender individuals. Such a law may, for example, explicitly criminalize impersonation of the other gender, including cross-dressing. A country is considered to have any criminalization or punitive regulation of sex work if selling and/or buying sexual services is criminalized, ancillary activities associated with selling and/or buying sexual services are criminalized, profiting from organizing and/or managing sexual services is criminalized, and/or there are other punitive and/or administrative regulations of sex work.

INVESTING TO END AIDS

Eastern and southern Africa has successfully mobilized resources for the region's AIDS responses during the last decade. Both domestic and international resources increased by 33% between 2010 and 2020. Most of this increase occurred during the 2010–2017 period; the last few years have seen resource availability flatten. In 2020, the United States President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) contributed 38% and 11% of regional resources, respectively. A further 41% of resources was mobilized from domestic sources. The amount of resources available in 2020 was similar to the amount needed in 2025. However, a considerable proportion of 2020 resources were not allocated to the programme areas or populations facing the biggest gaps, limiting their impact. It will be vital for the region to emphasize and implement allocative and technical efficiency processes in its programmes in order to use the available resources more efficiently.


RESOURCE AVAILABILITY FOR HIV, EASTERN AND SOUTHERN AFRICA, 2010–2020, AND ESTIMATED RESOURCE NEEDS FOR HIV BY 2025



Source: UNAIDS financial estimates and projections, 2021 (http://hivfinancial.unaids.org/hivfinancialdashboards.html).

Note: The resource estimates are presented in constant 2019 US dollars.

YEAR-TO-YEAR CHANGE IN RESOURCE AVAILABILITY FOR HIV, EASTERN AND SOUTHERN AFRICA, 2010–2011 TO 2019–2020



Source: UNAIDS financial estimates, 2021 (http://hivfinancial.unaids.org/hivfinancialdashboards.html).



ANGOLA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	29 000	26 000	22 000
	[24 000–35 000]	[21 000–33 000]	[16 000–28 000]
New HIV infections (0–14)	7800	7700	5200
	[6200–9800]	[6200–9800]	[3300–7400]
New HIV infections (women, 15+)	13 000	12 000	11 000
	[10 000–16 000]	[9200–15 000]	[8600–14 000]
New HIV infections (men, 15+)	8400	6500	5200
	[6600–11 000]	[4800–8400]	[3700–7100]
HIV incidence per 1000 population	1.31 [1.07–1.56]	0.99 [0.77–1.23]	0.69 [0.52–0.89]
AIDS-related deaths			
AIDS-related deaths (all ages)	14 000	14 000	16 000
	[11 000–17 000]	[11 000–18 000]	[12 000–21 000]
AIDS-related deaths (0–14)	5100	5500	4500
	[4200–6300]	[4400–6900]	[3200–6100]
AIDS-related deaths (women, 15+)	5100	4600	6900
	[3800–6500]	[3100–6000]	[4900–8800]
AIDS-related deaths (men, 15+)	3400	4200	5000
	[2600–4600]	[3100–5600]	[3700–6500]
People living with HIV			
People living with HIV (all ages)	250 000	310 000	340 000
	[200 000–290 000]	[260 000–360 000]	[280 000–400 000]
People living with HIV (0-14)	31 000	39 000	39 000
	[25 000–38 000]	[31 000–47 000]	[31 000–49 000]
People living with HIV (women, 15+)	130 000	170 000	190 000
	[110 000–150 000]	[140 000–200 000]	[160 000–230 000]
People living with HIV (men, 15+)	84 000	99 000	100 000
	[68 000–100 000]	[83 000–120 000]	[87 000–130 000]
HIV prevalence (15–49)	1.9 [1.6–2.2]	1.9 [1.7–2.3]	1.8 [1.5–2.1]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Both criminalized and prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	Require HIV testing or disclosure for some permits
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

report discriminatory attitudes towards people living with HIV	34.6
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent	
VIOLENCE	
Proportion of ever-married or partnered women aged 15–49 years who experienced	2016
physical or sexual violence from a male intimate partner in the past 12 months	25.9


2016

STIGMA AND DISCRIMINATION


Percentage of women aged 15-49 years who

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020		US\$ 5 992 845	US\$ 783 096	US\$ 2 593 778		US\$ 10 428 830

EPIDEMIC TRANSITION METRICS




^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).



^{**} Programme data—not representative; includes people with negative results.

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	14% [11–18%]	68% [54–84%]
Final vertical transmission rate including during breastfeeding	30.8% [29.3–32.3%]	18.6% [14.9–21.6%]
Early infant diagnosis	2.5% [2–3.1%]	2.4% [2–3.1%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	11 000 [6800 –15 000]
People living with HIV who started TB preventive therapy (2018)	41.9%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2015)	
— Women	32.5%
— Men	31.6%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2016)	
— Women	32.1%
— Men	63.3%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2015)	29.8%
Men aged 15–49 years who are circumcised (2016)	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

BOTSWANA

COUNTRY DATA

EPIDEMIC ESTIMATES					
	2010	2015	2020		
New HIV infections					
New HIV infections (all ages)	14 000	12 000	8900		
	[12 000–15 000]	[10 000–13 000]	[7100–11 000]		
New HIV infections (0–14)	1300	760	<500		
	[990–1700]	[<500–1100]	[<200–<500]		
New HIV infections (women, 15+)	6900	6300	5400		
	[6000–7800]	[5400–7200]	[4300–6500]		
New HIV infections (men, 15+)	5800	4500	3300		
	[5000–6700]	[3800–5200]	[2600–4100]		
HIV incidence per 1000 population	8.38 [7.35–9.47]	6.3 [5.38–7.16]	4.39 [3.51–5.57]		
AIDS-related deaths					
AIDS-related deaths (all ages)	6600	5100	5100		
	[5700–7700]	[4300–6000]	[4300–6000]		
AIDS-related deaths (0–14)	1000	<500	<500		
	[830–1300]	[<500–620]	[<200-<500]		
AIDS-related deaths (women, 15+)	3000	2200	2100		
	[2600–3500]	[1800–2700]	[1800–2700]		
AIDS-related deaths (men, 15+)	2600	2500	2800		
	[2200–3300]	[2100–3100]	[2300–3200]		
People living with HIV					
People living with HIV (all ages)	330 000	360 000	370 000		
	[310 000–350 000]	[340 000–380 000]	[350 000–400 000]		
People living with HIV (0–14)	18 000	13 000	7500		
	[16 000–20 000]	[9900–15 000]	[5400–9200]		
eople living with HIV (women, 15+)	180 000	200 000	220 000		
	[170 000–190 000]	[190 000–210 000]	[200 000–230 000]		
People living with HIV (men, 15+)	140 000	150 000	150 000		
	[130 000–150 000]	[140 000–160 000]	[140 000–160 000]		
HIV prevalence (15–49)	23.2 [22.4–23.9]	22.1 [20.9–22.8]	19.9 [18.2–21]		

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents 12 years or younger
Spousal consent for married women to access sexual and reproductive health services	Yes
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes

residence permits or for certain groups

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	
Percentage of people living with HIV denied	2013
the last 12 months	3
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their	2013
consent	2

VIOLENCE

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 10 716 702 US\$ 158 991 773 Last available report: 2017

EPIDEMIC TRANSITION METRICS 25 000 12 30 000 Number of people of people 30 000 10 20 000 25 000 8 20 000 15 000 20 000 Number of 6 15 000 10 000 Number 4 10 000 10 000 5 000 2 5 000 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 New HIV infections Incidence:prevalence ratio New HIV infections AIDS-related deaths All-cause deaths among • • • • • Target

Change in new
HIV infections
since 2010

-37%

Change in AIDS-related deaths = -22% since 2010


Incidence:
prevalence = 2.37
ratio

Incidence: = 1.2

the HIV population

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population			•••		
HIV prevalence	42.2%	14.8%			
HIV testing and status awareness					
Antiretroviral therapy coverage	87.6%	73.5%			
Condom use	75.7%	77.5%			
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2017)	1 401 897	616 964			

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	76% [67–84%]	100% [90–100%]
Final vertical transmission rate including during breastfeeding	9.2% [7.5–10.8%]	1.9% [1.6–2.3%]
Early infant diagnosis	46.4% [41.1–55.6%]	>95% [93.8- >95%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	3300 [2600 -4200]
People living with HIV who started TB preventive therapy (2018)	
Women who tested positive for HIV among those screened for cervical cancer (programme data) (2018)	29.9%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	3.1%
Knowledge of HIV prevention among young people aged 15–24 years (2016)	9
— Women	47.4%

47.1%

2259

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

— Women

— Men

- Men

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15-49 years who are circumcised

Voluntary medical male circumcisions
performed according to national standards 3171
(2020)

People who received PrEP at least once during the reporting period (2020)

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

COMOROS

COUNTRY DATA

	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100–<100]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100- <100]
New HIV infections (men, 15+)	<100	<100	<100
	[<100–<100]	[<100–<100]	[<100–<100]
HIV incidence per 1000 population	0.01 [<0.01–0.04]	0.01 [<0.01–0.03]	<0.01 [<0.01–0.02]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100–<100]
AIDS-related deaths (0–14)			
	[]	[–]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100– <100]	[<100–<100]	[<100-<100]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100–<100]
People living with HIV			
People living with HIV (all ages)	<200	<200	<200
	[<100-<500]	[<100–<500]	[<100- <500]
People living with HIV (0-14)			
	[]	[]	[–]
People living with HIV (women, 15+)	<100	<100	<100
	[<100- <200]	[<100–<200]	[<100– <200]
People living with HIV (men, 15+)	<100	<100	<100
	[<100– <100]	[<100–<200]	[<100–<200]
HIV prevalence (15–49)	<0.1 [<0.1–<0.1]	<0.1 [<0.1– <0.1]	<0.1 [<0.1–<0.1]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	No

residence permits or for certain groups

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49

years who report discriminatory attitudes towards people living with HIV		
	•••	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who		

reported a health-care professional told others about their HIV status without their consent


VIOLENCE


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020		US\$ 168 666		US\$ 930 111	US\$ 3782	US\$ 1 102 560

EPIDEMIC TRANSITION METRICS

since 2010






^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

ratio

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••		•••	•••	
HIV prevalence	0.8%	0.4%	1.8%		
HIV testing and status awareness	100%	100%	100%		
Antiretroviral therapy coverage					
Condom use	35.8%	56.2%	43.8%		
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2016)	7888	12 479			

since 2010

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]
Early infant diagnosis	% [–%]	% [–%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	1 [0–3]
People living with HIV who started TB preventive therapy (2018)	0%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years (2012)	
— Women	19.1%
— Men	23.9%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2012)	
— Women	28.4%
— Men	59.7%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised (2012)	Not applicable
Voluntary medical male circumcisions	Not

Harm reduction

— Use of sterile injecting equipment at last injection

applicable

...

No

No

- Needles and syringes distributed per person who injects

performed according to national standards

People who received PrEP at least once

during the reporting period

- Coverage of opioid substitution therapy
- Safe injection rooms available (2021)

— Naloxone available (2021)

ERITREA

COUNTRY DATA

EPIDEMIC ESTIMATES	EPIDEMIC ESTIMATES		
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	680	<500	<500
	[<500–1100]	[<200–670]	[<200–500]
New HIV infections (0–14)	<200	<100	<100
	[<200-<500]	[<100- <200]	[<100-<100]
New HIV infections (women, 15+)	<500	<200	<200
	[<200–510]	[<100-<500]	[<100-<500]
New HIV infections (men, 15+)	<500	<200	<100
	[<200–<500]	[<100-<500]	[<100–<200]
HIV incidence per 1000 population	0.22 [0.13–0.36]	0.11 [0.05–0.2]	0.07 [0.03–0.14]
AIDS-related deaths			
AIDS-related deaths (all ages)	720	<500	<500
	[<500–1100]	[<200–590]	[<200–520]
AIDS-related deaths (0–14)	<200	<100	<100
	[<100- <200]	[<100-<200]	[<100-<100]
AIDS-related deaths (women, 15+)	<500	<200	<200
	[<200–540]	[<100–<500]	[<100-<500]
AIDS-related deaths (men, 15+)	<500	<200	<200
	[<200–<500]	[<100-<500]	[<100-<500]
People living with HIV			
People living with HIV (all ages)	16 000	14 000	13 000
	[13 000–21 000]	[11 000–18 000]	[9600–16 000]
People living with HIV (0–14)	1600	1100	710
	[1200–2100]	[820–1500]	[<500–1000]
People living with HIV (women, 15+)	8800	7600	7100
	[6900–11 000]	[5900–10 000]	[5400–9300]
People living with HIV (men, 15+)	6000	5300	4700
	[4700–7900]	[4100–6700]	[3600–6000]
HIV prevalence (15–49)	0.9 [0.7–1.1]	0.7 [0.5–0.9]	0.5 [0.4–0.7]

Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	
Criminalization of transgender people	
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV		
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their

VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

Mandatory HIV testing for marriage, work or residence permits or for certain groups

Spousal consent for married women to access


sexual and reproductive health services

LAWS AND POLICIES

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 7 237 751 US\$ 7 237 751 Last available report: 2020


EPIDEMIC TRANSITION METRICS



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS Men who People who Transgender Sex workers Prisoners have sex inject drugs people with men Estimated size of population **HIV** prevalence 14.8% 1.4% HIV testing and status awareness Antiretroviral therapy coverage Condom use 99.5% Coverage of HIV prevention programmes Avoidance of health care because of stigma and 6% discrimination Expenditures in US\$ (2019) ...

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	27% [20–36%]	73% [50–100%]
Final vertical transmission rate including during breastfeeding	28.8% [24.1–33.5%]	19.3% [11.1–26.1%]
Early infant diagnosis	% [%]	36.7% [26–53%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	140 [59–250]
People living with HIV who started TB preventive therapy (2018)	46.5%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

THE TREVERTION	
Adults aged 15+ years with unsuppressed viral load	0.2%
Knowledge of HIV prevention among young people aged 15–24 years (2010)	
— Women	24.7%
— Men	33.8%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	

— Men

Women aged 15–49 years who have their demand for family planning satisfied by

modern methods	•••
Men aged 15–49 years who are circumcised	Not applicable

Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

Harm reduction

- Women

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapyNaloxone available (2021)
- Safe injection rooms available (2021)

ESWATINI

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	14 000	10 000	4800
	[12 000–15 000]	[9100–12 000]	[4000–5900]
New HIV infections (0–14)	1600	730	<500
	[1200–1800]	[520–950]	[<500–550]
New HIV infections (women, 15+)	7400	6100	2900
	[6400–8300]	[5300–7000]	[2400–3700]
New HIV infections (men, 15+)	4600	3500	1500
	[4000–5400]	[3000–4200]	[1300–1900]
HIV incidence per 1000 population	15.7 [13.97–17.65]	11.81 [10.26–13.64]	5.28 [4.28–6.6]
AIDS-related deaths			
AIDS-related deaths (all ages)	5100	3300	2400
	[4500–6100]	[2900–3700]	[2000–2900]
AIDS-related deaths (0–14)	1500	500	<500
	[1300–1700]	[<500 <u>–</u> 650]	[<200-<500]
AIDS-related deaths (women, 15+)	1900	1600	1200
	[1500–2300]	[1400–1800]	[970–1500]
AIDS-related deaths (men, 15+)	1700	1200	1000
	[1400–2300]	[1000–1400]	[840–1200]
People living with HIV			
People living with HIV (all ages)	170 000	200 000	200 000
	[170 000–180 000]	[180 000–210 000]	[190 000–220 000]
People living with HIV (0–14)	16 000	13 000	8700
	[14 000–17 000]	[11 000–14 000]	[7500–9700]
People living with HIV (women, 15+)	100 000	110 000	120 000
	[95 000 –1 10 000]	[110 000–120 000]	[110 000–130 000]
People living with HIV (men, 15+)	58 000	68 000	72 000
	[54 000–65 000]	[63 000–75 000]	[66 000–79 000]
HIV prevalence (15–49)	27.6 [26.9–28.3]	28.9 [28–29.6]	26.8 [25.4–28.1]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	

residence permits or for certain groups

Last available report: 2019

STIGMA AND DISCRIMINATION

years who report discriminatory attitudes towards people living with HIV	•••	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who		

reported a health-care professional told others about their HIV status without their consent

VIOLENCE


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2019	US\$ 798 545	US\$ 40 945 032	US\$ 42 866 397	US\$ 9 911 517	US\$ 1 869 459	US\$ 102 113 481

EPIDEMIC TRANSITION METRICS 20 000 20 000 12 000 20 Number of people Number of people of people 10 000 15 000 15 15 000 8 000 Percent 10 000 10 10 000 6 000 4 000 5 000 5 5 000 2 000 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 New HIV infections Incidence:prevalence ratio New HIV infections AIDS-related deaths All-cause deaths among ••••• Target the HIV population Change in AIDS-Change in new Incidence: 64% -53% **HIV** infections 2.42 1.1 related deaths prevalence mortality ratio since 2010 since 2010 ratio

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population			•••		46 800
HIV prevalence	60.8%	27.2%			
HIV testing and status awareness	100%	100%			
Antiretroviral therapy coverage					
Condom use	50%	79.6%			
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2019)	268 442				

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION 2010 2020

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	68% [59-74%]	95% [82–100%]
Final vertical transmission rate including during breastfeeding	12.9% [11.4–13.9%]	3.7% [2.7–5.4%]
Early infant diagnosis	39.2% [35.8–46.5%]	% [%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	2500 [1900 –3100]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.8%
Knowledge of HIV prevention among young people aged 15–24 years (2014)	
— Women	49.1%
— Men	50.9%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	
— Men	
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised (2019)	29.3%
Voluntary medical male circumcisions performed according to national standards (2020)	8639

Harm reduction

Use of sterile injecting equipment at last injection

9125

No

No

- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy

People who received PrEP at least once

during the reporting period (2020)

Naloxone available (2021)Safe injection rooms available (2021)

ETHIOPIA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	27 000	17 000	12 000
	[14 000–47 000]	[8800–30 000]	[6100–21 000]
New HIV infections (0–14)	8900	4500	2800
	[4500–15 000]	[2300–7700]	[1400–4700]
New HIV infections (women, 15+)	11 000	8100	6100
	[5200–20 000]	[3900–15 000]	[2900–11 000]
New HIV infections (men, 15+)	7000	4400	2900
	[3300–14 000]	[2100–8600]	[1400–5600]
HIV incidence per 1000 population	0.36 [0.19–0.65]	0.2 [0.1–0.36]	0.12 [0.06–0.21]
AIDS-related deaths			
AIDS-related deaths (all ages)	26 000	16 000	13 000
	[15 000–44 000]	[9400–27 000]	[7300–21 000]
AIDS-related deaths (0–14)	8300	3600	2000
	[4100–14 000]	[1800–6100]	[980–3300]
AIDS-related deaths (women, 15+)	11 000	7700	6200
	[5700–18 000]	[4200–13 000]	[3300–11 000]
AIDS-related deaths (men, 15+)	7300	5000	4500
	[4400–12 000]	[3000–8300]	[2700–7400]
People living with HIV			
People living with HIV (all ages)	650 000	640 000	620 000
	[520 000–790 000]	[520 000–780 000]	[500 000–760 000]
People living with HIV (0-14)	97 000	65 000	44 000
	[65 000 –1 40 000]	[43 000–90 000]	[29 000–62 000]
People living with HIV (women, 15+)	340 000	360 000	360 000
	[280 000–410 000]	[290 000–430 000]	[290 000–440 000]
People living with HIV (men, 15+)	210 000	220 000	220 000
	[170 000–250 000]	[180 000–270 000]	[180 000–260 000]
HIV prevalence (15–49)	1.4 [1.1–1.7]	1.1 [0.9–1.4]	0.9 [0.7–1.1]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, penalty not specified
Drug use or possession for personal use is an offence	Possession of drugs for personal use is specified as a criminal offence
Criminalization of transgender people	
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

residence permits or for certain groups

years who report discriminatory attitudes towards people living with HIV (2016 refers to women only)	59.9	58.5
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced		2016
physical or sexual violence from a male intimate partner in the past 12 months		19.8

2011

2016

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2019	US\$ 1 466 640	US\$ 7 718 534	US\$ 92 697 314	US\$ 76 039 344	US\$ 2 425 235	US\$ 188 670 046

EPIDEMIC TRANSITION METRICS 140 000 120 000 15 80 000 00 000 0 100 000 0 80 000 Number of people 120 000 Number of people 60 000 100 000 10 Percent 80 000 Number of 40 000 60 000 60 000 40 000 40 000 20 000 20 000 20 000 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 New HIV infections Incidence:prevalence ratio New HIV infections AIDS-related deaths All-cause deaths among • • • • • Target the HIV population Change in new Change in AIDS-Incidence: Incidence: 1.88 **HIV** infections related deaths prevalence mortality ratio*


ratio

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••			•••	
HIV prevalence					
HIV testing and status awareness					
Antiretroviral therapy coverage					
Condom use					
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2019)	3 233 249				

since 2010

HIV TESTING AND TREATMENT CASCADE

since 2010



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	25% [18–33%]	92% [66–100%]
Final vertical transmission rate including during breastfeeding	32.3% [22.4–40.9%]	15% [10.4–18.9%]
Early infant diagnosis	48.5% [36.3–69.7%]	40.9% [31.1–57.1%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	7600 [5300 –10 000]
People living with HIV who started TB preventive therapy (2018)	49.3%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	0.2%
Knowledge of HIV prevention among young people aged 15–24 years (2016)	
— Women	24.3%
— Men	39.1%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2016)	
— Women	21.3%
— Men	54%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2016)	61.3%
Men aged 15–49 years who are circumcised (2016)	91%
Voluntary medical male circumcisions performed according to national standards (2020)	34 786
People who received PrEP at least once during the reporting period (2020)	2870

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KENYA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	71 000	48 000	33 000
	[45 000–120 000]	[31 000–79 000]	[21 000–55 000]
New HIV infections (0–14)	15 000	6800	5200
	[11 000–27 000]	[4800–12 000]	[3700–9500]
New HIV infections (women, 15+)	34 000	27 000	19 000
	[21 000–57 000]	[17 000–44 000]	[12 000–32 000]
New HIV infections (men, 15+)	21 000	14 000	8900
	[13 000–37 000]	[8900–25 000]	[5500–15 000]
HIV incidence per 1000 population	1.96 [1.24–3.24]	1.18 [0.75–1.95]	0.72 [0.46–1.19]
AIDS-related deaths			
AIDS-related deaths (all ages)	53 000	33 000	19 000
	[38 000–80 000]	[24 000–50 000]	[14 000–30 000]
AIDS-related deaths (0–14)	14 000	6200	3100
	[8300–26 000]	[3800–12 000]	[1900–6000]
AIDS-related deaths (women, 15+)	25 000	12 000	7500
	[19 000–38 000]	[9400 –1 9 000]	[5700 –11 000]
AIDS-related deaths (men, 15+)	14 000	14 000	8900
	[9400–21 000]	[9700–22 000]	[6000–14 000]
People living with HIV			
People living with HIV (all ages)	1 400 000	1 400 000	1 400 000
	[1 200 000–1 600 000]	[1 200 000–1 700 000]	[1 300 000–1 700 000]
People living with HIV (0–14)	180 000	130 000	82 000
	[150 000–230 000]	[100 000–160 000]	[67 000–100 000]
People living with HIV (women, 15+)	750 000	810 000	870 000
	[650 000–880 000]	[700 000–950 000]	[750 000 –1 000 000]
People living with HIV (men, 15+)	460 000	480 000	480 000
	[410 000–540 000]	[420 000–560 000]	[420 000–570 000]
HIV prevalence (15–49)	5.7 [5–6.7]	5 [4.4–5.9]	4.2 [3.7–4.9]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

residence permits or for certain groups

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their	

VIOLENCE

consent

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 795 089 915 Last available report: 2020 US\$ 313 719 143 US\$ 74 984 891

EPIDEMIC TRANSITION METRICS 250 000 200 000 15 150 000 Number of people Number of people -200 000 150 000 10 100 000 150 000 Percent 5 100 000 100 000 5 50 000 50 000 50 000 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 New HIV infections Incidence:prevalence ratio New HIV infections AIDS-related deaths All-cause deaths among ••••• Target

Change in new
HIV infections
since 2010

-53%

Change in AIDS-related deaths = -63% since 2010

Incidence:
prevalence = 2.33
ratio


Incidence: and the HIV population

Incidence: and the HIV population

Incidence: and the HIV population

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence					
HIV testing and status awareness	95.5%		94.0%		
Antiretroviral therapy coverage	73%	62.8%	67.6%		
Condom use	92%		75.9%		
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2020)	4 694 344	2 807 712	2 756 462		

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	55% [43–68%]	94% [74–100%]
Final vertical transmission rate including during breastfeeding	19.7% [15.7–28.5%]	9.7% [7.7–13.9%]
Early infant diagnosis	65.8% [54.4–85.2%]	76% [61.4- >95%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	40 000 [25 000 –60 000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

HIV PREVENTION	·
Adults aged 15+ years with unsuppressed viral load	0.9%
Knowledge of HIV prevention among young people aged 15–24 years (2014)	
— Women	56.6%
— Men	63.7%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2014)	
— Women	40%
— Men	44.5%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised (2014)	92.6%
Voluntary medical male circumcisions performed according to national standards (2020)	77 120
People who received PrEP at least once during the reporting period (2020)	52 229
Harm reduction	
 Use of sterile injecting equipment at last injection (2017) 	88.4%

- Needles and syringes distributed per

- Safe injection rooms available (2021)

person who injects (2018)

— Coverage of opioid substitution

therapy (2020)

— Naloxone available (2021)

137

9.7%

Yes

No

LESOTHO

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	19 000	14 000	7700
	[16 000–22 000]	[12 000–17 000]	[6300–9800]
New HIV infections (0–14)	1700	690	<500
	[1300–2100]	[630–860]	[<500–710]
New HIV infections (women, 15+)	9800	8000	4600
	[8100–12 000]	[6700–9600]	[3700–5700]
New HIV infections (men, 15+)	7200	5200	2700
	[6000–9500]	[4300–6600]	[2100–3600]
HIV incidence per 1000 population	12.05 [10.23–14.52]	8.95 [7.39–10.88]	4.91 [4.04–6.38]
AIDS-related deaths			
AIDS-related deaths (all ages)	7700	7100	4700
	[6300–10 000]	[5600–10 000]	[3800–6100]
AIDS-related deaths (0–14)	1500	850	<500
	[1200–1800]	[720–1100]	[<500–570]
AIDS-related deaths (women, 15+)	3300	3000	2200
	[2500–4500]	[2200–4400]	[1800–2900]
AIDS-related deaths (men, 15+)	2900	3300	2100
	[2300–4900]	[2600–5300]	[1700–2800]
People living with HIV			
People living with HIV (all ages)	280 000	290 000	280 000
	[260 000–310 000]	[270 000–330 000]	[260 000–310 000]
People living with HIV (0–14)	21 000	14 000	8700
	[18 000–23 000]	[12 000–16 000]	[7500–10 000]
People living with HIV (women, 15+)	150 000	170 000	170 000
	[140 000–170 000]	[160 000–190 000]	[150 000–190 000]
People living with HIV (men, 15+)	100 000	110 000	110 000
	[95 000– 1 20 000]	[100 000–130 000]	[99 000–120 000]
HIV prevalence (15–49)	24 [23.3–24.9]	24.1 [23.4–24.8]	21.1 [20.3–21.9]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

residence permits or for certain groups

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49

years who report discriminatory attitudes towards people living with HIV		
	•••	•••
Percentage of people living with HIV denied		2013
the last 12 months		4
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their		2013
consent		3.7


VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


Last available report: 2017 US\$ 20 847 761 US\$ 62 306 071 US\$ 24 636 737 US\$ 144 355 US\$ 110 299 410

EPIDEMIC TRANSITION METRICS



KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population			•••	•••	•••	
HIV prevalence					31.4%	
HIV testing and status awareness	63.8%	82.2%				
Antiretroviral therapy coverage					80.1%	
Condom use	62.3%	46.4%				
Coverage of HIV prevention programmes						
Avoidance of health care because of stigma and discrimination	8%	8%				
Expenditures in US\$ (2017)	547 721	303 215				

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	74% [62–85%]	96% [78–100%]
Final vertical transmission rate including during breastfeeding	15.6% [13.9–17.1%]	6% [4.8–8.1%]
Early infant diagnosis	87.1% [75.5- >95%]	71.2% [62.6–87.1%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	8400 [5400 –12 000]
People living with HIV who started TB preventive therapy (2018)	33%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	4.4%
Knowledge of HIV prevention among young people aged 15–24 years (2014)	
— Women	37.6%
— Men	30.9%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2014)	
— Women	76%
— Men	76.6%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised (2019)	68.5%
2 2	9802

Harm reduction

— Use of sterile injecting equipment at
last injection

_	Needles and syri	nges c	distributed	per
	person who injec	ts		

 Coverage of opioid substitution
therapy
— Naloxone available (2021)

— Safe injection rooms available (2021)

MADAGASCAR

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	2300	4400	6000
	[1800–2900]	[3400–5500]	[4200–9300]
New HIV infections (0–14)	<500	<500	580
	[<200- <500]	[<500–510]	[<500–810]
New HIV infections (women, 15+)	960	1800	2500
	[720–1200]	[1400–2400]	[1700–3800]
New HIV infections (men, 15+)	1100	2200	2900
	[890–1500]	[1600–2800]	[2000–4600]
HIV incidence per 1000 population	0.11 [0.09–0.14]	0.19 [0.15–0.23]	0.22 [0.16–0.35]
AIDS-related deaths			
AIDS-related deaths (all ages)	<500	1100	1800
	[<500–640]	[830–1400]	[1400–2400]
AIDS-related deaths (0–14)	<200	<500	<500
	[<100- <200]	[<200-<500]	[<500-<500]
AIDS-related deaths (women, 15+)	<200	<500	590
	[<200– <500]	[<500– <500]	[<500–800]
AIDS-related deaths (men, 15+)	<500	<500	830
	[<200-<500]	[<500–660]	[620–1100]
People living with HIV			
People living with HIV (all ages)	11 000	24 000	42 000
	[8500–15 000]	[20 000–31 000]	[34 000–56 000]
People living with HIV (0–14)	590	1200	2100
	[<500–750]	[960–1500]	[1700–2700]
People living with HIV (women, 15+)	5000	11 000	19 000
	[3500–6400]	[8400–13 000]	[15 000–24 000]
People living with HIV (men, 15+)	5800	12 000	21 000
	[4400–7500]	[9800–16 000]	[17 000–28 000]
HIV prevalence (15–49)	0.1 [<0.1–0.1]	0.2 [0.1–0.2]	0.3 [0.2–0.4]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

residence permits or for certain groups

STIGN	1A AN	ND DI	ISCRII	TANIN	TON

Percentage of women aged 15–49 years who report discriminatory attitudes towards	 2018
people living with HIV	 72.2
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	


Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent


VIOLENCE


Proportion of ever-married or partnered	2018
women aged 15-49 years who experienced	
physical or sexual violence from a male	
intimate partner in the past 12 months	16


EXPENDITURES								
Financing sources								
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total		
Last available report: 2019	US\$ 3	US\$ 1652		US\$ 1553	US\$ 183	US\$ 3919		

EPIDEMIC TRANSITION METRICS









Change in new
HIV infections = 159%
since 2010

Change in AIDS-related deaths = 264% since 2010

Incidence:
prevalence = 14.16
ratio


Incidence: mortality ratio*

* The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population				•••	
HIV prevalence	5.5%		8.5%		0.3%
HIV testing and status awareness	100%**	100%**	100%**		
Antiretroviral therapy coverage					
Condom use	62.8%	57.2%	41.8%		
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2017)	198 919	105 376	14 599		

^{**} Programme data—not representative; includes people with negative results.

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	4% [3–5%]	17% [13–23%]
Final vertical transmission rate including during breastfeeding	45.2% [42.4–48.2%]	38.6% [36.1–41.9%]
Early infant diagnosis	% [–%]	% [%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	960 [610–1400]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2015)	
— Women	22.9%
— Men	25.5%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	
— Men	
Women aged 15–49 years who have their	

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

demand for family planning satisfied by

Harm reduction

 Use of sterile injecting equipment at last injection (2016) 	68.4%
 Needles and syringes distributed per person who injects (2019) 	113
 Coverage of opioid substitution therapy 	
— Naloxone available (2021)	No
— Safe injection rooms available (2021)	No

MALAWI

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	57 000	37 000	21 000
	[50 000–65 000]	[32 000–45 000]	[16 000–27 000]
New HIV infections (0–14)	15 000	6300	2500
	[13 000–18 000]	[4000–8000]	[2100–3300]
New HIV infections (women, 15+)	24 000	20 000	12 000
	[21 000–30 000]	[17 000–24 000]	[9400–16 000]
New HIV infections (men, 15+)	17 000	11 000	5800
	[14 000–21 000]	[9200–14 000]	[4300–7700]
HIV incidence per 1000 population	4.25 [3.78–4.92]	2.49 [2.14–2.99]	1.21 [0.94–1.57]
AIDS-related deaths			
AIDS-related deaths (all ages)	39 000	19 000	12 000
	[34 000–47 000]	[16 000–25 000]	[10 000–15 000]
AIDS-related deaths (0–14)	12 000	4700	1800
	[10 000–14 000]	[3400–5800]	[1500–2200]
AIDS-related deaths (women, 15+)	16 000	7400	5200
	[12 000–20 000]	[6100–11 000]	[4400–6900]
AIDS-related deaths (men, 15+)	11 000	6900	4600
	[9200–15 000]	[5400–10 000]	[3900–6700]
People living with HIV			
People living with HIV (all ages)	930 000	970 000	990 000
	[880 000–990 000]	[920 000–1 100 000]	[930 000 –1 100 000]
People living with HIV (0-14)	130 000	98 000	62 000
	[120 000–140 000]	[83 000–110 000]	[52 000–71 000]
People living with HIV (women, 15+)	490 000	550 000	600 000
	[460 000–540 000]	[520 000–600 000]	[560 000–650 000]
People living with HIV (men, 15+)	300 000	320 000	330 000
	[280 000–330 000]	[300 000–360 000]	[310 000–360 000]
HIV prevalence (15–49)	10.7 [10.2–11.1]	9.7 [9.3–10]	8.1 [7.6–8.5]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No, but prosecutions exist based on general criminal laws
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Criminalized
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

STIGMA AND DISCRIMINATION	N	
Percentage of women and men aged 15–49 years who report discriminatory attitudes	2010	2016
towards people living with HIV (2016 refers to women only)	16.5	17.6
Percentage of people living with HIV denied health services because of their HIV status in		2016
the last 12 months		1.7
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their		2016
consent		6.1
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male	2010	2016
intimate partner in the past 12 months	22.1	24.3

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


... US\$ 216 957 062 US\$ 23 001 US\$ 119 153 648 Last available report: 2020

EPIDEMIC TRANSITION METRICS 120 000 100 000 12 100 000 120 000 ed 100 000 80 000 60 000 40 000 20 000 0 Number of people Number of people 10 80 000 80 000 8 60 000 60 000 6 40 000 40 000 4 20 000 20 000 2 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 New HIV infections Incidence:prevalence ratio New HIV infections AIDS-related deaths All-cause deaths among • • • • • Target the HIV population Change in AIDS-Change in new Incidence: -70% -64% 2.08 1.1 **HIV** infections related deaths prevalence mortality ratio since 2010 since 2010 ratio

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	36 100				14 000
HIV prevalence	49.9%	12.9%			19%
HIV testing and status awareness	99.2%	79.4%		80.8%**	
Antiretroviral therapy coverage	90.7%	85.5%		91.5%	100%
Condom use	65%	79.4%			
Coverage of HIV prevention programmes	68%	65%			
Avoidance of health care because of stigma and discrimination	49%	12.9%			
Expenditures in US\$ (2020)	14 392	54 520			

^{**} Programme data—not representative; includes people with negative results.

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	27% [22–30%]	100% [84–100%]
Final vertical transmission rate including during breastfeeding	29.9% [28.6–31.1%]	6.3% [5.5–7.4%]
Early infant diagnosis	% [%]	78.6% [70.7- >95%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	16 000 [9900 –23 000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV (2016)	18.7%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	1.5%
Knowledge of HIV prevention among young people aged 15–24 years (2016)	
— Women	41.1%
— Men	44.3%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2016)	
— Women	49.9%
— Men	76.3%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2016)	73.9%
Men aged 15–49 years who are circumcised (2016)	27.8%
Voluntary medical male circumcisions performed according to national standards (2020)	47 316
People who received PrEP at least once during the reporting period (2019)	459
Harm reduction	
 Use of sterile injecting equipment at last injection 	

- Needles and syringes distributed per

- Safe injection rooms available (2021)

No

No

— Coverage of opioid substitution

— Naloxone available (2021)

person who injects

therapy

MAURITIUS

COUNTRY DATA

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	1300	990	980	
	[1100–1500]	[760–1200]	[640–1400]	
New HIV infections (0–14)	<100	<100	<100	
	[<100–<100]	[<100-<100]	[<100-<100]	
New HIV infections (women, 15+)	<500	<500	<500	
	[<500– <500]	[<500–<500]	[<200-<500]	
New HIV infections (men, 15+)	880	680	670	
	[700–1100]	[510–850]	[<500–980]	
HIV incidence per 1000 population	1.07 [0.88–1.27]	0.81 [0.62–0.99]	0.8 [0.52–1.13]	
AIDS-related deaths				
AIDS-related deaths (all ages)	620	660	820	
	[<500–810]	[560–880]	[720–1000]	
AIDS-related deaths (0–14)	<100	<100	<100	
	[<100– <100]	[<100-<100]	[<100-<100]	
AIDS-related deaths (women, 15+)	<500	<500	<500	
	[<200– <500]	[<200–<500]	[<200-<500]	
AIDS-related deaths (men, 15+)	<500	<500	570	
	[<500–550]	[<500–600]	[<500–760]	
People living with HIV				
People living with HIV (all ages)	12 000	14 000	14 000	
	[11 000–14 000]	[12 000–16 000]	[12 000–16 000]	
People living with HIV (0–14)	<200	<200	<100	
	[<100- <200]	[<100–<200]	[<100-<200]	
People living with HIV (women, 15+)	3800	4100	4200	
	[3200–4200]	[3400–4500]	[3500–4900]	
People living with HIV (men, 15+)	8300	9300	9500	
	[7300–9900]	[8200–11 000]	[8100–11 000]	
HIV prevalence (15–49)	1.6 [1.5–1.7]	1.7 [1.6–1.8]	1.7 [1.5–1.8]	

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	Yes
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes

residence permits or for certain groups

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49

years who report discriminatory attitudes towards people living with HIV	
Percentage of people living with HIV denied	2013
the last 12 months	28.9
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their	2013
consent	27.9


VIOLENCE

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 1 675 382 US\$ 7 524 015 Last available report: 2010 US\$ 265 468 US\$ 4 894 627 US\$ 397 312


EPIDEMIC TRANSITION METRICS



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population				•••	
HIV prevalence			32.3%	28.4%	17.3%
HIV testing and status awareness	78.9%	86.6%	71.1%		
Antiretroviral therapy coverage			51.7%		79.1%
Condom use			45.4%	45.4%	
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	65% [55–71%]	100% [100–100%]
Final vertical transmission rate including during breastfeeding	22.7% [20.6–23.9%]	13% [11.6–14.5%]
Early infant diagnosis	% [–%]	63.5% [56.3–80.6%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	36 [22–53]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	17.7%

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	1.1%
Knowledge of HIV prevention among young people aged 15–24 years (2014)	
— Women	4.4%
— Men	30%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	
— Men	

Women aged 15-49 years who have their

demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2018)	3
Harm reduction	
 Use of sterile injecting equipment at last injection (2017) 	92.2%
 Needles and syringes distributed per person who injects (2018) 	89

53.6%

— Coverage of opioid substitution

- Safe injection rooms available (2021)

therapy (2018) — Naloxone available (2021)

MOZAMBIQUE

COUNTRY DATA

	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	150 000	120 000	98 000
	[85 000–240 000]	[72 000–200 000]	[57 000–160 000]
New HIV infections (0–14)	29 000	16 000	13 000
	[19 000–51 000]	[10 000–27 000]	[8300–22 000]
New HIV infections (women, 15+)	69 000	67 000	55 000
	[40 000–110 000]	[39 000 –1 10 000]	[32 000–90 000]
New HIV infections (men, 15+)	48 000	41 000	30 000
	[27 000–80 000]	[23 000–69 000]	[17 000–50 000]
HIV incidence per 1000 population	6.92 [3.97–11.65]	5.11 [2.93–8.61]	3.5 [2–5.88]
AIDS-related deaths			
AIDS-related deaths (all ages)	65 000	50 000	38 000
	[47 000–92 000]	[36 000–70 000]	[27 000–53 000]
AIDS-related deaths (0–14)	18 000	10 000	6800
	[10 000–34 000]	[5800–19 000]	[3900–13 000]
AIDS-related deaths (women, 15+)	28 000	21 000	15 000
	[21 000–40 000]	[15 000–29 000]	[11 000–21 000]
AIDS-related deaths (men, 15+)	19 000	19 000	16 000
	[14 000–26 000]	[14 000–26 000]	[11 000–22 000]
People living with HIV			
People living with HIV (all ages)	1 500 000	1 800 000	2 100 000
	[1 200 000–1 900 000]	[1 500 000–2 200 000]	[1 700 000–2 500 000]
People living with HIV (0–14)	150 000	140 000	130 000
	[120 000–210 000]	[110 000–200 000]	[100 000–170 000]
eople living with HIV (women, 15+)	830 000	1 000 000	1 200 000
	[670 000 –1 000 000]	[830 000 –1 300 000]	[990 000–1 500 000]
People living with HIV (men, 15+)	520 000	630 000	710 000
	[420 000–650 000]	[510 000–780 000]	[570 000–880 000]
HIV prevalence (15–49)	11.8 [9.5–14.8]	12 [9.6–15.1]	11.5 [9.2–14.4]


LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Sex work is not subject to punitive regulations or is not criminalized
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

STIGMA AND DISCRIMINATION	ON	
Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	2011	2015
(2015 refers to women only)	28	20.7
Percentage of people living with HIV denied		2013
the last 12 months		3.4
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male	2011	2015
intimate partner in the past 12 months	27.7	15.5

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 370 271 108 US\$ 78 547 589 US\$ 13 797 988 US\$ 557 780 695 Last available report: 2019


EPIDEMIC TRANSITION METRICS



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence					
HIV testing and status awareness					
Antiretroviral therapy coverage					
Condom use					
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2019)	144 055	227 062			184 300

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	25% [18–34%]	100% [82–100%]
Final vertical transmission rate including during breastfeeding	33.5% [27.6–43.8%]	13.5% [11.1–17.6%]
Early infant diagnosis	36.4% [27.2–51%]	82.9% [62.1- >95%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	58 000 [38 000 -83 000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	5%
Knowledge of HIV prevention among young people aged 15–24 years (2015)	
— Women	30.8%
— Men	30.2%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2015)	
— Women	42%
— Men	46.5%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2015)	55.5%
Men aged 15–49 years who are circumcised (2011)	47.4%
Voluntary medical male circumcisions performed according to national standards 2020)	113 227
People who received PrEP at least once during the reporting period (2020)	18 513
Harman and seather	


Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

NAMIBIA

New HIV infections (all ages)	EPIDEMIC ESTIMATES			
New HIV infections (all ages)		2010	2015	2020
New HIV infections (all ages) (9500-12 000) (7300-10 000) (4600-6700) (4600-6700) (1500	New HIV infections			
	New HIV infections (all ages)			
Alex HIV infections (women, 15+) [4700–6700] [4300–6200] [2800–4200] [2800–4200] [3100–4700] [2400–3800] [1400–2300] [14000–23000] [14000–23000] [14000–23000] [14000–23000] [14000–23000] [14000–23000] [14000–23000] [14000–13000] [12000–23000] [12000–13000] [12000–13000] [12000–1400	New HIV infections (0–14)			
	lew HIV infections (women, 15+)			
AIDS-related deaths 3600 2900 3000 2500–3600 25000–3600 2500000 250000 2500000 250000 2500000 2500000 2500000 2500000	New HIV infections (men, 15+)			
AIDS-related deaths (all ages) 3600 2900 3000 [2500–3600] [2500–3600] [2500–3600] AIDS-related deaths (0–14) 770 560 <500 [760–1200] [760–1200] [760–1200] [1200–2000] [1000–1700] [1200–1700] [1200–1900] AIDS-related deaths (men, 15+) 1100 1100 1200 [930–1600] [900–1500] [900–1500] People living with HIV People living with HIV (all ages) 180 000 200 000 210 000 [170 000–220 000] [170 000–220 000] [170 000–220 000] [170 000–220 000] [170 000–1500	-IIV incidence per 1000 population	5.66 [5.03–6.73]	4.11 [3.58–5.05]	2.44 [2.02–3.03]
State Stat	AIDS-related deaths			
Tool	AIDS-related deaths (all ages)			
1200-2000 1000-1700 1200-1900 1200-1900 1100 1200 1200 1100 1200	AIDS-related deaths (0–14)			
People living with HIV	AIDS-related deaths (women, 15+)			
180 000 200 000 210	AIDS-related deaths (men, 15+)			
170 000-200 000 190 000-220 000 190 000-230 000 190 000-230 000 16 000	eople living with HIV			
People living with HIV (0-14) [14 000-17 000] [11 000-15 000] [7300-9300] People living with HIV (women, 15+) 100 000 120 000 130 000 People living with HIV (men, 15+) 63 000 68 000 71 000 People living with HIV (men, 15+) 63 000 68 000 71 000 People living with HIV (men, 15+) 63 000-71 000] [64 000-76 000] [66 000-80 000]	eople living with HIV (all ages)			
People living with HIV (women, 15+) [97 000–110 000] [110 000–130 000] [120 000–140 000] People living with HIV (men, 15+) 63 000 68 000 71 000 [58 000–71 000] [64 000–76 000] [66 000–80 000]	eople living with HIV (0–14)			
eople living with HIV (men, 15+) [58 000–71 000] [64 000–76 000] [66 000–80 000]	eople living with HIV (women, 15+)			
	eople living with HIV (men, 15+)			
IIV prevalence (15–49) 13.3 [12.8–13.9] 12.7 [12.2–13.3] 11.6 [11–12.3]	HIV prevalence (15–49)	13.3 [12.8–13.9]	12.7 [12.2–13.3]	11.6 [11–12.3]








Last available report: 2016 US\$ 3 365 760 US\$ 96 140 893 US\$ 48 941 066 US\$ 13 271 251 ... US\$ 162 654 206

COUNTRY DATA

HIV TESTING AND TREATMENT CASCADE



All ages	90% [84–99%]	88% [82–97%] 181 696	80% [75–88%]
Children (0-14)	81% [70–89%]	75% [65–82%] 6290	60% [52–67%]
Women (15+)	92% [86–102%]	92% [86–102%] 117 164	85% [80–95%]
Men (15+)	87% [81–97%]	82% [76–91%] 58 242	73% [68–81%]

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION		
	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	68% [58–77%]	100% [100–100%]
Final vertical transmission rate including during breastfeeding	13.1% [11.5–14.5%]	3.8% [3.5–4.4%]
Early infant diagnosis	41.9% [36.8–50.6%]	>95% [>95– >95%]

RWANDA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	9600	5800	4200
	[8100–13 000]	[4600–8000]	[3000–6300]
New HIV infections (0–14)	2400	740	510
	[1800–2900]	[630–1100]	[<500–850]
New HIV infections (women, 15+)	4100	3200	2500
	[3300–5400]	[2500–4400]	[1700–3700]
New HIV infections (men, 15+)	3100	1800	1200
	[2500–4600]	[1400–2900]	[830–1900]
HIV incidence per 1000 population	1.02 [0.86–1.35]	0.53 [0.42–0.74]	0.34 [0.24–0.51]
AIDS-related deaths			
AIDS-related deaths (all ages)	5900	3600	2500
	[4700–7600]	[3100–4800]	[2100–3300]
AIDS-related deaths (0–14)	1900	780	<500
	[1600–2200]	[610–1000]	[<500–590]
AIDS-related deaths (women, 15+)	2000	1400	1000
	[1400–2800]	[1200–1900]	[850–1400]
AIDS-related deaths (men, 15+)	2100	1400	1100
	[1500–3100]	[1100–2300]	[880–1500]
People living with HIV			
People living with HIV (all ages)	210 000	220 000	220 000
	[200 000–230 000]	[200 000–240 000]	[200 000–250 000]
People living with HIV (0–14)	28 000	20 000	12 000
	[25 000–32 000]	[17 000–23 000]	[9500–15 000]
eople living with HIV (women, 15+)	110 000	120 000	130 000
	[100 000–120 000]	[110 000–130 000]	[120 000–150 000]
eople living with HIV (men, 15+)	74 000	78 000	80 000
	[69 000–85 000]	[72 000–90 000]	[74 000–91 000]
HIV prevalence (15–49)	3.3 [3.1–3.5]	2.9 [2.7–3.1]	2.5 [2.3–2.7]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	
Spousal consent for married women to access sexual and reproductive health services	
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

residence permits or for certain groups

Percentage of women and men aged 15–49 years who report discriminatory attitudes	2010	2015
towards people living with HIV (2015 refers to women only)	14.4	9.9
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		•••
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their		•••

STIGMA AND DISCRIMINATION

VIOLENCE Proportion of ever-married or partnered 2010 2015 women aged 15-49 years who experienced physical or sexual violence from a male

intimate partner in the past 12 months

44.3

20.6

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2015		US\$ 19 877 495	US\$ 97 029 539	US\$ 95 605 601	US\$ 5 077 320	US\$ 217 589 955

consent

EPIDEMIC TRANSITION METRICS 30 000 25 000 15 25 000 Number of people 25 000 Number of people 20 000 20 000 20 000 10 15 000 Percent 15 000 5 15 000 10 000 10 000 10 000 5 5 000 5 000 5 000 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 New HIV infections Incidence:prevalence ratio New HIV infections AIDS-related deaths

Change in new
HIV infections
since 2010 = -56%

Change in AIDS-related deaths = -59% since 2010

Incidence:
prevalence = 1.90
ratio

• • • • • Target

2000 2005 2010 2015 202


New HIV infections

All-cause deaths among the HIV population

Incidence: mortality ratio = 1.2

KEY POPULATIONS Men who People who Transgender Sex workers Prisoners have sex inject drugs people with men Estimated size of population 13 700 ... **HIV** prevalence 35.5% 4% HIV testing and status 77.2% 83.0% awareness 36.3% Antiretroviral therapy coverage 54.9% 82% Condom use Coverage of HIV prevention programmes Avoidance of health care because of stigma and discrimination Expenditures in US\$ (2015) 218 310 240 246 ...

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	59% [50–68%]	98% [82–100%]
Final vertical transmission rate including during breastfeeding	20.2% [18–22.2%]	6.4% [5.4–9.1%]
Early infant diagnosis	64.2% [54.7–82.2%]	85.5% [74.8- >95%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	1500 [1100 –1900]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	0.2%
Knowledge of HIV prevention among young people aged 15–24 years (2015)	
— Women	64.6%
— Men	64.3%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2015)	
— Women	47.5%
— Men	65.9%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2015)	63.9%
Men aged 15–49 years who are circumcised (2015)	29.6%
Voluntary medical male circumcisions performed according to national standards (2020)	471 926
People who received PrEP at least once during the reporting period (2020)	4307


Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)— Safe injection rooms available (2021)

SEYCHELLES

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					300
HIV prevalence			23%		4.8%
HIV testing and status awareness	98.1%		3.8%		
Antiretroviral therapy coverage			42%		
Condom use			44.1%		
Coverage of HIV prevention programmes			75.4%		
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2019)		572	63 508		1353

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	1 [0–5]
People living with HIV who started TB preventive therapy (2018)	
Women who tested positive for HIV among those screened for cervical cancer (programme data) (2019)	100%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	10%

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

Women		
— Men		

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	3
Harm reduction	

 Use of sterile injecting equipment at last injection (2017) 	58.5%
— Needles and syringes distributed per	10

person who injects (2020)	
 Coverage of opioid substitution therapy (2020) 	86%
— Naloxone available (2021)	

• • •	
 Safe injection rooms available (2021) 	

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020		US\$ 1 927 143				US\$ 2 136 667

COUNTRY DATA

LAWS AND POLICIES		STIGMA AND DISCRIMINATIO	N
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission		Percentage of women and men aged 15–49 years who report discriminatory attitudes	
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work	towards people living with HIV	
Criminalization of same-sex sexual acts	No specific legislation	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Drug use or possession for personal use is an offence		Percentage of people living with HIV who reported a health-care professional told	
Criminalization of transgender people	Neither criminalized nor prosecuted	others about their HIV status without their consent	
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE	
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years	Proportion of ever-married or partnered women aged 15–49 years who experienced	2016
Spousal consent for married women to access sexual and reproductive health services	smission Any criminalization or punitive regulation of sex work Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of the last 12 months Percentage of people living with health services because of	physical or sexual violence from a male intimate partner in the past 12 months	53.4
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No		

SOUTH AFRICA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	420 000	310 000	230 000
	[270 000–570 000]	[200 000–420 000]	[150 000–310 000]
New HIV infections (0–14)	45 000	17 000	12 000
	[28 000–77 000]	[9900–30 000]	[6900–31 000]
New HIV infections (women, 15+)	230 000	180 000	140 000
	[140 000–300 000]	[120 000–240 000]	[93 000–190 000]
New HIV infections (men, 15+)	150 000	110 000	77 000
	[92 000–210 000]	[71 000–160 000]	[48 000–110 000]
HIV incidence per 1000 population	9.56 [5.82–13.41]	6.65 [4.04–9.3]	4.6 [2.78–6.43]
AIDS-related deaths			
AIDS-related deaths (all ages)	160 000	93 000	83 000
	[72 000–260 000]	[40 000 –1 70 000]	[43 000 –1 50 000]
AIDS-related deaths (0–14)	22 000	5700	3900
	[11 000–37 000]	[2100–11 000]	[1200–11 000]
AIDS-related deaths (women, 15+)	71 000	38 000	29 000
	[30 000 –1 20 000]	[18 000–72 000]	[16 000–54 000]
AIDS-related deaths (men, 15+)	71 000	49 000	49 000
	[31 000–110 000]	[20 000–88 000]	[22 000–89 000]
People living with HIV			
People living with HIV (all ages)	5 800 000	7 000 000	7 800 000
	[3 700 000–7 800 000]	[4 500 000–9 200 000]	[5 200 000–10 000 000]
People living with HIV (0-14)	360 000	380 000	310 000
	[220 000–520 000]	[230 000–570 000]	[200 000–540 000]
People living with HIV (women, 15+)	3 400 000	4 200 000	4 800 000
	[2 100 000–4 400 000]	[2 700 000–5 400 000]	[3 200 000–6 100 000]
People living with HIV (men, 15+)	2 100 000	2 500 000	2 700 000
	[1 300 000–2 900 000]	[1 600 000–3 200 000]	[1 800 000–3 400 000]
HIV prevalence (15–49)	17.7 [11.1–23.4]	19.2 [12.3–25]	19.1 [12.1–24.7]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No, but prosecutions exist based on general criminal laws
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	Possession of drugs for personal use is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No


Percentage of women aged 15–49 years who report discriminatory attitudes towards	•••	2017
people living with HIV		16.9
Percentage of people living with HIV denied		2014
the last 12 months		3.2
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced	2012	2017
physical or sexual violence from a male intimate partner in the past 12 months	5.1	30.3


STIGMA AND DISCRIMINATION


EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


US\$ 87 187 US\$ 1 917 857 763 US\$ 453 231 491 US\$ 130 242 218 US\$ 150 370 US\$ 2 501 569 030 Last available report: 2018

EPIDEMIC TRANSITION METRICS









Change in new HIV infections = -45% since 2010

Change in AIDSrelated deaths since 2010 = -50% Incidence:
prevalence = 2.98
ratio

Incidence: mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population		309 700			166 400	
HIV prevalence		18.1%	21.8%		11.1%	
HIV testing and status awareness	81.0%	66.0%	79.8%			
Antiretroviral therapy coverage	46.8%	69%	40.5%		98.8%	
Condom use		71.8%	57.1%			
Coverage of HIV prevention programmes						
Avoidance of health care because of stigma and discrimination						
Expenditures in US\$ (2018)	11 641 615	6 154 774	1 107 517	424 143	5 577 758	

HIV ($\boldsymbol{\sim}$	\smallfrown	ΠV	П	\smallfrown	D	D	П	1	EG
THE V	U	U	LL.	Ш	U	LV.	D	علا	ш	

Estimated number of incident tuberculosis cases among people living with HIV (2018)	177 000 [127 000 –235 000]
People living with HIV who started TB preventive therapy (2018)	65%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	5.8%
Knowledge of HIV prevention among young people aged 15–24 years (2016)	
— Women	46.1%
— Men	45.6%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2016)	
— Women	61.4%
— Men	73.1%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2016)	79.7%
Men aged 15–49 years who are circumcised	
Voluntary medical male circumcisions performed according to national standards (2020)	164 499

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	71% [43–100%]	97% [60–100%]		
Final vertical transmission rate including during breastfeeding	15.3% [14–18.7%]	3.9% [3.2–7.5%]		
Early infant diagnosis	60.7% [50.3–82.5%]	86.8% [66.9- >95%]		

Harm reduction

People who received PrEP at least once

during the reporting period (2020)

Use of sterile injecting equipment at last injection	
 Needles and syringes distributed per person who injects (2020) 	36
 Coverage of opioid substitution therapy (2020) 	0.7%
— Naloxone available (2021)	Yes
— Safe injection rooms available (2021)	No

106 401

SOUTH SUDAN

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	15 000	16 000	17 000
	[11 000–20 000]	[12 000–21 000]	[12 000–25 000]
New HIV infections (0–14)	3200	2700	3000
	[2400–4300]	[1800–3800]	[1900–4200]
New HIV infections (women, 15+)	6800	8400	9300
	[5200–9000]	[6000–11 000]	[6300–13 000]
New HIV infections (men, 15+)	5100	5300	5100
	[3800–6900]	[3800–7000]	[3400–7400]
HIV incidence per 1000 population	1.41 [1.07–1.85]	1.36 [0.97–1.77]	1.37 [0.92–1.95]
AIDS-related deaths			
AIDS-related deaths (all ages)	10 000	10 000	8900
	[7400–14 000]	[7200–13 000]	[6000–12 000]
AIDS-related deaths (0–14)	2300	2100	2000
	[1700–3100]	[1500–2800]	[1300–2800]
AIDS-related deaths (women, 15+)	4700	4300	3900
	[3200–6100]	[3000–5800]	[2600–5600]
AIDS-related deaths (men, 15+)	3400	3600	3000
	[2400–4600]	[2600–4900]	[2000–4200]
People living with HIV			
People living with HIV (all ages)	140 000	160 000	180 000
	[110 000–180 000]	[120 000–200 000]	[140 000–230 000]
People living with HIV (0–14)	17 000	17 000	16 000
	[13 000–23 000]	[13 000–22 000]	[11 000–21 000]
People living with HIV (women, 15+)	72 000	85 000	100 000
	[56 000–93 000]	[66 000–110 000]	[78 000–130 000]
People living with HIV (men, 15+)	52 000	57 000	63 000
	[40 000–66 000]	[45 000–73 000]	[48 000–79 000]
HIV prevalence (15–49)	2.2 [1.7–2.8]	2.2 [1.7–2.8]	2.3 [1.8–2.9]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

residence permits or for certain groups

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	•••
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent	


VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

Last available report: 2015 US\$ 9 521 814 US\$ 15 522 478 US\$ 25 044 292


EPIDEMIC TRANSITION METRICS



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence	16%				
HIV testing and status awareness	76.3%				
Antiretroviral therapy coverage	75.3%				
Condom use	43.7%				
Coverage of HIV prevention programmes	16.3%				
Avoidance of health care because of stigma and discrimination	12.1%				
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	8% [6–11%]	44% [31–57%]
Final vertical transmission rate including during breastfeeding	39.7% [36.4–42.9%]	29.3% [25.4–33.2%]
Early infant diagnosis	% [–%]	11% [8.5–15.6%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	1900 [1200 –2800]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load

Knowledge of HIV prevention among young people aged 15–24 years (2010)

— Women	9.8%
— Men	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

— Women

— Men

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15-49 years who are circumcised

Voluntary medical male circumcisions	
performed according to national standards	1453
(2019)	

People who received PrEP at least once during the reporting period

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

UGANDA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	94 000	66 000	38 000
	[85 000–110 000]	[58 000–80 000]	[31 000–48 000]
New HIV infections (0–14)	23 000	11 000	5300
	[19 000–26 000]	[10 000–12 000]	[4300–8100]
New HIV infections (women, 15+)	42 000	34 000	21 000
	[36 000–50 000]	[29 000–42 000]	[17 000–28 000]
New HIV infections (men, 15+)	29 000	20 000	11 000
	[25 000–37 000]	[17 000–28 000]	[8900–16 000]
HIV incidence per 1000 population	3.35 [3.04–3.9]	1.99 [1.75–2.43]	0.95 [0.78–1.22]
AIDS-related deaths			
AIDS-related deaths (all ages)	56 000	32 000	22 000
	[50 000–65 000]	[27 000–41 000]	[20 000–27 000]
AIDS-related deaths (0–14)	17 000	9100	4300
	[15 000–19 000]	[7800–10 000]	[3300–6200]
AIDS-related deaths (women, 15+)	24 000	11 000	9100
	[20 000–28 000]	[8400 –1 4 000]	[7800–11 000]
AIDS-related deaths (men, 15+)	15 000	13 000	9000
	[13 000–19 000]	[10 000–17 000]	[7800 –1 1 000]
People living with HIV			
People living with HIV (all ages)	1 200 000	1 300 000	1 400 000
	[1 100 000–1 300 000]	[1 200 000–1 400 000]	[1 300 000–1 600 000]
People living with HIV (0–14)	160 000	130 000	98 000
	[140 000–180 000]	[120 000–140 000]	[88 000–110 000]
People living with HIV (women, 15+)	600 000	710 000	820 000
	[560 000–650 000]	[670 000–780 000]	[760 000–910 000]
People living with HIV (men, 15+)	400 000	460 000	490 000
	[380 000–450 000]	[430 000–510 000]	[460 000–550 000]
HIV prevalence (15–49)	6.8 [6.5–7.2]	6.3 [6.1–6.7]	5.4 [5.1–5.8]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (14 years - life)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

residence permits or for certain groups

Percentage of women and men aged 15–49 years who report discriminatory attitudes	2011	2016
towards people living with HIV	26.2	33.2
Percentage of people living with HIV denied		2013
the last 12 months		4.2
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		•••
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male	2011	2016
intimate partner in the past 12 months	33.3	29.9

STIGMA AND DISCRIMINATION

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


US\$ 462 799 745 US\$ 430 654 322 Last available report: 2020

EPIDEMIC TRANSITION METRICS 150 000 120 000 120 000 12 120 000 ed 100 000 ed 80 000 fo 60 000 ed 40 000 ed 40 000 0 000 120 000 ed 100 000 80 000 60 000 40 000 20 000 0 Number of people 10 8 100 000 6 4 50 000 2 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 New HIV infections Incidence:prevalence ratio New HIV infections AIDS-related deaths All-cause deaths among ••••• Target the HIV population Change in AIDS-Change in new Incidence: -60% HIV infections 60% 2.68 1.2 related deaths prevalence mortality ratio since 2010 since 2010 ratio

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••		•••	•••	
HIV prevalence	31.3%		17%		4%
HIV testing and status awareness	88.0%**	54.0%**	45.0%**	100%**	
Antiretroviral therapy coverage	65%	66%	78%	13%	89.1%
Condom use			4%		
Coverage of HIV prevention programmes			8%		
Avoidance of health care because of stigma and discrimination	9.3%		64%		
Expenditures in US\$ (2019)		9718			

^{**} Programme data—not representative; includes people with negative results.

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	32% [28–36%]	100% [80–100%]
Final vertical transmission rate including during breastfeeding	25.7% [24.5–26.9%]	5.9% [4.9–7.8%]
Early infant diagnosis	10.6% [9.3–12.4%]	66.2% [59–82.3%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	34 000 [20 000 –52 000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	0.9%
Knowledge of HIV prevention among young people aged 15–24 years (2016)	
— Women	45.7%
— Men	44.8%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2016)	
— Women	38.3%
— Men	62.4%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2016)	53.8%
Men aged 15–49 years who are circumcised (2011)	26.8%
Voluntary medical male circumcisions performed according to national standards (2020)	516 615
People who received PrEP at least once during the reporting period (2020)	58 428
Harm reduction	

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)

— Safe injection rooms available (2021)

No

No

UNITED REPUBLIC OF TANZANIA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	110 000	97 000	68 000
	[96 000–120 000]	[87 000–120 000]	[57 000–81 000]
New HIV infections (0–14)	20 000	16 000	10 000
	[16 000–24 000]	[12 000–20 000]	[6000–14 000]
New HIV infections (women, 15+)	49 000	49 000	37 000
	[43 000–58 000]	[43 000–59 000]	[31 000–45 000]
New HIV infections (men, 15+)	37 000	31 000	21 000
	[32 000–46 000]	[27 000–41 000]	[17 000–26 000]
HIV incidence per 1000 population	2.62 [2.38–3.04]	2.08 [1.85–2.49]	1.26 [1.05–1.5]
AIDS-related deaths			
AIDS-related deaths (all ages)	64 000	41 000	32 000
	[56 000–75 000]	[35 000–52 000]	[28 000–39 000]
AIDS-related deaths (0–14)	16 000	11 000	8300
	[14 000–19 000]	[8500 –1 3 000]	[5600–11 000]
AIDS-related deaths (women, 15+)	27 000	12 000	11 000
	[23 000–33 000]	[10 000–17 000]	[9700–13 000]
AIDS-related deaths (men, 15+)	20 000	18 000	13 000
	[17 000–27 000]	[14 000–24 000]	[11 000–17 000]
People living with HIV			
People living with HIV (all ages)	1 400 000	1 600 000	1 700 000
	[1 300 000–1 500 000]	[1 500 000–1 700 000]	[1 600 000–1 900 000]
People living with HIV (0–14)	160 000	140 000	110 000
	[150 000–180 000]	[120 000–160 000]	[93 000 –1 30 000]
People living with HIV (women, 15+)	700 000	860 000	1 000 000
	[670 000–760 000]	[820 000–940 000]	[960 000 –1 100 000]
People living with HIV (men, 15+)	500 000	560 000	610 000
	[470 000–550 000]	[520 000–620 000]	[570 000–680 000]
HIV prevalence (15–49)	5.2 [5–5.4]	5.1 [4.8–5.3]	4.7 [4.4–4.9]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (14 years - life)
Drug use or possession for personal use is an offence	The law allows possession of a certain amount of drugs
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	No

residence permits or for certain groups

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV		
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		2013 8.7
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced	2015	2016
physical or sexual violence from a male intimate partner in the past 12 months	29.5	29.6

STIGMA AND DISCRIMINATION


EXPENDITURES						
Financing sources						
Domestic private Domestic public International: International: Total Global Fund all others						Total

US\$ 381 789 Last available report: 2019 US\$ 5 817 741 US\$ 156 057 711

EPIDEMIC TRANSITION METRICS 150 000 200 000 140 000 15 200 000 eld 050 000 150 000 50 000 120 000 Number of people 10 100 000 Percent 80 000 Number of 60 000 5 50 000 40 000 20 000 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 New HIV infections Incidence:prevalence ratio New HIV infections AIDS-related deaths All-cause deaths among • • • • • Target the HIV population Change in AIDS-Change in new Incidence: Incidence: -35% **-49%** 3.92 HIV infections prevalence 1.6 related deaths mortality ratio since 2010 since 2010 ratio

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population			***	•••	
HIV prevalence	15.4%	8.4%			
HIV testing and status awareness	98.3%		97.6%		
Antiretroviral therapy coverage					
Condom use	72.4%				
Coverage of HIV prevention programmes	20%				
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	48% [41–55%]	84% [69–95%]
Final vertical transmission rate including during breastfeeding	23.3% [22–24.7%]	11.1% [8.1–13.4%]
Early infant diagnosis	29.2% [24.3–36.8%]	55% [48.6–67.3%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	40 000 [19 000 -69 000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Knowledge of HIV prevention among young people aged 15–24 years (2012)	
— Women	40.1%
— Men	46.7%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2017)	
— Women	30.3%
— Men	46.5%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2016)	55.1%
Men aged 15–49 years who are circumcised (2016)	80.3%
Voluntary medical male circumcisions performed according to national standards (2020)	539 859
People who received PrEP at least once during the reporting period	

Use of sterile injecting equipment at last injection	
Needles and syringes distributed per person who injects (2017)	15

person who injects (2017)	
 Coverage of opioid substitution therapy (2020) 	25.6%
— Naloxone available (2021)	No
— Safe injection rooms available (2021)	No

ZAMBIA

COUNTRY DATA

	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	74 000	73 000	69 000
	[66 000–84 000]	[65 000–87 000]	[55 000–88 000]
New HIV infections (0–14)	14 000	11 000	8300
	[11 000–16 000]	[8600–13 000]	[6200–11 000]
New HIV infections (women, 15+)	35 000	39 000	39 000
	[30 000–40 000]	[33 000–46 000]	[31 000–50 000]
New HIV infections (men, 15+)	25 000	24 000	21 000
	[22 000–32 000]	[20 000–31 000]	[17 000–31 000]
HIV incidence per 1000 population	5.22 [4.7–5.95]	4.47 [3.94–5.33]	3.64 [2.9–4.73]
AIDS-related deaths			
AIDS-related deaths (all ages)	35 000	26 000	24 000
	[30 000–41 000]	[23 000–32 000]	[21 000–29 000]
AIDS-related deaths (0–14)	9900	6600	5300
	[8600–11 000]	[5500–7800]	[3900–7000]
AIDS-related deaths (women, 15+)	14 000	11 000	10 000
	[11 000–17 000]	[9600–14 000]	[8800–13 000]
AIDS-related deaths (men, 15+)	11 000	8200	8700
	[9300–14 000]	[6800–10 000]	[7500–11 000]
People living with HIV			
People living with HIV (all ages)	1 100 000	1 300 000	1 500 000
	[1 000 000–1 200 000]	[1 200 000–1 400 000]	[1 400 000–1 600 000]
People living with HIV (0–14)	110 000	97 000	82 000
	[100 000–120 000]	[88 000–110 000]	[73 000–93 000]
People living with HIV (women, 15+)	580 000	700 000	850 000
	[550 000–620 000]	[670 000–760 000]	[790 000–940 000]
People living with HIV (men, 15+)	390 000	460 000	520 000
	[370 000–420 000]	[430 000–500 000]	[490 000–580 000]
HIV prevalence (15–49)	12.1 [11.7–12.5]	11.8 [11.4–12.1]	11.1 [10.5–11.6]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No, but prosecutions exist based on general criminal laws
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (14 years - life)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Criminalized
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

STIGN	ΛΑ ΑΝ	ם מו	SCBIN	NINATI	
					$\mathbf{y}_{\mathbf{N}}$

Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	•••	
health services because of their HIV status in			
	health services because of their HIV status in		

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent

VIOLENCE

Proportion of ever-married or partnered women aged 15–49 years who experienced	2014	2018
physical or sexual violence from a male intimate partner in the past 12 months	26.5	25.3

EXPENDITURES					
Financing sources					
Domest	c private Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


US\$ 5 575 275 US\$ 191 383 331 US\$ 52 195 454 US\$ 249 154 060 Last available report: 2020

EPIDEMIC TRANSITION METRICS 150 000 120 000 100 000 15 120 000 ed 100 000 80 000 60 000 40 000 20 000 0 Number of people Number of people 80 000 10 100 000 60 000 Percent 40 000 5 50 000 20 000 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 New HIV infections Incidence:prevalence ratio New HIV infections AIDS-related deaths All-cause deaths among • • • • • Target the HIV population Change in AIDS-Change in new Incidence: -30% -6% related deaths 4.75 **HIV** infections prevalence 2.1 mortality ratio since 2010 since 2010 ratio

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					20 800
HIV prevalence	48.8%				
HIV testing and status awareness	56.1%**	75.7%**	48.8%**	61.4%**	
Antiretroviral therapy coverage	85.9%				100%
Condom use					
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

^{**} Programme data—not representative; includes people with negative results.

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	58% [51–65%]	80% [70–89%]
Final vertical transmission rate including during breastfeeding	22.3% [20.9–23.6%]	13.4% [11.1–16.1%]
Early infant diagnosis	31.7% [28.2–39.3%]	64.8% [58.3–74.9%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	36 000 [23 000 –51 000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV (2016)	27.3%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	2.7%
Knowledge of HIV prevention among young people aged 15–24 years (2018)	
— Women	42.6%
— Men	40.6%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2018)	
— Women	34.5%
— Men	53.5%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2018)	66.2%
Men aged 15–49 years who are circumcised (2018)	31.8%
Voluntary medical male circumcisions performed according to national standards (2020)	661 796
People who received PrEP at least once during the reporting period (2020)	110 714
Harm reduction	

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy — Naloxone available (2021) No

No

- Safe injection rooms available (2021)

ZIMBABWE

COUNTRY DATA

EPIDEMIC ESTIMATES								
	2010	2015	2020					
New HIV infections								
New HIV infections (all ages)	73 000	45 000	25 000					
	[52 000–100 000]	[32 000–63 000]	[18 000–35 000]					
New HIV infections (0–14)	17 000	7700	5100					
	[10 000–26 000]	[4700–12 000]	[3100–8000]					
New HIV infections (women, 15+)	31 000	22 000	13 000					
	[22 000–44 000]	[16 000–32 000]	[8800–18 000]					
New HIV infections (men, 15+)	25 000	15 000	7300					
	[17 000–36 000]	[11 000–22 000]	[5100–11 000]					
HIV incidence per 1000 population	6.63 [4.72–9.4]	3.61 [2.57–5.11]	1.74 [1.24–2.47]					
AIDS-related deaths								
AIDS-related deaths (all ages)	61 000	27 000	22 000					
	[50 000–72 000]	[22 000–32 000]	[18 000–26 000]					
AIDS-related deaths (0–14)	14 000	6100	3500					
	[9400–21 000]	[4100–9100]	[2400–5300]					
AIDS-related deaths (women, 15+)	26 000	11 000	9500					
	[21 000–32 000]	[8900–14 000]	[7600–12 000]					
AIDS-related deaths (men, 15+)	21 000	9900	9300					
	[17 000–24 000]	[8200–12 000]	[7600–11 000]					
People living with HIV								
People living with HIV (all ages)	1 200 000	1 300 000	1 300 000					
	[1 100 000–1 300 000]	[1 200 000–1 400 000]	[1 200 000–1 400 000]					
People living with HIV (0-14)	140 000	110 000	79 000					
	[120 000–170 000]	[91 000–130 000]	[66 000–92 000]					
People living with HIV (women, 15+)	630 000	690 000	720 000					
	[580 000–690 000]	[630 000–760 000]	[660 000–790 000]					
People living with HIV (men, 15+)	450 000	470 000	470 000					
	[410 000–490 000]	[430 000–520 000]	[430 000–520 000]					
HIV prevalence (15–49)	15.2 [13.7–16.8]	14 [12.5–15.4]	11.9 [10.7–13.1]					

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

N	
2015	2019
20.9	28.7
	2014
	6.3
	2014
	4.3
2015	2019
19.8	19
	2015 20.9 2015

EXPENDITURES								
Financing sources								
Domestic private Domestic public International: International: International: Total								


... US\$ 8 572 550 US\$ 152 967 248 US\$ 102 120 239 ... US\$ 263 660 037 Last available report: 2019

EPIDEMIC TRANSITION METRICS 200 000 200 000 12 150 000 200 000 eldo 150 000 fo 100 000 50 000 Number of people 10 150 000 8 100 000 Percent 5 100 000 6 4 50 000 50 000 2 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 New HIV infections Incidence:prevalence ratio New HIV infections AIDS-related deaths All-cause deaths among • • • • • Target the HIV population Change in AIDS-Incidence: Change in new 66% -63% 1.95 0.9 **HIV** infections related deaths prevalence mortality ratio since 2010 since 2010 ratio

KEY POPULATIONS								
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners			
Estimated size of population	•••			•••	20 900			
HIV prevalence	42.2%	21.1%		27.5%				
HIV testing and status awareness	75.4%**	99.7%		81.1%				
Antiretroviral therapy coverage	58.5%	73.3%						
Condom use	43.4%	69.2%		82%				
Coverage of HIV prevention programmes	34.5%	25.5%		27.9%				
Avoidance of health care because of stigma and discrimination	39.3%	8.3%		10.8%				
Expenditures in US\$ (2019)	2 704 452	203 375						

^{**} Programme data—not representative; includes people with negative results.

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	30% [23–35%]	87% [68–100%]
Final vertical transmission rate including during breastfeeding	23.9% [17.6–32%]	8.7% [6.4–11.6%]
Early infant diagnosis	9.2% [7.6 –1 2%]	75.9% [64.7- >95%]

Fatimeted and a of incident to be analysis	19 000
Estimated number of incident tuberculosis	[14 000
cases among people living with HIV (2018)	-24 0001

HIV COMORBIDITIES

People living with HIV who started TB preventive therapy (2018) Cervical cancer screening of women living 26%

People coinfected with HIV and hepatitis C virus starting hepatitis C treatment

HIV PREVENTION

with HIV (2015)

Adults aged 15+ years with unsuppressed viral load

2%

No

No

Knowledge of HIV prevention among young people aged 15-24 years (2015)

_	vvomen	40.3%
_	Men	46.6%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49 years (2015)

— Women	66.7%
— Men	85.4%

Women aged 15-49 years who have their demand for family planning satisfied by

Men aged 15-49 years who are circumcised

84.8% modern methods (2015)

14.3% (2016)Voluntary medical male circumcisions performed according to national standards 82 060

People who received PrEP at least once 48 583 during the reporting period (2020)

Harm reduction

(2020)

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

WESTERN AND CENTRAL AFRICA



he HIV response across western and central Africa is improving, but not fast enough to end AIDS as a public health threat by 2030. Over the past year, the COVID-19 pandemic has disrupted HIV and other health services, and it has highlighted the vulnerability of people in the region to public health, climatic, socioeconomic and security shocks, along with the pressing need for inclusive social protection systems.

There were 37% fewer new HIV infections in the region in 2020 compared with 2010—steady progress, but far short of the 75% reduction agreed by the United Nations (UN) General Assembly. The region also accounted for more than one third of new HIV infections among children globally in 2020, reflecting ongoing gaps in efforts to prevent vertical transmission, including low coverage of maternal and newborn health services. Overall, 44% of pregnant women living with HIV in western and central Africa were not receiving antiretroviral therapy in 2020.

Key populations and their sexual partners accounted for 72% of new adult HIV infections, and women and girls (aged 15 to 49 years) represented 65%. Adolescent girls and young women continue to be heavily affected by HIV, with a relatively high prevalence of violence against women and girls a contributing risk factor.

Coverage of HIV testing and antiretroviral therapy has grown at a quicker pace in recent years, with nearly three quarters (73%) of people living with HIV receiving antiretroviral therapy in 2020 and 59% virally suppressed. However, just 24% of children (aged 0 to 14 years) living with HIV were virally suppressed in the same year, with poor case finding and linkage to treatment the major gaps.

Stronger political leadership and effective multisectoral partnerships are essential for making health systems more resilient, mobilizing increased domestic resources for high-impact interventions, allocating those resources for programmes focusing on key populations, and removing the user fees and other legal and policy barriers that deter the uptake of life-saving services.


Reaching HIV service targets for 2025 requires addressing human rights and gender barriers, including HIV-related stigma and discrimination, criminalization of key populations and other punitive laws, and the traditional gender roles that condone violence and disempower women and girls. There is also a need to continue the transformation of health systems by promoting peoplecentered service modalities.


Community-based and other civil society organizations (such as faith-based organizations) are playing stronger roles in the regional response. These organizations are crucial to reaching key and other neglected populations with suitable services, including scaling up access to pre-exposure prophylaxis (PrEP). The West and Central Africa Civil Society Institute is expected to help expand such activities, with the objective of expanding community-led services in the region.

PRIORITY ACTIONS FOR ENDING AIDS

- Reduce stigma and discrimination and gender-based violence by transforming harmful gender and other discriminatory social norms, and by creating an enabling environment for health.
- Ensure preparedness for comprehensive HIV service delivery during humanitarian emergencies and pandemics.
- Scale up high-impact combination HIV prevention for key populations and adolescent girls and young people.
- Strengthen peoplecentred health systems, including community systems, to deliver results for the most vulnerable.
- Close gaps in service availability and the uptake of paediatric HIV treatment to prevent vertical transmission.
- Promote an accountable, inclusive and sustainable HIV response through multisectoral partnerships, including for issues beyond HIV.
- Establish health situation rooms, improve resource tracking and develop new analytics for epidemiological estimates, including analysis of the contributions of key populations to specific epidemics.

PROPORTION OF CHILDREN (AGED 0-14 YEARS) LIVING WITH HIV WITH SUPPRESSED VIRAL LOAD, WESTERN AND CENTRAL AFRICA, 2016–2020






Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).

The single biggest paediatric treatment challenge in western and central Africa is to rapidly find children who are living with HIV and link them to care. Just 24% of children living with HIV in the region had suppressed viral loads in 2020 (Figure above). Family-based index testing and integrating HIV screening with other child health services are critical to closing this gap. Data show that once children are diagnosed and linked to care, the majority do well, with seven in 10 on treatment having suppressed viral loads.


STATE OF THE PANDEMIC

NUMBER OF NEW HIV INFECTIONS AND AIDS-RELATED DEATHS, WESTERN AND CENTRAL AFRICA, 2000–2020




Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).

DISTRIBUTION OF NEW HIV INFECTIONS BY POPULATION GROUP AND SEX (AGED 15–49 YEARS), WESTERN AND CENTRAL AFRICA, 2020



Source: UNAIDS special analysis, 2021 (see methods annex).

HIV PREVALENCE AMONG KEY POPULATIONS, REPORTING COUNTRIES IN WESTERN AND CENTRAL AFRICA, 2016–2020




- Sex workers (n = 19)

 Gay men and other men who have sex with men (n = 19)
- People who inject drugs (n = 7)
- Transgender people (n = 5)
- Prisoners (n = 15)

Source: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/). Note: (n = number of countries). Total number of reporting countries = 25.

How to read this chart



REPORTED ESTIMATED SIZE OF KEY POPULATIONS, WESTERN AND CENTRAL AFRICA, 2018–2020

	National adult population (aged 15–49 years) in 2020 or relevant year	Sex workers	Sex workers as per cent of adult population (aged 15–49 years)	Gay men and other men who have sex with men	Gay men and other men who have sex with men as per cent of adult population (aged 15–49 years)	People who inject drugs	People who inject drugs as per cent of adult population (aged 15–49 years)	Transgender people	Transgender people as per cent of adult population (aged 15–49 years)	Prisoners	Prisoners as per cent of adult population (aged 15-49 years)
Cameroon	12 900 000										
Central African Republic	2 300 000	3900		3000							
Chad	7 500 000	19 500		2100		700					
Côte d'Ivoire	12 900 000			56 000		3000		700		42 400	0.33%
Democratic Republic of the Congo	49 300 000	350 000	0.76%			156 000	0.34%			36 700	0.07%
Gambia	1 100 000			1700						700	0.06%
Mali	9 000 000	18 100		4100							
Mauritania	2 100 000	8500		7600							
Nigeria	103 000 000					326 000	0.32%				
Niger	10 100 000			53 700	0.53%						
Senegal	7 900 000			52 500	0.66%	900	0.01%			11 000	0.14%
Togo	4 000 000									5000	0.13%
Estimated regional proportion as per c adult population (aged 15–49 years)	ent of		0.60%		0.64%		0.05%		-		-

National population size estimate

Insufficient data

Local population size estimate

No data

Sources: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/); Spectrum Demproj module, 2021.

Note 1: Estimates shown are government-provided estimates reported for 2018–2020. Additional and alternative estimates may be available from different sources, including the Key Populations Atlas (https://kpatlas.unaids.org/), academic publications or institutional documents. Note 2: The regions covered by the local population size estimate are as follows:

Central African Republic: Capitale (Bangui), prefectures (Berbérati and Bouar), subprefectures (Boali and Carnot).

Chad: Eleven cities in the country.

Côte d'Ivoire: Abengourou, Abidjan, Bouaké, Divo, Gagnoa, Issia, Korhogo, Man, Ouangolodougou, San-Pédro and Yakro (gay men and other men who have sex with men); Bouaké, San-Pédro and Yamoussoukro (people who inject drugs); Abidjan (transgender people). Gambia: Banjul.

Mali: Bamako, Kayes, Koulikoro, Mopti, Ségou and Sikasso (sex workers); Bamako, Gao, Kayes, Koulikoro, Mopti, Ségou and Sikasso (gay men and other men who have sex with men).

Mauritania: The six biggest cities in the country.


Note 3: The reported values for gay men and other men who have sex with men are presented as a per cent of the adult population (aged 15–49 years) for consistency across key populations. The percentage of this population out of the adult male population (aged 15-49 years) will be approximately twice the values shown.

^a Quick Start Guide for Spectrum, 2020. Geneva: UNAIDS; 2020 (https://www.unaids.org/sites/default/files/media_asset/QuickStartGuide_ Spectrum_en.pdf).

^b Technical brief: recommended population size estimates of men who have sex with men. Geneva: WHO, UNAIDS; 2020.

HIV SERVICES

PEOPLE LIVING WITH HIV, PEOPLE NEWLY INFECTED IN THE PAST SIX MONTHS, AND HIV TESTING AND TREATMENT CASCADE, ADULTS (AGED 15+ YEARS), WESTERN AND CENTRAL AFRICA, 2016–2020




Source: UNAIDS special analysis, 2021.


Number of children

HIV TESTING AND TREATMENT CASCADE, CHILDREN (AGED 0-14 YEARS) COMPARED TO ADULTS (AGED 15 YEARS AND OLDER), WESTERN AND CENTRAL AFRICA, 2020

Children (aged 0-14 years) living with HIV





Adults (aged 15 years and older) living with HIV




Source: UNAIDS special analysis, 2021.

HIV TESTING AND TREATMENT CASCADE, WOMEN (AGED 15+ YEARS) COMPARED TO MEN (AGED 15+ YEARS), WESTERN AND CENTRAL AFRICA, 2020





Men (aged 15+ years) living with HIV



Source: UNAIDS special analysis, 2021.

LAWS AND POLICIES

PUNITIVE AND DISCRIMINATORY LAWS, WESTERN AND CENTRAL AFRICA, 2021

POLICIES	Criminalization of transgender people	Criminalization of sex work	Criminalization of same-sex sexual acts	Law allows for possession of a certain limited amount of drugs for personal use	Parental consent for adolescents to access HIV testing	Laws criminalizing the transmission of, non-disclosure of or exposure to HIV transmission	Laws or policies restricting the entry, stay and residence of people living with HIV	Mandatory HIV testing for marriage, work or residence permits or for certain groups
Benin	1		1					1
Burkina Faso	1	5	1	1				1
Burundi	3	6	14			23		17
Cabo Verde			14			23		
Cameroon	1							1
Central African Republic	1		1					1
Chad	1				18	24		1
Congo	2		2					2
Côte d'Ivoire	1		1					1
Democratic Republic of the Congo	2		2		19	23		2
Equatorial Guinea	1	9	1		20			1
Gabon	2	10	14					1
Gambia		11	14			23		1
Ghana	2							2
Guinea	2	12	15					1
Guinea-Bissau	2		2	28	21	23		2
Liberia	2							2
Mali	1		1		22			1
Mauritania	1		1	1				1
Niger	1							1
Nigeria	1							1
Sao Tome and Principe	2	2	2					2
Senegal	1		16	1				1
Sierra Leone	1	13				25		1
Togo	1							1

Criminalization of transgender people

- Criminalized and/or prosecuted
- Neither criminalized nor prosecuted
- Data not available

Criminalization of sex work

- Any criminalization or punitive regulation of sex work
- Sex work is not subject to punitive regulations or is not criminalized
- Issue is determined/differs at the subnational level
- Data not available

Criminalization of same-sex sexual acts

- Death penalty
- Imprisonment (14 years–life, up to 14 years) or no penalty specified
- Laws penalizing same-sex sexual acts have been decriminalized or never existed, or no specific legislation
- Data not available

Law allows for possession of a certain limited amount of drugs for personal use

- No
- Yes
- Data not available

Parental consent for adolescents to access HIV testing

- Yes, for adolescents younger than 18
- Yes, for adolescents younger than 14 or 16
- Yes, for adolescents younger than 12
- No
- Data not available

Laws criminalizing the transmission of, non-disclosure of or exposure to HIV transmission

- Ye:
- No, but prosecutions exist based on general criminal laws
- No
- Data not available

Laws or policies restricting the entry, stay and residence of people living with HIV

- Deport, prohibit short and/or long stay and require
 HIV testing or disclosure for some permits
- Prohibit short and/or long stay and require HIV testing or disclosure for some permits
- Require HIV testing or disclosure for some permits
- No restrictions
- Data not available

Mandatory HIV testing for marriage, work or residence permits or for certain groups

- Yes
- No
- Data not available

Sources


- 1. UNAIDS National Commitments and Policy Instrument, 2021 (see http://lawsandpolicies.unaids.org/).
- 2. UNAIDS National Commitments and Policy Instrument, 2019 (see http://lawsandpolicies.unaids.org/).
- 3. UNAIDS National Commitments and Policy Instrument, 2017 (see http://lawsandpolicies.unaids.org/).
- 4. Benin. Penal Code 2018 (https://assemblee-nationale.bj/wp-content/uploads/2020/03/le-nouveau-code-penal-2018.pdf).
- 5. Burkina Faso. Penal Code 2019. Article 533-20; Burkina Faso. Loi no. 025-2018. Articles 533-20, 533-27, 533-28 (https://www.refworld.org/docid/3ae6b5cc0.html).
- 6. Burundi. Penal Code 2009. Article 538 and 548 (https://ihl-databases.icrc.org/applic/ihl/ihl-nat.nsf/0/ cb9d300d8db9fc-37c125707300338af2/\$FILE/Code%20P%c3%a9nal%20du%20Burundi%20.pdf).
- 7. Cabo Verde. Penal Code, 2004. Article 148 (https://www.wipo.int/edocs/lexdocs/laws/pt/cv/cv001pt. pdf).
- 8. Côte d'Ivoire. Penal Code (https://www.refworld.org/docid/3ae6b5860.html%22%3Ehttp://www.refworld.org/docid/3ae6b5860.html%22%3Ehttp://www.refworld.org/docid/3ae6b5860.html%3C/a%3E%3C/p>).
- 9. Equatorial Guinea. Penal Code. Article 452(bis) (https://acjr.org.za/resource-centre/penal-code-ofequatorial-guinea-1963/view).
- 10. Gabon. Penal Code, 2018. Article 402-1 (http://www.droit-afrique.com/uploads/Gabon-Code-2019- penal.pdf).
- 11. Gambia. Criminal Code. Article 248 (https://www.wipo.int/edocs/lexdocs/laws/en/mu/mu008en. pdf).
- 12. Guinea. Penal Code. Articles 346 and 351 (https://www.refworld.org/docid/44a3eb9a4.html).
- 13. Sierra Leone. Sexual Offences Act. Article 17 (http://www.sierra-leone.org/Laws/2012-12.pdf).
- 14. Mendos LR. State-sponsored homophobia, 2020. Geneva: International Lesbian, Gay, Bisexual, Trans and Intersex Association; December 2020 (https://ilga.org/downloads/ILGA_State_Sponsored_Homophobia_2019_light.pdf).
- 15. Guinea. Penal Code 2016. Article 274 (https://www.refworld.org/docid/44a3eb9a4.html).
- Senegal. Code Penal. Art 319 (https://www.ilo.org/dyn/natlex/docs/ELECTRONIC/70562/85594/F-2143944421/SEN-70562. pdf)
- 17. UNAIDS National Commitments and Policy Instrument, 2018 (see http://lawsandpolicies.unaids.org/).
- 18. Chad. Loi N°019/PR/2007 du 15 Novembre 2007 portant lutte contre VIH/SIDA/IŜT et protection des Droits des Personnes Vivant avec le VIH/SIDA. Articles 10 and 21 (https://www.ilo.org/wcmsp5/groups/public/---ed_protect/---protrav/---ilo_aids/documents/legaldocument/wcms_126793.pdf).
- 19. Sexual Rights Initiative database [database]. Sexual Rights Initiative; c2016 (http://sexualrightsdatabase.org/map/21/Adult%20 sex%20work).
- 20. Equatorial Guinea. Article 25 Ley N 3/2005 de fecha 9 de mayo sobre la prevencion y la lucha contra las infecciones de transmision sexual/VIH SIDA y la defensa de los derechos humanos de las personas afectada.
- 21. Guinea. Loi L/2005025/AN. Adoptant et promulguant la loi relative à la prévention, la prise en charge et le contrôle du VIH/SIDA, 2005 (http://www.ilo.org/aids/legislation/lang--en/index.htm).
- 22. Mali. Normes et Procédures des Services de Dépistage du VIH au Mali: Haut Conseil National de Lutte Contre le SIDA, 2017.
- 23. Global HIV Criminalisation Database [database]. Amsterdam: HIV Justice Network (https://www.hivjustice.net/global-hiv-criminalisation-database/).
- 24. Chad. Loi N°019/PR/2007 du 15 novembre 2007 portant lutte contre VIH/SIDA/IST et protection des Droits des Personnes Vivant avec le VIH/SIDA. Articles 50–55 (https://www.ilo.org/wcmsp5/groups/public/---ed_protect/---protrav/---ilo_aids/documents/legaldocument/wcms_126793.pdf).
- 25. Sierra Leone. Prevention and Control of HIV and AIDS Act 2007. Section 21.3 (https://sierralii.org/sl/legislation/act/2007/8).
- 26. Still not welcome: HIV-related travel restrictions. Geneva: UNAIDS, UNDP; 2019 (https://www.unaids.org/sites/default/files/media_asset/hiv-related-travel-restrictions-explainer_en.pdf).
- 27. Côte d'Ivoire. Loi organique no. 2014-424 du 14 juillet 2014. Article 4 (https://www.pnlsci.com/wp-content/uploads/2020/08/LOI-VIH-PROMULGUEE.pdf).
- 28. Guinea-Bissau. Decreto-Lei n° 2-B, de 28 de Outubro de 1993 (https://fecongd.org/pdf/crianca/CodigoPenal.pdf).

Note: A country is considered to have criminalized transgender persons if it uses the law to punish transgender individuals. Such a law may, for example, explicitly criminalize impersonation of the other gender, including cross-dressing. A country is considered to have any criminalization or punitive regulation of sex work if selling and/or buying sexual services is criminalized, ancillary activities associated with selling and/or buying sexual services are criminalized, profiting from organizing and/or managing sexual services is criminalized, and/or there are other punitive and/or administrative regulations of sex work.

INVESTING TO END AIDS

There is a substantial funding gap in western and central Africa. The resources available for HIV responses in the region in 2020 were approximately three quarters the amount needed in 2025. Total HIV resources in the region declined by 11% between 2010 and 2020. Domestic resources have increased by 6% during the last decade, peaking in 2018 before declining by 15% over the next two years. The sources of international funding have changed significantly in the region. The United States President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) increased their contributions to the region by 23% and 85%, respectively, between 2010 and 2020, while all other international resources have reduced their contributions by 79%. Both external and domestic resources need to grow in order to meet the 2025 targets. Resource availability per person living with HIV will have to be increased from the current US\$ 398 in 2020 to US\$ 539 by 2025.


RESOURCE AVAILABILITY FOR HIV, WESTERN AND CENTRAL AFRICA, 2010–2020, AND ESTIMATED RESOURCE NEEDS FOR HIV BY 2025



Source: UNAIDS financial estimates and projections, 2021 (http://hivfinancial.unaids.org/hivfinancialdashboards.html).

Note: The resource estimates are presented in constant 2019 US dollars.

YEAR-TO-YEAR CHANGE IN RESOURCE AVAILABILITY FOR HIV, WESTERN AND CENTRAL AFRICA, 2010–2011 TO 2019–2020



Source: UNAIDS financial estimates, 2021 (http://hivfinancial.unaids.org/hivfinancialdashboards.html).



BENIN

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	5000	3900	2300
	[4100–6300]	[2900–5600]	[1600–4000]
New HIV infections (0–14)	2000	1500	670
	[1600–2500]	[1000–2100]	[500–1400]
New HIV infections (women, 15+)	1700	1500	1000
	[1300–2300]	[1100–2300]	[710–1800]
New HIV infections (men, 15+)	1200	910	550
	[970–1700]	[670–1400]	[<500 <u>–</u> 950]
HIV incidence per 1000 population	0.56 [0.46–0.71]	0.39 [0.29–0.55]	0.19 [0.14–0.34]
AIDS-related deaths			
AIDS-related deaths (all ages)	2600	2700	2000
	[2100–3400]	[2000–3700]	[1500–3000]
AIDS-related deaths (0–14)	1500	1300	690
	[1200–1800]	[960–1700]	[<500–1200]
AIDS-related deaths (women, 15+)	500	530	550
	[<500–730]	[<500–860]	[<500–850]
AIDS-related deaths (men, 15+)	690	890	800
	[<500–980]	[640–1300]	[630–1100]
People living with HIV			
People living with HIV (all ages)	68 000	75 000	75 000
	[59 000–79 000]	[65 000–88 000]	[65 000–94 000]
People living with HIV (0-14)	13 000	12 000	8900
	[11 000–15 000]	[9600–14 000]	[7000–12 000]
People living with HIV (women, 15+)	34 000	39 000	43 000
	[29 000–39 000]	[34 000–47 000]	[37 000–53 000]
People living with HIV (men, 15+)	22 000	23 000	23 000
	[19 000–26 000]	[21 000–28 000]	[21 000–29 000]
HIV prevalence (15–49)	1.2 [1–1.4]	1.1 [1–1.3]	0.9 [0.8–1.2]


LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV (2018 refers to women only)	2014 67.1	2018 73
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male		2018
intimate partner in the past 12 months		13.9

STIGMA AND DISCRIMINATION

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


... US\$ 8 629 360 US\$ 22 220 326 Last available report: 2020



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATION					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence	8.5%	7%	2.2%	21.9%	4.1%
HIV testing and status awareness	59.2%	84.1%	71.2%	88.5%	
Antiretroviral therapy coverage					
Condom use	83.5%	66%	51.8%	86.8%	
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2020)	720 072				

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	13% [10–15%]	98% [75–100%]
Final vertical transmission rate including during breastfeeding	30.2% [28.2–32.2%]	11.2% [9.4–16.9%]
Early infant diagnosis	% [–%]	38.4% [29.5–50%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	940 [610–1400]
People living with HIV who started TB preventive therapy (2018)	7.1%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.4%
Knowledge of HIV prevention among young people aged 15–24 years (2017)	
— Women	15%
— Men	18.6%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2017)	
— Women	22.9%
— Men	36%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2018)	28.8%
Men aged 15–49 years who are circumcised (2012)	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction	
 Use of sterile injecting equipment at last injection (2017) 	94.6%

- Needles and syringes distributed per

- Safe injection rooms available (2021)

No

No

— Coverage of opioid substitution

— Naloxone available (2021)

person who injects

therapy

BURKINA FASO

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	6300	2600	2100
	[4800–8000]	[1800–3600]	[1200–3100]
New HIV infections (0–14)	4200	1300	1300
	[3100–5200]	[960–1800]	[800–2100]
New HIV infections (women, 15+)	1100	730	<500
	[800–1600]	[<500–1200]	[<500–770]
New HIV infections (men, 15+)	1000	560	<500
	[700–1500]	[<500–940]	[<200–540]
HIV incidence per 1000 population	0.42 [0.32–0.54]	0.15 [0.11–0.21]	0.1 [0.06–0.15]
AIDS-related deaths			
AIDS-related deaths (all ages)	7200	5300	3300
	[5500–9300]	[4000–6800]	[2400–4300]
AIDS-related deaths (0–14)	3300	2200	1100
	[2500–4100]	[1500–2700]	[780–1700]
AIDS-related deaths (women, 15+)	1900	1100	780
	[1400–2600]	[840–1500]	[560–1000]
AIDS-related deaths (men, 15+)	2000	2100	1400
	[1500–2600]	[1600–2600]	[1000–1800]
People living with HIV			
People living with HIV (all ages)	120 000	110 000	97 000
	[100 000–140 000]	[93 000 –1 30 000]	[81 000–110 000]
People living with HIV (0–14)	35 000	25 000	16 000
	[28 000–42 000]	[19 000–31 000]	[12 000–21 000]
eople living with HIV (women, 15+)	47 000	48 000	49 000
	[40 000–54 000]	[41 000–56 000]	[40 000–56 000]
People living with HIV (men, 15+)	39 000	36 000	32 000
	[33 000–46 000]	[31 000–41 000]	[28 000–37 000]
HIV prevalence (15–49)	1.1 [0.9–1.3]	0.9 [0.7–1]	0.7 [0.5–0.8]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	No

residence permits or for certain groups

STIGMA AND DISCRIMINATION


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV		
	•••	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		•••
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		•••

VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


Last available report: 2017 US\$ 2 875 787 US\$ 18 027 894 US\$ 39 055 319



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population			•••	•••	
HIV prevalence	5.4%	1.9%			2.2%
HIV testing and status awareness	74.7%	67.9%			
Antiretroviral therapy coverage					
Condom use	92.9%	87.2%			
Coverage of HIV prevention programmes	46.8%	76.4%			
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

2010	2020
21%	89%
[17–26%]	[69–100%]
31.6%	12%
[29.7–33.4%]	[9.2–16.1%]
7.1%	10%
[5.6–9.7%]	[8.4–12.8%]
	21% [17–26%] 31.6% [29.7–33.4%] 7.1%

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	930 [600–1300]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2010)	
— Women	31.1%
— Men	35.8%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2010)	
— Women	59%
— Men	74.2%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not
(2010)	applicable
2 2	applicable Not applicable

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution — Naloxone available (2021)


No

No

- Safe injection rooms available (2021)

BURUNDI

	2010	2015	2020
	2010	2013	2020
lew HIV infections			
New HIV infections (all ages)	4300	2800	1700
	[3200–5500]	[1900–4000]	[1100–2600]
ew HIV infections (0-14)	1900	1200	950
	[1500–2400]	[790–1600]	[640–1300]
ew HIV infections (women, 15+)	1300	960	<500
	[820–1700]	[550–1400]	[<500–780]
lew HIV infections (men, 15+)	1100	690	<500
	[680–1700]	[<500–1100]	[<200–510]
IIV incidence per 1000 population	0.52 [0.39–0.67]	0.29 [0.2–0.41]	0.15 [0.1–0.22]
IDS-related deaths			
IDS related deaths (all ages)	5900	3500	1700
AIDS-related deaths (all ages)	[4900–7000]	[2700–4300]	[1300–2200]
AIDS-related deaths (0-14)	1700	1000	680
iD3-Telated deaths (0-14)	[1400–2000]	[720–1300]	[<500–940]
AIDS-related deaths (women, 15+)	2200	960	<500
in 3-related deaths (women, 101)	[1700–2700]	[660–1300]	[<500–540]
AIDS-related deaths (men, 15+)	2000	1500	600
iiD3-related deaths (men, 13+)	[1600–2500]	[1200–1900]	[<500–790]
eople living with HIV			
eople living with HIV (all ages)	95 000	87 000	83 000
copie iiviig viiii iiiv (aii ages)	[86 000–110 000]	[78 000–98 000]	[73 000–95 000]
eople living with HIV (0-14)	20 000	14 000	9700
	[17 000–23 000]	[11 000–16 000]	[7300–12 000]
eople living with HIV (women, 15+)	43 000	43 000	44 000
3	[39 000–48 000]	[39 000–48 000]	[39 000–50 000]
eople living with HIV (men, 15+)	32 000	30 000	29 000
	[29 000–38 000]	[27 000–34 000]	[26 000–33 000]
IIV prevalence (15–49)	1.6 [1.5–1.8]	1.3 [1.1–1.4]	1 [0.9–1.1]
· · · · · · · · · · · · · · · · · · ·			





COUNTRY DATA

HIV TESTING AND TREATMENT CASCADE

105% [94-119%]

85% [76–95%]

Men (15+)



ELIMINATION OF MOTHER-TO	-CHILD TRAN	ISMISSION
	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	38% [32–45%]	55% [45–63%]
Final vertical transmission rate including during preastfeeding	28.1% [25.5–30.4%]	16.4% [13.4–20.6%]
Early infant diagnosis	8.6% [% 11%]	80.2%

[6.9-11%]

46 179

23 812

82% [73–92%]


96% [85-109%]

73% [66–82%]

[69.5->95%]

CABO VERDE

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)			
	[–]	[]	[–]
New HIV infections (0–14)			
	[–]	[]	[–]
New HIV infections (women, 15+)			
	[]	[]	[]
New HIV infections (men, 15+)			
	[]	[]	[]
HIV incidence per 1000 population	[]	[]	[]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<100
	[<100- <200]	[<100-<100]	[<100-<100]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100- <100]	[<100– <100]	[<100-<100]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100-<100]
People living with HIV			
People living with HIV (all ages)	1900	2100	2400
	[1600–2300]	[1800–2400]	[2000–2900]
People living with HIV (0-14)			
	[]	[]	[]
People living with HIV (women, 15+)	890	1000	1200
	[730–1100]	[890–1200]	[1000–1400]
People living with HIV (men, 15+)	900	1000	1200
	[750–1100]	[890–1200]	[980–1400]
HIV prevalence (15–49)	0.6 [0.5–0.7]	0.6 [0.5–0.7]	0.5 [0.4–0.7]



Incidence:

prevalence

ratio

Incidence:

mortality ratio

Change in AIDS-

related deaths

since 2010

Change in new

HIV infections


since 2010



-49%

COUNTRY DATA

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION			
	2010	2020	
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]	
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]	
Early infant diagnosis	% [–%]	% [%]	

CAMEROON

COUNTRY DATA


		0045	
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	35 000	24 000	15 000
	[31 000–41 000]	[20 000–28 000]	[12 000–19 000]
New HIV infections (0–14)	8300	4000	4500
	[6800–10 000]	[2800–5300]	[2900–5600]
New HIV infections (women, 15+)	17 000	13 000	7600
	[15 000–21 000]	[11 000–17 000]	[5900 –1 0 000]
New HIV infections (men, 15+)	9400	6100	3000
	[7800–12 000]	[4900–8000]	[2200–4100]
HIV incidence per 1000 population	1.83 [1.62–2.12]	1.07 [0.9–1.27]	0.6 [0.47–0.75]
AIDS-related deaths			
AIDS-related deaths (all ages)	26 000	25 000	14 000
	[23 000–31 000]	[21 000–29 000]	[12 000–17 000]
AIDS-related deaths (0–14)	7100	4100	3500
	[6000–8100]	[3100–5000]	[2500–4400]
AIDS-related deaths (women, 15+)	13 000	12 000	5800
	[11 000–16 000]	[9700–14 000]	[4500–7400]
AIDS-related deaths (men, 15+)	5900	8900	4800
	[4800–8400]	[7700–11000]	[4000–5800]
People living with HIV			
People living with HIV (all ages)	520 000	520 000	500 000
	[490 000–570 000]	[490 000–560 000]	[470 000–540 000]
People living with HIV (0–14)	56 000	45 000	35 000
	[48 000–62 000]	[38 000–52 000]	[27 000–41 000]
People living with HIV (women, 15+)	300 000	310 000	310 000
	[280 000–330 000]	[290 000–340 000]	[290 000–340 000]
People living with HIV (men, 15+)	160 000	160 000	150 000
	[150 000–180 000]	[150 000–180 000]	[140 000–160 000]
HIV prevalence (15–49)	4.3 [4.1–4.5]	3.7 [3.4–3.9]	3 [2.7–3.2]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No, but prosecutions exist based on general criminal laws
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	The law allows possession of a certain amount of drugs
Criminalization of transgender people	Prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV		
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		•••
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced	2014	2018
physical or sexual violence from a male intimate partner in the past 12 months	32.7	20

STIGMA AND DISCRIMINATION


EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2013	US\$ 13 745 789	US\$ 14 805 716	US\$ 12 252 577	US\$ 14 302 281	US\$ 17 442 940	US\$ 72 549 303



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population				•••	
HIV prevalence	24.3%	20.6%			4%
HIV testing and status awareness	97.0%	67.3%			
Antiretroviral therapy coverage	99.1%	97.2%			
Condom use	96%				
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination	4.7%	13.5%			
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION 2010 2020 Percentage of pregnant women living with HIV 40% 64%

 accessing antiretroviral medicines
 [34-47%]
 [50-74%]

 Final vertical transmission rate including during breastfeeding
 24.2%
 17.1%

 [23.1-25.6%]
 [14.3-19.2%]

 Early infant diagnosis
 20.4%
 52.6%

 [16.8-26.9%]
 [45.6-67%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	13 000 [8700 –19 000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load

Knowledge of HIV prevention among young people aged 15–24 years (2018)

_	Women	40.6%
_	Men	35.8%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2018)

— vvomen	43.4%
— Men	62.6%

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

performed according to national standards

Men aged	15-49 years	who are	circumcised	Not
(2011)				applicable

Voluntary medical male circumcisions	Not

applicable

No

People who received PrEP at least once	1969
during the reporting period (2020)	1707

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021) No

Safe injection rooms available (2021)

CENTRAL AFRICAN REPUBLIC

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
lew HIV infections			
lew HIV infections (all ages)			
	[]	[–]	[]
lew HIV infections (0–14)			
	[]	[–]	[]
lew HIV infections (women, 15+)			
	[]	[]	[]
lew HIV infections (men, 15+)			
	[]	[]	[]
IIV incidence per 1000 population	[]	[]	[]
IDS-related deaths			
IDS-related deaths (all ages)	7900	5800	3200
	[6300–9700]	[4500–7200]	[2300–4400]
IDS-related deaths (0–14)	1500	880	<500
	[1200–1800]	[660–1200]	[<500–730]
IDS-related deaths (women, 15+)	3700	2900	1200
	[2900–4700]	[2300–3500]	[800–1700]
IDS-related deaths (men, 15+)	2700	2000	1500
	[2100–3500]	[1500–2600]	[1100–2000]
eople living with HIV			
eople living with HIV (all ages)	120 000	100 000	88 000
	[110 000–140 000]	[84 000–120 000]	[73 000–110 000]
eople living with HIV (0–14)	13 000	8900	5800
	[11 000–16 000]	[7200–11 000]	[4500–7800]
eople living with HIV (women, 15+)	65 000	53 000	51 000
	[57 000–75 000]	[45 000–62 000]	[42 000–61 000]
eople living with HIV (men, 15+)	47 000	37 000	31 000
	[40 000–54 000]	[31 000–45 000]	[26 000–39 000]
IV prevalence (15–49)	5 [4.4–5.9]	3.9 [3.3–4.6]	2.9 [2.4–3.6]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

Last available report: 2018


		MOITANIN

Percentage of women and men aged 15-49

VIOLENCE

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2018	US\$ 696 331	US\$ 799 650		US\$ 8 075 418		US\$ 10 943 141



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population			***	•••	
HIV prevalence	15%	6.5%			3.6%
HIV testing and status awareness	57.1%	61.8%			
Antiretroviral therapy coverage	61.4%	60%			
Condom use	79.6%	30%			
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination	84.8%				
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION		
	2010	2020
Percentage of pregnant women living with HIV	33%	71%

accessing antiretroviral medicines	[28–41%]	[55–90%]
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]
Early infant diagnosis	<1%	29.8%

[<1-<1%]

[23.6-38.4%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	6600 [4200 –9400]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	100%

HIV PREVENTION

Adults aged	15+	years	with	unsuppressed
viral load				

Knowledge of HIV prevention among young people aged 15–24 years (2010)

— Women	17.4%
— Men	25%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

_	Women		

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15-49 years who are circumcised

Voluntary medical male circumcisions performed according to national standards

People who received PrEP at least once during the reporting period

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)


Yes

No

— Safe injection rooms available (2021)

CHAD

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	7100	5300	3500
	[5500–9000]	[3600–7300]	[2200–5700]
New HIV infections (0–14)	2600	1700	1000
	[1900–3500]	[1100–2500]	[600–1700]
New HIV infections (women, 15+)	2700	2200	1700
	[1900–3500]	[1600–3200]	[1000–2600]
New HIV infections (men, 15+)	1900	1300	850
	[1300–2500]	[910–2000]	[520–1400]
HIV incidence per 1000 population	0.62 [0.48–0.79]	0.39 [0.27–0.54]	0.22 [0.14–0.36]
AIDS-related deaths			
AIDS-related deaths (all ages)	4200	3800	3000
	[3000–5900]	[2500–5200]	[2000–4300]
AIDS-related deaths (0–14)	2100	1300	850
	[1600–2700]	[870–1900]	[520–1400]
AIDS-related deaths (women, 15+)	1200	1300	970
	[690–1800]	[750–1800]	[630–1400]
AIDS-related deaths (men, 15+)	930	1200	1200
	[560–1500]	[790–1700]	[760–1600]
People living with HIV			
People living with HIV (all ages)	110 000	110 000	110 000
	[87 000 –1 30 000]	[91 000 –1 30 000]	[90 000–130 000]
People living with HIV (0–14)	17 000	14 000	11 000
	[13 000–23 000]	[11 000–19 000]	[7600–15 000]
People living with HIV (women, 15+)	53 000	59 000	63 000
	[43 000–64 000]	[49 000–69 000]	[51 000–75 000]
People living with HIV (men, 15+)	36 000	39 000	38 000
	[29 000–45 000]	[32 000–46 000]	[32 000–46 000]
HIV prevalence (15–49)	1.6 [1.3–1.9]	1.4 [1.1–1.6]	1.1 [0.9–1.3]




^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2013	US\$ 123 770	US\$ 4 622 591		US\$ 7 037 322	US\$ 2 509 164	US\$ 17 632 654

COUNTRY DATA

HIV TESTING AND TREATMENT CASCADE

Men (15+)



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION			
	2010	2020	
Percentage of pregnant women living with HIV accessing antiretroviral medicines	19% [15–23%]	87% [65–100%]	
Final vertical transmission rate including during breastfeeding	30.3% [28.2–32.8%]	14.5% [10.6–19.4%]	
Early infant diagnosis	2.3% [1.7–3.1%]	21.9% [17.6–29.4%]	

65% [53–76%]

24 785

...% [...-...%]

70% [58–83%]

CONGO

COUNTRY DATA

	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	7200	8600	10 000
	[5100–9300]	[4800–13 000]	[4500–22 000]
New HIV infections (0–14)	1800	1800	2100
	[1400–2300]	[1200–2600]	[1100–3700]
New HIV infections (women, 15+)	3600	4800	5900
	[2400–4700]	[2600–7700]	[2300–13 000]
New HIV infections (men, 15+)	1800	2000	2100
	[1200–2300]	[1100–3200]	[840–4600]
HIV incidence per 1000 population	1.77 [1.26–2.28]	1.87 [1.03–2.95]	1.94 [0.86–4.19]
AIDS-related deaths			
AIDS-related deaths (all ages)	5200	5500	6100
	[4300–6100]	[4300–6700]	[4100–8500]
AIDS-related deaths (0–14)	1400	1300	1500
	[1100–1700]	[900–1700]	[890–2300]
AIDS-related deaths (women, 15+)	2700	2700	3200
	[2200–3200]	[2100–3300]	[2100–4300]
AIDS-related deaths (men, 15+)	1100	1500	1500
	[860–1300]	[1200–1800]	[980–1900]
People living with HIV			
People living with HIV (all ages)	88 000	98 000	110 000
	[76 000–100 000]	[76 000–120 000]	[80 000–170 000]
People living with HIV (0-14)	10 000	9900	11 000
	[8500–12 000]	[7800–12 000]	[7600–15 000]
People living with HIV (women, 15+)	53 000	60 000	72 000
	[45 000–60 000]	[46 000–72 000]	[50 000–110 000]
People living with HIV (men, 15+)	26 000	28 000	31 000
	[22 000–29 000]	[22 000–34 000]	[22 000–46 000]
HIV prevalence (15–49)	3.4 [2.9–3.9]	3.3 [2.6–4.2]	3.3 [2.2–5.2]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

residence permits or for certain groups

STIGMA AND DISCRIMINATION


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	•••	
Percentage of people living with HIV denied		2015
the last 12 months		6.1
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their		2015
consent		17.9


VIOLENCE


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

Last available report: 2010 US\$ 8 104 228 US\$ 16 472 586









Change in new
HIV infections = 41%
since 2010

Change in AIDSrelated deaths = 18% since 2010 Incidence:
prevalence = 8.86
ratio

Incidence: mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population			•••	•••		
HIV prevalence	8.1%	41.2%			3.9%	
HIV testing and status awareness						
Antiretroviral therapy coverage						
Condom use	86.3%	64.1%				
Coverage of HIV prevention programmes						
Avoidance of health care because of stigma and discrimination	17.2%	10.4%				
Expenditures in US\$						

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	5700 [2900 –9400]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION

Adults	aged	15+	years	with	unsuppressed
viral lo	ad				

Knowledge of HIV prevention among young people aged 15–24 years (2015)

— Women	26.7%
— Men	45.3%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2012)

— Women	38.3%
— Men	58%

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged	15-49 years	who are	circumcised	Not
(2012)				applicable

Voluntary medical male circumcisions	Not
performed according to national standards	applicable

People who received PrEP at least once during the reporting period

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	11% [9–14%]	14% [8–22%]
Final vertical transmission rate including during breastfeeding	32.5% [30.8–34.5%]	32.5% [29.8–35.7%]
Early infant diagnosis	8.1% [6.5–10.8%]	<1% [<1–1.6%]

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

CÔTE D'IVOIRE

COUNTRY DATA


EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	22 000	12 000	6200	
	[17 000–30 000]	[9000–17 000]	[3500–10 000]	
New HIV infections (0–14)	5200	1700	1200	
	[3800–6700]	[1300–2800]	[510–2200]	
New HIV infections (women, 15+)	9600	6500	3200	
	[7300–13 000]	[4600–8800]	[2000–5000]	
New HIV infections (men, 15+)	7400	4100	1800	
	[5700–12 000]	[3000–6300]	[1100–3000]	
HIV incidence per 1000 population	1.14 [0.88–1.53]	0.55 [0.4–0.77]	0.24 [0.14–0.39]	
AIDS-related deaths				
AIDS-related deaths (all ages)	31 000	20 000	9400	
	[25 000–38 000]	[16 000–26 000]	[7300–12 000]	
AIDS-related deaths (0–14)	5200	2400	800	
	[4100–6300]	[1900–3200]	[510–1200]	
AIDS-related deaths (women, 15+)	13 000	8700	3900	
	[10 000–16 000]	[6800–11 000]	[3100–5100]	
AIDS-related deaths (men, 15+)	13 000	9200	4700	
	[11 000–17 000]	[7400–12 000]	[3600–6300]	
People living with HIV				
People living with HIV (all ages)	500 000	430 000	380 000	
	[440 000–580 000]	[380 000–490 000]	[340 000–430 000]	
People living with HIV (0–14)	60 000	37 000	21 000	
	[51 000–69 000]	[30 000–44 000]	[16 000–27 000]	
People living with HIV (women, 15+)	260 000	250 000	240 000	
	[240 000–300 000]	[220 000–280 000]	[210 000–270 000]	
People living with HIV (men, 15+)	170 000	150 000	120 000	
	[150 000–210 000]	[130 000–170 000]	[110 000–140 000]	
HIV prevalence (15–49)	3.8 [3.4–4.1]	2.8 [2.5–3.1]	2.1 [1.8–2.3]	

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

Percentage of women and men aged 15–49 years who report discriminatory attitudes	2012	2016
towards people living with HIV (2016 refers to women only)	44.5	53
Percentage of people living with HIV denied		2016
the last 12 months		2.4
Percentage of people living with HIV who reported a health-care professional told others about their		2016
consent		3.4
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months		

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


Last available report: 2016



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population	•••		•••	•••	42 400	
HIV prevalence	4.8%	7.7%	3.4%	24.7%	1.2%	
HIV testing and status awareness	99.4%	100%				
Antiretroviral therapy coverage					93.8%	
Condom use	63.1%	83.2%	24.9%			
Coverage of HIV prevention programmes	96.2%	39.1%				
Avoidance of health care because of stigma and discrimination	13.9%	5.5%	9.3%	22.6%		
Expenditures in US\$ (2012)	1 232 054	245 854	25 480			

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION 2010 2020 Percentage of pregnant women living with HIV 51% 89%

accessing antiretroviral medicines	[41–60%]	[70–100%]
Final vertical transmission rate including during breastfeeding	22.7% [20.2–25.1%]	7.8% [3.9–12.2%]
Early infant diagnosis	25.3%	60.8%

[20.9-33.4%]

[52.2-77.3%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	7100 [4500 –10 000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	0.9%
Knowledge of HIV prevention among young people aged 15–24 years (2015)	
— Women	24%
— Men	33%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2016)	
— Women	30.4%
— Men	41.8%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2016)	33.7%
Men aged 15–49 years who are circumcised (2012)	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	345
Harm reduction	

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

DEMOCRATIC REPUBLIC OF THE CONGO

COUNTRY DATA

New HIV infections (all ages) 39 000 30 000 20 000 32 000 32 000 32 000 32 000 32 000 32 000 32 000 32 000 32 000 3800 32 000 30 000 3800 3800 30 000 3800 3800 30 000 3800 30 000 3800 30 000 3800 30 000 30 000 3800 30 00		2010	2015	2020
New HIV infections (all ages) (32 000–47 000] (23 000–37 000] (13 000–29 000]	New HIV infections			
New HIV infections (0-14)	New HIV infections (all ages)			
New HIV infections (women, 15+)	New HIV infections (0–14)			
New HIV infections (men, 15+) [5100-8900] [3400-6800] [1400-3900] [1400-3900] [1400-3900] [1400-3900] [1400-3900] [1400-3900] [1400-3900] [1400-3900] [1400-3900] [1400-3900] [1400-3900] [1400-3900] [1400-3900] [1400-3900] [1400-3900] [1400-3900] [1400-3900] [14000-3900] [15000-2000] [15000-38000] [1500-2000] [15000-2000] [15000-2000] [15000-2000] [15000-2000] [15000-38000] [15000-9000] [15000-9000] [15000-9000] [15000-9000] [15000-9000] [15000-9000] [15000-9000] [15000-9000] [15000-9000] [15000-9000] [15000-9000] [15000-8000] [15000-36000] [15000-36000] [170000-36000] [170000-36000] [170000-36000] [170000-36000] [170000-36000] [170000-14000] [1100000-14000] [110000-14000] [110000-14000] [110000-14000] [1	New HIV infections (women, 15+)			
AIDS-related deaths AIDS-related deaths (all ages) 42 000 32 000 17 000 [35 000–49 000] [25 000–38 000] 113 000–22 000] AIDS-related deaths (0–14) 12 000 8700 7200 AIDS-related deaths (women, 15+) [18 000–26 000] [18 000–26 000] [19 000–19 000] [4500–900] AIDS-related deaths (men, 15+) 8000 7200 3200 [4500–900] AIDS-related deaths (men, 15+) 8000 7200 3200 [6400–9800] [5600–8900] [2500–4200] People living with HIV People living with HIV (all ages) [470 000–610 000] [430 000–580 000] [430 000–580 000] [430 000–580 000] [56 000–85 000] People living with HIV (women, 15+) 310 000 300 000 310 000 People living with HIV (women, 15+) 130 000 120 000 [100 000–140 000] [110 000–140 000] [110 000–140 000] [110 000–140 000] [110 000–140 000] [110 000–140 000]	New HIV infections (men, 15+)			
AIDS-related deaths (all ages) 42 000 [35 000–49 000] [25 000–38 000] [13 000–22 000] AIDS-related deaths (0–14) [9900–14 000] [9900–14 000] [6900–10 000] [5200–9000] AIDS-related deaths (women, 15+) [18 000–26 000] [18 000–26 000] [18 000–26 000] [19 000–19 000] [10 000–19 000] [25 000–42 00] [25 000–42 00] [25 000–42 00] [25 000–42 00] [25 000–42 00] [25 000–42 00] [25 000–42 00] [25 000–42 00] [25 000–42 00] [25 000–42 00] [25 000–42 00] People living with HIV (all ages) [47 0 000–610 000] [43 0 000–58 0 000] [43 0 000–58 0 000] [56 000–85 000] [57 0 000–85 000] [57 0 000–85 000] [27 0 000–36 0 000] [27 0 000–36 0 000] [27 0 000–36 0 000] [27 0 000–36 0 000] [27 0 000–36 0 000] [10 0 000–140 000] [11 0 000–140 000] [11 0 000–140 000]	HIV incidence per 1000 population	0.51 [0.41–0.61]	0.33 [0.25–0.41]	0.18 [0.12–0.28]
AIDS-related deaths (all ages) [35 000–49 000] [25 000–38 000] [13 000–22 000] [19 000–14 000] [9900–14 000] [9900–14 000] [16 000 [18 000–26 000] [18 000–26 000] [18 000–26 000] [18 000–26 000] [19 000–19 000] [10 000–19 000] [10 000–19 000] [10 000–19 000] [10 000–19 000] [10 000–19 000] [10 000–19 000] [10 000–19 000] [10 000–19 000] [10 000–19 000] [10 000–19 000] [10 000–19 000] [10 000–19 000] [10 000–19 000] [10 000–140 000] [11 000–140 000]	AIDS-related deaths			
AIDS-related deaths (0-14) [9900-14 000] [6900-10 000] [5200-9000] AIDS-related deaths (women, 15+) 22 000 16 000 [12 000-19 000] [4500-9000] AIDS-related deaths (men, 15+) 8000 7200 3200 [6400-9800] [5600-8900] [2500-4200] People living with HIV People living with HIV (all ages) 540 000 510 000 510 000 [470 000-610 000] [430 000-580 000] [430 000-580 000] People living with HIV (0-14) [83 000-110 000] [83 000-95 000] [56 000-85 000] People living with HIV (women, 15+) [270 000-360 000] [270 000-360 000] People living with HIV (men, 15+) 130 000 120 000 120 000 People living with HIV (men, 15+) 110 000-150 000] [100 000-140 000] 1110 000-140 000]	AIDS-related deaths (all ages)			
AIDS-related deaths (women, 15+) [18 000–26 000] [12 000–19 000] [4500–9000] [8000 [5600–8900] [5600–8900] [2500–4200] People living with HIV People living with HIV (all ages) [470 000–610 000] [430 000–580 000] [440 000–580 000] [440 000–580 000] [440 000–580 000] [440 000–580 000] [440 000–580 000] [440 000–580 000] [440 000–580 000] [440 000–580 000] [440 000–580 000] [440 000–580 000] [440 000–580 000] [440 000–580 000] [440 000–580 000]	AIDS-related deaths (0–14)			
People living with HIV (all ages) [5600–8900] [2500–4200] [2500–4200] [2500–4200] [2500–4200] [2500–4200] [2500–4200] [2500–4200] [2500–4200] [2500–4200] [2500–4200] [2500–4200] [2500–4200] [2500–4200] [2500–4200] [2500–4200] [2500–4200] [2500–4200] [2500–2580 000] [25000–580 000] [25000–580 000] [25000–580 000] [25000–580 000] [25000–85 000] [25000–85 000] [25000–85 000] [25000–85 000] [270000–360 000] [2700000–360 000] [270000–360 000] [AIDS-related deaths (women, 15+)			
People living with HIV (all ages) 540 000 [470 000–610 000] [430 000–580 000] [430 000–580 000] [430 000–580 000] [430 000–580 000] 71 000 [83 000–110 000] [68 000–95 000] [56 000–85 000] People living with HIV (women, 15+) [270 000–360 000] [260 000–350 000] [270 000–360 000] [270 000–360 000] [270 000–360 000] [270 000–140 000] [110 000–140 000]	AIDS-related deaths (men, 15+)		· 	
People living with HIV (all ages) [470 000–610 000] [430 000–580 000] [430 000–580 000] People living with HIV (0–14) 98 000 82 000 71 000 [83 000–110 000] [68 000–95 000] [56 000–85 000] 310 000 300 000 310 000 [270 000–360 000] [260 000–350 000] [270 000–360 000] People living with HIV (men, 15+) 130 000 120 000 120 000 [110 000–150 000] [100 000–140 000] [110 000–140 000]	People living with HIV			
People living with HIV (0-14) [83 000-110 000] [68 000-95 000] [56 000-85 000] People living with HIV (women, 15+) 310 000 300 000 310 000 People living with HIV (men, 15+) 130 000 120 000 120 000 People living with HIV (men, 15+) 130 000 120 000 120 000 I 10 000-150 000] [110 000-140 000] [110 000-140 000]	People living with HIV (all ages)			
People living with HIV (women, 15+) [270 000–360 000] [260 000–350 000] [270 000–360 000] People living with HIV (men, 15+) 130 000 120 000 120 000 120 000 [110 000–150 000] [100 000–140 000] [110 000–140 000]	People living with HIV (0-14)			
People living with HIV (men, 15+) [110 000–150 000] [100 000–140 000] [110 000–140 000]	People living with HIV (women, 15+)			
HIV prevalence (15–49) 1.1 [1–1.3] 0.9 [0.8–1] 0.7 [0.6–0.9]	People living with HIV (men, 15+)			
	HIV prevalence (15–49)	1.1 [1–1.3]	0.9 [0.8–1]	0.7 [0.6–0.9]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	
Spousal consent for married women to access sexual and reproductive health services	
Mandatory HIV testing for marriage, work or	No

residence permits or for certain groups

STIGMA AND DISCRIMINATION


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	•••	
Percentage of people living with HIV denied		2012
health services because of their HIV status in the last 12 months		6.1
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		•••

VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


Last available report: 2017 US\$ 600 897 US\$ 18 662 067 US\$ 60 388 722 US\$ 79 284 139 US\$ 5 177 947 US\$ 174 572 249



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	350 300		155 800	•••	36 700
HIV prevalence	7.5%	7.1%	3.9%		2.5%
HIV testing and status awareness					
Antiretroviral therapy coverage					
Condom use	73.9%	50.6%	26.5%		
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2014)	6188	185 650			

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION			
	2010	2020	
Percentage of pregnant women living with HIV	6%	39%	
accessing antiretroviral medicines	[5–7%]	[31–47%]	

38.8%

[36.9-40.7%]

27.8%

[23.9-30.4%]

Early infant diagnosis 2.5% 10.6% [1.9–3.3%] [8.9–13.7%]

Final vertical transmission rate including during

breastfeeding

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	31 000 [9400 -65 000]
People living with HIV who started TB preventive therapy (2018)	38.7%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	27.8%

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2014)	
— Women	18.6%
— Men	24.9%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2014)	
— Women	22.6%
— Men	30.7%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	

People who received PrEP at least once	
•	Not oplicable
during the reporting period (2020)	553

 Use of sterile injecting equipment at last injection (2019) 	50.6%
— Needles and syringes distributed per	0


Needies and syringes distributed per	
person who injects (2020)	
Carrage of a signal and agreement	

 Coverage of opioid substitution 	
therapy	
— Naloxone available (2021)	

— Safe injection rooms available (2021)

EQUATORIAL GUINEA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)			
	[]	[]	[]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)			
	[]	[]	[]
New HIV infections (men, 15+)			
	[–]	[]	[]
HIV incidence per 1000 population	[]	[]	[]
AIDS-related deaths			
AIDS-related deaths (all ages)	1500	1800	2300
	[1100–2000]	[1300–2400]	[1600–3400]
AIDS-related deaths (0–14)	<500	<500	<500
	[<500-<500]	[<500–530]	[<500–770]
AIDS-related deaths (women, 15+)	560	<500	<500
	[<500–780]	[<500–680]	[<500–810]
AIDS-related deaths (men, 15+)	530	990	1300
	[<500–770]	[740–1300]	[1000–1800]
People living with HIV			
People living with HIV (all ages)	34 000	52 000	68 000
	[28 000–42 000]	[43 000–63 000]	[52 000–94 000]
People living with HIV (0-14)	2200	2800	3500
	[1700–2700]	[2200–3500]	[2600–4900]
People living with HIV (women, 15+)	16 000	25 000	35 000
	[14 000–20 000]	[21 000–31 000]	[27 000–48 000]
People living with HIV (men, 15+)	16 000	24 000	29 000
	[13 000–19 000]	[20 000–30 000]	[22 000–41 000]
HIV prevalence (15–49)	5.7 [4.7–6.8]	6.8 [5.7–8.6]	7.3 [5.5–10.3]




^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2013	US\$ 260 066	US\$ 7 844 051			US\$ 132 193	US\$ 8 715 789

COUNTRY DATA

HIV TESTING AND TREATMENT CASCADE

Men (15+)



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION		
	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	15% [12–18%]	31% [22–44%]
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]
Early infant diagnosis	% [–%]	4.5% [3.2–6.3%]

21% [16–29%]

6042

...% [...-...%]

37% [28–52%]

GABON

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	2500	1800	1000
	[1900–3400]	[1100–2700]	[520–2100]
New HIV infections (0–14)	730	510	<500
	[560–990]	[<500–720]	[<200-<500]
New HIV infections (women, 15+)	1200	910	570
	[850–1800]	[530–1500]	[<500–1200]
New HIV infections (men, 15+)	550	<500	<200
	[<500–820]	[<500–590]	[<100-<500]
HIV incidence per 1000 population	1.64 [1.23–2.23]	0.96 [0.61–1.46]	0.48 [0.24–0.99]
AIDS-related deaths			
AIDS-related deaths (all ages)	2400	1600	930
	[1600–3500]	[1000–2300]	[630–1400]
AIDS-related deaths (0–14)	610	<500	<500
	[<500–820]	[<500–570]	[<200-<500]
AIDS-related deaths (women, 15+)	1400	780	<500
	[940–2000]	[<500–1200]	[<500–720]
AIDS-related deaths (men, 15+)	<500	<500	<500
	[<500–690]	[<500–580]	[<200–<500]
People living with HIV			
People living with HIV (all ages)	45 000	47 000	46 000
	[37 000–56 000]	[39 000–56 000]	[38 000–56 000]
People living with HIV (0–14)	3900	3400	2900
	[3000–5200]	[2600–4500]	[2100–3700]
People living with HIV (women, 15+)	28 000	30 000	30 000
	[23 000–35 000]	[25 000–35 000]	[25 000–37 000]
People living with HIV (men, 15+)	13 000	14 000	13 000
	[11 000–16 000]	[12 000–16 000]	[11 000–16 000]
HIV prevalence (15–49)	4.4 [3.6–5.3]	3.7 [3.1–4.3]	3 [2.4–3.7]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No, but prosecutions exist based on general criminal laws
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes

STIGMA AND DISCRIMINATION


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	
Percentage of people living with HIV denied health services because of their HIV status in	2013
the last 12 months	13.7
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent	

VIOLENCE

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES								
	Financing sources							
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total		


US\$ 5 825 622 Last available report: 2018 US\$ 5 551 216



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population			•••	•••		
HIV prevalence						
HIV testing and status awareness						
Antiretroviral therapy coverage						
Condom use						
Coverage of HIV prevention programmes						
Avoidance of health care because of stigma and discrimination						
Expenditures in US\$						

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

2010	2020
21%	90%
[17–27%]	[67–100%]
23.9%	10%
[22.3–25.5%]	[7.4–14.9%]
4.6%	2.5%
[3.6–6.6%]	[1.9–3.4%]
	21% [17–27%] 23.9% [22.3–25.5%] 4.6%

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	4100 [1700 –7600]
People living with HIV who started TB preventive therapy (2018)	
Women who tested positive for HIV among those screened for cervical cancer (programme data) (2019)	0.4%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	100%

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2012)	
— Women	29.8%
— Men	36.1%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2012)	
— Women	54.5%
— Men	74.8%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised (2012)	Not applicable
Voluntary medical male circumcisions	Not

Harm reduction

Use of sterile injecting equipment at
 last injection ...

applicable

...

 Needles and syringes distributed per person who injects

performed according to national standards

People who received PrEP at least once

during the reporting period

- Coverage of opioid substitution therapy ...
 Naloxone available (2021) ...
- Safe injection rooms available (2021)

GAMBIA

COUNTRY DATA

EPIDEMIC ESTIMATES					
	2010	2015	2020		
New HIV infections					
New HIV infections (all ages)	2100	2000	2100		
	[1700–2800]	[1500–2800]	[1300–3400]		
New HIV infections (0–14)	<500	<500	<500		
	[<500–<500]	[<200–<500]	[<500–550]		
New HIV infections (women, 15+)	1000	1000	1000		
	[810–1300]	[720–1400]	[630–1700]		
New HIV infections (men, 15+)	760	750	740		
	[580–990]	[540–1000]	[<500–1300]		
HIV incidence per 1000 population	1.25 [0.97–1.61]	1.03 [0.75–1.43]	0.93 [0.59–1.51]		
AIDS-related deaths					
AIDS-related deaths (all ages)	1300	1200	1300		
	[960–1700]	[880–1600]	[880–1800]		
AIDS-related deaths (0–14)	<500	<500	<500		
	[<500-<500]	[<200-<500]	[<200-<500]		
AIDS-related deaths (women, 15+)	580	<500	<500		
	[<500–750]	[<500–680]	[<500–700]		
AIDS-related deaths (men, 15+)	<500	<500	560		
	[<500–580]	[<500–640]	[<500–750]		
People living with HIV					
People living with HIV (all ages)	21 000	24 000	27 000		
	[17 000–26 000]	[20 000–30 000]	[21 000–35 000]		
People living with HIV (0–14)	2300	2200	2200		
	[1800–2900]	[1700–2800]	[1600–2900]		
People living with HIV (women, 15+)	11 000	13 000	15 000		
	[8800–13 000]	[11 000–16 000]	[12 000–20 000]		
People living with HIV (men, 15+)	7600	8700	9500		
	[6000–9500]	[6900–11 000]	[7500–13 000]		
HIV prevalence (15–49)	1.9 [1.6–2.3]	1.9 [1.5–2.3]	1.8 [1.4–2.3]		

Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	
Criminalization of transgender people	
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years

No

|--|

Percentage of women and men aged 15–49 years who report discriminatory attitudes	2013	2018
towards people living with HIV (2018 refers to women only)	51	72.3
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		

VIOLENCE

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EX	B -	м.	_	
-			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	


Spousal consent for married women to access


sexual and reproductive health services Mandatory HIV testing for marriage, work or residence permits or for certain groups


LAWS AND POLICIES


EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International:	International:	International:	Total

Last available report: 2019 US\$ 1 019 975 US\$ 1 019 975









HIV infections since 2010

Change in AIDS-0% related deaths since 2010

Incidence: 7.81 prevalence ratio


mortality ratio*

* The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••			•••	
HIV prevalence	11%	34.4%			
HIV testing and status awareness	100%**	100%			
Antiretroviral therapy coverage	11.2%	4.8%			
Condom use	84.4%	55.1%			
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination	0.3%	8.2%			
Expenditures in US\$					

^{**} Programme data—not representative; includes people with negative results.

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	46% [37–58%]	46% [36–60%]
Final vertical transmission rate including during breastfeeding	27.9% [24.7–30.7%]	28.9% [25.5–32.5%]
Early infant diagnosis	% [–%]	14% [10.6–17.6%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	790 [590–1000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2013)	
— Women	25.8%
— Men	32.3%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2013)	
— Women	32.3%
— Men	67.2%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	15

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

GHANA

COUNTRY DATA

	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	24 000	23 000	19 000
	[20 000–30 000]	[19 000–29 000]	[14 000–25 000]
New HIV infections (0–14)	5600	4900	3700
	[4500–6800]	[3600–6200]	[2400–5100]
New HIV infections (women, 15+)	12 000	12 000	11 000
	[9500–15 000]	[9400–15 000]	[7700–14 000]
New HIV infections (men, 15+)	6800	5900	4600
	[5500–9100]	[4700–8500]	[3400–7000]
HIV incidence per 1000 population	1.02 [0.84–1.27]	0.84 [0.69–1.1]	0.63 [0.47–0.85]
AIDS-related deaths			
AIDS-related deaths (all ages)	20 000	16 000	13 000
	[17 000–24 000]	[13 000–21 000]	[10 000–17 000]
AIDS-related deaths (0–14)	4600	3600	3000
	[3900–5400]	[2800–4500]	[2200–3900]
AIDS-related deaths (women, 15+)	10 000	7800	5100
	[8400–12 000]	[6100–10 000]	[3800–7000]
AIDS-related deaths (men, 15+)	5200	5100	4700
	[4200–6800]	[4100–6600]	[3800–6100]
People living with HIV			
People living with HIV (all ages)	310 000	330 000	350 000
	[270 000–360 000]	[290 000–380 000]	[300 000–410 000]
People living with HIV (0-14)	42 000	35 000	29 000
	[36 000–48 000]	[29 000–41 000]	[23 000–35 000]
People living with HIV (women, 15+)	170 000	190 000	220 000
	[150 000–200 000]	[170 000–220 000]	[190 000–250 000]
People living with HIV (men, 15+)	94 000	100 000	100 000
	[82 000–110 000]	[90 000 –1 20 000]	[89 000–120 000]
HIV prevalence (15–49)	2 [1.7–2.2]	1.8 [1.6–2.1]	1.7 [1.4–1.9]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	

residence permits or for certain groups

STIGMA AND DISCRIMINATION


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	•••	
	•••	•••
Percentage of people living with HIV denied		2014
the last 12 months		1.4
Percentage of people living with HIV who		2014
reported a health-care professional told		2014
others about their HIV status without their		
consent		7.9

VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

Financing sources International: International: International: Total	EXPENDITURES					
Domestic private Domestic public Total		Fina	ncing sources			
PEPFAR Global Fund all others	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


US\$ 67 413 057 Last available report: 2018 US\$ 11 074 132 US\$ 34 124 926 US\$ 9 082 121 US\$ 12 083 138 US\$ 348 411



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population			•••	•••	
HIV prevalence	6.9%	18%			0.4%
HIV testing and status awareness					
Antiretroviral therapy coverage	99%	3.7%			100%
Condom use	89.9%				
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2018)	2 575 600				

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	33% [27–39%]	72% [57–86%]		
Final vertical transmission rate including during	31.4%	20.8%		

 breastfeeding
 [29.6–33.3%]
 [16.7–24.1%]

 Early infant diagnosis
 <1%</td>
 41.4%

 [<1–1.1%]</th>
 [34.7–51.8%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	8600 [4100 –15 000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

IIIV PREVEIVITOIN	
Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2014)	
— Women	19.9%
— Men	27.2%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2014)	
— Women	17.1%
— Men	39.1%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised (2014)	Not applicable

Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy

— Naloxone available (2021)

— Safe injection rooms available (2021)

GUINEA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	8000	7100	5300
	[7300–9000]	[6500–8000]	[4800–5900]
New HIV infections (0–14)	1900	1800	920
	[1700–2100]	[1500–2000]	[780–1100]
New HIV infections (women, 15+)	3700	3500	2900
	[3300–4400]	[3100–4100]	[2500–3400]
New HIV infections (men, 15+)	2400	1900	1400
	[2100–2800]	[1700–2300]	[1300–1800]
HIV incidence per 1000 population	0.82 [0.75–0.92]	0.65 [0.59–0.73]	0.42 [0.38–0.47]
AIDS-related deaths			
AIDS-related deaths (all ages)	3900	3700	3300
	[3500–4500]	[3100–4300]	[2900–3800]
AIDS-related deaths (0–14)	1400	1100	790
	[1300–1500]	[870–1200]	[630–900]
AIDS-related deaths (women, 15+)	1700	1400	1200
	[1400–2100]	[1100–1800]	[990–1500]
AIDS-related deaths (men, 15+)	790	1200	1300
	[630–1000]	[970–1500]	[1000–1600]
People living with HIV			
People living with HIV (all ages)	92 000	100 000	110 000
	[88 000–98 000]	[99 000–110 000]	[110 000–120 000]
People living with HIV (0-14)	12 000	11 000	9700
	[10 000–13 000]	[9200–12 000]	[8200–11 000]
People living with HIV (women, 15+)	51 000	60 000	68 000
	[49 000–55 000]	[56 000–64 000]	[64 000–73 000]
People living with HIV (men, 15+)	29 000	33 000	36 000
	[27 000–33 000]	[31 000–37 000]	[33 000–39 000]
HIV prevalence (15–49)	1.6 [1.6–1.6]	1.6 [1.5–1.6]	1.4 [1.4–1.4]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

Percentage of women and men aged 15–49 years who report discriminatory attitudes	2016	2018
towards people living with HIV (2018 refers to women only)	80	79.7
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months		•••

EXPENDITURES						
	Financing sources					
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

... US\$ 1 383 049 ... US\$ 25 567 092 ... US\$ 34 475 926 Last available report: 2020

the HIV population


EPIDEMIC TRANSITION METRICS 12 000 20 15 000 Number of people Number of people 6 000 of people 10 000 15 5 000 8 000 10 000 Percent 4 000 10 6 000 3 000 Number 5 000 4 000 2 000 5 2 000 1 000 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 New HIV infections Incidence:prevalence ratio New HIV infections AIDS-related deaths All-cause deaths among • • • • • Target

Incidence:

ratio

prevalence

* The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).



Change in AIDS-

related deaths

since 2010

Change in new


HIV infections

since 2010

** Programme data—not representative; includes people with negative results.

-34%

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	20% [16–22%]	94% [78–100%]
Final vertical transmission rate including during breastfeeding	35.9% [34.2–37.7%]	16.6% [15.3–17.9%]
Early infant diagnosis	5.3% [4.4–6.7%]	43.2% [39.2–52.2%]

HIV COMORBIDITIES

4.63

Estimated number of incident tuberculosis cases among people living with HIV (2018)	5400 [3500 –7700]
People living with HIV who started TB preventive therapy (2018)	32.2%
Women who tested positive for HIV among those screened for cervical cancer (programme data) (2018)	55.9%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

mortality ratio*

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2018)	
— Women	20.7%
Man	24 E9/

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2018)

— Women	28.6%
— Men	49.6%

Not

Women aged 15–49 years who have their demand for family planning satisfied by modern methods


Men aged 15–49 years who are circumcised	applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

GUINEA-BISSAU

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	3200	2200	1700
	[2800–3800]	[1800–2700]	[1300–2000]
New HIV infections (0–14)	850	<500	<500
	[730–1000]	[<500–540]	[<500–590]
New HIV infections (women, 15+)	1400	1100	770
	[1100–1700]	[910–1400]	[580–950]
New HIV infections (men, 15+)	970	670	<500
	[790–1200]	[530–850]	[<500–520]
HIV incidence per 1000 population	2.24 [1.91–2.66]	1.35 [1.09–1.64]	0.88 [0.7–1.06]
AIDS-related deaths			
AIDS-related deaths (all ages)	2100	1900	1500
	[1800–2500]	[1500–2200]	[1200–1800]
AIDS-related deaths (0–14)	610	<500	<500
	[540–710]	[<500–<500]	[<500–<500]
AIDS-related deaths (women, 15+)	920	770	<500
	[760–1100]	[580–950]	[<500–630]
AIDS-related deaths (men, 15+)	590	740	660
	[<500–800]	[620–920]	[540–810]
People living with HIV			
People living with HIV (all ages)	36 000	38 000	37 000
	[32 000–41 000]	[34 000–42 000]	[33 000–41 000]
People living with HIV (0–14)	4600	4000	3500
	[4100–5200]	[3500–4600]	[2900–4100]
People living with HIV (women, 15+)	19 000	21 000	22 000
	[17 000–21 000]	[18 000–23 000]	[20 000–24 000]
People living with HIV (men, 15+)	13 000	13 000	12 000
	[11 000–15 000]	[11 000–15 000]	[10 000–14 000]
HIV prevalence (15–49)	3.9 [3.6–4.4]	3.6 [3.3–4]	3 [2.7–3.4]




^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2010		US\$ 611 774			US\$ 3 959 113	US\$ 5 258 837

COUNTRY DATA

HIV TESTING AND TREATMENT CASCADE




All ages	6/% [59-/4%]	21 967	% [–%]
Children (0-14)	34% [28–39%]	34% [28–39%] 1173	% [%]
Women (15+)	75% [67–84%]	73% [65–81%] 16 016	% [%]
Men (15+)	61% [53–69%]	40% [35–46%] 4778	% [%]

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	14% [12–17%]	57% [46–66%]		
Final vertical transmission rate including during breastfeeding	35.7% [34–37.4%]	23.4% [21–25.4%]		
Early infant diagnosis	%	17.3% [15–21.4%]		

LIBERIA

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	2500	1900	1400	
	[2000–3200]	[1400–2700]	[810–2200]	
New HIV infections (0–14)	660	<500	<500	
	[<500–840]	[<500–530]	[<200-<500]	
New HIV infections (women, 15+)	1100	970	730	
	[800–1400]	[670–1300]	[<500–1100]	
New HIV infections (men, 15+)	790	610	<500	
	[590–1000]	[<500–850]	[<500–670]	
HIV incidence per 1000 population	0.67 [0.53–0.85]	0.45 [0.32–0.62]	0.29 [0.17–0.45]	
AIDS-related deaths				
AIDS-related deaths (all ages)	2900	2300	1300	
	[2400–3500]	[1900–2800]	[1000–1800]	
AIDS-related deaths (0–14)	570	<500	<200	
	[<500–680]	[<500-<500]	[<200-<500]	
AIDS-related deaths (women, 15+)	1300	1000	<500	
	[1100–1600]	[810–1200]	[<500–650]	
AIDS-related deaths (men, 15+)	990	940	660	
	[810–1300]	[790–1100]	[520–830]	
People living with HIV				
People living with HIV (all ages)	39 000	37 000	35 000	
	[34 000–46 000]	[32 000–44 000]	[29 000–43 000]	
People living with HIV (0–14)	5200	4100	2800	
	[4400–6100]	[3300–4900]	[2100–3700]	
eople living with HIV (women, 15+)	20 000	20 000	20 000	
	[17 000–23 000]	[17 000–23 000]	[17 000–24 000]	
People living with HIV (men, 15+)	14 000	13 000	12 000	
	[12 000–17 000]	[11 000–16 000]	[9800–15 000]	
HIV prevalence (15–49)	1.7 [1.5–1.9]	1.4 [1.2–1.6]	1.1 [0.9–1.4]	




^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2015	US\$ 8130			US\$ 10 272 345		US\$ 10 280 475

COUNTRY DATA

HIV TESTING AND TREATMENT CASCADE



		18 515	
Children (0–14)	31% [23–41%]	31% [23–41%] 842	% [%]
Women (15+)	76% [62–91%]	65% [54–78%] 13 216	48% [40–58%]
Men (15+)	55% [45–67%]	37% [30–45%] 4457	27% [22–33%]

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	26% [21–33%]	81% [62–100%]		
Final vertical transmission rate including during breastfeeding	31.3% [29.2–32.7%]	17.1% [11.8–21.5%]		
Early infant diagnosis	4.1% [3.2–5.7%]	20.1% [15.7–26.4%]		

MALI

COUNTRY DATA

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	7700	6400	5100	
	[5900–10 000]	[4500–8500]	[3300–8300]	
New HIV infections (0–14)	2700	2300	2100	
	[2200–3400]	[1700–3000]	[1500–2800]	
New HIV infections (women, 15+)	2800	2300	1700	
	[2000–3600]	[1500–3300]	[1000–2900]	
New HIV infections (men, 15+)	2200	1800	1400	
	[1600–2900]	[1300–2500]	[810–2300]	
HIV incidence per 1000 population	0.54 [0.41–0.7]	0.39 [0.27–0.51]	0.27 [0.17–0.43]	
AIDS-related deaths				
AIDS-related deaths (all ages)	6400	6100	4600	
	[5100–7900]	[4700–7600]	[3300–6300]	
AIDS-related deaths (0–14)	2200	1800	1500	
	[1800–2600]	[1300–2200]	[1100–1900]	
AIDS-related deaths (women, 15+)	2400	2000	1400	
	[1800–3100]	[1500–2600]	[1000–2000]	
AIDS-related deaths (men, 15+)	1900	2300	1600	
	[1500–2300]	[1800–2700]	[1200–2100]	
People living with HIV				
People living with HIV (all ages)	120 000	110 000	110 000	
	[99 000–130 000]	[95 000 –1 40 000]	[90 000–130 000]	
People living with HIV (0–14)	19 000	16 000	14 000	
	[16 000–22 000]	[14 000–20 000]	[11 000–18 000]	
People living with HIV (women, 15+)	57 000	58 000	59 000	
	[48 000–66 000]	[49 000–70 000]	[49 000–72 000]	
People living with HIV (men, 15+)	40 000	39 000	37 000	
	[34 000–47 000]	[32 000–46 000]	[30 000–45 000]	
HIV prevalence (15–49)	1.3 [1.1–1.5]	1.1 [0.9–1.4]	0.9 [0.7–1.1]	

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

Percentage of women and men aged 15–49 years who report discriminatory attitudes	2013	2015
towards people living with HIV (2015 refers to women only)	45.8	55.9
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		


STIGMA AND DISCRIMINATION

 -4	over-married	

Proportion of ever-married or partnered	2013	2018
women aged 15-49 years who experienced		
physical or sexual violence from a male		
intimate partner in the past 12 months	26.6	20.9

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


US\$ 20 632 751 US\$ 33 224 961 Last available report: 2019



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS Men who People who Transgender Sex workers Prisoners have sex inject drugs people with men Estimated size of population ... **HIV** prevalence 8.7% 12.6% 11.7% 1.6% HIV testing and status 100% 95.1% 100% awareness Antiretroviral therapy coverage ... 75 9% 41.8% Condom use 98% 60.6% Coverage of HIV prevention 54.4% programmes Avoidance of health care because of stigma and discrimination **Expenditures in US\$** ...

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION		
	2010	2020
Percentage of pregnant women living with HIV	28%	28%

 accessing antiretroviral medicines
 [24–34%]
 [23–36%]

 Final vertical transmission rate including during breastfeeding
 31.3%
 30.6%

 [29.2–33.4%]
 [27.5–33.2%]

Early infant diagnosis 6.1% 13.4% [5.1–7.4%] [10.6–16.7%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	1000 [670–1500]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Hai

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2018)	
— Women	15.6%
— Men	16.2%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2018)	
— Women	15.3%
— Men	39.1%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2018)	41.4%
Men aged 15–49 years who are circumcised (2013)	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	258

rm reduction		
 Use of sterile injecting equipment at last injection 		
 Needles and syringes distributed per person who injects (2017) 	2	
Coverage of opioid substitution		

Coverage of opioid substitution therapy
 Naloxone available (2021) No

Safe injection rooms available (2021)

No

MAURITANIA

COUNTRY DATA


EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)			
	[]	[]	[]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)			
	[–]	[]	[-]
New HIV infections (men, 15+)			
	[]	[]	[]
HIV incidence per 1000 population	[]	[]	[]
AIDS-related deaths			
AIDS-related deaths (all ages)	530	550	<500
	[<500–630]	[<500–680]	[<500–590]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100–<200]	[<100–<100]	[<100-<100]
AIDS-related deaths (women, 15+)	<200	<200	<200
	[<200–<200]	[<200–<500]	[<200-<500]
AIDS-related deaths (men, 15+)	<500	<500	<500
	[<500-<500]	[<500–<500]	[<200–<500]
People living with HIV			
People living with HIV (all ages)	9600	9000	8500
	[8400–11 000]	[7700–11 000]	[7000–11 000]
People living with HIV (0–14)	820	710	650
	[730–930]	[610–820]	[540–800]
People living with HIV (women, 15+)	3700	3700	3700
	[3200–4100]	[3100–4300]	[3100–4600]
People living with HIV (men, 15+)	5100	4700	4200
	[4400–6000]	[3900–5500]	[3400–5300]
HIV prevalence (15–49)	0.5 [0.4–0.6]	0.4 [0.3–0.5]	0.3 [0.2–0.4]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, death penalty
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

STIGMA AND DISCRIMINATION	N	
Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV (2015 refers to women only)	2011 70.5	2015 76
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months		

EXPENDITURES						
Financing sources						
Domestic private Domestic public International: Int						Total


US\$ 1 915 820 US\$ 2 731 148 Last available report: 2013



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population				•••		
HIV prevalence	9%	23.4%				
HIV testing and status awareness						
Antiretroviral therapy coverage						
Condom use						
Coverage of HIV prevention programmes						
Avoidance of health care because of stigma and discrimination						
Expenditures in US\$						

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION 2010 2020 Percentage of pregnant women living with HIV 9% 20%

accessing antiretroviral medicines	[8–11%]	[15–26%]
Final vertical transmission rate including during breastfeeding	% [–%]	% [%]
Early infant diagnosis	% [–%]	% [%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	120 [33–270]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults	aged	15+	years	with	unsuppressed
viral lo	ad				

Knowledge of HIV prevention among young people aged 15–24 years (2015)

— Women	8.3%
— Men	8.9%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

	Women	
_	vvomen	

_	M	en

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

NIGER

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	1300	1300	1200
	[1000–1600]	[1100–1600]	[910–1400]
lew HIV infections (0–14)	<500	<500	<500
	[<500-<500]	[<500–590]	[<500–570]
lew HIV infections (women, 15+)	600	510	<500
	[<500–730]	[<500–620]	[<500-<500]
New HIV infections (men, 15+)	<500	<500	<500
	[<500-<500]	[<500–<500]	[<500–<500]
HIV incidence per 1000 population	0.08 [0.06–0.1]	0.07 [0.06–0.08]	0.05 [0.04–0.06]
AIDS-related deaths			
AIDS-related deaths (all ages)	2200	1700	1100
	[1800–2700]	[1300–2000]	[870–1300]
AIDS-related deaths (0–14)	520	<500	<500
	[<500–610]	[<500–<500]	[<500-<500]
AIDS-related deaths (women, 15+)	630	<500	<500
	[<500 <u>–</u> 830]	[<500–550]	[<500-<500]
AIDS-related deaths (men, 15+)	1100	870	<500
	[830–1300]	[700–1100]	[<500–590]
eople living with HIV			
eople living with HIV (all ages)	37 000	33 000	31 000
	[33 000–42 000]	[30 000–37 000]	[28 000–35 000]
eople living with HIV (0–14)	5200	4000	3200
	[4500–6000]	[3400–4700]	[2700–3700]
eople living with HIV (women, 15+)	16 000	16 000	17 000
	[14 000–18 000]	[15 000–18 000]	[15 000–19 000]
eople living with HIV (men, 15+)	16 000	13 000	12 000
	[14 000–18 000]	[12 000–15 000]	[10 000–13 000]
HIV prevalence (15–49)	0.4 [0.4–0.5]	0.3 [0.3–0.3]	0.2 [0.2–0.2]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

residence permits or for certain groups

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	 	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their		


VIOLENCE

consent

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


US\$ 5 496 393 US\$ 7 110 841 Last available report: 2020 US\$ 9949



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS Men who People who Transgender Sex workers Prisoners have sex inject drugs people with men Estimated size of population 53 700 **HIV** prevalence 9.5% 6.4% HIV testing and status 83.7% 57.5% awareness Antiretroviral therapy coverage 92 7% Condom use 89.6% Coverage of HIV prevention 58.3% 53.4% ... programmes Avoidance of health care because of stigma and discrimination **Expenditures in US\$**

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	89% [77–100%]	36% [32–40%]
Final vertical transmission rate including during breastfeeding	14.1% [11.5–16.5%]	27.4% [25–29%]
Early infant diagnosis	% [–%]	2.9% [2.6–3.2%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	800 [510–1100]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.1%
Knowledge of HIV prevention among young people aged 15–24 years (2016)	
— Women	15.8%
— Men	25.5%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2012)	
— Women	35.1%
— Men	64.3%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not applicable

	аррисавіе
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy — Naloxone available (2021)

No

No

- Safe injection rooms available (2021)

NIGERIA

COUNTRY DATA


EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	110 000	95 000	86 000
	[63 000–210 000]	[52 000–170 000]	[47 000–150 000]
New HIV infections (0–14)	25 000	17 000	21 000
	[14 000–41 000]	[9800–28 000]	[12 000–34 000]
New HIV infections (women, 15+)	50 000	46 000	39 000
	[26 000–94 000]	[24 000–86 000]	[20 000–75 000]
New HIV infections (men, 15+)	41 000	33 000	25 000
	[21 000–78 000]	[17 000–63 000]	[13 000–49 000]
HIV incidence per 1000 population	0.72 [0.39–1.31]	0.53 [0.29–0.95]	0.42 [0.23–0.76]
AIDS-related deaths			
AIDS-related deaths (all ages)	68 000	48 000	49 000
	[42 000–110 000]	[29 000–78 000]	[30 000–80 000]
AIDS-related deaths (0–14)	18 000	11 000	12 000
	[10 000–30 000]	[6500–19 000]	[7000–21 000]
AIDS-related deaths (women, 15+)	26 000	16 000	16 000
	[15 000–44 000]	[9100–27 000]	[9300–28 000]
AIDS-related deaths (men, 15+)	25 000	20 000	20 000
	[15 000–41 000]	[13 000–34 000]	[12 000–33 000]
People living with HIV			
People living with HIV (all ages)	1 400 000	1 600 000	1 700 000
	[1 100 000–1 900 000]	[1 200 000–2 100 000]	[1 300 000–2 300 000]
People living with HIV (0–14)	150 000	130 000	130 000
	[100 000–230 000]	[89 000–200 000]	[85 000–190 000]
People living with HIV (women, 15+)	710 000	840 000	960 000
	[530 000–940 000]	[630 000–1 100 000]	[720 000–1 300 000]
People living with HIV (men, 15+)	550 000	610 000	650 000
	[420 000–740 000]	[460 000–820 000]	[490 000–860 000]
HIV prevalence (15–49)	1.4 [1.1–1.9]	1.4 [1–1.9]	1.3 [0.9–1.7]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	2016	2018
(2018 refers to women only)	52.8	59.2
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male	2013	2018
intimate partner in the past 12 months	10.9	13.8

STIGMA AND DISCRIMINATION

EXPENDITURES						
		Fina	ancing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020	US\$ 197 273	US\$ 91 477 781	US\$ 355 296 799	US\$ 80 370 485	US\$ 4 771 460	US\$ 532 371 498



150 000 Number of people 100 000 50 000 2000 2005 2010 2015 2020 AIDS-related deaths

25 20 Percent 15 10 0 2000 2005 2010 2015 2020 Incidence:prevalence ratio • • • • • Target

150 000 Number of people 100 000 50 000 2000 2005 2010 2015 2020 New HIV infections All-cause deaths among the HIV population

Change in new HIV infections since 2010

-26%

Change in AIDS--28% related deaths since 2010


Incidence: 4.94 prevalence ratio

mortality ratio

1.3

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population			326 100		
HIV prevalence	16.7%	20.9%	6.2%	18.5%	2.8%
HIV testing and status awareness	69.0%	58.5%	37.2%	59.0%	
Antiretroviral therapy coverage	23.7%	26.3%	25%	19.5%	
Condom use	85.5%	69.8%	46.5%	65.9%	
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

2010	2020
31%	44%
[21–44%]	[30–63%]
30.4%	24.9%
[24.8–36.1%]	[20.4–29.6%]
9.6%	23.4%
[6.6–14.7%]	[16.4–34.5%]
	31% [21–44%] 30.4% [24.8–36.1%] 9.6%

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	53 000 [34 000 –75 000]
People living with HIV who started TB preventive therapy (2018)	61.6%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.3%
Knowledge of HIV prevention among young people aged 15–24 years (2018)	
— Women	42.6%
— Men	33.7%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2018)	
— Women	35.7%
— Men	64.6%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2018)	35.7%
Men aged 15–49 years who are circumcised (2013)	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	37 736

Harm reduction

 Use of sterile injecting equipment at last injection 	
 Needles and syringes distributed per person who injects (2020) 	0


person who injects (2020)	
 Coverage of opioid substitution therapy 	
— Naloxone available (2021)	Yes

— Safe injection rooms available (2021)

SAO TOME AND PRINCIPE

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••		•••	•••	
HIV prevalence	1.4%	3.2%			8.2%
HIV testing and status awareness	100%	100%			
Antiretroviral therapy coverage					5.9%
Condom use	43.8%	60.8%			
Coverage of HIV prevention programmes	22.6%	82.5%			
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	38 [13–78]
People living with HIV who started TB preventive therapy (2018)	8.7%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years (2014)	
— Women	42.2%
— Men	43.2%
Condom use at last sex with a non-marital.	

non-cohabiting partner among people aged 15-49 years

— Women	
— Men	

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction	

 Use of sterile injecting equipment at last injection 	
 Needles and syringes distributed per person who injects 	
 Coverage of opioid substitution therapy 	
— Naloxone available (2021)	

- Safe injection rooms available (2021)

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

Last available report: 2014 US\$ 25 403 US\$ 30 800 US\$ 235 140 US\$ 751 806

COUNTRY DATA

LAWS AND POLICIES		STIGMA AND DISCRIMINATION	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No, but prosecutions exist based on general criminal laws	Percentage of women and men aged 15–49 years who report discriminatory attitudes	
Criminalization of sex work among consenting adults	Sex work is not subject to punitive regulations or is not criminalized	towards people living with HIV	
Criminalization of same-sex sexual acts	No specific legislation	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Drug use or possession for personal use is an offence		Percentage of people living with HIV who reported a health-care professional told	
Criminalization of transgender people	Neither criminalized nor prosecuted	others about their HIV status without their consent	
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE	
Parental consent for adolescents to access HIV testing	No	Proportion of ever-married or partnered women aged 15–49 years who experienced	
Spousal consent for married women to access sexual and reproductive health services	No	physical or sexual violence from a male intimate partner in the past 12 months	
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No		

SENEGAL

COUNTRY DATA


EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	2100	1300	1200
	[1800–2600]	[1100–1600]	[960–1600]
New HIV infections (0–14)	930	550	<500
	[770–1200]	[<500 <u>–</u> 670]	[<500-<500]
New HIV infections (women, 15+)	580	<500	<500
	[<500–730]	[<500–<500]	[<500–600]
New HIV infections (men, 15+)	630	<500	<500
	[510–810]	[<500–540]	[<500–670]
HIV incidence per 1000 population	0.18 [0.15–0.21]	0.1 [0.08–0.12]	0.08 [0.06–0.1]
AIDS-related deaths			
AIDS-related deaths (all ages)	1900	2100	1100
	[1500–2500]	[1600–2600]	[890–1300]
AIDS-related deaths (0–14)	710	550	<500
	[590–860]	[<500–660]	[<500–<500]
AIDS-related deaths (women, 15+)	<500	560	<500
	[<200– <500]	[<500–800]	[<500–<500]
AIDS-related deaths (men, 15+)	980	990	550
	[710–1300]	[770–1200]	[<500 <u>–</u> 680]
People living with HIV			
People living with HIV (all ages)	47 000	42 000	39 000
	[41 000–54 000]	[37 000–47 000]	[35 000–44 000]
People living with HIV (0-14)	6200	5300	3900
	[5300–7300]	[4600–6200]	[3300–4600]
People living with HIV (women, 15+)	21 000	21 000	21 000
	[18 000–25 000]	[19 000–23 000]	[19 000–24 000]
People living with HIV (men, 15+)	19 000	16 000	14 000
	[17 000–22 000]	[14 000–17 000]	[13 000–16 000]
HIV prevalence (15–49)	0.6 [0.5–0.7]	0.4 [0.4–0.5]	0.3 [0.3–0.4]


LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV (2017 refers to women only)	2013 53.4	2017 65.5
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		2012 2.7
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced	2017	2019
physical or sexual violence from a male intimate partner in the past 12 months	12.2	10.2


STIGMA AND DISCRIMINATION

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2014	US\$ 1 677 138	US\$ 2 033 864		US\$ 10 826 741	US\$ 2 654 137	US\$ 17 191 880









Change in new **HIV** infections since 2010

Change in AIDSrelated deaths since 2010

Incidence: 3.13 prevalence ratio

mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••	52 500		•••	9500
HIV prevalence	4.8%	27.6%	3.7%		2%
HIV testing and status awareness	98.0%	63.4%	100%		
Antiretroviral therapy coverage	28.3%	37.8%			
Condom use	91.6%	75.8%	54.1%		
Coverage of HIV prevention programmes	65.5%	6.4%			
Avoidance of health care because of stigma and discrimination	19.1%				
Expenditures in US\$ (2014)	253 522	448 688	171 534		

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	910 [640–1200]
People living with HIV who started TB preventive therapy (2018)	10.4%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.1%
Knowledge of HIV prevention among young people aged 15–24 years (2017)	
— Women	26.2%
— Men	33.1%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2017)	
— Women	41.8%
— Men	70.8%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2017)	54.1%
Men aged 15–49 years who are circumcised	Not applicable

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	21% [19–25%]	74% [66–84%]
Final vertical transmission rate including during breastfeeding	27.4% [25–29.7%]	16.1% [14–19.6%]
Early infant diagnosis	11% [9.6–12.7%]	34.9% [30.7-39.4%]

Harm reduction

Voluntary medical male circumcisions

performed according to national standards

People who received PrEP at least once

during the reporting period (2020)

Use of sterile injecting equipment at last injection	
 Needles and syringes distributed per person who injects (2020) 	16
 Coverage of opioid substitution therapy (2020) 	10.4%
— Naloxone available (2021)	No

- Safe injection rooms available (2021)

applicable

Not

applicable

83

No

SIERRA LEONE

COUNTRY DATA


EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	6500	6200	5400
	[5500–7600]	[5100–7200]	[3900–7100]
New HIV infections (0–14)	2300	2000	2000
	[1800–2800]	[1500–2500]	[1400–2500]
New HIV infections (women, 15+)	2300	2500	2100
	[1900–2800]	[2000–3000]	[1500–3000]
New HIV infections (men, 15+)	1900	1700	1300
	[1600–2300]	[1300–2100]	[850–1800]
HIV incidence per 1000 population	1.05 [0.9–1.22]	0.9 [0.74–1.05]	0.7 [0.51–0.92]
AIDS-related deaths			
AIDS-related deaths (all ages)	4400	4200	3200
	[3700–5400]	[3500–4900]	[2700–3800]
AIDS-related deaths (0–14)	1700	1500	1400
	[1400–2100]	[1200–1800]	[1000–1700]
AIDS-related deaths (women, 15+)	1400	1200	720
	[1100–1800]	[900–1500]	[530–930]
AIDS-related deaths (men, 15+)	1200	1500	1100
	[980–1600]	[1200–1800]	[930–1400]
People living with HIV			
People living with HIV (all ages)	66 000	73 000	80 000
	[59 000–76 000]	[66 000–82 000]	[70 000–90 000]
People living with HIV (0–14)	13 000	12 000	11 000
	[11 000–16 000]	[10 000–15 000]	[9000–14 000]
People living with HIV (women, 15+)	30 000	36 000	42 000
	[27 000–34 000]	[32 000–40 000]	[37 000–48 000]
People living with HIV (men, 15+)	23 000	25 000	26 000
	[20 000–27 000]	[22 000–28 000]	[23 000–30 000]
HIV prevalence (15–49)	1.6 [1.4–1.8]	1.6 [1.4–1.8]	1.5 [1.3–1.7]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV (2017 refers to women only)	2011 51.2	2017 72.1
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		2013 1.2
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced	2013	2019
physical or sexual violence from a male intimate partner in the past 12 months	28.6	39.9

STIGMA AND DISCRIMINATION


EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2011	US\$ 40 385	US\$ 168 584	US\$ 2 957 997	US\$ 3000	US\$ 3 394 829	US\$ 20 905 243



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••		•••	•••	
HIV prevalence	6.7%	14%	8.5%	15.3%	8.7%
HIV testing and status awareness					
Antiretroviral therapy coverage					
Condom use					
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	23% [19–28%]	46% [37-55%]
Final vertical transmission rate including during breastfeeding	29.2% [27.8–30.8%]	23.1% [20.4–25.3%]
Early infant diagnosis	<1% [<1– <1%]	2.8% [2.4–3.6%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	2900 [1900 –4200]
People living with HIV who started TB preventive therapy (2018)	56.7%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load

Knowledge of HIV prevention among young people aged 15-24 years (2013)

— Women	28.8%
— Men	30%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49 years (2013)

— Women	6.8%
— Men	19.4%

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged	15-49 years	who	are	circumcised	Not
(2013)					applicable

Voluntary medical male circumcisions	Not

performed according to national standards	applicable
People who received PrEP at least once during the reporting period	

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021) No
- Safe injection rooms available (2021)

TOGO

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	7500	5200	3600
	[6800–8400]	[4800–5900]	[3300–3900]
New HIV infections (0–14)	2300	1300	1200
	[1900–2500]	[960–1600]	[820–1400]
New HIV infections (women, 15+)	3100	2500	1600
	[2700–3700]	[2100–2900]	[1400–1900]
New HIV infections (men, 15+)	2200	1500	810
	[1900–2600]	[1200–1800]	[690–1000]
HIV incidence per 1000 population	1.24 [1.13–1.4]	0.76 [0.69–0.86]	0.45 [0.42–0.5]
AIDS-related deaths			
AIDS-related deaths (all ages)	6600	4600	3000
	[6100–7400]	[4100–5300]	[2600–3400]
AIDS-related deaths (0–14)	1900	1100	810
	[1700–2000]	[840–1200]	[580–940]
AIDS-related deaths (women, 15+)	2800	1600	960
	[2500–3300]	[1300–2000]	[790–1200]
AIDS-related deaths (men, 15+)	1900	1900	1200
	[1700–2300]	[1700–2300]	[1000–1500]
People living with HIV			
People living with HIV (all ages)	110 000	110 000	110 000
	[110 000–120 000]	[110 000–120 000]	[110 000–120 000]
People living with HIV (0–14)	17 000	13 000	9700
	[16 000–18 000]	[11 000–14 000]	[7700 –1 1 000]
People living with HIV (women, 15+)	58 000	62 000	66 000
	[55 000–62 000]	[59 000–66 000]	[62 000–70 000]
People living with HIV (men, 15+)	38 000	39 000	36 000
	[36 000–42 000]	[36 000–42 000]	[34 000–39 000]
HIV prevalence (15–49)	2.8 [2.8–2.8]	2.5 [2.4–2.5]	2 [1.9–2.1]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

STIGMA AND DISCRIMINATION


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	
	 •••
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Percentage of people living with HIV who	2020

Percentage of people living with HIV who	2020
reported a health-care professional told	
others about their HIV status without their	
consent	13

VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2019	US\$ 1 964 091	US\$ 3 843 147	US\$ 2 905 953	US\$ 8 642 402	US\$ 1 467 324	US\$ 20 503 500



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population				•••	5000
HIV prevalence	13.2%	22%			4.7%
HIV testing and status awareness	96.8%	95.4%	44.7%		
Antiretroviral therapy coverage	66.9%	61.7%	1%		
Condom use	86.4%	80.2%			
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2019)	214 380	1 072 822	10 239	9600	2010

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	29% [24–32%]	64% [51–71%]
Final vertical transmission rate including during breastfeeding	31.4% [29.9–32.8%]	20.8% [17.8–22.2%]
Early infant diagnosis	17.2% [13.7–23%]	33.4% [30.1–41.6%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	490 [390–600]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2014)	
— Women	23.3%
— Men	31.6%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2014)	
— Women	42.9%
— Men	60.7%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised (2014)	Not applicable
Voluntary medical male circumcisions	Not

Harm reduction

arrii i caaction	
 Use of sterile injecting equipment at last injection 	
 Needles and syringes distributed per person who injects (2020) 	2
 Coverage of opioid substitution therapy 	

applicable

No

performed according to national standards

People who received PrEP at least once

— Naloxone available (2021)

- Safe injection rooms available (2021)

during the reporting period

ASIA AND THE PACIFIC

rogress against HIV in Asia and the Pacific continues to be uneven. Several countries have achieved wide and effective coverage of testing and treatment services, and Thailand and Viet Nam have reduced new HIV infections by at least 50% since 2010. Some countries are focusing on sustaining and integrating their HIV programmes in their overall health system and as part of efforts to achieve universal health coverage.

Contrary trends in other countries, however, saw new HIV infections in the region decline by only 21% overall between 2010 and 2020. Rapidly growing HIV epidemics are underway among key populations in countries such as Indonesia, Pakistan and the Philippines, with gay men and other men who have sex with men especially affected. Across the region, over 94% of new HIV infections are among key populations and their sexual partners, and more than one quarter of new infections are among young people (aged 15 to 24 years).

The centrality of community-led services became even more evident during the COVID-19 pandemic. Across the region, community-led organizations ensured the continuity of vital HIV services and commodities, including pre-exposure prophylaxis (PrEP) and antiretroviral therapy. These organizations operate in less-than-ideal conditions, however: despite positive legislative changes in some countries, hostile legal environments and policing practices—and stigma and discrimination—hinder the provision and use of HIV services for populations that need them the most.


The transition from a reliance on external funding to domestic financing of essential services for HIV, sexually transmitted infections (STIs) and viral hepatitis is proving to be a challenge for several countries, especially in the context of economic setbacks caused by the COVID-19 pandemic.

Moving forward, service delivery for combination HIV prevention and treatment needs to be modernized and diversified using innovative approaches, with improved investments in better programme management, coordination and capacity.

PRIORITY ACTIONS FOR ENDING AIDS

- Emphasize rightsbased approaches in policies and programmes, and tackle harmful social norms.
- Modernize differentiated service delivery, including scale-up of combination HIV prevention (particularly PrEP and harm reduction interventions), selftesting, multimonth dispensing, and maximizing the benefits of U = U (Undetectable = Untransmittable).
- Eliminate stigma and discrimination and other barriers to equitable service coverage.
- Mobilize sustainable domestic financing for prevention and treatment.
- Ensure inclusive and gender-responsive approaches, especially for young key populations.
- Reframe country responses to address inequalities through civil society and community engagement.

STATUS OF PRE-EXPOSURE PROPHYLAXIS (PREP) AVAILABILITY AND NUMBER OF PREP USERS, ASIA AND THE PACIFIC, 2020




Source: Global AIDS Monitoring, 2021; National Commitments and Policy Instrument and information from national programmes; Monitoring HIV pre-exposure prophylaxis uptake in Australia. Issue number 3. Sydney: University of New South Wales and the Kirby Institute; 2020. ^a Data on people receiving PrEP not available for India.

^b PrEP pilot/demonstration in Lao People's Democratic Republic was launched in January 2021.


STATE OF THE PANDEMIC

NUMBER OF NEW HIV INFECTIONS AND AIDS-RELATED DEATHS, ASIA AND THE PACIFIC, 2000–2020




Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).

DISTRIBUTION OF NEW HIV INFECTIONS BY POPULATION GROUP AND SEX (AGED 15–49 YEARS), ASIA AND THE PACIFIC, 2020



Source: UNAIDS special analysis, 2021 (see methods annex).


HIV PREVALENCE AMONG KEY POPULATIONS, REPORTING COUNTRIES IN ASIA AND THE PACIFIC, 2016–2020



- Sex workers (n = 19)
- Gay men and other men who have sex with men (n = 18)
- People who inject drugs (n = 13)
- Transgender people (n = 11)
- Prisoners (n = 10)

Source: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/). Note: (n = number of countries). Total number of reporting countries = 41. Additional countries have reported after the release of the Global Report. Their results, not included in this figure, are shown in the specific country sheets

How to read this chart



REPORTED ESTIMATED SIZE OF KEY POPULATIONS, ASIA AND THE PACIFIC, 2018–2020

	National adult population (aged 15–49 years) in 2020 or relevant year	Sex workers	Sex workers as per cent of adult population (aged 15-49 years)	Gay men and other men who have sex with men	Gay men and other men who have sex with men as per cent of adult population (aged 15–49 years)	People who inject drugs	People who inject drugs as per cent of adult population (aged 15–49 years)	Transgender people	Transgender people as per cent of adult population (aged 15–49 years)	Prisoners	Prisoners as per cent of adult population (aged 15-49 years)
Afghanistan	18 800 000			10 100		25 700					
Bhutan	440 000	600	0.14%					380	0.09%		
Cambodia	9 200 000										
India	752 000 000										
Indonesia	144 000 000	278 000	0.19%			34 500	0.02%	34 700	0.02%	268 000	0.19%
Lao People's Democratic Republic	3 800 000										
Malaysia	18 200 000	37 000	0.20%			75 000	0.41%				
Mongolia	1 700 000	6000		6500							
Nepal	15 000 000									22 000	0.15%
New Zealand	2 200 000									10 000	0.46%
Papua New Guinea	4 600 000	48 000	1.05%	36 000	0.78%						
Philippines	58 200 000	228 000	0.39%	681 000	1.17%	10 800	0.02%	204 000	0.35%		
Singapore	1 800 000									11 900	0.66%
Sri Lanka	10 300 000	30 000	0.29%	74 000	0.72%	2700	0.03%	2200	0.02%		
Thailand	34 200 000									358 000	1.05%
Viet Nam	51 600 000			256 000	0.50%						
Estimated regional proportion as per ceadult population (aged 15–49 years) ^a .	ent of		0.18%		0.82%		0.03%		0.01%		-

Sources: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/); Spectrum Demproj module, 2021.

Note 1: Estimates shown are government-provided estimates reported for 2018–2020. Additional and alternative estimates may be available from different sources, including the Key Populations Atlas (https://kpatlas.unaids.org/), academic publications or institutional documents. Note 2: The regions covered by the local population size estimates are as follows:

Afghanistan: Herat, Jalalabad, Kabul, Kandahar, Kunduz and Mazar (gay men and other men who have sex with men); Faizabad, Herat, Jalalabad, Kabul, Kandahar, Kunduz, Mazar and Zaranj (people who inject drugs).

Mongolia: Darkhan, Dornod, Khövsgöl and Ulaanbaatar (sex workers); Darkhan, Dornod, Orkhon and Ulaanbaatar (gay men and other men who


Note 3: The reported values for gay men and other men who have sex with men are presented as a per cent of the adult population (aged 15-49 years) for consistency across key populations. The percentage of this population out of the adult male population (aged 15-49 years) will be approximately twice the values shown.

^a Quick Start Guide for Spectrum, 2020. Geneva: UNAIDS; 2020 (https://www.unaids.org/sites/default/files/media_asset/QuickStartGuide_ Spectrum_en.pdf).

^b Technical brief: recommended population size estimates of men who have sex with men. Geneva: WHO, UNAIDS; 2020.

HIV SERVICES

PEOPLE LIVING WITH HIV, PEOPLE NEWLY INFECTED IN THE PAST SIX MONTHS, AND HIV TESTING AND TREATMENT CASCADE, ADULTS (AGED 15+ YEARS), ASIA AND THE PACIFIC, 2016–2020



Source: UNAIDS special analysis, 2021.

HIV TESTING COVERAGE AMONG KEY POPULATIONS, ASIA AND THE PACIFIC, 2016–2020





Source: Integrated biological and behavioral surveys, 2016–2020.

Note: Data were calculated based on 15 reporting countries for female sex workers and gay men and other men who have sex with men, nine reporting countries for transgender people, and 13 reporting countries for people who inject drugs.


Number of children

HIV TESTING AND TREATMENT CASCADE, CHILDREN (AGED 0-14 YEARS) COMPARED TO ADULTS (AGED 15 YEARS AND OLDER), ASIA AND THE PACIFIC, 2020







Adults (aged 15 years and older) living with HIV




Source: UNAIDS special analysis, 2021.

HIV TESTING AND TREATMENT CASCADE, WOMEN (AGED 15+ YEARS) COMPARED TO MEN (AGED 15+ YEARS), ASIA AND THE PACIFIC, 2020






Men (aged 15+ years) living with HIV




Source: UNAIDS special analysis, 2021.

INNOVATIVE ONLINE-TO-OFFLINE MODEL TO IMPROVE THE HIV TESTING SERVICE CASCADE, BY SELECTED POPULATION GROUP, VIET NAM, OCTOBER 2018 TO MARCH 2021

Online-to-offline HIV testing through online outreach workers




Online-to-offline HIV testing through appointment booking app



Source: USAID/PATH Healthy Markets Program data.


Note: Data are for transgender people and gay men and other men who have sex with men.

PROPORTION OF NEW ANTIRETROVIRAL THERAPY INITIATIONS, PEOPLE ON ANTIRETROVIRAL THERAPY AND TREATMENT GAP AMONG PEOPLE LIVING WITH HIV, ASIA AND THE PACIFIC, 2020



Source: UNAIDS epidemiological estimates, 2021; UNAIDS Global AIDS Monitoring, 2021; and Sankalak: Status of National AIDS Response. Second ed. New Delhi: NACO, Ministry of Health and Family Welfare [India]; 2020.

PROPORTION OF TUBERCULOSIS PATIENTS LIVING WITH HIV WHO ARE ON ANTIRETROVIRAL THERAPY, ASIA AND THE PACIFIC, 2019



Source: Global tuberculosis report 2020. Geneva: WHO; 2020.

^a Excluding new antiretroviral therapy initiation.

^b Country published estimates.

LAWS AND POLICIES

PUNITIVE AND DISCRIMINATORY LAWS, ASIA AND THE PACIFIC, 2021

POLICIES	Criminalization of transgender people	Criminalization of sex work	Criminalization of same-sex sexual acts	Law allows for possession of a certain limited amount of drugs for personal use	Parental consent for adolescents to access HIV testing	Laws criminalizing the transmission of, non-disclosure of or exposure to HIV transmission	Laws or policies restricting the entry, stay and residence of people living with HIV	Mandatory HIV testing for marriage, work or residence permits or for certain groups
Afghanistan	1	1	1	1	1	1		1
Australia	4	6	20			26		
Bangladesh	2	1	21		2	No1		2
Bhutan	1	1				26		1
Brunei Darussalam	4	7	20			26		2
Cambodia	1	1	1	1				1
China	1	1	1	1	1	1		1
Cook Islands						26		
Democratic People's Republic of Korea		8	20					
Fiji	3	1	1	1		27		
India	2	2	2	2		2		2
Indonesia	1	1	33	1	1	1		1
Japan		9	20					1
Kiribati	2	1	20	1		2		2
Lao People's Democratic Republic	1	1	1	1				1
Malaysia	5	1		1	2	28		1
Maldives	4	10	20			26		
Marshall Islands	3	11	20			29		3
Micronesia (Federated States of)	3	12	20			3		3
Mongolia	1	32	2			2		2
Myanmar	2	2	22			2		2
Nauru	3	13	20			3		3
Nepal	1	1		1		1		1
New Zealand	2	2	2					2
Niue	3							3
Pakistan	4	1	1	1		1		1
Palau	3	14	20			3		31
Papua New Guinea	1	1	23	1				1
Philippines	1	1	1	1				1
Republic of Korea	2	2	34					2
Samoa	3	15	20		25			25
Singapore	2	1		1	1	2		2
Solomon Islands		16	20					2
Sri Lanka	1	1	24	1		1		1
Thailand	1	1	1	1	1	1		1
Timor-Leste			20					
Tonga	3	17	20			3		3
Tuvalu	3	18	20			3		3
Vanuatu	3	19	20			3		3
Viet Nam	2		2			30		3

Criminalization of transgender people	Law allows for possession of a certain limited amount of	Laws or policies restricting the entry, stay and residence
Criminalized and/or prosecuted	drugs for personal use	of people living with HIV
■ Neither criminalized nor prosecuted	No	Deport, prohibit short and/or long stay and require
Data not available	Yes	HIV testing or disclosure for some permits
	Data not available	Prohibit short and/or long stay and require HIV
Criminalization of sex work		testing or disclosure for some permits
Any criminalization or punitive regulation of sex work	Parental consent for adolescents to access HIV testing	Require HIV testing or disclosure for some permits
Sex work is not subject to punitive regulations or is	Yes, for adolescents younger than 18	■ No restrictions
not criminalized	Yes, for adolescents younger than 14 or 16	Data not available
Issue is determined/differs at the subnational level	Yes, for adolescents younger than 12	
Data not available	No	Mandatory HIV testing for marriage, work or residence
	Data not available	permits or for certain groups
Criminalization of same-sex sexual acts		Yes
Death penalty	Laws criminalizing the transmission of,	No
Imprisonment (14 years–life, up to 14 years)	non-disclosure of or exposure to HIV transmission	Data not available
or no penalty specified	Yes	
Laws penalizing same-sex sexual acts have been	No, but prosecutions exist based on general	
decriminalized or never existed, or no specific	criminal laws	
legislation	■ No	
Data not available	Data not available	

Sources

- 1. UNAIDS National Commitments and Policy Instrument, 2021 (see http://lawsandpolicies.unaids.org/).
- 2. UNAIDS National Commitments and Policy Instrument, 2019 (see http://lawsandpolicies.unaids.org/).
- 3. UNAIDS National Commitments and Policy Instrument, 2017 (see http://lawsandpolicies.unaids.org/).
- 4. Chiam Z, Duffy S, González Gil M, Goodwin L, Mpemba Patel NT. Trans legal mapping report 2019: recognition before the law. Geneva: ILGA World: 2020.
- 5. Legal gender recognition in Malaysia: a legal and policy review in the context of human rights. Bangkok: Asia Pacific Transgender Network and SEED Malaysia; 2017 (https://www.undp.org/content/dam/rbap/docs/Research%20&%20Publications/hiv_aids/Malaysia-APTN_Publication_OnlineViewing.pdf).
- 6. South Australia. Summary Offences Act 1953. Section 25; Victoria. Sex Work Act 1994. Section 13; New South Wales. Summary Offence Act 1988. Section 19; Western Australia. Prostitution Act 2000. s25.
- 7. Brunei Darussalam. Penal Code 1951 (2016 edition). Prostitution, S 26/2012, section 294A (https://www.ilo.org/dyn/natlex/docs/ELECTRON-IC/78238/83493/F1602044948/BRN78238%202016%20Edition.pdf).
- 8. Democratic People's Republic of Korea. Criminal Law. Article 261 (Prostitution) (https://www.hrnk.org/uploads/pdfs/The%20Criminal%20 Law%20of%20the%20Democratic%20Republic%20of%20Korea_2009_%20(1).pdf).
- 9. Japan. Anti-Prostitution Law (1956).
- 10. Maldives. Penal Code 2014. Sections 615, 620 and 621 (https://www.law.upenn.edu/live/files/4203-maldives-penal-code-2014).
- 11. Marshall Islands. Criminal Code 2011. Article 251 (http://rmiparliament.org/cms/images/LEGISLATION/PRINCIPAL/2011/2011-0059/Criminal-Code 2011. 1 pdf)
- 12. Federated States of Micronesia. Chuuk State Code. Title 12, Chapter 28 (http://fsmlaw.org/chuuk/code/title12/T12_CH28.htm).
- Nauru. Crimes Act 2016. Section 107 (https://tbinternet.ohchr.org/Treaties/CEDAW/Shared%20Documents/NRU/INT_CEDAW_ARL_ NRU_28029_E.pdf).
- 14. Palau. Code of Palau. Anti-Prostitution Act. Chapter 36 (https://www.legal-tools.org/doc/1c32a2/pdf/).
- 15. Samoa. Crimes Act 2013. Sections 72 and 73 (https://www.ilo.org/dyn/natlex/natlex4.detail?p_lang=en&p_isn=93579&p_country=WSM&p_classification=01.04).
- 16. Solomon Islands. Penal Code. Section 153 (http://www.paclii.org/sb/legis/consol_act/pc66/).
- 17. Tonga. Criminal Offences Act. Section 81(4) (https://www.ilo.org/dyn/natlex/docs/ELECTRONIC/73337/95725/F665862081/TON73337.pdf).
- 18. Tuvalu. Penal Code. Sections 145 and 146 (http://tuvalu-legislation.tv/cms/images/LEGISLATION/ PRINCIPAL/1965/1965-0007/PenalCode_1.pdf).
- 19. Vanuatu. Penal Code. Section 148 (https://www.ilo.org/dyn/natlex/docs/ELECTRONIC/88512/101229/ F1616956608/VUT88512.pdf).
- 20. Mendos LR. State-sponsored homophobia, 2020. Geneva: International Lesbian, Gay, Bisexual, Trans and Intersex Association; December 2020 (https://ilga.org/downloads/ILGA_State_Sponsored_Homophobia_2019_light.pdf).
- 21. Bangladesh. Penal Code, 1860. Article 377 (http://bdlaws.minlaw.gov.bd/act-11/section-3233.html).
- 22. Myanmar. Penal Code. Art 377 (https://www.wipo.int/edocs/lexdocs/laws/en/mm/mm004en.pdf).
- 23. Papua New Guinea. Criminal Code Act 1974. Article 210 (http://www.paclii.org/pg/legis/consol_act/cca1974115.pdf).
- 24. Sri Lanka. Penal Code, 1885. Article 365 (http://hrlibrary.umn.edu/research/srilanka/statutes/Penal_Code.pdf).
- 25. UNAIDS National Commitments and Policy Instrument, 2018 (http://lawsandpolicies.unaids.org/).
- 26. Global HIV Criminalisation Database [database]. Amsterdam: HIV Justice Network (https://www.hivjustice.net/global-hiv-criminalisation-database/).
- 27. Fiji, Crimes Act. 2009, Part 18, Division 2, Section 383.
- 28. Malaysia. Penal Code, 2018. Articles 269–270 (https://www.ilo.org/dyn/natlex/docs/ELECTRONIC/61339/117909/F-833274986/MYS61339%20 2018.pdf).
- 29. Marshall Islands. Communicable Diseases Prevention and Control Act, 1988. S 1511 (http://rmiparliament.org/cms/images/LEGISLATION/PRINCIPAL/1988/1988-0028/CommunicableDiseasesPreventionandControlAct1988_1.pdf).
- 30. Viet Nam. Law on HIV/AIDS Prevention and Control (https://www.ilo.org/wcmsp5/groups/public/---ed_protect/---protrav/---ilo_aids/documents/legaldocument/wcms_113364.pdf).
- 31. Still not welcome: HIV-related travel restrictions. Geneva: UNAIDS, UNDP; 2019 (https://www.unaids.org/sites/default/files/media_asset/hiv-related-travel-restrictions-explainer_en.pdf).
- 32. Mongolia. Criminal Code. Article 124.2 (https://www.warnathgroup.com/wp-content/uploads/2015/03/Mongolia-Criminal-Code.pdf).
- 33. Indonesia. Criminal Code (Qanun Jinayat), Aceh Regulation No. 6/2014.
- 34. Republic of Korea. Military Criminal Act, 2016. Article 92-6 (https://elaw.klri.re.kr/eng_service/lawView.do?hseq=40239&lang=ENG).


Note: A country is considered to have criminalized transgender persons if it uses the law to punish transgender individuals. Such a law may, for example, explicitly criminalize impersonation of the other gender, including cross-dressing. A country is considered to have any criminalization or punitive regulation of sex work if selling and/or buying sexual services is criminalized, ancillary activities associated with selling and/or buying sexual services are criminalized, profiting from organizing and/or managing sexual services is criminalized, and/or there are other punitive and/or administrative regulations of sex work.

INVESTING TO END AIDS

Despite a steady increase in domestic investments, the total amount of resources available for HIV responses in Asia and the Pacific has remained stable over the last five years. HIV resources from domestic sources have doubled since 2010, but this has been offset by a 50% decline from international sources during the same period. Investments from the United States Government's bilateral contributions, the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) and other international sources have declined by 12%, 10% and 72%, respectively, since 2010.

In 2020, US\$ 3.5 billion was available for the HIV response in the region, 82% of which came from domestic funding. The Global Fund contributed 7% of the overall resources in 2020, and bilateral contributions from the United States Government represented 5%. There is a US\$ 5.7 billion gap between the resources available and the US\$ 9.2 billion needed to reach the region's annual resource needs in 2025.


RESOURCE AVAILABILITY FOR HIV, ASIA AND THE PACIFIC, 2010–2020, AND ESTIMATED RESOURCE NEEDS FOR HIV BY 2025



Source: UNAIDS financial estimates and projections, 2021 (http://hivfinancial.unaids.org/hivfinancialdashboards.html).

Note: The resource estimates are presented in constant 2019 US dollars.

YEAR-TO-YEAR CHANGE IN RESOURCE AVAILABILITY FOR HIV, ASIA AND THE PACIFIC, 2010–2011 TO 2019–2020



Source: UNAIDS financial estimates, 2021 (http://hivfinancial.unaids.org/hivfinancialdashboards.html).



AFGHANISTAN

COUNTRY DATA


EPIDEMIC ESTIMATES			
	2010	2015	2020
lew HIV infections			
lew HIV infections (all ages)	710	1100	1600
	[<500–1800]	[<500 <u></u> 4000]	[<500 <u>–</u> 6100]
lew HIV infections (0–14)	<100	<100	<200
	[<100- <200]	[<100-<500]	[<100–<500]
lew HIV infections (women, 15+)	<200	<500	<500
	[<100- <500]	[<200–1000]	[<200–1700]
lew HIV infections (men, 15+)	<500	740	1000
	[<200–1200]	[<500–2600]	[<500–4100]
IIV incidence per 1000 population	0.03 [0.01–0.07]	0.03 [0.01–0.12]	0.04 [0.01–0.16]
AIDS-related deaths			
NDS-related deaths (all ages)	<500	<500	540
	[<200–580]	[<200–1000]	[<200–1900]
IDS-related deaths (0–14)	<100	<100	<100
	[<100- <200]	[<100-<200]	[<100- <500]
NDS-related deaths (women, 15+)	<100	<100	<200
	[<100– <200]	[<100- <500]	[<100– <500]
NDS-related deaths (men, 15+)	<200	<500	<500
	[<100-<500]	[<100 <u>–</u> 630]	[<200–1200]
eople living with HIV			
eople living with HIV (all ages)	4600	7600	12 000
	[2300–11 000]	[3600–21 000]	[4700–43 000]
eople living with HIV (0-14)	<500	<500	560
	[<200–630]	[<500–1000]	[<500–1800]
eople living with HIV (women, 15+)	1200	2100	3300
	[620–2800]	[960–5600]	[1300–11 000]
eople living with HIV (men, 15+)	3100	5200	8000
	[1500–7300]	[2400–15 000]	[3200–30 000]
IIV prevalence (15–49)	<0.1 [<0.1–<0.1]	<0.1 [<0.1–0.1]	<0.1 [<0.1–0.2]


LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, death penalty
Drug use or possession for personal use is an offence	The law allows possession of a certain amount of drugs
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No


Percentage of women aged 15–49 years who report discriminatory attitudes towards	 2015
people living with HIV	 60.2
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent	
VIOLENCE	
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male	2015
intimate partner in the past 12 months	46.1


STIGMA AND DISCRIMINATION

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2018		US\$ 140 861		US\$ 9 936 908	US\$ 124	US\$ 10 077 893









Change in new **HIV** infections since 2010

Change in AIDS-123% related deaths since 2010

Incidence: 13.18 prevalence ratio

mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS							
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners		
Estimated size of population					•••		
HIV prevalence							
HIV testing and status awareness							
Antiretroviral therapy coverage							
Condom use							
Coverage of HIV prevention programmes							
Avoidance of health care because of stigma and discrimination							
Expenditures in US\$ (2018)	49 958	84 407	1 607 200				

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	320 [120–640]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2015)	
— Women	1%
— Men	6.3%
Condom use at last sex with a non-marital.	

Women aged 15-49 years who have their demand for family planning satisfied by modern methods (2015)

42.2%

No

Men aged (2015)	15–49	years	who	are	circumcised	Not applica	
							_

Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION			
	2010	2020	
Percentage of pregnant women living with HIV accessing antiretroviral medicines	2% [1–5%]	10% [4–33%]	
Final vertical transmission rate including during breastfeeding	48.4% [44.6–53.4%]	45% [38.8–50.4%]	
Early infant diagnosis	% [–%]	4.8% [1.4–12.5%]	

Ha

- Women

— Men

arm reduction	
 Use of sterile injecting equipment at last injection 	
 Needles and syringes distributed per person who injects (2020) 	102
 Coverage of opioid substitution therapy (2020) 	4.7%
— Naloxone available (2021)	Yes

Safe injection rooms available (2021)

AUSTRALIA

COUNTRY DATA

AIDS-related deaths (all ages) AIDS-related deaths (all ages) AIDS-related deaths (0-14) AIDS-related deaths (0-14) AIDS-related deaths (women, 15+) AIDS-related deaths (women, 15+) AIDS-related deaths (men, 15+) AI	TES	
New HIV infections (all ages) 1000 1000 750 1570-940 1770-1200 1770-1300 1570-940 1570-940 1770-1300 1570-940	2010 2015	2020
IV infections (men, 15+) [640–1100] [630–1100] [<500–820] [(5	E+/	
AIDS-related deaths Side	1	
Coople living with HIV (0-14) Coople living with HIV (0-14	0.05 [0.04–0.06] 0.04 [0.03–0.05	5] 0.03 [0.02–0.04]
(200 < 500) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100 < 100) (<100		
Carrelated deaths (women, 15+) Carrelated deaths (women, 15+) Carrelated deaths (men, 1		 []
Carrelated deaths (men, 15+)	15+\	
21 000 26 000 30 000 [17 000–23 000] [21 000–29 000] [24 000–34 000]	L)	
eople living with HIV (all ages) [17 000–23 000] [21 000–29 000] [24 000–34 000] eople living with HIV (0–14)		
eople living with HIV (0–14) [–] [–]		
2400 2400 4100		
ceople living with HIV (women, 15+) [2200–2900] [2900–3800] [3500–4600]	n, 15+) 2600 3400 [2200–2900] [2900–3800]	4100 [3500–4600]
eople living with HIV (men, 15+) 18 000 22 000 25 000 [15 000–21 000] [18 000–25 000] [20 000–29 000]	5+)	
HIV prevalence (15–49) 0.1 [<0.1–0.1] 0.1 [<0.1–0.1] 0.1 [<0.1–0.1]	0.1 [<0.1–0.1]	0.1 [<0.1–0.1]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No, but prosecutions exist based on general
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	
Laws or policies restricting the entry, stay and residence of people living with HIV	Yes
Parental consent for adolescents to access HIV testing	
Spousal consent for married women to access sexual and reproductive health services	
Mandatory HIV testing for marriage, work or	

residence permits or for certain groups

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49

years who report discriminatory attitudes towards people living with HIV	
	 •••
Percentage of people living with HIV denied health services because of their HIV status in	•••
the last 12 months	


Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent


VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 101 415 112 US\$ 101 415 112 Last available report: 2006







500

400

300





Change in new -25% **HIV** infections since 2010

Change in AIDS--84% related deaths since 2010


Incidence: 2.55 prevalence ratio

4.4 mortality ratio

KEY POPULATIONS

	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence		8.1%	1.7%		
HIV testing and status awareness		90.0%	85.0%		
Antiretroviral therapy coverage		78%			
Condom use					
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION			
	2010	2020	
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]	
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]	

Early infant diagnosis

...%

[...-..%]

...%

[...-..%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	30 [19–44]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	
— Men	
Women aged 15–49 years who have their	

demand for family planning satisfied by modern methods Not Men aged 15-49 years who are circumcised applicable

Voluntary medical male circumcisions Not performed according to national standards applicable People who received PrEP at least once ... during the reporting period


Harm reduction

- Use of sterile injecting equipment at 73% last injection (2018) - Needles and syringes distributed per 625 person who injects (2016)
- Coverage of opioid substitution 31% therapy (2018) — Naloxone available (2021)
- Safe injection rooms available (2021)

BHUTAN

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	600			•••	
HIV prevalence					
HIV testing and status awareness					
Antiretroviral therapy coverage					
Condom use					
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	3 [0–8]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2010)	
— Women	21%
— Men	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

у уе	ars	
— W	omen/	
M	on	

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who ar	e circumcised applicable
Voluntary medical male circum performed according to nation	
People who received PrEP at l during the reporting period	east once

Harm reduction

rm reduction	
 Use of sterile injecting equipment at last injection 	
 Needles and syringes distributed per person who injects 	
 Coverage of opioid substitution therapy 	

— Safe injection rooms available (2021)

— Naloxone available (2021)

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020		US\$ 850 255				US\$ 850 255


COUNTRY DATA

LAWS AND POLICIES		STIGMA AND DISCRIMINATION	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No, but prosecutions exist based on general	Percentage of women and men aged 15–49 years who report discriminatory attitudes	
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work	towards people living with HIV	
Criminalization of same-sex sexual acts	Yes, penalty not specified	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Drug use or possession for personal use is an offence		Percentage of people living with HIV who reported a health-care professional told	
Criminalization of transgender people	Neither criminalized nor prosecuted	others about their HIV status without their consent	
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE	
Parental consent for adolescents to access HIV testing		Proportion of ever-married or partnered women aged 15–49 years who experienced	
Spousal consent for married women to access sexual and reproductive health services		physical or sexual violence from a male intimate partner in the past 12 months	
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No		

BRUNEI DARUSSALAM

KEY POPULATION	S				
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence					0.9%
HIV testing and status awareness					
Antiretroviral therapy coverage					
Condom use					
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	3 [0–9]
People living with HIV who started TB preventive therapy (2018)	0%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2018)	0%

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

_	Women	
_	Men	

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

Harm reduction

— Use of sterile injecting equipment a	t
last injection	

_	Needles and syringes distributed per
	person who injects

_	Coverage of opioid substitution
	therapy

— Naloxone available (2021)	
-----------------------------	--

EXPENDITURES							
Financing sources							
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total	
Last available report:							

LAWS AND POLICIES		STIGMA AND DISCRIMINATION
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes	Percentage of women and men aged 15–49 years who report discriminatory attitudes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work	towards people living with HIV
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months
Drug use or possession for personal use is an offence		Percentage of people living with HIV who reported a health-care professional told
Criminalization of transgender people		others about their HIV status without their consent
Laws or policies restricting the entry, stay and residence of people living with HIV	Yes	VIOLENCE
Parental consent for adolescents to access HIV testing	No	Proportion of ever-married or partnered women aged 15–49 years who experienced
Spousal consent for married women to access sexual and reproductive health services	No	physical or sexual violence from a male intimate partner in the past 12 months
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes	

CAMBODIA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	2100	1400	1100
	[1900–2300]	[1200–1500]	[1000–1200]
New HIV infections (0–14)	<500	<200	<100
	[<500–520]	[<200–<500]	[<100– <200]
New HIV infections (women, 15+)	940	520	<500
	[840–1000]	[<500–570]	[<500–<500]
New HIV infections (men, 15+)	730	660	750
	[650–820]	[610–730]	[680–810]
HIV incidence per 1000 population	0.14 [0.13–0.16]	0.09 [0.08–0.09]	0.07 [0.06–0.07]
AIDS-related deaths			
AIDS-related deaths (all ages)	1500	1700	1200
	[1100–2300]	[990–2400]	[790–1500]
AIDS-related deaths (0–14)	<500	<200	<100
	[<200-<500]	[<100–<200]	[<100–<100]
AIDS-related deaths (women, 15+)	580	750	630
	[<500–940]	[<500–1200]	[<500–930]
AIDS-related deaths (men, 15+)	720	790	<500
	[<500–1100]	[520–1100]	[<500–610]
People living with HIV			
People living with HIV (all ages)	82 000	79 000	75 000
	[73 000–91 000]	[70 000–87 000]	[67 000–83 000]
People living with HIV (0–14)	6000	4500	2800
	[5200–7000]	[3800–5200]	[2300–3200]
People living with HIV (women, 15+)	40 000	40 000	38 000
	[36 000–44 000]	[36 000–44 000]	[34 000–42 000]
People living with HIV (men, 15+)	36 000	34 000	34 000
	[31 000–40 000]	[31 000–38 000]	[31 000–38 000]
HIV prevalence (15–49)	0.8 [0.7–0.9]	0.7 [0.6–0.8]	0.5 [0.5–0.6]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	No

residence permits or for certain groups

STIGMA AND DISCRIMINATION

•••	
	•••


reported a health-care professional told others about their HIV status without their consent


VIOLENCE


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 43 322 535 Last available report: 2015 US\$ 262 750 US\$ 8 157 098









Change in new HIV infections since 2010

-46%

Change in AIDS--24% related deaths since 2010

Incidence: prevalence ratio

1.51

Incidence: 0.7 mortality ratio


KEY POPULATIONS

	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence	3.2%	4%	15.2%	9.6%	
HIV testing and status awareness	100%	51.9%		66.8%	
Antiretroviral therapy coverage	82.8%	95.5%	30.8%	100%	
Condom use	88.8%	76.2%	8.7%	83.8%	
Coverage of HIV prevention programmes	99.7%	20.1%	78%	89.3%	
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2015)	3 161 184	1 304 384	327 921		

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	1100 [590–1700]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.1%
Knowledge of HIV prevention among young people aged 15–24 years (2014)	
— Women	37.6%
— Men	45.9%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2014)	
— Women	41.5%
— Men	72.8%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	

	0, 10 [10 10,0]	29 408	0170[70 707	
ELIMINATIO	ON OF MOTH	ER-TO-CHILI	TRANSM	MISSION
		20	110	2020
Percentage of preg accessing antiretro	nant women living wi viral medicines		3% 38%]	86% [74–97%]
man all and all and a second		J O.	40/	44.00/

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	33% [28–38%]	86% [74–97%]
Final vertical transmission rate including during breastfeeding	26.1% [23.6–28%]	11.8% [9.7–16.1%]
Early infant diagnosis	42.6% [36.6–52%]	77.8% [69.3–89.9%]

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	511
Harm reduction	
 Use of sterile injecting equipment at last injection (2017) 	93.5%
 Needles and syringes distributed per person who injects (2020) 	168
 Coverage of opioid substitution therapy (2020) 	6.4%
— Naloxone available (2021)	

- Safe injection rooms available (2021)

CHINA

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••		•••	•••	
HIV prevalence	0.2%	6%	4.8%		
HIV testing and status awareness	54.7%	62.2%	56.4%		
Antiretroviral therapy coverage		93.9%	88.1%		
Condom use	94.6%	90%	62.2%		
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES	
Estimated number of incident tuberculosis cases among people living with HIV (2018)	18 000 [9800 –28 000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	

People coinfected with HIV and hepatitis C virus starting hepatitis C treatment

HIV PREVENTION

- Men

Adults aged 15+ viral load	years with unsuppressed	
Knowledge of HI people aged 15-	V prevention among young 24 years	
— Women		

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

49 years			
— Wome	n		
— Men			

Women aged 15–49 years who have their demand for family planning satisfied by

modern methods	
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction — Use of sterile injecting equipment at	86.5%

rm reduction	
 Use of sterile injecting equipment at last injection (2015) 	86.5%
 Needles and syringes distributed per person who injects (2019) 	246
 Coverage of opioid substitution therapy 	
— Naloxone available (2021)	Yes

No


- Safe injection rooms available (2021)

EXPENDITURES						
		Finan	cing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2019	US\$ 12 385 500	US\$ 1 307 000 000				US\$ 1 320 389 000

LAWS AND POLICIES		STIGMA AND DISCRIMINATION			
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes	Percentage of women and men aged 15–49 years who report discriminatory attitudes			
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work	towards people living with HIV			
Criminalization of same-sex sexual acts	No specific legislation	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months			
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence	Percentage of people living with HIV who reported a health-care professional told			
Criminalization of transgender people	Neither criminalized nor prosecuted	others about their HIV status without their consent			
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE			
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years	Proportion of ever-married or partnered women aged 15–49 years who experienced			
Spousal consent for married women to access sexual and reproductive health services	No	physical or sexual violence from a male intimate partner in the past 12 months			
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No				

FIJI

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<100	<200	<200
	[<100- <200]	[<100- <500]	[<100-<500]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)	<100	<100	<100
	[<100–<100]	[<100- <100]	[<100–<200]
New HIV infections (men, 15+)	<100	<100	<100
	[<100-<100]	[<100– <200]	[<100–<200]
HIV incidence per 1000 population	0.08 [0.05–0.15]	0.12 [0.07–0.26]	0.16 [0.07–0.41]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<100
	[<100-<100]	[<100- <100]	[<100-<100]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100-<100]	[<100– <100]	[<100-<100]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100-<100]	[<100- <100]	[<100-<100]
People living with HIV			
People living with HIV (all ages)	<500	800	1300
	[<500–920]	[580–1400]	[790–2500]
People living with HIV (0-14)			
	[]	[]	[=]
People living with HIV (women, 15+)	<500	<500	570
	[<200-<500]	[<500–620]	[<500–1100]
People living with HIV (men, 15+)	<500	<500	660
	[<200– <500]	[<500 – 720]	[<500–1300]
HIV prevalence (15–49)	<0.1 [<0.1–0.2]	0.1 [0.1–0.2]	0.2 [0.1–0.4]



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2016		US\$ 509 384			US\$ 158 885	US\$ 668 269


HIV TESTING AND TREATMENT CASCADE

51% [32–102%]

48% [29–97%]

Women (15+)

Men (15+)



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]		
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]		
Early infant diagnosis	% [–%]	% [–%]		

42% [26–82%]

35% [21–70%]

237

231

22% [14–43%]

18% [11–36%]

INDIA

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population				•••	
HIV prevalence	1.6%	2.7%	6.3%	3.1%	2.1%
HIV testing and status awareness	88.0%	82.4%	78.3%	88.4%	
Antiretroviral therapy coverage	87.9%	90.9%	83.2%	97.9%	
Condom use		83.1%	54.1%	79.7%	
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2019)		51 459 906			

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES	
Estimated number of incident tuberculosis cases among people living with HIV (2018)	92 000 [63 000 –126 000]
People living with HIV who started TB preventive therapy (2018)	16.7%
Cervical cancer screening of women living with HIV (2016)	35%
People coinfected with HIV and hepatitis C	

HIV PREVENTION

virus starting hepatitis C treatment

Adults aged	15+ years	with	unsuppressed
viral load			

Knowledge of HIV prevention among young people aged 15-24 years (2016)

— Women	21.7%
— Men	31.5%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49 years (2016)

— Women	
— Men	40.8%

Women aged 15-49 years who have their demand for family planning satisfied by modern methods (2016)

Not

72.8%

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable

People who received PrEP at least once during the reporting period

Harm reduction

 Use of sterile injecting equipment at last injection (2020) 	95.8%
Needles and syringes distributed per	366

person who injects (2018) — Coverage of opioid substitution therapy (2018)

19.5%

— Naloxone available (2021)

- Safe injection rooms available (2021)

EXPENDITURES						
		Finan	cing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020		US\$ 414 285 714				US\$ 414 285 714

LAWS AND POLICIES		STIGMA AND DISCRIMINATION	NC	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No	Percentage of women and men aged 15–49 years who report discriminatory attitudes	2006	2016
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work	towards people living with HIV (2016 refers to women only)	35.1	32.8
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Drug use or possession for personal use is an offence		Percentage of people living with HIV who reported a health-care professional told		•••
Criminalization of transgender people	Neither criminalized nor prosecuted	others about their HIV status without their consent		
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE		
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years	nger than Proportion of ever-married or partnered women aged 15–49 years who experienced		2016
Spousal consent for married women to access sexual and reproductive health services	No	physical or sexual violence from a male intimate partner in the past 12 months	23	22
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No			

INDONESIA

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	277 600		34 500	34 700	
HIV prevalence	2.1%	17.9%	13.7%	11.9%	0.7%
HIV testing and status awareness	38.6%	55.5%	57.2%	65.0%	
Antiretroviral therapy coverage	22.4%	37.9%		34.4%	0.3%
Condom use	66.8%	69.6%	34.1%	68.9%	
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2018)	647 621	2 824 656	936 017		

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES	
Estimated number of incident tuberculosis cases among people living with HIV (2018)	21 000 [8900 -38 000]
People living with HIV who started TB preventive therapy (2018)	10.3%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	0.2%
Knowledge of HIV prevention among young people aged 15–24 years (2012)	
— Women	11.4%
— Men	10.3%
Condom use at last sex with a non-marital,	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

— Women	
— Men	

Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2017)

Men aged 15–49 years who are circumcised	Not applicable	
Voluntary medical male circumcisions performed according to national standards	Not applicable	
People who received PrEP at least once during the reporting period		

Harm reduction

Use of sterile injecting equipment at last injection (2019)	89.8%
 Needles and syringes distributed per person who injects (2020) 	1
 Coverage of opioid substitution therapy (2020) 	5.3%


Naloxone available (2021)
Safe injection rooms available (2021)
No

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available reports 2018	LIS\$ 10 495 015	115\$ 74 322 845	115\$ 9 760 803	LIS\$ 20 937 604	115\$ 1 348 653	IIS\$ 119 102 112

LAWS AND POLICIES		STIGMA AND DISCRIMINATION	N
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes	Percentage of women aged 15–49 years who report discriminatory attitudes towards	2017
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work	people living with HIV	68.7
Criminalization of same-sex sexual acts	Yes, penalty not specified	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence	Percentage of people living with HIV who reported a health-care professional told	2019
Criminalization of transgender people	Neither criminalized nor prosecuted	others about their HIV status without their consent	12.2
Laws or policies restricting the entry, stay and residence of people living with HIV	Prohibit short- and/or long-stay and require HIV testing or disclosure for some permits	VIOLENCE	
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years	Proportion of ever-married or partnered women aged 15–49 years who experienced	
Spousal consent for married women to access sexual and reproductive health services	No	physical or sexual violence from a male intimate partner in the past 12 months	
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No		

JAPAN


EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	1300	1200	600
	[970–1600]	[870–1600]	[<500–940]
New HIV infections (0–14)			
	[]	[]	[]
lew HIV infections (women, 15+)	<200	<100	<100
	[<100- <200]	[<100- <200]	[<100- <100]
New HIV infections (men, 15+)	1200	1100	560
	[860–1500]	[780–1500]	[<500–880]
HIV incidence per 1000 population	<0.01 [<0.01–0.01]	<0.01 [<0.01–0.01]	<0.01 [<0.01–<0.01]
AIDS-related deaths			
AIDS-related deaths (all ages)	<200	<500	<100
	[<200– <500]	[<200–<500]	[<100–<100]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100–<100]	[<100– <100]	[<100–<100]
AIDS-related deaths (men, 15+)	<200	<500	<100
	[<100-<500]	[<200– <500]	[<100-<100]
People living with HIV			
People living with HIV (all ages)	22 000	27 000	30 000
	[18 000–25 000]	[22 000–31 000]	[25 000–35 000]
People living with HIV (0–14)			
	[]	[]	[]
People living with HIV (women, 15+)	2300	2700	3000
	[2000–2500]	[2400–3000]	[2600–3300]
People living with HIV (men, 15+)	20 000	24 000	27 000
	[16 000–23 000]	[20 000–28 000]	[22 000–32 000]
HIV prevalence (15–49)	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2011		US\$ 67 907 854				US\$ 67 907 854

HIV TESTING AND TREATMENT CASCADE




ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]		
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]		
Early infant diagnosis	% [%]	% [–%]		

KIRIBATI

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence					
HIV testing and status awareness	100%**	100%**		100%**	
Antiretroviral therapy coverage					
Condom use	55.4%				
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2016)	1784	1784			

 $^{{\}tt ** Programme\ data--not\ representative;\ includes\ people\ with\ negative\ results.}$

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	
— Men	
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

Harm reduction	
 Use of sterile injecting equipment at last injection 	
 Needles and syringes distributed per person who injects 	
 Coverage of opioid substitution therapy 	
— Naloxone available (2021)	

 Safe injection rooms available (2021) 	

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2019		US\$ 165 150				US\$ 165 150

LAWS AND POLICIES		STIGMA AND DISCRIMINATION	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No	Percentage of women and men aged 15–49 years who report discriminatory attitudes	
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work	towards people living with HIV	
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Drug use or possession for personal use is an offence		Percentage of people living with HIV who reported a health-care professional told	
Criminalization of transgender people	Neither criminalized nor prosecuted	others about their HIV status without their consent	
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE	
Parental consent for adolescents to access HIV testing	No	Proportion of ever-married or partnered women aged 15–49 years who experienced	
Spousal consent for married women to access sexual and reproductive health services	No	physical or sexual violence from a male intimate partner in the past 12 months	
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No		

LAO PEOPLE'S DEMOCRATIC REPUBLIC

COUNTRY DATA

	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	1000	990	890
	[920–1100]	[890–1100]	[790–960]
New HIV infections (0–14)	<100	<100	<100
	[<100–<100]	[<100- <100]	[<100-<100]
New HIV infections (women, 15+)	<500	<500	<500
	[<500– <500]	[<500–<500]	[<500-<500]
New HIV infections (men, 15+)	550	540	520
	[<500–610]	[<500–600]	[<500–570]
HIV incidence per 1000 population	0.17 [0.15–0.19]	0.15 [0.14–0.17]	0.13 [0.11–0.14]
AIDS-related deaths			
AIDS-related deaths (all ages)	<200	<500	<500
	[<200–<500]	[<500–<500]	[<500-<500]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100– <100]	[<100-<100]	[<100-<100]
AIDS-related deaths (women, 15+)	<100	<100	<200
	[<100– <100]	[<100– <200]	[<100- <200]
AIDS-related deaths (men, 15+)	<100	<200	<200
	[<100-<200]	[<200–<500]	[<200-<500]
People living with HIV			
People living with HIV (all ages)	9000	12 000	15 000
	[8200–9800]	[11 000–14 000]	[14 000–16 000]
People living with HIV (0–14)	<500	<500	540
	[<500– <500]	[<500–550]	[<500–610]
People living with HIV (women, 15+)	3600	5000	6000
	[3200–3900]	[4500–5400]	[5500–6600]
People living with HIV (men, 15+)	5100	6900	8500
	[4600–5600]	[6400–7600]	[7800–9300]
HIV prevalence (15–49)	0.3 [0.2–0.3]	0.3 [0.3–0.4]	0.3 [0.3–0.4]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	The law allows possession of a certain amount of drugs
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

STI	G۱	ΛΑ Λ	٩N	D	D	IS	C	RI	N	Ш	N	A٦	П	O	Ν	I
_																


Percentage of women aged 15–49 years who report discriminatory attitudes towards	 2017
people living with HIV	 48.1
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their	


VIOLENCE


consent


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020		US\$ 409 216	US\$ 469 086	US\$ 2 708 181	US\$ 95 000	US\$ 4 287 471









Change in new
HIV infections = -14%
since 2010

Change in AIDS-related deaths = 69% since 2010

Incidence:
prevalence = 5.88
ratio

Incidence: mortality ratio*


* The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population						
HIV prevalence	0.8%	4.1%				
HIV testing and status awareness	39.2%	11.5%				
Antiretroviral therapy coverage						
Condom use	90.6%	35.1%				
Coverage of HIV prevention programmes	36.8%	7.8%				
Avoidance of health care because of stigma and discrimination	1.9%	1.7%				
Expenditures in US\$ (2020)	362 707	781 534				

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	720 [460–1000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION

Adults aged	15+ years	with	unsuppressed
viral load			

0.1%

Knowledge of HIV prevention among young people aged 15–24 years (2012)

— Women	24%
— Men	27.6%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

— Women

— Men

•••

3

No

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

during the reporting period (2020)

Men aged 15–49 years who are circumcised Not applicable

Voluntary medical male circumcisions Not applicable

People who received PrEP at least once 26

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects (2017)
- Coverage of opioid substitution therapyNaloxone available (2021)
- Safe injection rooms available (2021) No

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	15% [13–17%]	54% [46–61%]
Final vertical transmission rate including during breastfeeding	45.7% [43–48.5%]	32.5% [29.8–35.2%]
Early infant diagnosis	1.5% [1.3–1.9%]	51.9% [45.9–60.5%]

MALAYSIA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	5100	4800	6100
	[4600–5600]	[4300–5300]	[5300–6900]
New HIV infections (0–14)	<100	<100	<100
	[<100- <100]	[<100–<100]	[<100-<100]
New HIV infections (women, 15+)	910	810	660
	[780–1000]	[690–890]	[560–760]
New HIV infections (men, 15+)	4100	4000	5500
	[3700–4500]	[3600–4400]	[4800–6200]
HIV incidence per 1000 population	0.18 [0.17–0.2]	0.16 [0.14–0.18]	0.19 [0.17–0.22]
AIDS-related deaths			
AIDS-related deaths (all ages)	3500	3200	2000
	[2800–4200]	[2600–3800]	[1500–2500]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100-<100]
AIDS-related deaths (women, 15+)	<500	<500	<200
	[<200–<500]	[<200- <500]	[<200-<500]
AIDS-related deaths (men, 15+)	3300	2900	1800
	[2700–3800]	[2500–3400]	[1400–2200]
People living with HIV			
People living with HIV (all ages)	73 000	78 000	92 000
	[65 000–81 000]	[71 000–84 000]	[84 000–100 000]
People living with HIV (0–14)	570	520	<500
	[<500–730]	[<500–660]	[<500–<500]
People living with HIV (women, 15+)	12 000	15 000	17 000
	[10 000–13 000]	[13 000–16 000]	[16 000–19 000]
People living with HIV (men, 15+)	61 000	63 000	75 000
	[54 000–67 000]	[57 000–68 000]	[68 000–81 000]
HIV prevalence (15–49)	0.4 [0.3–0.4]	0.4 [0.3–0.4]	0.4 [0.3–0.4]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (14 years - life)
Drug use or possession for personal use is an offence	The law allows possession of a certain amount of drugs
Criminalization of transgender people	Both criminalized and prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	Yes
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

residence permits or for certain groups

STIGMA AND DISCRIMINATION


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Percentage of people living with HIV who reported a health-care professional told	•••

others about their HIV status without their consent

VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020	US\$ 976 127	US\$ 18 050 168		US\$ 1 335 347	US\$ 304 995	US\$ 20 694 927



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	37 000		75 000		
HIV prevalence	6.3%	21.6%	13.5%	10.9%	0.2%
HIV testing and status awareness	35.1%	43.3%	38.9%	43.0%	
Antiretroviral therapy coverage		62.6%	34.6%		
Condom use	83.5%	65.4%	25.7%	78.2%	
Coverage of HIV prevention programmes	40%	36.7%	1.4%	57.9%	
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2020)	68 342	435 559	1 038 380	95 221	47 872

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION			
	2010	2020	
Percentage of pregnant women living with HIV	58%	99%	
accessing antiretroviral medicines	[48_69%]	[81-100%]	

13.2%

1.7%

breastfeeding [10.8-15.1%] [0.6-3.2%]76.1% >95% Early infant diagnosis [65.2-90.8%] [81.6->95%]

Final vertical transmission rate including during

- Women — Men modern methods Men aged 15-49 years who are circumcised Voluntary medical male circumcisions performed according to national standards

Harm reduction	
 Use of sterile injecting equipment at last injection (2017) 	79.5%
 Needles and syringes distributed per person who injects (2020) 	11
 Coverage of opioid substitution therapy (2020) 	81.1%
— Naloxone available (2021)	No

- Safe injection rooms available (2021)

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	1900 [1600 –2200]
People living with HIV who started TB preventive therapy (2018)	37.9%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	19.2%

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	0.2%
Knowledge of HIV prevention among young people aged 15–24 years (2015)	
— Women	41.1%

41.8% - Men

...

Not

applicable

Not

applicable

No

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49 years

Women aged 15-49 years who have their demand for family planning satisfied by

People who received PrEP at least once

during the reporting period

MONGOLIA

COUNTRY DATA

PIDEMIC ESTIMATES			
	2010	2015	2020
ew HIV infections			
ew HIV infections (all ages)	<100	<100	<100
	[<100–<100]	[<100-<100]	[<100-<100]
ew HIV infections (0–14)			
	[]	[]	[]
ew HIV infections (women, 15+)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100- <100]
ew HIV infections (men, 15+)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100–<100]
IV incidence per 1000 population	0.02 [0.02–0.02]	0.02 [0.01–0.02]	0.01 [0.01–0.02]
IDS-related deaths			
IDS-related deaths (all ages)	<100	<100	<100
	[<100– <100]	[<100-<100]	[<100-<100]
IDS-related deaths (0-14)			
	[]	[]	[]
IDS-related deaths (women, 15+)	<100	<100	<100
	[<100–<100]	[<100–<100]	[<100-<100]
IDS-related deaths (men, 15+)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100-<100]
eople living with HIV			
eople living with HIV (all ages)	<500	540	650
	[<500- <500]	[<500–600]	[580–710]
eople living with HIV (0–14)			
	[]	[]	[]
eople living with HIV (women, 15+)	<100	<100	<200
	[<100–<100]	[<100–<200]	[<200–<200]
eople living with HIV (men, 15+)	<500	<500	510
	[<500-<500]	[<500–<500]	[<500–570]
IV prevalence (15–49)	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]


LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV (2018 refers to women only) Percentage of people living with HIV denied health services because of their HIV status in the last 12 months Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent VIOLENCE Proportion of ever-married or partnered women aged 15–49 years who experienced		
health services because of their HIV status in the last 12 months Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent VIOLENCE Proportion of ever-married or partnered	2014 72.7	2018 64.2
reported a health-care professional told others about their HIV status without their consent VIOLENCE Proportion of ever-married or partnered		
Proportion of ever-married or partnered		
·		
		2017
physical or sexual violence from a male intimate partner in the past 12 months		14.7

STIGMA AND DISCRIMINATION

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


... US\$ 3 032 500 US\$ 5 255 800 Last available report: 2016



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS Men who People who Transgender Sex workers Prisoners have sex inject drugs people with men Estimated size of population **HIV** prevalence 0% 7.7% 0% 0% HIV testing and status 94.3% 96.1% awareness 90.6% Antiretroviral therapy coverage Condom use 88.5% Coverage of HIV prevention 26.1% ... programmes Avoidance of health care because of stigma and 3.1% 47.1% discrimination Expenditures in US\$ (2019) 300 000 500 000

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV	%	%		
accessing antiretroviral medicines	[%]	[–%]		

444444	[,0]	[,0]
Final vertical transmission rate including during	%	%
breastfeeding	[%]	[%]
Early infant diagnosis	%	%
Larry Illiant diagnosis	[%]	[%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	15 [2–39]
People living with HIV who started TB preventive therapy (2018)	0%
Women who tested positive for HIV among those screened for cervical cancer (programme data) (2019)	100%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	33.3%

HIV PREVENTION

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years (2014)	
— Women	22.8%
— Men	20.7%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged	

- Women - Men Women aged 15-49 years who have their

demand for family planning satisfied by modern methods Man agod 15-49 years who are circumcised

Men aged 15–49 years who are circumcised	applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2019)	1

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy — Naloxone available (2021)
- Safe injection rooms available (2021)

MYANMAR

COUNTRY DATA

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	 [–]	 [–]	 [–]	
New HIV infections (0–14)	 [–]	 [–]	 [–]	
New HIV infections (women, 15+)	 [–]	 [–]	 [–]	
New HIV infections (men, 15+)	 []	 []	 []	
HIV incidence per 1000 population	[]	[]	[]	
AIDS-related deaths				
AIDS-related deaths (all ages)	 [–]	 []	 [–]	
AIDS-related deaths (0–14)	 [–]	 [–]	 [–]	
AIDS-related deaths (women, 15+)	 []	 []	 [–]	
AIDS-related deaths (men, 15+)	 []	 []	 []	
People living with HIV				
People living with HIV (all ages)	 []	 []	 [–]	
People living with HIV (0-14)	 []	 []	 [–]	
People living with HIV (women, 15+)	 []	 []	 []	
People living with HIV (men, 15+)	 []	 [–]	 []	
HIV prevalence (15–49)	[–]	[]	[–]	

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (14 years - life)
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes

residence permits or for certain groups

Last available report: 2017

Percentage of women aged 15–49 years who report discriminatory attitudes towards	•••	2016
people living with HIV		63.3
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		•••
Percentage of people living with HIV who reported a health-care professional told		

2016


STIGMA AND DISCRIMINATION

VIOLENCE

others about their HIV status without their

Proportion of ever-married or partnered	2016
women aged 15-49 years who experienced	
physical or sexual violence from a male	
intimate partner in the past 12 months	11


EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2017	US\$ 2 382 058	US\$ 20 212 929	US\$ 12 248 661	US\$ 51 148 388	US\$ 20 477 207	US\$ 106 469 242



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population				•••	
HIV prevalence	8.3%	8.8%	19%		4.7%
HIV testing and status awareness	41.0%	31.3%	27.9%		
Antiretroviral therapy coverage	59.1%	44.1%	14.1%		
Condom use	89.9%	56.8%	21.9%		
Coverage of HIV prevention programmes	50.4%	28.6%	34.2%		
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2017)	4 492 080	2 856 177	14 000 727		

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]		
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]		
Early infant diagnosis	1.2% [<1–1.4%]	% [–%]		

HIV COMORBIDITIES	
Estimated number of incident tuberculosis cases among people living with HIV (2018)	15 000 [10 000 –22 000]
People living with HIV who started TB preventive therapy (2018)	15.5%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2016)	
— Women	16.2%
— Men	17.8%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2016)	
— Women	
— Men	77.4%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2016)	74.9%
Men aged 15–49 years who are circumcised (2016)	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction — Use of sterile injecting equipment at last injection (2017)	90.8%

 Needles and syringes distributed per person who injects (2019) 	369
 Coverage of opioid substitution therapy (2019) 	21%
— Naloxone available (2021)	
— Safe injection rooms available (2021)	

NEPAL

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	2100	1200	750
	[1800–2300]	[1100–1300]	[670–820]
New HIV infections (0–14)	<500	<200	<100
	[<200–<500]	[<100- <200]	[<100–<100]
New HIV infections (women, 15+)	880	500	<500
	[770–980]	[<500–550]	[<500-<500]
New HIV infections (men, 15+)	960	580	<500
	[850–1100]	[520–640]	[<500–<500]
HIV incidence per 1000 population	0.08 [0.07–0.09]	0.05 [0.04–0.05]	0.03 [0.02–0.03]
AIDS-related deaths			
AIDS-related deaths (all ages)	1400	930	640
	[1200–1700]	[740–1100]	[<500–820]
AIDS-related deaths (0–14)	<200	<100	<100
	[<200-<200]	[<100-<100]	[<100-<100]
AIDS-related deaths (women, 15+)	<500	<500	<500
	[<200-<500]	[<200–<500]	[<200-<500]
AIDS-related deaths (men, 15+)	1000	610	<500
	[860–1200]	[<500–740]	[<500–510]
People living with HIV			
People living with HIV (all ages)	31 000	29 000	30 000
	[28 000–34 000]	[26 000–31 000]	[28 000–33 000]
People living with HIV (0-14)	1400	1500	1200
	[1200–1600]	[1300–1600]	[1100–1400]
People living with HIV (women, 15+)	11 000	13 000	13 000
	[9600–12 000]	[11 000–14 000]	[12 000–14 000]
People living with HIV (men, 15+)	19 000	15 000	16 000
	[17 000–21 000]	[13 000–16 000]	[14 000–17 000]
HIV prevalence (15–49)	0.2 [0.2–0.2]	0.2 [0.1–0.2]	0.1 [0.1–0.1]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	

residence permits or for certain groups

STI	GN	/IA AN	ID DI	SCRI	MINAT	ION


Percentage of women and men aged 15–49 years who report discriminatory attitudes	2011	2016
towards people living with HIV (2016 refers to women only)	28.3	38
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		•••
Parameters of magnic living with HIV who		

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent

VIOLENCE

Proportion of ever-married or partnered	2011	2016
women aged 15-49 years who experienced		
physical or sexual violence from a male		
intimate partner in the past 12 months	14.3	11.2


EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2019		US\$ 18 430	US\$ 26 032	US\$ 63 458	US\$ 6787	US\$ 115 983



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS Men who People who Transgender Sex workers Prisoners have sex inject drugs people with men Estimated size of population ... 22 000 **HIV** prevalence 4.2% 5% 2.7% 8.5% HIV testing and status 95.2% 89.6% 98.3% 89.4% awareness Antiretroviral therapy coverage 66.3% Condom use 88 2% 94.6% 91.5% Coverage of HIV prevention 34.8% 79.7% 67.8% 29.8% programmes Avoidance of health care because of stigma and ${\it discrimination}$ Expenditures in US\$ (2019) 5834 6758 9306 811

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION 2010 2020 16% 40% Percentage of pregnant women living with HIV

[13-19%] accessing antiretroviral medicines [34-47%] Final vertical transmission rate including during 48.8% 36.8% breastfeeding [46.5-50.8%] [34.7-38.5%] 3.5% 87% Early infant diagnosis

[2.9-4.3%]

[74.3->95%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	380 [320–450]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years (2016)	
— Women	20.7%
— Men	27.1%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2016)	
— Women	
— Men	67.6%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2016)	56.3%
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable

m reduction	
 Use of sterile injecting equipment at last injection (2020) 	96.2%
 Needles and syringes distributed per person who injects (2020) 	81
 Coverage of opioid substitution therapy (2020) 	2.8%
— Naloxone available (2021)	Yes
— Safe injection rooms available (2021)	

284

People who received PrEP at least once

during the reporting period (2020)

Har

NEW ZEALAND

COUNTRY DATA

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	<200	<200	<200	
	[<200- <200]	[<200–<200]	[<100- <200]	
New HIV infections (0–14)				
	[]	[]	[]	
New HIV infections (women, 15+)	<100	<100	<100	
	[<100-<100]	[<100-<100]	[<100–<100]	
New HIV infections (men, 15+)	<200	<200	<200	
	[<200- <200]	[<100- <200]	[<100-<200]	
HIV incidence per 1000 population	0.04 [0.03–0.04]	0.03 [0.02–0.04]	0.02 [0.01–0.03]	
AIDS-related deaths				
AIDS-related deaths (all ages)	<100	<100	<100	
	[<100- <100]	[<100-<100]	[<100- <100]	
AIDS-related deaths (0–14)				
	[]	[]	[]	
AIDS-related deaths (women, 15+)	<100	<100	<100	
	[<100-<100]	[<100-<100]	[<100– <100]	
AIDS-related deaths (men, 15+)	<100	<100	<100	
	[<100- <100]	[<100-<100]	[<100-<100]	
People living with HIV				
People living with HIV (all ages)	2400	3000	3600	
	[2100–2700]	[2600–3400]	[3100–4000]	
People living with HIV (0–14)				
	[]	[]	[]	
People living with HIV (women, 15+)	<500	540	570	
	[<500-<500]	[<500–600]	[510–630]	
People living with HIV (men, 15+)	1900	2500	3000	
	[1600–2200]	[2100–2900]	[2500–3400]	
HIV prevalence (15–49)	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Sex work is not subject to punitive regulations or is not criminalized
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	Yes
Parental consent for adolescents to access HIV testing	No
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	Yes

residence permits or for certain groups

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49	
years who report discriminatory attitudes	
towards people living with HIV	
	•••

Percentage of people living with HIV denied health services because of their HIV status in the last 12 months


Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent

VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


Last available report: 2017 US\$ 30 068 244



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS Men who People who Transgender Sex workers Prisoners have sex inject drugs people with men Estimated size of population ... 10 000 **HIV** prevalence HIV testing and status 64.0% awareness Antiretroviral therapy coverage Condom use Coverage of HIV prevention programmes Avoidance of health care because of stigma and $\ discrimination$ Expenditures in US\$ (2017) 27 733 7107 46 128 3554 ...

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION			
	2010	2020	
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]	
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]	
	0/.	0/_	

[...-..%]

Early infant diagnosis

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	6 [2–13]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	
— Men	
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions	Not

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction	

[...-..%]

— Use of sterile injecting equipment at last injection

233

- Needles and syringes distributed per person who injects (2018)
- Coverage of opioid substitution therapy
- Naloxone available (2021) - Safe injection rooms available (2021)

PAKISTAN

COUNTRY DATA

	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	14 000	19 000	25 000
	[13 000–15 000]	[18 000–20 000]	[24 000–27 000]
New HIV infections (0–14)	<500	720	1600
	[<500-<500]	[650–800]	[1500–1700]
New HIV infections (women, 15+)	2200	3600	4800
	[2000–2400]	[3300–4000]	[4400–5300]
New HIV infections (men, 15+)	11 000	15 000	19 000
	[11 000–12 000]	[14 000–15 000]	[18 000–20 000]
HIV incidence per 1000 population	0.08 [0.07–0.08]	0.1 [0.09–0.1]	0.12 [0.11–0.12]
AIDS-related deaths			
AIDS-related deaths (all ages)	1400	4900	8200
	[1200–1500]	[4400–5300]	[7500–8900]
AIDS-related deaths (0–14)	<200	<500	890
	[<200- <200]	[<500-<500]	[820–950]
AIDS-related deaths (women, 15+)	<100	500	1100
	[<100- <100]	[<500–560]	[960–1200]
AIDS-related deaths (men, 15+)	1100	4000	6200
	[960–1300]	[3600–4400]	[5700–6800]
People living with HIV			
People living with HIV (all ages)	67 000	130 000	200 000
	[62 000–71 000]	[120 000–130 000]	[190 000–210 000]
People living with HIV (0–14)	650	2000	4900
	[590–720]	[1800–2200]	[4600–5300]
People living with HIV (women, 15+)	7300	21 000	38 000
	[6700–7800]	[20 000–22 000]	[36 000–40 000]
People living with HIV (men, 15+)	59 000	100 000	160 000
	[55 000–63 000]	[98 000 –1 10 000]	[150 000–160 000]
HIV prevalence (15–49)	<0.1 [<0.1–<0.1]	0.1 [<0.1–0.1]	0.2 [0.1–0.2]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, death penalty
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Both criminalized and prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

residence permits or for certain groups

Last available report: 2019

STIGMA AND DISCRIMINATION


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	•••	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who		


others about their HIV status without their consent


VIOLENCE


Proportion of ever-married or partnered	2013	2018
women aged 15-49 years who experienced		
physical or sexual violence from a male		
intimate partner in the past 12 months	18	14.5

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2019	US\$ 5 578 386	US\$ 1 551 621		US\$ 1 244 723		US\$ 8 428 830









Change in new HIV infections = 84% since 2010

Change in AIDS-related deaths = 507% since 2010

Incidence:
prevalence = 12.70
ratio


Incidence: mortality ratio*

^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••			•••	
HIV prevalence	3.8%	3.7%	21%	5.5%	2%
HIV testing and status awareness	66.7%**	53.6%**	46.1%**	74.7%**	
Antiretroviral therapy coverage	5%	0.8%	16.2%	10.2%	99.2%
Condom use	35.1%	22.4%	15.3%	24.4%	
Coverage of HIV prevention programmes	0.7%	1.2%	1.6%	1.1%	
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

^{**} Programme data—not representative; includes people with negative results.

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	4% [3–5%]	% [–%]
Final vertical transmission rate including during breastfeeding	61.2% [56.5–66.3%]	66.8% [63.2–71.9%]
Early infant diagnosis	1.2% [<1–1.4%]	% [–%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	3800 [2500 –5400]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load
Knowledge of HIV prevention among young people aged 15–24 years (2017)

— Women 1.8%— Men 5.9%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

— Women

— Men

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Not
applicable

Harm reduction

 Use of sterile injecting equipment at last injection (2016) 	72.5%
 Needles and syringes distributed per person who injects (2018) 	46
 Coverage of opioid substitution therapy 	
— Naloxone available (2021)	No

No

— Safe injection rooms available (2021)

PAPUA NEW GUINEA

COUNTRY DATA


EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	2500	3100	3400
	[1600–3500]	[1900–4300]	[2100–4900]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)	1100	1600	1900
	[720–1600]	[990–2200]	[1200–2700]
New HIV infections (men, 15+)	880	1000	1100
	[560–1200]	[650–1500]	[690–1600]
HIV incidence per 1000 population	0.36 [0.22–0.5]	0.39 [0.24–0.55]	0.39 [0.24–0.56]
AIDS-related deaths			
AIDS-related deaths (all ages)	720	<500	<500
	[<500–1200]	[<500–930]	[<500–830]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<500	<200	<100
	[<100-<500]	[<100- <500]	[<100- <200]
AIDS-related deaths (men, 15+)	<200	<200	<200
	[<100-<500]	[<100- <500]	[<100-<200]
People living with HIV			
People living with HIV (all ages)	33 000	42 000	55 000
	[21 000–44 000]	[29 000–55 000]	[37 000–71 000]
People living with HIV (0-14)			
	[]	[]	[]
People living with HIV (women, 15+)	17 000	23 000	31 000
	[11 000–23 000]	[15 000–29 000]	[21 000–40 000]
People living with HIV (men, 15+)	13 000	16 000	21 000
	[8700–17 000]	[11 000–21 000]	[14 000–27 000]
HIV prevalence (15–49)	0.7 [0.5–1]	0.8 [0.5–1.1]	0.9 [0.6–1.2]


LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Both criminalized and prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	Require HIV testing or disclosure for some permits
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes

Percentage of women aged 15–49 years who report discriminatory attitudes towards people living with HIV	 2018
people aving with the	 36
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent	
VIOLENCE	
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male	2018
intimate partner in the past 12 months	47.6


STIGMA AND DISCRIMINATION

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available reports 2010	115\$ 73 582	115\$ 7 556 596	115\$ 3 289 985	LIS\$ 8 446 411	IIS\$ 319 217	115\$ 23 819 723









Change in new **HIV** infections since 2010

Change in AIDS--38% related deaths since 2010

Incidence: prevalence ratio

6.26

HIV COMORBIDITIES

mortality ratio*

^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population	48 300	35 900				
HIV prevalence	15.5%	7.7%				
HIV testing and status awareness		59.0%				
Antiretroviral therapy coverage						
Condom use	31.7%					
Coverage of HIV prevention programmes						
Avoidance of health care because of stigma and discrimination						
Expenditures in US\$ (2019)	1 874 400	455 550				

Estimated number of incident tuberculosis cases among people living with HIV (2018)	2700 [2200 –3300]
People living with HIV who started TB preventive therapy (2018)	20.7%
Cervical cancer screening of women living with HIV	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load

People coinfected with HIV and hepatitis C virus starting hepatitis C treatment

Knowledge of HIV prevention among young people aged 15-24 years (2017)

_	Women	24.4%
_	Men	26.2%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49 years (2018)

— Women	18%
— Men	33.2%

Women aged 15-49 years who have their demand for family planning satisfied by modern methods (2018)

49.2%

Men aged 15–49 years who are circumcised	applicable
Wilming and Parker Land Committee	N

Voluntary medical male circumcisions Not performed according to national standards applicable

during the reporting period

Harm reduction

— Use of sterile injecting equipment at last injection


People who received PrEP at least once

- Needles and syringes distributed per person who injects
- Coverage of opioid substitution
- Naloxone available (2021) - Safe injection rooms available (2021)

No

No

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]
Early infant diagnosis	% [–%]	% [–%]

PHILIPPINES


COUNTRY DATA


EPIDEMIC ESTIMATES				
	2010	2015	2020	
ew HIV infections				
ew HIV infections (all ages)	5000	9800	17 000	
	[4500–5300]	[9000–11 000]	[15 000–18 000]	
ew HIV infections (0–14)	<100	<100	<200	
	[<100–<100]	[<100–<200]	[<200–<200]	
ew HIV infections (women, 15+)	<500	610	1100	
	[<500-<500]	[530–680]	[960–1200]	
ew HIV infections (men, 15+)	4600	9100	15 000	
	[4200–4900]	[8400–9900]	[14 000–17 000]	
IV incidence per 1000 population	0.05 [0.05–0.06]	0.1 [0.09–0.1]	0.15 [0.14–0.17]	
IDS-related deaths				
IDS-related deaths (all ages)	<200	<500	820	
	[<200-<500]	[<500–500]	[600–1100]	
IDS-related deaths (0–14)	<100	<100	<100	
	[<100-<100]	[<100-<100]	[<100-<100]	
IDS-related deaths (women, 15+)	<100	<100	<200	
	[<100- <100]	[<100-<100]	[<100-<200]	
IDS-related deaths (men, 15+)	<200	<500	640	
	[<200–<500]	[<500–<500]	[<500 <u>–</u> 860]	
eople living with HIV				
eople living with HIV (all ages)	17 000	51 000	120 000	
	[15 000–18 000]	[47 000–55 000]	[110 000–120 000]	
eople living with HIV (0–14)	<100	<500	590	
	[<100– <200]	[<500-<500]	[500–680]	
eople living with HIV (women, 15+)	1100	3100	7100	
	[1000–1200]	[2800–3400]	[6500–7700]	
eople living with HIV (men, 15+)	16 000	48 000	110 000	
	[14 000–17 000]	[44 000–51 000]	[99 000–120 000]	
IV prevalence (15–49)	<0.1 [<0.1–<0.1]	<0.1 [<0.1–0.1]	0.2 [0.2–0.2]	


LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No


STIGMA AND DISCRIMINATION	ON	
Percentage of women aged 15–49 years who report discriminatory attitudes towards		2017
people living with HIV		71.2
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		•••
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced	2013	2017
physical or sexual violence from a male intimate partner in the past 12 months	7.1	5.5

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2013	US\$ 17 814	US\$ 4 522 803		US\$ 3 180 753	US\$ 2 018 819	US\$ 10 319 421









Change in new HIV infections = 237% since 2010

Change in AIDS-related deaths = 315% since 2010

Incidence:
prevalence = 14.50
ratio

Incidence: mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	227 400	680 600	10 800	203 300	
HIV prevalence		5%		3.9%	
HIV testing and status awareness	66.6%	28.4%	26.9%	36.3%	
Antiretroviral therapy coverage					
Condom use	85.3%	40.1%		40.6%	
Coverage of HIV prevention programmes	71.8%	14.6%	51.8%	37.6%	
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV	CO	MO	KЫ	ווטו	IES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	10 000 [4100 –19 000]
People living with HIV who started TB preventive therapy (2018)	51.9%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION

Adults	aged	15+	years	with	unsuppressed
viral lo	ad				

Knowledge of HIV prevention among young people aged 15–24 years (2017)

— Women	20.2%
— Men	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2017)

— Women	10.3%
— Men	

Women aged 15–49 years who have their demand for family planning satisfied by

Men aged 15-49 years who are circumcised

demand for family planning satisfied by modern methods (2017)	56.1%	
Man and 15 40 years who are singuistical	Not	

Men aged 15–49 years who are circumcised	applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once	

Harm reduction

during the reporting period

 Use of sterile injecting equipment at last injection (2015) 	63.6%
Needles and syringes distributed per	

	person with injects
_	Coverage of opioid substitution
	therapy

– Naloxone available (2021)	No
– Safe injection rooms available (2021)	No

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION


	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	14% [12–17%]	26% [23–31%]
Final vertical transmission rate including during breastfeeding	43% [39.8–45.9%]	34.9% [32.8–37.3%]
Early infant diagnosis	8.2% [6.5–10%]	6.3% [5.4–7.3%]

SAMOA

KEY POPULATION	S				
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population			•••	•••	
HIV prevalence	0%	0%		0%	
HIV testing and status awareness	100%**	100%**		100%**	
Antiretroviral therapy coverage			•••		
Condom use	54.6%	4.4%	•••	64.1%	
Coverage of HIV prevention programmes	100%	100%		100%	
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2017)	4688	13 423	1953	8018	3906

 $[\]hbox{** Programme data} \hbox{$-$not representative; includes people with negative results.}$

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	0 [0–2]
People living with HIV who started TB preventive therapy (2018)	0%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

THEVERTION	
Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	

Women	aged	15–4	9 years	who	have	their	
demand	for f	amily	plannin	g sat	isfied	by	
modern	meth	ods					

Men aged 15-49 years who are circumcised

— Coverage of opioid substitution

therapy

— Men

Men aged 15–49 years who are circumcised	applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction	
 Use of sterile injecting equipment at last injection 	
 Needles and syringes distributed per person who injects 	

Not

— Naloxone available (2021)	
— Safe injection rooms available (2021)	

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2019		US\$ 12 115		US\$ 58 077	US\$ 9615	US\$ 79 808

LAWS AND POLICIES		STIGMA AND DISCRIMINATION	ON	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission		Percentage of women and men aged 15–49 years who report discriminatory attitudes		
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work	towards people living with HIV		
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Drug use or possession for personal use is an offence		Percentage of people living with HIV who reported a health-care professional told others about their		
Criminalization of transgender people		consent		
Laws or policies restricting the entry, stay and residence of people living with HIV	Yes	VIOLENCE		
Parental consent for adolescents to access HIV testing		Proportion of ever-married or partnered women aged 15–49 years who experienced		
Spousal consent for married women to access sexual and reproductive health services		physical or sexual violence from a male intimate partner in the past 12 months		
Mandatory HIV testing for marriage, work or residence permits or for certain groups				

SINGAPORE

COUNTRY DATA

	2010	2015	2020
New HIV infections			
New The Infections	<500	<500	<100
New HIV infections (all ages)	[<500-<500]	[<200-<500]	[<100-<100]
lew HIV infections (0–14)	 []	 []	 [–]
	<100	<100	<100
ew HIV infections (women, 15+)	[<100-<100]	[<100-<100]	[<100- <100]
	<500	<500	<100
New HIV infections (men, 15+)	[<500-<500]	[<200-<500]	[<100-<100]
HIV incidence per 1000 population	0.12 [0.11–0.13]	0.06 [0.05–0.08]	<0.01 [<0.01–0.01]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<100
AIDS-related deaths (all ages)	[<100-<200]	[<100-<100]	[<100-<100]
IDS-related deaths (0-14)			•••
110011010000000000000000000000000000000	[]	[]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
dibb-related deaths (Wolliell, 101)	[<100-<100]	[<100-<100]	[<100-<100]
AIDS-related deaths (men, 15+)	<100	<100	<100
ADS-related deaths (men, 13+)	[<100-<200]	[<100-<100]	[<100-<100]
People living with HIV			
Decade listan with HIV (all acce)	6100	7600	8000
People living with HIV (all ages)	[5500–6700]	[6700–8400]	[6800–9100]
People living with HIV (0-14)			
copic irving with the (o 14)	[]	[]	[]
eople living with HIV (women, 15+)	650	720	720
copie iring with the (women, 197)	[590–720]	[640–790]	[630–800]
People living with HIV (men, 15+)	5500	6800	7300
	[4900–6000]	[6000–7600]	[6200–8300]
IV prevalence (15–49)	0.2 [0.2–0.3]	0.3 [0.2–0.3]	0.2 [0.2–0.3]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	Yes
Parental consent for adolescents to access HIV testing	No
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes

residence permits or for certain groups

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49

years who report discriminatory attitudes towards people living with HIV		
	•••	
Percentage of people living with HIV denied health services because of their HIV status in		
the last 12 months		


Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent


VIOLENCE


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 59 986 667 Last available report: 2020 US\$ 59 986 667









HIV infections since 2010

Change in AIDSrelated deaths since 2010

Incidence: 0.35 prevalence ratio

mortality ratio*

^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••			•••	11 000
HIV prevalence	0%	2.2%	1.5%		1.1%
HIV testing and status awareness					
Antiretroviral therapy coverage					100%
Condom use	100%	64.5%			
Coverage of HIV prevention programmes	98%				
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	35 [22–50]
People living with HIV who started TB preventive therapy (2018)	0%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	


HIV TESTING AND TREATMENT CASCADE

Women (15+)

Men (15+)

...% [...-...%]

...% [...-...%]



HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years	

— Women

- Men Condom use at last sex with a non-marital, non-cohabiting partner among people aged

15-49 years - Women

modern methods

— Men Women aged 15-49 years who have their demand for family planning satisfied by

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2017)	24

...

...% [...-...%]

...% [...-...%]

...% [...-...%]

...% [...-...%]

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [– %]		
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]		
Early infant diagnosis	% [%]	% [–%]		

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

SRI LANKA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<500	<500	<200
	[<500-<500]	[<500-<500]	[<200–<200]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)	<100	<100	<100
	[<100- <200]	[<100-<100]	[<100–<100]
New HIV infections (men, 15+)	<200	<200	<200
	[<200-<500]	[<200–<200]	[<100- <200]
HIV incidence per 1000 population	0.01 [0.01–0.02]	0.01 [0.01–0.01]	<0.01 [<0.01–<0.01]
AIDS-related deaths			
AIDS-related deaths (all ages)	<500	<500	<200
	[<200- <500]	[<200–<500]	[<100-<200]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100–<100]
AIDS-related deaths (men, 15+)	<200	<200	<100
	[<200- <500]	[<200–<200]	[<100- <100]
People living with HIV			
People living with HIV (all ages)	3900	3800	3700
	[3400–4400]	[3400–4300]	[3400–4100]
People living with HIV (0-14)			
	[]	[]	[]
People living with HIV (women, 15+)	1100	1200	1100
	[1000–1300]	[1000–1300]	[990–1200]
People living with HIV (men, 15+)	2700	2600	2600
	[2400–3100]	[2300–2900]	[2300–2900]
HIV prevalence (15–49)	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Possession of drugs for personal use is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

residence permits or for certain groups

STIGMA AND DISCRIMINATION


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	•••	
	•••	•••
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who		


reported a health-care professional told others about their HIV status without their consent


VIOLENCE


Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020		US\$ 2 887 356		US\$ 8 170 632	US\$ 36 601	US\$ 11 094 589









Change in new HIV infections = -57% since 2010

Change in AIDS-related deaths = -56% since 2010

Incidence:
prevalence = 3.44
ratio

Incidence: mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	30 000	73 800	2700	2200	
HIV prevalence	0.3%	0.2%		0.5%	0%
HIV testing and status awareness	29.9%	40.3%	7.7%	36.9%	
Antiretroviral therapy coverage					
Condom use	83.6%	82.8%	25.5%	76.3%	
Coverage of HIV prevention programmes	12.7%	27%	2.7%	38.5%	
Avoidance of health care because of stigma and discrimination	6.8%	5.2%	7.7%	5.5%	
Expenditures in US\$					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	56 [34–84]
People living with HIV who started TB preventive therapy (2018)	31.6%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	0%

HIV TESTING AND TREATMENT CASCADE



	People living with HIV who know their status	People living with HIV on treatment	People living with HIV who are virally suppressed	
All ages	70% [63–77%]	58% [53–64%] 2167	53% [48–59%]	
Children (0-14	4)% [%]	% [%] 	% [%]	
Women (15+)	75% [67–81%]	52% [47–56%] 565	46% [42–50%]	
Men (15+)	68% [61–75%]	61% [55–67%] 1564	56% [51–62%]	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among voung	

people aged 15–24 years

— Women ...
— Men ...

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

49 years — Women

Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2016)

74.2%

80.5%

No

Men aged 15–49 years who are circumcised	applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable

People who received PrEP at least once during the reporting period (2020)

Harm reduction

— Men

 Use of sterile injecting equipment at 	
last injection (2018)	

Needles and syringes distributed per person who injects

Coverage of opioid substitution therapyNaloxone available (2021)

— Safe injection rooms available (2021)

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]
Early infant diagnosis	% [–%]	% [–%]

THAILAND

COUNTRY DATA

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	15 000	11 000	6600	
	[14 000–16 000]	[9600–12 000]	[6000–7200]	
New HIV infections (0–14)	670	<200	<100	
	[560–770]	[<100- <200]	[<100–<100]	
New HIV infections (women, 15+)	4900	2600	1400	
	[4300–5500]	[2200–2800]	[1200–1600]	
New HIV infections (men, 15+)	9500	8000	5200	
	[8500–10 000]	[7200–8900]	[4600–5700]	
HIV incidence per 1000 population	0.23 [0.2–0.25]	0.16 [0.14–0.17]	0.1 [0.09–0.11]	
AIDS-related deaths				
AIDS-related deaths (all ages)	29 000	22 000	12 000	
	[22 000–36 000]	[17 000–27 000]	[9800 –1 6 000]	
AIDS-related deaths (0–14)	1200	<500	<200	
	[1000–1300]	[<500–520]	[<100-<200]	
AIDS-related deaths (women, 15+)	10 000	9400	6100	
	[7400–13 000]	[7200–12 000]	[4400–8100]	
AIDS-related deaths (men, 15+)	18 000	12 000	5900	
	[14 000–22 000]	[9600–15 000]	[4600–7500]	
People living with HIV				
People living with HIV (all ages)	620 000	550 000	500 000	
	[560 000–680 000]	[500 000–600 000]	[450 000–550 000]	
People living with HIV (0-14)	12 000	6400	2400	
	[10 000–15 000]	[5200–7500]	[2000–2700]	
People living with HIV (women, 15+)	280 000	250 000	220 000	
	[250 000–310 000]	[220 000–270 000]	[190 000–240 000]	
People living with HIV (men, 15+)	330 000	300 000	280 000	
	[300 000–370 000]	[270 000–330 000]	[260 000–310 000]	
HIV prevalence (15–49)	1.6 [1.4–1.8]	1.3 [1.1–1.5]	1 [0.9–1.2]	


LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a non-criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

Percentage of women and men aged 15–49 years who report discriminatory attitudes	2015	2019
towards people living with HIV (2019 refers to women only)	26.1	26.7
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their		2018
consent		13
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male		

STIGMA AND DISCRIMINATION

intimate partner in the past 12 months


EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2019	US\$ 255 509	US\$ 271 162 577	US\$ 11 451 383	US\$ 7 142 318	US\$ 5 297 711	US\$ 295 888 256



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population				•••	358 000
HIV prevalence	2.8%	11.9%		11%	0.9%
HIV testing and status awareness	66.4%	52.8%	38.1%	68.4%	
Antiretroviral therapy coverage	9.3%		43%		66.5%
Condom use	83.1%	77.8%	39.6%	78.8%	
Coverage of HIV prevention programmes	82.1%	49.5%		44.2%	
Avoidance of health care because of stigma and discrimination	5.1%	9.3%	4.7%	5.9%	
Expenditures in US\$ (2019)	3 634 416	6 727 966	1 748 342	149 303	115 642

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

2010	2020
94%	98%
[79–100%]	[82–100%]
7.2%	1.7%
[6.8–7.6%]	[1.6–1.7%]
45.3%	>95%
[38.5–54.9%]	[83.9- >95%]
	94% [79–100%] 7.2% [6.8–7.6%] 45.3%

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	11 000 [8200 –14 000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	


HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.2%
Knowledge of HIV prevention among young people aged 15–24 years (2016)	
— Women	46%
— Men	45.1%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2017)	
— Women	76.8%
— Men	75%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2016)	96.5%
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	13 769

ing the reporting period (2020)	13 / 09
rm reduction	
 Use of sterile injecting equipment at last injection (2020) 	95%
 Needles and syringes distributed per person who injects (2019) 	11
 Coverage of opioid substitution therapy (2020) 	9%
— Naloxone available (2021)	No
— Safe injection rooms available (2021)	No

Har

TIMOR-LESTE

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	<100	<200	<200	
	[<100- <200]	[<100- <200]	[<100-<500]	
New HIV infections (0–14)				
	[]	[]	[]	
New HIV infections (women, 15+)	<100	<100	<100	
	[<100–<100]	[<100-<100]	[<100-<100]	
New HIV infections (men, 15+)	<100	<100	<100	
	[<100–<100]	[<100-<100]	[<100- <200]	
HIV incidence per 1000 population	0.07 [0.06–0.1]	0.09 [0.06–0.13]	0.1 [0.05–0.17]	
AIDS-related deaths				
AIDS-related deaths (all ages)	<100	<100	<100	
	[<100- <100]	[<100-<100]	[<100-<100]	
AIDS-related deaths (0–14)				
	[]	[]	[]	
AIDS-related deaths (women, 15+)	<100	<100	<100	
	[<100–<100]	[<100-<100]	[<100-<100]	
AIDS-related deaths (men, 15+)	<100	<100	<100	
	[<100- <100]	[<100-<100]	[<100-<100]	
People living with HIV				
People living with HIV (all ages)	<500	830	1200	
	[<500–740]	[640–1100]	[920–1700]	
People living with HIV (0–14)				
	[]	[]	[]	
People living with HIV (women, 15+)	<200	<500	<500	
	[<200-<500]	[<500–<500]	[<500–570]	
People living with HIV (men, 15+)	<500	500	760	
	[<200-<500]	[<500 <u>–</u> 650]	[550–1000]	
HIV prevalence (15–49)	<0.1 [<0.1–0.1]	0.1 [<0.1–0.2]	0.2 [0.1–0.2]	



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2009		US\$ 21 000		US\$ 1 743 620	US\$ 38 394	US\$ 1 803 014

COUNTRY DATA

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-	CHILD TRAN	ISMISSION
	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]
inal vertical transmission rate including during preastfeeding	% [–%]	% [–%]
Early infant diagnosis	%	%

195

399

52% [38–72%]

...% [...-...%]

[...-..%]

[...-..%]

96% [69–132%]

Men (15+)

VIET NAM

COUNTRY DATA

	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	14 000	11 000	6100
	[13 000–16 000]	[9300–11 000]	[5300–6700]
New HIV infections (0–14)	<500	<500	<500
	[<500–590]	[<500–570]	[<200–<500]
New HIV infections (women, 15+)	4500	3200	2000
	[3900–5100]	[2800–3500]	[1700–2200]
New HIV infections (men, 15+)	9400	6900	3900
	[8300–10 000]	[6100–7600]	[3400–4300]
HIV incidence per 1000 population	0.16 [0.15–0.18]	0.12 [0.1–0.13]	0.06 [0.06–0.07]
AIDS-related deaths			
AIDS-related deaths (all ages)	6000	4900	3800
	[4600–7500]	[3600–6400]	[2900–5000]
AIDS-related deaths (0–14)	<500	<200	<100
	[<200-<500]	[<200-<500]	[<100-<100]
AIDS-related deaths (women, 15+)	1300	920	850
	[940–1700]	[580–1400]	[530–1300]
AIDS-related deaths (men, 15+)	4400	3800	2900
	[3400–5500]	[2800–4800]	[2200–3800]
People living with HIV			
People living with HIV (all ages)	210 000	240 000	250 000
	[190 000–230 000]	[210 000–260 000]	[230 000–270 000]
People living with HIV (0–14)	3400	4300	4300
	[2800–3900]	[3500–5100]	[3500–5000]
People living with HIV (women, 15+)	60 000	73 000	80 000
	[54 000–67 000]	[65 000–79 000]	[73 000–87 000]
People living with HIV (men, 15+)	150 000	160 000	160 000
	[130 000–160 000]	[140 000–170 000]	[150 000–180 000]
HIV prevalence (15–49)	0.4 [0.3–0.4]	0.4 [0.3–0.4]	0.3 [0.3–0.4]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	.,

residence permits or for certain groups

STIGMA AND DISCRIMINATION


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	•••	
Percentage of people living with HIV denied		2014
the last 12 months		1.8
Percentage of people living with HIV who		•••
reported a health-care professional told		
others about their HIV status without their		
consent		


VIOLENCE


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

Last available report: 2012 US\$ 30 327 094 US\$ 28 917 091 US\$ 95 446 487









Change in new HIV infections = -57% since 2010

Change in AIDS-related deaths = -36% since 2010

Incidence:
prevalence = 2.46
ratio

Incidence: mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population		256 000			
HIV prevalence	3.1%	13.3%	12.7%		
HIV testing and status awareness	53.5%	68.8%	54.6%		
Antiretroviral therapy coverage	21.3%	21.6%	64%		
Condom use	89.6%	65.2%	41.9%		
Coverage of HIV prevention programmes	26.5%	25.5%	24.1%		
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

ПΙΥ	CO	RBI	ווטו	IE2

Estimated number of incident tuberculosis cases among people living with HIV (2018)	6000 [3800 –8600]
People living with HIV who started TB preventive therapy (2018)	38.6%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION

sed

0.1%

Knowledge of HIV prevention among young people aged 15–24 years (2014)

— Women	49.3%
— Men	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

— Women

— Men

...

147

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Not applicable
Not applicable
18 841
98.2%

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION


ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION						
	2010	2020				
Percentage of pregnant women living with HIV accessing antiretroviral medicines	61% [51–72%]	90% [77–100%]				
Final vertical transmission rate including during breastfeeding	18.6% [15.6–20.9%]	9.7% [7.2–11.8%]				
Early infant diagnosis	% [–%]	54.6% [48.3–63.9%]				

	last injection (2019)
_	Needles and syringes distributed per
	person who injects (2020)

 Coverage of opioid substitution therapy (2020) 	27.7
— Naloxone available (2021)	

— Safe injection rooms available (2021)

LATIN **AMERICA**



These shortcomings reflect that key populations have inadequate access to suitable HIV services, and that they continue to experience stigma and discrimination, physical and sexual harassment, violence and other human rights violations. These barriers are undermining the impact of HIV prevention and

children dying of AIDS-related causes in 2020.


There is a dearth of detailed strategic information available on key populations in many countries, and HIV services for key populations continue to be significantly underfunded in nearly all countries in the region, despite generally strong resource availability. Countries need to reallocate HIV resources to high-impact programmes that reach and benefit key populations, including expanded provision of pre-exposure prophylaxis (PrEP). In 2020, only six of 17 countries in the region reported that that PrEP was provided within the national health system, and only one reported offering self-testing.

COVID-19 has damaged economies in the region, placing health systems under additional strain and driving millions of people into financial peril. Quick and creative responses, however—such as implementing multimonth dispensing and sharing antiretroviral medicine stocks among countries in the region—managed to limit disruptions to HIV services in most countries. Close to 90% of countries in Latin America are implementing social protection strategies or policies, although only a few of those programmes are explicitly benefitting people living with HIV and key populations.

PRIORITY ACTIONS FOR ENDING AIDS


- Promote equitable access to effective and innovative combination HIV prevention within the frameworks of the Sustainable Development Goals and universal health coverage.
- Enact protective legislation, including antidiscrimination and gender identity laws.
- Empower and fully resource gender-sensitive and innovative community-led responses.
- Implement
 evidence-informed
 and human rights based national
 responses, with
 efficient allocation of
 domestic resources
 and sustainable
 financing.
- Expand multimonth dispensing and transition to dolutegravir-based first-line regimens.
- Guarantee access to comprehensive HIV services for migrants and asylum seekers.

SHARE OF GROSS DOMESTIC PRODUCT LOST AS A RESULT OF THE COVID-19 PANDEMIC, SELECTED COUNTRY GROUPINGS, 2020



Source: Szmigiera M. GDP loss due to COVID-19, by economy, 2020. In: statista.com [Internet]. 1 June 2021 (https://www.statista.com/statistics/1240594/gdp-loss-covid-19-economy/).


DISTRIBUTION OF COVID-19-RELATED DEATHS, GLOBAL, THROUGH MAY 2021



Source: Elflein J. COVID-19 deaths worldwide as of May 31, 2021, by country. In: statista.com [Internet]. 31 May 2021 (https://www.statista.com/statistics/1101643/latin-america-caribbean-coronavirus-cases/).


STATE OF THE PANDEMIC

NUMBER OF NEW HIV INFECTIONS AND AIDS-RELATED DEATHS, LATIN AMERICA, 2000-2020




Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).

DISTRIBUTION OF NEW HIV INFECTIONS BY POPULATION GROUP AND SEX (AGED 15-49 YEARS), LATIN AMERICA, 2020



Source: UNAIDS special analysis, 2021 (see methods annex).


HIV PREVALENCE AMONG KEY POPULATIONS, REPORTING COUNTRIES IN LATIN AMERICA, 2016–2020



- Sex workers (n = 14)
 Gay men and other men who have sex with men (n = 15)
 People who inject drugs (n = 2)
- Transgender people (n = 14)
- Prisoners (n = 11)

Source: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/). Note: (n = number of countries). Total number of reporting countries = 17. Additional countries have reported after the release of the Global Report. Their results, not included in this figure, are shown in the specific country sheets

How to read this chart



REPORTED ESTIMATED SIZE OF KEY POPULATIONS, LATIN AMERICA, 2018-2020

	National adult population (aged 15–49 years) in 2020 or relevant year	Sex workers	Sex workers as per cent of adult population (aged 15–49 years)	Gay men and other men who have sex with men	Gay men and other men who have sex with men as per cent of adult population (aged 15–49 years)	People who inject drugs	People who inject drugs as per cent of adult population (aged 15–49 years)	Transgender people	Transgender people as per cent of adult population (aged 15–49 years)	Prisoners	Prisoners as per cent of adult population (aged 15–49 years)
Bolivia (Plurinational State of)	6 100 000										
Brazil	114 000 000									702 000	0.62%
Chile	9 800 000										0.03%
Colombia	27 400 000			300 000						120 000	0.45%
Costa Rica	2 600 000							400			0.61%
Guatemala	9 200 000			116 000	1.27%			4300	0.05%		0.27%
Mexico	66 100 000	244 000	0.37%	1 226 000	1.85%			123 000	0.19%		0.31%
Nicaragua	3 600 000									19 700	0.55%
Panama	2 200 000	8600		30 000				2000			
Paraguay	3 900 000	9000		32 200				1200			
Peru	17 100 000			260 000	1.52%						
Uruguay	1 700 000			28 600	1.68%			1600	0.09%		
Venezuela (Bolivarian Republic of)	14 600 000							15 000	0.10%		
Estimated regional proportion as per of adult population 15–49 years) ^{a, b} :	ent		0.25%		1.69%		-		0.06%		-

■ National population size estimate

Insufficient data

Local population size estimate

No data

Sources: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/); Spectrum Demproj module, 2021.

Note 1: Estimates shown are government-provided estimates reported for 2018–2020. Additional and alternative estimates may be available from different sources, including the Key Populations Atlas (https://kpatlas.unaids.org/), academic publications or institutional documents. Note 2: The regions covered by the local population size estimate are as follows:

Colombia: Bogotá, Cali and Medellín.

Costa Rica: Gran Área Metropolitana.

Panama: Azuero, Bocas del Toro, Chiriquí, Coclé, Comarca Ngäbe-Buglé, Panamá Centro, Panamá Este, Panamá Norte, Panamá Oeste and

Paraguay: Alto Paraná, Amambay, Área Metropolitana (Asunción and Central) and Caaguazú (sex workers); Alto Paraná, Asunción, Caaguazú and Central (gay men and other men who have sex with men); Amambay, Asunción and Central (transgender people).


Note 3: The reported values for gay men and other men who have sex with men are presented as a per cent of the adult population (aged 15–49 years) for consistency across key populations. The percentage of this population out of the adult male population (aged 15-49 years) will be approximately twice the values shown.

^a Quick Start Guide for Spectrum, 2020. Geneva: UNAIDS; 2020 (https://www.unaids.org/sites/default/files/media_asset/QuickStartGuide_ Spectrum_en.pdf).

^b Technical brief: recommended population size estimates of men who have sex with men. Geneva: WHO, UNAIDS; 2020.


HIV SERVICES

PEOPLE LIVING WITH HIV, PEOPLE NEWLY INFECTED IN THE PAST SIX MONTHS, AND HIV TESTING AND TREATMENT CASCADE, ADULTS (AGED 15+ YEARS), LATIN AMERICA, 2016–2020



Source: UNAIDS special analysis, 2021.


PERCENTAGE OF PEOPLE LIVING WITH HIV WITH A CD4 CELL COUNT <200 CELLS/MM3 AT DIAGNOSIS, SELECTED COUNTRIES IN LATIN AMERICA, 2020




Source: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/).


Number of children

HIV TESTING AND TREATMENT CASCADE, CHILDREN (AGED 0-14 YEARS) COMPARED TO ADULTS (AGED 15 YEARS AND OLDER), LATIN AMERICA, 2020







Adults (aged 15 years and older) living with HIV




Source: UNAIDS special analysis, 2021.

HIV TESTING AND TREATMENT CASCADE, WOMEN (AGED 15+ YEARS) COMPARED TO MEN (AGED 15+ YEARS), LATIN AMERICA, 2020





Men (aged 15+ years) living with HIV



Source: UNAIDS special analysis, 2021.

LAWS AND DOLICIES

PUNITIVE AND DISCRIMINATORY LAWS SCORECARD, LATIN AMERICA, 2021

POLICIES	Criminalization of transgender people	Criminalization of sex work	Criminalization of same-sex sexual acts	Law allows for possession of a certain limited amount of drugs for personal use	Parental consent for adolescents to access HIV testing	Laws criminalizing the transmission of, non-disclosure of or exposure to HIV transmission	Laws or policies restricting the entry, stay and residence of people living with HIV	Mandatory HIV testing for marriage, work or residence permits or for certain groups
Argentina	1	1	1	1	1	1		1
Bolivia (Plurinational State of)	2	2	2		2	2		2
Brazil	1	1	1	1	1	1		1
Chile	1		5	1		1		1
Colombia	2	1	1	1				2
Costa Rica	1	1	1	1				1
Ecuador	2	1	2			9		2
El Salvador	1		1			10		1
Guatemala	1		1					1
Honduras	1	1	1		8			1
Mexico	2	1	1	1		1		1
Nicaragua	1		1			1		1
Panama	1	1				11		1
Paraguay	1		1			1		1
Peru	1		6					1
Uruguay	2	2	2			2		1
Venezuela (Bolivarian Republic of)	1	1	1	7	1	1		1

Criminalization of transgender people

- Criminalized and/or prosecuted
- Neither criminalized nor prosecuted
- Data not available

Criminalization of sex work

- Any criminalization or punitive regulation of sex work
- Sex work is not subject to punitive regulations or is not criminalized
- Issue is determined/differs at the subnational level
- Data not available

Criminalization of same-sex sexual acts

- Death penalty
- Imprisonment (14 years–life, up to 14 years) or no penalty specified
- Laws penalizing same-sex sexual acts have been decriminalized or never existed, or no specific leaislation
- Data not available

Law allows for possession of a certain limited amount of drugs for personal use

- No
- Yes
- Data not available

Parental consent for adolescents to access HIV testing

- Yes, for adolescents younger than 18
- Yes, for adolescents younger than 14 or 16
- Yes, for adolescents younger than 12
- No
- Data not available

Laws criminalizing the transmission of, non-disclosure of or exposure to HIV transmission

- No, but prosecutions exist based on general criminal laws
- No
- Data not available

Laws or policies restricting the entry, stay and residence of people living with HIV

- Deport, prohibit short and/or long stay and require HIV testing or disclosure for some permits
- Prohibit short and/or long stay and require HIV testing or disclosure for some permits
- Require HIV testing or disclosure for some permits
- No restrictions
- Data not available

Mandatory HIV testing for marriage, work or residence permits or for certain groups

- No
- Data not available

Sources.


- 1. UNAIDS National Commitments and Policy Instrument, 2021 (see http://lawsandpolicies.unaids.org/).
- 2. UNAIDS National Commitments and Policy Instrument, 2019 (see http://lawsandpolicies.unaids.org/).
- 3. El Salvador. Penal Code. Articles 170 and 170A.
- 4. Nicaragua. Ley 641. Articulo 178 (https://www.poderjudicial.gob.ni/pjupload/noticia_reciente/CP_641.pdf).
- Chile. Modifica el Código Penal, El Código de Procedimiento Penal y Otros Cuerpos Legalese en Materias Relativas al Delito de Violacion: Ley N° 19.617. Artículo 365. (https://www.leychile.cl/Navegar?idNorma=138814&idParte=8346393&idVersion=1999-07-12).
- 6. Mendos LR. State-sponsored homophobia, 2020. Geneva: International Lesbian, Gay, Bisexual, Trans and Intersex Association; December 2020 (https://ilga.org/downloads/ILGA_State_Sponsored_Homophobia_2019_light.pdf).
- 7. Bolivarian Republic of Venezuela. Article 70 of the Ley Orgánica Contra el Tráfico Ilícito y el Consumo de Sustancias Estupefacientes y Psicotrópicas, 2005 (https://web.oas.org/mla/en/G_Countries_MLA/Ven_multla_leg_esp_13.doc.pdf).
- 8. Honduras. Ley Especial sobre VIH/SIDA, 1999. Article 60 (http://www.poderjudicial.gob.hn/CEDIJ/Leyes/Documents/LeyEspecialVIHSIDA.pdf).
- 9. Ecuador. Ley 11, Registro Oficial 58, 14 de abril de 2000. Ley para la prevencion y asistencia integral del VIH SIDA (http://www.coalicionecuatoriana.org/web/pdfs/LEYPARALAPREVENCIONASISTENCIA INTEGRALDELVIHSIDA.pdf).
- 10. El Salvador. Diario Oficial, 12 de Enero de 2017. Art 15 (http://asp.salud.gob.sv/regulacion/pdf/ley/ley_proteccion_control_infeccion_provocada_por_vih.pdf).
- 11. Panama. Texto Unico del Código Penal de la República de Panamá. Art 308.
- 12. Still not welcome: HIV-related travel restrictions. Geneva: UNAIDS, UNDP; 2019 (https://www.unaids.org/sites/default/files/media_asset/hiv-related-travel-restrictions-explainer_en.pdf).

Note: A country is considered to have criminalized transgender persons if it uses the law to punish transgender individuals. Such a law may, for example, explicitly criminalize impersonation of the other gender, including cross-dressing. A country is considered to have any criminalization or punitive regulation of sex work if selling and/or buying sexual services is criminalized, ancillary activities associated with selling and/or buying sexual services are criminalized, profiting from organizing and/or managing sexual services is criminalized, and/or there are other punitive and/or administrative regulations of sex work.

INVESTING TO END AIDS

Most countries in Latin America have successfully mobilized large amounts of domestic resources for their HIV responses. There is just an 8% gap between the resources available in the region in 2020 and the amount needed in 2025. However, a stabilization in HIV infections and slow reductions in AIDS-related mortality suggests that much better use of available resources is required. Domestic resources increased by 79% from 2010 to 2020, accounting for 98% of all HIV resources in 2020. Resources from international sources decreased by 55% over the same period. In aggregate, the resources for HIV in the region increased by 70% during the last decade. There is a need to bring down the unit prices of antiretroviral medicines and to increase spending on HIV prevention programmes that are focused on key populations at higher risk of HIV infection.


RESOURCE AVAILABILITY FOR HIV, LATIN AMERICA, 2010–2020, AND ESTIMATED RESOURCE NEEDS FOR HIV BY 2025



Source: UNAIDS financial estimates and projections, 2021 (http://hivfinancial.unaids.org/hivfinancialdashboards.html).

Note: The resource estimates are presented in constant 2019 US dollars.

YEAR-TO-YEAR CHANGE IN RESOURCE AVAILABILITY FOR HIV, LATIN AMERICA, 2010– 2011 TO 2019–2020



Source: UNAIDS financial estimates, 2021 (http://hivfinancial.unaids.org/hivfinancialdashboards.html).



ARGENTINA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	6100	6000	5600
	[5300–6800]	[5200–7000]	[4600–6800]
New HIV infections (0–14)	<200	<100	<100
	[<100- <200]	[<100- <200]	[<100–<200]
New HIV infections (women, 15+)	1700	1700	1500
	[1500–1900]	[1400–2000]	[1300–1800]
New HIV infections (men, 15+)	4300	4200	4000
	[3600–5000]	[3500–5000]	[3200–5000]
HIV incidence per 1000 population	0.15 [0.13–0.17]	0.14 [0.12–0.16]	0.13 [0.1–0.15]
AIDS-related deaths			
AIDS-related deaths (all ages)	1500	1300	1400
	[1100–1900]	[1000–1700]	[1100–1800]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100-<100]
AIDS-related deaths (women, 15+)	<500	<500	<500
	[<500-<500]	[<500–<500]	[<500-<500]
AIDS-related deaths (men, 15+)	1100	1000	1100
	[820–1500]	[720–1300]	[780–1400]
People living with HIV			
People living with HIV (all ages)	100 000	120 000	140 000
	[92 000–110 000]	[110 000–130 000]	[130 000–150 000]
People living with HIV (0–14)	1600	1400	1200
	[1400–1700]	[1200–1600]	[940–1400]
People living with HIV (women, 15+)	30 000	36 000	43 000
	[28 000–32 000]	[34 000–39 000]	[39 000–46 000]
People living with HIV (men, 15+)	69 000	83 000	96 000
	[61 000–75 000]	[74 000–91 000]	[85 000–110 000]
HIV prevalence (15–49)	0.4 [0.3–0.4]	0.4 [0.4–0.4]	0.4 [0.3–0.4]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	Possession of drugs for personal use is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	No

residence permits or for certain groups

STIGMA AND DISCRIMINATION


Percentage of women and men aged 15-49

VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES							
	Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total	


US\$ 627 390 000 US\$ 1 860 000 US\$ 625 340 000 Last available report: 2016



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS							
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners		
Estimated size of population	•••			•••			
HIV prevalence					2.7%		
HIV testing and status awareness							
Antiretroviral therapy coverage					87.4%		
Condom use							
Coverage of HIV prevention programmes							
Avoidance of health care because of stigma and discrimination							
Expenditures in US\$							

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	95% [86–100%]	97% [87–100%]
Final vertical transmission rate including during breastfeeding	6.1% [5–7%]	4.3% [3.2–5.5%]
Early infant diagnosis	% [–%]	81.9% [73.5–91.5%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	830 [470–1300]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV (2016)	43.6%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.2%
Knowledge of HIV prevention among young people aged 15–24 years (2012)	
— Women	40.3%
— Men	***
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	
— Men	
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	

Men aged 15-49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

Harm reduction

- Use of sterile injecting equipment at last injection ...

 Needles and syringes distributed per
- Needles and syringes distributed per person who injects
 Coverage of opioid substitution therapy
- merapy

 Naloxone available (2021)

 No

 Safe injection rooms available (2021)

 No

BOLIVIA (PLURINATIONAL STATE OF)

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	1000	1100	870
	[840–1200]	[880–1400]	[660–1100]
New HIV infections (0–14)	<100	<100	<100
	[<100- <200]	[<100-<100]	[<100- <100]
New HIV infections (women, 15+)	<500	<500	<500
	[<500–520]	[<500–590]	[<500-<500]
New HIV infections (men, 15+)	520	580	<500
	[<500–650]	[<500–730]	[<500–610]
HIV incidence per 1000 population	0.1 [0.09–0.13]	0.1 [0.08–0.13]	0.08 [0.06–0.1]
AIDS-related deaths			
AIDS-related deaths (all ages)	590	<500	<200
	[<500–790]	[<500–530]	[<200-<500]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100–<100]	[<100–<100]	[<100-<100]
AIDS-related deaths (women, 15+)	<500	<200	<100
	[<500–<500]	[<200– <500]	[<100- <200]
AIDS-related deaths (men, 15+)	<500	<200	<100
	[<200– <500]	[<200-<500]	[<100-<100]
People living with HIV			
People living with HIV (all ages)	12 000	14 000	17 000
	[9900–14 000]	[12 000–16 000]	[15 000–20 000]
People living with HIV (0-14)	700	590	<500
	[590–890]	[<500–740]	[<500–610]
People living with HIV (women, 15+)	4900	6000	7500
	[4200–5900]	[5100–7100]	[6300–8800]
People living with HIV (men, 15+)	6000	7500	9400
	[5000–7200]	[6200–8800]	[7700 –1 1 000]
HIV prevalence (15–49)	0.2 [0.2–0.2]	0.2 [0.2–0.2]	0.2 [0.2–0.2]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Sex work is not subject to punitive regulations or is not criminalized
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	Yes
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

STI	GN	1A AI	ND D	ISCRIN	ITANIN	ON


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Percentage of people living with HIV who reported a health-care professional told	

others about their HIV status without their consent

VIOLENCE

Proportion of ever-married or partnered	2016
women aged 15–49 years who experienced	
ohysical or sexual violence from a male	
ntimate partner in the past 12 months	39.4

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2012	US\$ 2 112 301	US\$ 4 786 726		US\$ 3 549 926	US\$ 97 951	US\$ 11 768 762



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS Men who People who Transgender Sex workers Prisoners have sex inject drugs people with men Estimated size of population ... **HIV** prevalence 22.6% HIV testing and status 63.8% awareness 32% Antiretroviral therapy coverage Condom use 66% 80% Coverage of HIV prevention 33.9% 55.3% ... programmes Avoidance of health care because of stigma and discrimination **Expenditures in US\$**

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

2010	2020
43%	98%
[36–52%]	[83–100%]
24.8%	12.9%
[21.7–27.6%]	[9.8–16.6%]
46.7%	%
[38.3–58.1%]	[–%]
	43% [36–52%] 24.8% [21.7–27.6%] 46.7%

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	540 [340–770]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	•••
— Men	
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	
— Men	
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not applicable

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

BRAZIL

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	47 000	47 000	48 000
	[22 000–70 000]	[22 000–70 000]	[23 000–70 000]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)			
	[]	[]	[]
New HIV infections (men, 15+)			
	[=]	[=]	[=]
HIV incidence per 1000 population	0.25 [0.11–0.36]	0.23 [0.11–0.35]	0.23 [0.11–0.34]
AIDS-related deaths			
AIDS-related deaths (all ages)	14 000	16 000	13 000
	[5800–23 000]	[6500–25 000]	[5200–21 000]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)			
	[]	[]	[]
AIDS-related deaths (men, 15+)			
	[]	[]	[]
People living with HIV			
People living with HIV (all ages)	640 000	790 000	930 000
	[310 000–940 000]	[380 000 –1 100 000]	[450 000–1 400 000]
People living with HIV (0–14)			
	[–]	[]	[]
People living with HIV (women, 15+)			
	[]	[]	[]
People living with HIV (men, 15+)			
	[–]	[–]	[–]
HIV prevalence (15–49)	0.5 [0.2–0.7]	0.5 [0.2–0.8]	0.6 [0.3–0.8]

LAW	S AN	ND P	OLIC	IES

Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents 12 years or younger
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	No

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49

years who report discriminatory attitudes towards people living with HIV	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	•••

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent


VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

residence permits or for certain groups

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International:	International:	International:	Total


Last available report: 2020 US\$ 559 236 021 US\$ 559 236 021



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••		***	•••	702 100
HIV prevalence	5.3%	18.3%		30%	
HIV testing and status awareness	52.3%	72.6%		76.9%	
Antiretroviral therapy coverage					
Condom use		64.3%		70.8%	
Coverage of HIV prevention programmes	22.4%	29.8%		59.3%	
Avoidance of health care because of stigma and discrimination		17.3%			
Expenditures in US\$ (2020)		183 721			

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION			
	2010	2020	
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]	
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]	

Early infant diagnosis

...%

[...-..%]

...%

[...-..%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	11 000 [9300 –13 000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

- Men

Adults aged 15+ years with unsuppresse viral load	d
Knowledge of HIV prevention among you people aged 15–24 years	ıng
— Women	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged

15–49 years

WomenMen

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	23 327

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)

No

No

— Safe injection rooms available (2021)

CHILE

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	3100	4700	5000
	[2600–3600]	[4000–5500]	[4200–6100]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)	520	840	1000
	[<500–600]	[720–970]	[880–1200]
New HIV infections (men, 15+)	2500	3800	3900
	[2100–3000]	[3100–4500]	[3200–4900]
HIV incidence per 1000 population	0.18 [0.15–0.21]	0.26 [0.22–0.3]	0.26 [0.22–0.32]
AIDS-related deaths			
AIDS-related deaths (all ages)			
	[]	[]	[]
AIDS-related deaths (0–14)			
	[–]	[]	[]
AIDS-related deaths (women, 15+)			
	[]	[]	[]
AIDS-related deaths (men, 15+)			
	[]	[]	[]
People living with HIV			
People living with HIV (all ages)	36 000	54 000	77 000
	[32 000–40 000]	[48 000–59 000]	[68 000–86 000]
People living with HIV (0–14)			
	[]	[]	[]
People living with HIV (women, 15+)	6100	9200	14 000
	[5600–6600]	[8400–9900]	[13 000–15 000]
People living with HIV (men, 15+)	30 000	44 000	63 000
	[26 000–33 000]	[38 000–49 000]	[55 000–71 000]
HIV prevalence (15–49)	0.3 [0.3–0.3]	0.4 [0.4–0.5]	0.6 [0.5–0.6]

WS		\mathbf{D}	
W	Δ		

Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	No
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	No

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49

years who report discriminatory attitudes towards people living with HIV	
Percentage of people living with HIV denied health services because of their HIV status in	
the last 12 months	

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent

VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

residence permits or for certain groups

EXPENDITORES						
		Finar	ncing sources			
	Domestic private	Domestic public	International:	International:	International:	Total
	Domestic private	Domestic public	PEPFAR	Global Fund	all others	rotai

US\$ 325 931 502 Last available report: 2019 US\$ 120 172 875 US\$ 205 742 308 US\$ 14 298


2000 2005 2010 2015 2020


All-cause deaths among


New HIV infections

the HIV population


EPIDEMIC TRANSITION METRICS







HIV TESTING AND TREATMENT CASCADE



All ages	91% [81–101%]	70% [62–78%] 54 153	63% [56–70%]
Children (0-14)	% [%]	% [%] 	% [%]
Women (15+)	% [%]	% [%] 	% [%]
Men (15+)	% [%]	% [%] 	% [%]

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]
Early infant diagnosis	% [–%]	% [%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	360 [290–420]
People living with HIV who started TB preventive therapy (2018)	4.6%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	52%

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	0.2%
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2016)	
— Women	26.1%
— Men	49.2%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	546

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy — Naloxone available (2021)
- Safe injection rooms available (2021)

No

No

COLOMBIA

COUNTRY DATA


EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	10 000	9600	9300
	[7500–13 000]	[6500–13 000]	[5800–14 000]
New HIV infections (0–14)	<500	<200	<200
	[<200– <500]	[<200–<500]	[<100- <500]
New HIV infections (women, 15+)	1400	870	740
	[1000–1800]	[590–1300]	[<500–1200]
New HIV infections (men, 15+)	8800	8600	8400
	[6300–12 000]	[5800–12 000]	[5200–13 000]
HIV incidence per 1000 population	0.23 [0.17–0.3]	0.2 [0.14–0.28]	0.18 [0.12–0.29]
AIDS-related deaths			
AIDS-related deaths (all ages)	7200	3100	3000
	[5200–9500]	[2000–4600]	[1700–4800]
AIDS-related deaths (0–14)	<200	<200	<200
	[<200–<500]	[<100-<200]	[<100- <200]
AIDS-related deaths (women, 15+)	1300	<500	<500
	[870–1700]	[<500–<500]	[<200-<500]
AIDS-related deaths (men, 15+)	5700	2600	2700
	[4100–7600]	[1700–4100]	[1500–4300]
People living with HIV			
People living with HIV (all ages)	120 000	150 000	180 000
	[100 000–150 000]	[120 000–180 000]	[150 000–220 000]
People living with HIV (0–14)	2400	1800	1400
	[1900–3000]	[1400–2300]	[1100–1900]
People living with HIV (women, 15+)	24 000	26 000	29 000
	[19 000–28 000]	[21 000–31 000]	[23 000–35 000]
People living with HIV (men, 15+)	97 000	120 000	150 000
	[78 000–120 000]	[97 000 –1 50 000]	[120 000–190 000]
HIV prevalence (15–49)	0.4 [0.3–0.5]	0.4 [0.4–0.5]	0.4 [0.4–0.6]


LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Sex work is not subject to punitive regulations or is not criminalized
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No


STIGMA AND DISCRIMINATION	NC	
Percentage of women and men aged 15–49 years who report discriminatory attitudes	2010	2015
towards people living with HIV (2015 refers to women only)	44.7	37.2
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced	2010	2015
physical or sexual violence from a male intimate partner in the past 12 months	37.4	33.3


EXPENDITURES						
Financing sources						
Domestic private Domestic public International: International: International: Total PEPFAR Global Fund all others						

US\$ 34 547 857 US\$ 84 674 170 US\$ 119 528 046 Last available report: 2013









Change in new
HIV infections
since 2010

-10%

Change in AIDS-related deaths = -58% since 2010

Incidence:
prevalence = 5.15
ratio

Incidence: mortality ratio*

* The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••		•••	•••	120 000
HIV prevalence	1.2%	17%		21.4%	0.7%
HIV testing and status awareness	90.6%	33.0%**	68.1%**	38.4%	
Antiretroviral therapy coverage	72.1%	89.2%		78.6%	91.8%
Condom use	98.3%	17%		74.6%	
Coverage of HIV prevention programmes		38%			
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

^{**} Programme data—not representative; includes people with negative results.

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION			
	2010	2020	
Percentage of pregnant women living with HIV	73%	70%	

accessing antiretroviral medicines	[58–90%]	[57–85%]
Final vertical transmission rate including during breastfeeding	20.3% [16.4–23.2%]	15.7% [12.3–20.9%]
	%	%

 Early infant diagnosis
 ...%
 ...%

 [...-..%]
 [...-..%]

HIV COMORBIDITIES	
Estimated number of incident tuberculosis cases among people living with HIV (2018)	2100 [1600 –2700]
People living with HIV who started TB preventive therapy (2018)	0.9%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2018)	82.4%

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.2%
Knowledge of HIV prevention among young people aged 15–24 years (2015)	
— Women	31.63%
— Men	28.52%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2015)	
— Women	42.4%
— Men	70.5%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2015)	86.6%
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

3 1 31	
rm reduction	
 Use of sterile injecting equipment at last injection 	
 Needles and syringes distributed per person who injects (2019) 	22
 Coverage of opioid substitution therapy 	

— Naloxone available (2021)

- Safe injection rooms available (2021)

Har

COSTA RICA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	590	960	1700
	[530–660]	[850–1100]	[1400–2000]
lew HIV infections (0–14)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100- <100]
lew HIV infections (women, 15+)	<500	<500	730
	[<500–<500]	[<500–<500]	[630–860]
New HIV infections (men, 15+)	<500	510	890
	[<500-<500]	[<500–600]	[710–1100]
HIV incidence per 1000 population	0.13 [0.12–0.15]	0.2 [0.18–0.22]	0.34 [0.29–0.39]
AIDS-related deaths			
AIDS-related deaths (all ages)	<200	<200	<500
	[<200– <200]	[<200-<500]	[<500–<500]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100– <100]	[<100-<100]	[<100–<100]
IDS-related deaths (women, 15+)	<100	<200	<200
	[<100– <200]	[<200–<200]	[<200–<500]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100-<100]
eople living with HIV			
eople living with HIV (all ages)	7000	10 000	16 000
	[6500–7600]	[9200–11 000]	[14 000–17 000]
eople living with HIV (0–14)	<200	<200	<500
	[<200– <200]	[<200-<500]	[<500–<500]
eople living with HIV (women, 15+)	2900	4000	6300
	[2700–3200]	[3700–4300]	[5700–6800]
eople living with HIV (men, 15+)	3900	5700	9100
	[3500–4300]	[5100–6400]	[7800–10 000]
HIV prevalence (15–49)	0.2 [0.2–0.2]	0.3 [0.3–0.3]	0.4 [0.4–0.5]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Sex work is not subject to punitive regulations or is not criminalized
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	No
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	

residence permits or for certain groups


STIGMA AND DISCRIMINATION

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	•••	
Percentage of people living with HIV denied		2014
the last 12 months		8.8
Percentage of people living with HIV who		2014
reported a health-care professional told		2014
others about their HIV status without their		
consent		15.5

VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020	US\$ 3 052 190	US\$ 58 370 524		US\$ 906 847	US\$ 159 230	US\$ 62 614 488



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS Men who People who Transgender Sex workers Prisoners have sex inject drugs people with men Estimated size of population ... 15 800 **HIV** prevalence 1.4% 15.4% 24.6% 0.3% HIV testing and status 100%** 100% 100% awareness 62 1% Antiretroviral therapy coverage 74% Condom use 39.2% 78.6% Coverage of HIV prevention 83.3% ... programmes Avoidance of health care because of stigma and discrimination 200 964 120 020 Expenditures in US\$ (2020)

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	0% [0 – 0%]	68% [61–76%]
Final vertical transmission rate including during breastfeeding	43.3% [41.1–45.5%]	45.7% [43.5–47.8%]
Early infant diagnosis	39.8% [31.5–50%]	28.6% [25.5–31.7%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	54 [35–77]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.2%
Knowledge of HIV prevention among young people aged 15–24 years (2011)	
— Women	33.1%
— Men	
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	
— Men	
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)— Safe injection rooms available (2021)

No

No

^{**} Programme data—not representative; includes people with negative results.

ECUADOR

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	2500	2500	2100
	[1500–4300]	[1500–4200]	[1100–4200]
New HIV infections (0–14)	<200	<200	<200
	[<100-<500]	[<100-<500]	[<100-<500]
New HIV infections (women, 15+)	670	680	610
	[<500–1100]	[<500–1100]	[<500–1200]
New HIV infections (men, 15+)	1700	1600	1300
	[1000–2900]	[990–2800]	[720–2800]
HIV incidence per 1000 population	0.17 [0.1–0.29]	0.15 [0.09–0.26]	0.12 [0.07–0.24]
AIDS-related deaths			
AIDS-related deaths (all ages)	970	1100	<500
	[530–1800]	[600–2000]	[<500–900]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100–<200]	[<100-<200]	[<100- <200]
AIDS-related deaths (women, 15+)	<500	<200	<200
	[<200–<500]	[<100-<200]	[<100- <200]
AIDS-related deaths (men, 15+)	670	910	<500
	[<500_1200]	[<500–1700]	[<200–570]
People living with HIV			
People living with HIV (all ages)	31 000	37 000	45 000
	[22 000–47 000]	[26 000–55 000]	[31 000–67 000]
People living with HIV (0-14)	920	930	930
	[660–1300]	[600–1500]	[560–1500]
People living with HIV (women, 15+)	8200	11 000	14 000
	[5700–12 000]	[7300–16 000]	[8900–20 000]
People living with HIV (men, 15+)	22 000	26 000	31 000
	[15 000–33 000]	[18 000–38 000]	[21 000–45 000]
HIV prevalence (15–49)	0.3 [0.2–0.5]	0.3 [0.2–0.5]	0.3 [0.2–0.5]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Sex work is not subject to punitive regulations or is not criminalized
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

residence permits or for certain groups

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49

years who report discriminatory attitudes towards people living with HIV	
	 •••
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	•••


Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent


VIOLENCE


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

Last available report: 2020 US\$ 10 976 937 US\$ 10 976 937









Change in new
HIV infections = -16%
since 2010

Change in AIDS-related deaths = -53% since 2010

Incidence: prevalence = 4.60 ratio

Incidence: mortality ratio*


* The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••		•••	•••	
HIV prevalence		16.5%		34.8%	0.6%
HIV testing and status awareness		56.3%		60.4%	
Antiretroviral therapy coverage					89.7%
Condom use	69.7%			94%	
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2018)		213 487		213 487	80 003

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	1000 [760–1300]
People living with HIV who started TB preventive therapy (2018)	4.8%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



J	
HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.1%
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable	
Voluntary medical male circumcisions performed according to national standards	Not applicable	
People who received PrEP at least once during the reporting period (2020)	277	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	46% [32–73%]	61% [41–89%]
Final vertical transmission rate including during breastfeeding	22.4% [17.7–27%]	16.4% [11.4–22.8%]
Early infant diagnosis	<1% [<1–1.3%]	% [–%]

Harm reduction

— Men

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)

Safe injection rooms available (2021)

EL SALVADOR

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	1600	1200	850
	[1400–1700]	[1100–1400]	[620–1100]
New HIV infections (0–14)	<200	<100	<100
	[<100- <200]	[<100- <100]	[<100–<100]
New HIV infections (women, 15+)	720	560	<500
	[630–800]	[<500–640]	[<500–510]
New HIV infections (men, 15+)	750	590	<500
	[630–850]	[<500–690]	[<500–530]
HIV incidence per 1000 population	0.26 [0.23–0.28]		0.13 [0.1–0.17]
AIDS-related deaths			
AIDS-related deaths (all ages)	<500	<500	630
	[<500–<500]	[<500–550]	[520–750]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100– <100]	[<100-<100]	[<100–<100]
AIDS-related deaths (women, 15+)	<200	<500	<500
	[<200– <500]	[<200–<500]	[<500-<500]
AIDS-related deaths (men, 15+)	<100	<200	<200
	[<100-<200]	[<100-<500]	[<200–<500]
People living with HIV			
People living with HIV (all ages)	21 000	24 000	25 000
	[19 000–22 000]	[22 000–26 000]	[23 000–27 000]
People living with HIV (0–14)	590	580	530
	[540–630]	[520–620]	[<500–580]
People living with HIV (women, 15+)	9700	11 000	11 000
	[9000–10 000]	[11 000–12 000]	[10 000–12 000]
People living with HIV (men, 15+)	10 000	12 000	13 000
	[9100–11 000]	[11 000–13 000]	[11 000–14 000]
HIV prevalence (15–49)	0.5 [0.5–0.6]	0.6 [0.5–0.6]	0.5 [0.4–0.5]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

STIGMA AND DISCRIMINATION


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	•••	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told		

others about their HIV status without their consent

VIOLENCE

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020	US\$ 2 235 626	US\$ 28 763 001	US\$ 6 525 119	US\$ 5 140 323	US\$ 1 110 550	US\$ 48 174 777



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population				•••	
HIV prevalence	2.8%	16.3%		22.3%	0%
HIV testing and status awareness	89.5%	77.3%		74.4%	
Antiretroviral therapy coverage					
Condom use	18.3%	69%		76.3%	
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2020)	717 680	2 362 520		592 628	465 503

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	30% [26–33%]	43% [38–49%]
Final vertical transmission rate including during breastfeeding	31.1% [29.8–32.5%]	27.2% [24.9–28.9%]
Early infant diagnosis	31.4% [27.1–37.6%]	46.5% [41.2–53.2%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	260 [190–340]
People living with HIV who started TB preventive therapy (2018)	72.9%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.3%
Knowledge of HIV prevention among young people aged 15–24 years (2014)	
— Women	31.1%
— Men	33.9%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	

Women aged 15-49 years who have their demand for family planning satisfied by

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

Harm reduction

— Men

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021) No
- Safe injection rooms available (2021)

GUATEMALA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
lew HIV infections			
New HIV infections (all ages)	1600	980	770
	[970–2600]	[660–1500]	[500–1200]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)	<500	<200	<200
	[<500–750]	[<100- <500]	[<100- <500]
New HIV infections (men, 15+)	580	<500	<500
	[<500–1000]	[<500–650]	[<200–610]
IIV incidence per 1000 population	0.12 [0.07–0.19]	0.07 [0.04–0.1]	0.05 [0.03–0.07]
AIDS-related deaths			
AIDS-related deaths (all ages)	810	910	760
	[580–1100]	[560–1500]	[<500–1200]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<200	<200	<500
	[<200-<500]	[<200– <500]	[<200–510]
AIDS-related deaths (men, 15+)	<500	<500	<500
	[<200–<500]	[<500–770]	[<200-<500]
People living with HIV			
eople living with HIV (all ages)	34 000	35 000	33 000
	[27 000–44 000]	[28 000–46 000]	[28 000–43 000]
eople living with HIV (0–14)			
	[]	[]	[]
People living with HIV (women, 15+)	12 000	13 000	12 000
	[9700–17 000]	[10 000–17 000]	[10 000–16 000]
People living with HIV (men, 15+)	18 000	18 000	18 000
	[15 000–24 000]	[15 000–24 000]	[15 000–23 000]
HIV prevalence (15–49)	0.4 [0.3–0.5]	0.3 [0.2–0.4]	0.2 [0.2–0.3]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

Last available report: 2019

CTICN	A A A	CCDIN	MOITAMIN
	/I A A I		MINIA I II DINI


Percentage of women aged 15–49 years who report discriminatory attitudes towards		2015
people living with HIV	•••	57.3
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		


Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent


VIOLENCE


5

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2019	US\$ 479 896	US\$ 19 830 959	US\$ 2 405 559	US\$ 4 780 864		US\$ 27 943 484









Change in new **HIV** infections since 2010

Change in AIDSrelated deaths since 2010

Incidence: 2.31 prevalence ratio

mortality ratio*


* The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population	•••	116 500	•••	4300	25 200	
HIV prevalence	1%	9%		22.2%		
HIV testing and status awareness	85.9%	77.9%		92.2%		
Antiretroviral therapy coverage	3.7%	47.6%		23.7%	57.2%	
Condom use	97.4%	69.3%		66.2%		
Coverage of HIV prevention programmes	29%	26%		16%		
Avoidance of health care because of stigma and discrimination						
Expenditures in US\$ (2019)	271 681	2256				

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	310 [230–400]
People living with HIV who started TB preventive therapy (2018)	10.7%
Women who tested positive for HIV among those screened for cervical cancer (programme data) (2018)	11.1%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	6.8%

HIV TESTING AND TREATMENT CASCADE



People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	6.8%
HIV PREVENTION	
Adults aged 15+ years with unsuppressed	0.1%
virai ioad	
Knowledge of HIV prevention among young people aged 15–24 years (2015)	
Knowledge of HIV prevention among young	22.2%

- Women — Men Women aged 15-49 years who have their demand for family planning satisfied by modern methods (2015)

45.5%	
66.2%	

19.9%

Men aged 15-49 years who are circumcised Not applicable

(=0.0)	аррисавио
Voluntary medical male circumcisions	Not
performed according to national standards	applicable

People who received PrEP at least once	404
during the reporting period (2020)	484

Harm reduction

15-49 years (2015)

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution

— Naloxone available (2021) No - Safe injection rooms available (2021) No

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]
Early infant diagnosis	% [–%]	% [–%]

HONDURAS

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	760	710	710
	[570–980]	[540–950]	[530–960]
New HIV infections (0–14)	<200	<200	<100
	[<200–<200]	[<100- <200]	[<100- <200]
New HIV infections (women, 15+)	<200	<200	<200
	[<200–<500]	[<100- <200]	[<100-<200]
New HIV infections (men, 15+)	<500	<500	<500
	[<500 <u>–</u> 660]	[<500–670]	[<500–680]
HIV incidence per 1000 population	0.09 [0.07–0.12]	0.08 [0.06–0.11]	0.07 [0.06–0.1]
AIDS-related deaths			
AIDS-related deaths (all ages)	1200	870	680
	[920–1500]	[690–1100]	[540–840]
AIDS-related deaths (0–14)	<200	<100	<100
	[<200–<200]	[<100–<200]	[<100–<100]
AIDS-related deaths (women, 15+)	<500	<500	<500
	[<500–<500]	[<200–<500]	[<200-<500]
AIDS-related deaths (men, 15+)	690	520	<500
	[540–850]	[<500–650]	[<500-<500]
People living with HIV			
People living with HIV (all ages)	25 000	23 000	22 000
	[22 000–28 000]	[20 000–26 000]	[20 000–26 000]
People living with HIV (0–14)	2200	1300	810
	[1900–2500]	[1200–1600]	[680–960]
People living with HIV (women, 15+)	9800	9200	8700
	[8700–11 000]	[8200–10 000]	[7700–9800]
People living with HIV (men, 15+)	13 000	13 000	13 000
	[11 000–15 000]	[11 000–15 000]	[11 000–15 000]
HIV prevalence (15–49)	0.4 [0.4–0.5]	0.3 [0.3–0.3]	0.2 [0.2–0.3]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Sex work is not subject to punitive regulations or is not criminalized
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	Possession of drugs for personal use is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

residence permits or for certain groups


W = 1 N P A P A	NATION

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	
Percentage of people living with HIV denied health services because of their HIV status in	2013
the last 12 months	4.1
Percentage of people living with HIV who reported a health-care professional told	2013
others about their HIV status without their consent	9.9

VIOLENCE

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020	US\$ 6 807 458	US\$ 12 416 687	US\$ 2 588 126	US\$ 3 624 635	US\$ 806	US\$ 25 695 177



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence	3%	10%		6.4%	1.1%
HIV testing and status awareness					
Antiretroviral therapy coverage		95.5%			
Condom use	74%	55.8%		41.2%	
Coverage of HIV prevention programmes		70.6%		83%	
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2020)	645 468	1 275 908		64 637	131 219

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	40% [35–46%]	37% [32–42%]
Final vertical transmission rate including during breastfeeding	21.8% [20–23.5%]	24.6% [21.1–26.6%]
Early infant diagnosis	93.4% [77.9– >95%]	45.1% [39.4–52.1%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	230 [170–300]
People living with HIV who started TB preventive therapy (2018)	57.7%
Women who tested positive for HIV among those screened for cervical cancer (programme data) (2019)	2.9%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	0%

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.2%
Knowledge of HIV prevention among young people aged 15–24 years (2011)	
— Women	33.1%
— Men	34.7%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2012)	
— Women	
— Men	60.9%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	

Men aged 15–49 years who are circumcised	Not applicable	
Voluntary medical male circumcisions performed according to national standards	Not applicable	
People who received PrEP at least once during the reporting period		

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy ...
 Naloxone available (2021) No

No

— Safe injection rooms available (2021)

MEXICO

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	244 100	1 226 000		122 700	200 000
HIV prevalence	0.8%	11.9%	2.9%	4.9%	
HIV testing and status awareness	65.8%	39.8%		62.3%	
Antiretroviral therapy coverage					
Condom use	84.4%	65.3%		74.9%	
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2015)	2 896 831	12 296 685	1 744 655		

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES	
Estimated number of incident tuberculosis cases among people living with HIV (2018)	2800 [2100 –3600]
People living with HIV who started TB preventive therapy (2018)	1%
Women who tested positive for HIV among those screened for cervical cancer (programme data) (2019)	27.7%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.2%
Knowledge of HIV prevention among young people aged 15–24 years (2015)	
— Women	31.3%
— Men	
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	
— Men	
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	2143

— Use of sterile injecting equipment at

— Needles and syringes distributed per

- Safe injection rooms available (2021)

person who injects (2018)

— Coverage of opioid substitution

6

9.3%

Yes

Yes

Harm reduction

last injection

therapy (2018)

— Naloxone available (2021)

EXPENDITURES						
		Finar	cing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2015	US\$ 67 939 646	US\$ 867 060 986			US\$ 1 190 948	US\$ 936 191 579

COUNTRY DATA

LAWS AND POLICIES		STIGMA AND DISCRIMINATION	NC	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No	Percentage of women aged 15–49 years who report discriminatory attitudes towards		2015
Criminalization of sex work among consenting adults	Issue is determined/differs at subnational level	people living with HIV		15.4
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed			
Drug use or possession for personal use is an offence	No	Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		•••
Criminalization of transgender people	Neither criminalized nor prosecuted			
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE		
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years	than Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months		2016
Spousal consent for married women to access sexual and reproductive health services	No			8.1
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No			

NICARAGUA

COUNTRY DATA

	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	710	760	740
	[540–960]	[500–1100]	[<500–1100]
New HIV infections (0–14)	<100	<100	<100
	[<100–<100]	[<100–<100]	[<100–<100]
New HIV infections (women, 15+)	<500	<500	<500
	[<200– <500]	[<200–<500]	[<200–<500]
New HIV infections (men, 15+)	<500	500	500
	[<500–640]	[<500–730]	[<500–790]
HIV incidence per 1000 population	0.12 [0.09–0.17]	0.12 [0.08–0.18]	0.11 [0.07–0.17]
AIDS-related deaths			
AIDS-related deaths (all ages)	<500	<500	<500
	[<200-<500]	[<200-<500]	[<200-<500]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100– <100]	[<100- <100]	[<100- <100]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100– <200]	[<100– <100]	[<100- <200]
AIDS-related deaths (men, 15+)	<200	<500	<200
	[<100-<500]	[<200–<500]	[<100-<500]
People living with HIV			
People living with HIV (all ages)	7500	9400	12 000
	[5500–9700]	[7300–12 000]	[8700–15 000]
People living with HIV (0–14)	<500	<500	<500
	[<200– <500]	[<200–<500]	[<200–<500]
People living with HIV (women, 15+)	2200	2900	3700
	[1600–2800]	[2300–3800]	[2800–4700]
People living with HIV (men, 15+)	5100	6300	7700
	[3700–6700]	[4800–8100]	[5700–10 000]
HIV prevalence (15–49)	0.2 [0.2–0.3]	0.2 [0.2–0.3]	0.2 [0.2–0.3]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	Possession of drugs for personal use is specified as a non-criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	No

residence permits or for certain groups

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49


years who report discriminatory attitudes towards people living with HIV	
Percentage of people living with HIV denied	2013
the last 12 months	4
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their	2013
consent	8.1


VIOLENCE


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 9 155 592 Last available report: 2010 US\$ 1 150 592 US\$ 9 682 304 US\$ 2 793 096 US\$ 24 894 867









Change in new
HIV infections = 4%
since 2010

Change in AIDSrelated deaths = -199 since 2010 Incidence:
prevalence = 6.41
ratio

Incidence: mortality ratio*


* The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					19 700
HIV prevalence	2.2%	8.8%	0%	9.5%	0.3%
HIV testing and status awareness	69.9%	98.8%		95.9%	
Antiretroviral therapy coverage					
Condom use	88%	56.9%		75.6%	
Coverage of HIV prevention programmes	88.4%	70.8%		87.4%	
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	140 [100–190]
People living with HIV who started TB preventive therapy (2018)	31%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	100%

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION

Adults	aged	15+	years	with	unsuppressed	
viral lo	ad					

Knowledge of HIV prevention among young people aged 15–24 years

- Women
- Men

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

- Women
- Men

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	66% [49–88%]	100% [88–100%]
Final vertical transmission rate including during breastfeeding	21.2% [16.5–25.2%]	8.6% [5.9–10.8%]
Early infant diagnosis	39.5% [30.1–48.7%]	54.9% [42.9–70.3%]

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy

— Naloxone available (2021)

— Safe injection rooms available (2021)

No


No

PANAMA

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population			•••		
HIV prevalence	1.1%	13.4%		29.8%	1.8%
HIV testing and status awareness	99.2%**	99.5%		100%**	
Antiretroviral therapy coverage		93.6%			91%
Condom use	98.8%	67.9%		63.8%	
Coverage of HIV prevention programmes	100%	100%		100%	
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2018)	233 812	809 144			

 $[\]hbox{** Programme data} \hbox{$-$not representative; includes people with negative results.}$

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	400 [300–510]
People living with HIV who started TB preventive therapy (2018)	26.2%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	0.5%
Knowledge of HIV prevention among young people aged 15–24 years (2013)	
— Women	37.1%
— Men	
Condom use at last sex with a non-marital.	

non-cohabiting partner among people aged 15-49 years

49 years		
— Women		
— Men		

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

Harm reduction

ariir reduction	
 Use of sterile injecting equipment at last injection 	
 Needles and syringes distributed per person who injects 	
 Coverage of opioid substitution therapy 	
— Naloxone available (2021)	No

 Safe injection rooms available (2021) 	No

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020		US\$ 3 260 822				US\$ 3 260 822

•••

COUNTRY DATA

LAWS AND POLICIES		STIGMA AND DISCRIMINATION		
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes	Percentage of women and men aged 15–49 years who report discriminatory attitudes		
Criminalization of sex work among consenting adults	Sex work is not subject to punitive regulations or is not criminalized	towards people living with HIV		
Criminalization of same-sex sexual acts	No specific legislation	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence	Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
Criminalization of transgender people	Neither criminalized nor prosecuted			
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE		
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent	Proportion of ever-married or partnered women aged 15–49 years who experienced		
Spousal consent for married women to access sexual and reproductive health services	No	physical or sexual violence from a male intimate partner in the past 12 months		
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No			

PARAGUAY

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	1000	1000	890
	[720–1700]	[690–1600]	[560–1400]
New HIV infections (0–14)	<100	<100	<100
	[<100–<200]	[<100- <100]	[<100-<100]
New HIV infections (women, 15+)	<500	<500	<500
	[<500–680]	[<500–660]	[<500–580]
New HIV infections (men, 15+)	570	560	500
	[<500–950]	[<500–890]	[<500–830]
HIV incidence per 1000 population	0.17 [0.12–0.28]	0.16 [0.1–0.24]	0.13 [0.08–0.21]
AIDS-related deaths			
AIDS-related deaths (all ages)	630	570	<500
	[<500–1000]	[<500–950]	[<500–640]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100–<100]
AIDS-related deaths (women, 15+)	<500	<500	<200
	[<200-<500]	[<200–<500]	[<200– <500]
AIDS-related deaths (men, 15+)	<500	<500	<200
	[<200–530]	[<200-<500]	[<100-<500]
People living with HIV			
People living with HIV (all ages)	15 000	17 000	19 000
	[12 000–22 000]	[13 000–23 000]	[14 000–26 000]
People living with HIV (0–14)	500	<500	<500
	[<500–700]	[<500–620]	[<500–<500]
People living with HIV (women, 15+)	6200	6800	7500
	[4700–8800]	[5200–9700]	[5800–10 000]
eople living with HIV (men, 15+)	8700	9500	11 000
	[6600–12 000]	[7200–13 000]	[8000–15 000]
HIV prevalence (15–49)	0.4 [0.3–0.5]	0.4 [0.3–0.5]	0.3 [0.3–0.5]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	Require HIV testing or disclosure for some permits
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes

STICK	<i>A</i>	וח חו	CCDIM	
	MA AN	וט טו	\mathbf{SCRHMI}	INATION

Percentage of women aged 15–49 years who report discriminatory attitudes towards	 2016
people living with HIV	 35
Percentage of people living with HIV denied	2016
the last 12 months	16.5
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their	2016
consent	19.8

VIOLENCE


Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES


residence permits or for certain groups


LAI LINDITORLS						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 1 320 204 US\$ 90 150 US\$ 1 410 354 Last available report: 2020









Change in new HIV infections = -15% since 2010

Change in AIDS-related deaths = -45% since 2010

Incidence:
prevalence = 4.81
ratio

Incidence: mortality ratio*


* The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS							
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners		
Estimated size of population	•••						
HIV prevalence	1.5%	21.9%		31.7%			
HIV testing and status awareness	66.9%	80.3%		49.8%			
Antiretroviral therapy coverage		26.1%					
Condom use	98.5%	76.6%		71.5%			
Coverage of HIV prevention programmes							
Avoidance of health care because of stigma and discrimination	5%	16.6%		6.3%			
Expenditures in US\$ (2018)	286 860	88 695	13 611				

	~	\neg ι	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	\frown	D	ы		171	-
HIV (S	~ 17	Ш	U	K	D.	ע		

Estimated number of incident tuberculosis cases among people living with HIV (2018)	260 [210–310]
People living with HIV who started TB preventive therapy (2018)	13.7%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	0%

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION

Adults	aged	15+	years	with	unsuppressed
viral lo	ad				

0.2%

Knowledge of HIV prevention among young people aged 15–24 years (2016)

— Women	27.5%
— Men	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

— Women

— Men

...

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable	
Voluntary medical male circumcisions performed according to national standards	Not applicable	
People who received PrEP at least once during the reporting period		

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

3069

41% [32-57%]

61% [45-85%]

34% [27-48%]

51% [38-71%]

78% [61-107%]

99% [73-137%]

Women (15+)

Men (15+)

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	50% [37–73%]	96% [70–100%]
Final vertical transmission rate including during breastfeeding	20.7% [19.4–22.1%]	10% [9.2 –1 1%]
Early infant diagnosis	25% [15.9–38.5%]	69% [47.4–94.1%]

Harm reduction

— Use of sterile injecting equipment at	
last injection	

— Needles and syringes distributed pe	er
person who injects	

 Coverage of opioid substitution
therapy

– Naloxone available (2021)	No
– Safe injection rooms available (2021)	No

PERU

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	4200	3600	4100
	[3500–5200]	[2900–4700]	[3100–5500]
lew HIV infections (0–14)	<200	<200	<200
	[<200- <500]	[<200– <500]	[<200–<500]
lew HIV infections (women, 15+)	710	690	850
	[690–1100]	[660–1100]	[860–1400]
New HIV infections (men, 15+)	3300	2800	3100
	[2600–4000]	[2000–3400]	[2100–3900]
HIV incidence per 1000 population	0.15 [0.12–0.18]	0.12 [0.1–0.16]	0.13 [0.1–0.17]
AIDS-related deaths			
AIDS-related deaths (all ages)	1800	1300	960
	[1400–2400]	[960–1900]	[720–1200]
AIDS-related deaths (0–14)	<200	<100	<100
	[<200– <200]	[<100- <200]	[<100- <200]
NDS-related deaths (women, 15+)	<200	<200	<200
	[<100- <200]	[<100– <200]	[<100– <200]
NIDS-related deaths (men, 15+)	1500	1200	800
	[1200–2100]	[770–1700]	[560–970]
eople living with HIV			
eople living with HIV (all ages)	59 000	70 000	91 000
	[52 000–68 000]	[62 000–81 000]	[80 000–100 000]
eople living with HIV (0-14)	1500	1300	1300
	[1400–1900]	[1300–1800]	[1300–1900]
eople living with HIV (women, 15+)	11 000	14 000	18 000
	[10 000–13 000]	[13 000–18 000]	[17 000–24 000]
eople living with HIV (men, 15+)	47 000	55 000	71 000
	[40 000–53 000]	[47 000–62 000]	[60 000–80 000]
HIV prevalence (15–49)	0.3 [0.3–0.4]	0.3 [0.3–0.4]	0.3 [0.3–0.4]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No, but prosecutions exist based on general criminal laws
Criminalization of sex work among consenting adults	
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes

residence permits or for certain groups

STIGMA AND DISCRIMINATION


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	•••	
Percentage of people living with HIV denied		2018
the last 12 months		20.7
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their		2018
consent		15

VIOLENCE

Proportion of ever-married or partnered	2010	2016
women aged 15–49 years who experienced		
physical or sexual violence from a male		
intimate partner in the past 12 months	13.9	10.8

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


US\$ 68 448 770 US\$ 6 262 175 US\$ 74 710 945 Last available report: 2020



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••	260 300			
HIV prevalence	1.3%	6.9%		7.4%	0.5%
HIV testing and status awareness	29.4%				
Antiretroviral therapy coverage					88.3%
Condom use					
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	41% [38–50%]	89% [89–100%]
Final vertical transmission rate including during breastfeeding	19.4% [18.8–23.4%]	8.7% [9.4–15.2%]
Early infant diagnosis	% [–%]	22.4% [16.9–22.3%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	2400 [1800 –3000]
People living with HIV who started TB preventive therapy (2018)	9%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.1%
Knowledge of HIV prevention among young people aged 15–24 years (2016)	
— Women	75.3%
— Men	0%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2012)	
— Women	26.8%
— Men	
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2017)	39%
Men aged 15–49 years who are circumcised	Not applicable

Not

applicable

330

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)

Voluntary medical male circumcisions

performed according to national standards

People who received PrEP at least once

during the reporting period (2020)

— Safe injection rooms available (2021)

URUGUAY

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population		28 600	•••	1600	•••
HIV prevalence	1%	8.5%			1.3%
HIV testing and status awareness					
Antiretroviral therapy coverage					
Condom use		57.2%			
Coverage of HIV prevention programmes		55.3%			
Avoidance of health care because of stigma and discrimination		2.4%			
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	190 [150–230]
People living with HIV who started TB preventive therapy (2018)	11.4%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2018)	9.6%

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years (2013)	
— Women	34.5%
— Men	
C	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

47 years	
— Women	
— Men	

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15-49 years who are circumcised

	applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2018)	54
Harm reduction — Use of sterile injecting equipment at	

Not

irm reduction	
 Use of sterile injecting equipment at last injection 	
 Needles and syringes distributed per person who injects 	
 Coverage of opioid substitution therapy 	
— Naloxone available (2021)	

- Safe injection rooms available (2021)

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2007	US\$ 6 543 398	US\$ 6 851 169			US\$ 291 464	US\$ 14 077 809

COUNTRY DATA

LAWS AND POLICIES		STIGMA AND DISCRIMINATION	NC
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No	Percentage of women and men aged 15–49 years who report discriminatory attitudes	
Criminalization of sex work among consenting adults	Sex work is not subject to punitive regulations or is not criminalized	towards people living with HIV	
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Drug use or possession for personal use is an offence		Percentage of people living with HIV who reported a health-care professional told	
Criminalization of transgender people	Neither criminalized nor prosecuted	others about their HIV status without their consent	
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE	
Parental consent for adolescents to access HIV testing	No	Proportion of ever-married or partnered women aged 15–49 years who experienced	
Spousal consent for married women to access sexual and reproductive health services	No	physical or sexual violence from a male intimate partner in the past 12 months	
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No		

VENEZUELA (BOLIVARIAN REPUBLIC OF)

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	6500	4900	2200
	[5000–7500]	[3600–6000]	[970–3500]
New HIV infections (0–14)	740	540	<500
	[650–830]	[<500–660]	[<500–<500]
New HIV infections (women, 15+)	2600	2000	850
	[2000–3100]	[1400–2400]	[<500–1400]
New HIV infections (men, 15+)	3200	2400	1000
	[2400–3900]	[1700–3100]	[<500–1700]
HIV incidence per 1000 population	0.23 [0.18–0.27]	0.16 [0.12–0.2]	0.08 [0.03–0.12]
AIDS-related deaths			
AIDS-related deaths (all ages)	2200	3400	4200
	[1900–2600]	[2800–4100]	[3700–4700]
AIDS-related deaths (0–14)			
	[<500–550]	[<500–520]	[<500– <500]
AIDS-related deaths (women, 15+)	1200	1900	2500
	[1000–1400]	[1700–2200]	[2300–2700]
AIDS-related deaths (men, 15+)	540	990	1400
	[<500–730]	[650–1400]	[1100–1800]
People living with HIV			
People living with HIV (all ages)	110 000	120 000	100 000
	[100 000–120 000]	[110 000–130 000]	[91 000–110 000]
People living with HIV (0-14)	3900	4100	3300
	[3600–4100]	[3700–4400]	[2900–3700]
People living with HIV (women, 15+)	47 000	48 000	40 000
	[44 000–49 000]	[44 000–51 000]	[36 000–45 000]
People living with HIV (men, 15+)	60 000	66 000	60 000
	[54 000–65 000]	[59 000–73 000]	[52 000–67 000]
HIV prevalence (15–49)	0.6 [0.6–0.7]	0.6 [0.6–0.7]	0.5 [0.4–0.6]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

STIGMA AND DISCRIMINATION


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV		
	•••	•••
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		•••
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		


VIOLENCE


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 7 350 000 Last available report: 2020 US\$ 4 154 970 US\$ 14 752 970







Change in new
HIV infections = -66%
since 2010

Change in AIDS-related deaths = 89% since 2010

Incidence:
prevalence = 2.13
ratio

Incidence: mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••		***	14 600	
HIV prevalence	3.7%	22.3%		35.8%	
HIV testing and status awareness	100%	96.6%		94.4%	
Antiretroviral therapy coverage		89.8%			
Condom use	86.7%	56%		18.6%	
Coverage of HIV prevention programmes	8.2%				
Avoidance of health care because of stigma and discrimination	7.5%				
Expenditures in US\$ (2020)	75 000	160 000			

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	1200 [410–2500]
People living with HIV who started TB preventive therapy (2018)	2.3%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



virus starting hepatitis C treatment	•••
HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.3%

Knowledge of HIV prevention among young people aged 15–24 years

— Women

Men
Condom use at last sex with a non-marital,

non-cohabiting partner among people aged 15–49 years

— Women

— Men

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised applicable

Voluntary medical male circumcisions Performed according to national standards

People who received PrEP at least once during the reporting period

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	14% [12–15%]	30% [24–35%]		
Final vertical transmission rate including during breastfeeding	33.4% [31.8–35%]	29.8% [25.2–33.4%]		
Early infant diagnosis	% [–%]	% [–%]		

Harm reduction

— Use of sterile injecting equipment at
last injection

Needles and syringes distributed per person who injects

 Coverage of opioid substitution 	
therapy	

– Naloxone available (2021)	No
- Safe injection rooms available (2021)	No



he Caribbean has made steady progress against AIDS, especially in providing life-saving testing and treatment to people living with HIV. AIDSrelated deaths have been cut in half since 2010, although the region fell short of the 2020 testing and treatment targets: 82% [70–96%] of people living with HIV knew their HIV status, 82% [68–97%] who knew their HIV-positive status were receiving treatment and 89% [74->98%] of people on treatment were virally suppressed.

Community-led organizations in the region have shown that, if they are adequately supported, they can play a major role in addressing inequalities in HIV service access through more efficient case finding and strengthened linkage to treatment and care, and by ensuring confidential and consistent psychosocial support along the continuum of care. These organizations are especially adept at reaching key populations who, along with their sexual partners, accounted for 68% of new HIV infections in the region in 2020.

The COVID-19 pandemic and natural disasters have disrupted health systems, exacerbating financial, technical and human resource gaps in health services. Overcoming these disruptions and continuing HIV service expansion towards the 2025 targets requires the full implementation of best practices in combination prevention, testing and treatment. This includes self-testing, rights-based index testing, multimonth dispensing and transition to more effective first-line

The pandemic has also fueled gender-based violence, which—along with gender inequalities and stigma and discrimination—continue to impede the region's HIV response. Despite some policy progress towards eliminating gender- and sex-based discrimination, unequal gender relations remain the norm, and sexual minorities are exposed to harsh social stigma and discrimination. An integrated approach to HIV, sexual and reproductive health, and gender-based violence services would help reach adolescent girls and young women and neglected key populations.

PRIORITY ACTIONS FOR ENDING AIDS

- Strengthen regional and national ownership and governance of HIV responses.
- Implement policies that remove structural barriers to HIV services.
- Repeal laws and policies that criminalize people living with and at risk of HIV.
- Strengthen strategic HIV and sexually transmitted infection (STI) programme planning, monitoring and evaluation, and accountability.
- Improve data quality and strengthen surveillance for monitoring the HIV response and providing evidence for strategic decision-making.
- Eliminate vertical transmission in additional countries and ensure the re-validation of countries that have already been validated.




Brandy Rodriguez of the Trinidad and Tobago Transgender Coalition. On International Transgender Day of Visibility (31 March 2021), the United Caribbean Trans Network launched the results of a study that features feedback from transgender and other gender-diverse respondents from 11 countries in the region, garnered from surveys, individual interviews and focus group sessions. Respondents identified the inability to change their gender marker, employment discrimination and discrimination in health services as the top challenges facing the community. Except for Cuba, no Caribbean country allows transgender people to modify their gender on official identification.

Credit: Trinidad and Tobago Newsday/Ayanna Kinsale

STATE OF THE PANDEMIC

NUMBER OF NEW HIV INFECTIONS AND AIDS-RELATED DEATHS, CARIBBEAN, 2000-2020




Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).

DISTRIBUTION OF NEW HIV INFECTIONS BY POPULATION GROUP AND SEX (AGED 15–49 YEARS), CARIBBEAN, 2020



Source: UNAIDS special analysis, 2021 (see methods annex).


HIV PREVALENCE AMONG KEY POPULATIONS, REPORTING COUNTRIES IN THE CARIBBEAN, 2016–2020



- Sex workers (n = 9)
 Gay men and other men who have sex with men (n = 8)
 People who inject drugs (n = 0)
 Transgender people (n = 3)
- Prisoners (n = 7)

Source: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/). Note: (n = number of countries). Total number of reporting countries = 17.

How to read this chart



REPORTED ESTIMATED SIZE OF KEY POPULATIONS, CARIBBEAN, 2018–2020

	National adult population (aged 15–49 years) in 2020 or relevant year	Sex workers	Sex workers as per cent of adult population (aged 15-49 years)	Gay men and other men who have sex with men	Gay men and other men who have sex with men as per cent of adult population (aged 15–49 years)	People who inject drugs	People who inject drugs as per cent of adult population (aged 15–49 years)	Transgender people	Transgender people as per cent of adult population (aged 15–49 years)	Prisoners	Prisoners as per cent of adult population (aged 15-49 years)
Bahamas	210 000									2300	1.11%
Dominican Republic	5 800 000									29 000	0.50%
Haiti	6 100 000									12 000	0.19%
Jamaica	1 600 000			42 000	2.65%				0.24%		
Saint Lucia	101 000			3000	2.97%					500	0.51%
Saint Vincent and the Grenadines	56 000										
Suriname	300 000										
Estimated regional proportion as per cadult population (aged 15–49 years) ^a	ent of		-		1.35%		-		0.19%		-

Sources: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/); Spectrum Demproj module, 2021; World Population Prospects 2019 [Internet]. New York: United Nations Department of Economic and Social Affairs; c2020 (https://population.un.org/wpp/)(custom data acquired via website).


Note 1: Estimates shown are government-provided estimates reported for 2018–2020. Additional and alternative estimates may be available from different sources, including the Key Populations Atlas (https://kpatlas.unaids.org/), academic publications or institutional documents. Note 2: The reported values for gay men and other men who have sex with men are presented as a per cent of the adult population (aged 15–49 years) for consistency across key populations. The percentage of this population out of the adult male population (aged 15-49 years) will be approximately twice the values shown.

^a Quick Start Guide for Spectrum, 2020. Geneva: UNAIDS; 2020 (https://www.unaids.org/sites/default/files/media_asset/QuickStartGuide_ Spectrum_en.pdf).

^b Technical brief: recommended population size estimates of men who have sex with men. Geneva: WHO, UNAIDS; 2020.

HIV SERVICES


PEOPLE LIVING WITH HIV, PEOPLE NEWLY INFECTED IN THE PAST SIX MONTHS, AND HIV TESTING AND TREATMENT CASCADE, ADULTS (AGED 15+ YEARS), CARIBBEAN, 2016–2020




Source: UNAIDS special analysis, 2021.

HIV TESTING AND TREATMENT CASCADE, CHILDREN (AGED 0-14 YEARS) COMPARED TO ADULTS (AGED 15 YEARS AND OLDER), CARIBBEAN, 2020

Children (aged 0-14 years) living with HIV





Adults (aged 15 years and older) living with HIV




Source: UNAIDS special analysis, 2021.

HIV TESTING AND TREATMENT CASCADE, WOMEN (AGED 15+ YEARS) COMPARED TO MEN (AGED 15+ YEARS), CARIBBEAN, 2020





Men (aged 15+ years) living with HIV



Source: UNAIDS special analysis, 2021.

LAWS AND POLICIES

PUNITIVE AND DISCRIMINATORY LAWS SCORECARD, CARIBBEAN, 2021

POLICIES	Criminalization of transgender people	Criminalization of sex work	Criminalization of same-sex sexual acts	Law allows for possession of a certain limited amount of drugs for personal use	Parental consent for adolescents to access HIV testing	Laws criminalizing the transmission of, non-disclosure of or exposure to HIV transmission	Laws or policies restricting the entry, stay and residence of people living with HIV	Mandatory HIV testing for marriage, work or residence permits or for certain groups
Antigua and Barbuda	2	2	7		2	2		2
Bahamas	1		1					1
Barbados	1		8					1
Belize	4		9		12	15		
Cuba	2	5	9					2
Dominica	3		9			3		3
Dominican Republic	1	1	1	1		1		1
Grenada		6	9					
Guyana	2			1	12	2		2
Haiti	1	1	1	1		2		1
Jamaica	2			2				2
Saint Kitts and Nevis	1			1		1		1
Saint Lucia	2		10					2
Saint Vincent and the Grenadines		2	9					2
Suriname	3		9			3		13
Trinidad and Tobago	1	1	17, 18	1	14	1		1

Criminalization of transgender people

- Criminalized and prosecuted
- Neither criminalized nor prosecuted
- Data not available

Criminalization of sex work

- Any criminalization or punitive regulation of sex work
- Sex work is not subject to punitive regulations or is not criminalized
- Issue is determined/differs at the subnational level
- Data not available

Criminalization of same-sex sexual acts

- Death penalty
- Imprisonment (14 years–life, up to 14 years) or no penalty specified
- Laws penalizing same-sex sexual acts have been decriminalized or never existed, or no specific legislation
- Data not available

Law allows for possession of a certain limited amount of drugs for personal use

- No
- Yes
- Data not available

Parental consent for adolescents to access HIV testing

- Yes, for adolescents younger than 18
- Yes, for adolescents younger than 14 or 16
- Yes, for adolescents younger than 12
- No
- Data not available

Laws criminalizing the transmission of, non-disclosure of or exposure to HIV transmission

- Ye
- No, but prosecutions exist based on general criminal laws
- No
- Data not available

Laws or policies restricting the entry, stay and residence of people living with $\ensuremath{\mathsf{HIV}}$

- Deport, prohibit short and/or long stay and require HIV testing or disclosure for some permits
- Prohibit short and/or long stay and require HIV testing or disclosure for some permits
- Require HIV testing or disclosure for some permits
- No restrictions
- Data not available

$\label{eq:manual_manual_manual} \mbox{Mandatory HIV testing for marriage, work or residence} \\ \mbox{permits or for certain groups}$

- Yes
- No
- Data not available

Sources


- 1. UNAIDS National Commitments and Policy Instrument, 2021 (see http://lawsandpolicies.unaids.org/).
- 2. UNAIDS National Commitments and Policy Instrument, 2019 (see http://lawsandpolicies.unaids.org/).
- 3. UNAIDS National Commitments and Policy Instrument, 2017 (see http://lawsandpolicies.unaids.org/).
- 4. Chiam Z, Duffy S, González Gil M, Goodwin L, Mpemba Patel NT. Trans legal mapping report 2019: recognition before the law. Geneva: ILGA World; 2020.
- 5. Cuba. Penal Code. Article 302 (https://www.wipo.int/edocs/lexdocs/laws/es/cu/cu004es.pdf).
- 6. Grenada. Criminal Code. Chapter 72A (76 of 1958), section 137 (30) (https://prostitution.procon.org/ sourcefiles/GrenadaCriminalCode.pdf).
- Antigua and Barbuda. The Sexual Offences Act, 1995 (https://www.ilo.org/dyn/natlex/docs/ELECTRONIC/42538/79312/ F1146620290/ATG42538.pdf).
- 8. Barbados. Sexual Offences Act (1992) provisions. Section 9 (https://www2.ohchr.org/english/bodies/hrc/docs/ngos/lgbti2.pdf).
- 9. Mendos LR. State-sponsored homophobia, 2020. Geneva: International Lesbian, Gay, Bisexual, Trans and Intersex Association; December 2020 (https://ilga.org/downloads/ILGA_State_Sponsored_Homophobia_2019_light.pdf).
- 10. Saint Lucia. Criminal Code, 2005. Art 133 (http://www.govt.lc/media.govt.lc/www/resources/legislation/Criminal%20Code.pdf).
- 11. Trinidad and Tobago. Sexual Offences Act, 27 of 1986. Art 13 (https://rgd.legalaffairs.gov.tt/laws2/Alphabetical_List/lawspdfs/11.28.pdf).
- 12. Sexual Rights Initiative database [database]. Sexual Rights Initiative; c2016 (http://sexualrightsdatabase.org/map/21/Adult%20 sex%20work).
- 13. UNAIDS National Commitments and Policy Instrument, 2018 (see http://lawsandpolicies.unaids.org/).
- 14. National HIV testing and counselling policy. Port of Spain: Ministry of Health [Trinidad and Tobago]; 2006 (www.health.gov.tt/downloads/DownloadItem.aspx?id=258).
- 15. Global HIV Criminalisation Database [database]. Amsterdam: HIV Justice Network (https://www.hivjustice.net/global-hiv-criminalisation-database/).
- 16. Still not welcome: HIV-related travel restrictions. Geneva: UNAIDS, UNDP; 2019 (https://www.unaids.org/sites/default/files/media_asset/hiv-related-travel-restrictions-explainer_en.pdf).
- 17. Republic of Trinidad and Tobago. Claim No. CV2017-00720, 12 April 2018 (http://webopac.ttlawcourts.org/LibraryJud/Judgments/HC/rampersad/2017/cv_17_00720DD12apr2018.pdf).
- 18. Republic of Trinidad and Tobago. Claim No. CV2017-00720, 20 September 2018 (http://webopac.ttlawcourts.org/LibraryJud/Judgments/HC/rampersad/2017/cv_17_00720DD20sep2018.pdf).

Note: A country is considered to have criminalized transgender persons if it uses the law to punish transgender individuals. Such a law may, for example, explicitly criminalize impersonation of the other gender, including cross-dressing. A country is considered to have any criminalization or punitive regulation of sex work if selling and/or buying sexual services is criminalized, ancillary activities associated with selling and/or buying sexual services are criminalized, profiting from organizing and/or managing sexual services is criminalized, and/or there are other punitive and/or administrative regulations of sex work.

INVESTING TO END AIDS

The resources available for HIV responses in the Caribbean in 2020 were 74% of the region's resource targets for 2025. Relatively large investments per person living with HIV—including a large proportion of donor support—have coincided with steady reductions in the rates of infections and deaths. Resource availability has fluctuated in recent years, rising by 15% between 2017 and 2018, followed by a 13% decrease between 2018 and 2019. It then rose again, increasing 7% between 2019 and 2020.


RESOURCE AVAILABILITY FOR HIV, CARIBBEAN, 2010–2020, AND ESTIMATED RESOURCE NEEDS FOR HIV BY 2025



Source: UNAIDS financial estimates and projections, 2021 (http://hivfinancial.unaids.org/hivfinancialdashboards.html).

Note: The resource estimates are presented in constant 2019 US dollars.

YEAR-TO-YEAR CHANGE IN RESOURCE AVAILABILITY FOR HIV, CARIBBEAN, 2010–2011 TO 2019–2020



Source: UNAIDS financial estimates, 2021 (http://hivfinancial.unaids.org/hivfinancialdashboards.html).



BAHAMAS

COUNTRY DATA

	2010	2015	2020
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<500	<200	<200
	[<200-<500]	[<200–<200]	[<100-<200]
New HIV infections (0-14)			
	[]	[]	[]
New HIV infections (women, 15+)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100-<100]
New HIV infections (men, 15+)	<100	<100	<100
Teer in a milections (men, 197)	[<100-<200]	[<100-<100]	[<100–<100]
HIV incidence per 1000 population	0.57 [0.49–0.66]	0.42 [0.35–0.5]	0.28 [0.24–0.34]
AIDS-related deaths			
AIDS-related deaths (all ages)			<u>:</u>
, 120 : 0.1101	[]	[]	[]
AIDS-related deaths (0-14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	 r	 r 1	 []
	[=]	[]	[]
AIDS-related deaths (men, 15+)			
<u> </u>	[]	[]	[]
People living with HIV			
People living with HIV (all ages)	4600	4800	4700
eopie living with thiv (all ages)	[4000–5300]	[4200–5400]	[4200–5300]
People living with HIV (0-14)			 .
	[]	[]	[]
People living with HIV (women, 15+)	2200	2300	2300
copic inning with the (women, 197)	[1900–2500]	[2000–2600]	[2000–2500]
People living with HIV (men, 15+)	2200	2300	2300
reopie living with niv (men, 13+)	[1900–2600]	[2000–2700]	[2000–2700]
HIV prevalence (15–49)	1.7 [1.5–1.9]	1.4 [1.3–1.6]	1.2 [1–1.3]
117 01 0 1 01 10 10 10 17 /	[1.0 1.7]	1.1[1.0 1.0]	1.2 [1 1.0]

LAWS AND POLIC	IIES	LIC

Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV		
	•••	•••
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their

VIOLENCE


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

V	4-1-1			
		ND	1545	1

residence permits or for certain groups

EXPENDITURES						
		Finar	cing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


Last available report: 2009 US\$ 12 749 US\$ 4 402 073 US\$ 301 889 US\$ 4 901 265



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS Men who People who Transgender Sex workers Prisoners have sex inject drugs people with men Estimated size of population 2300 ... **HIV** prevalence 19.6% 3.8% HIV testing and status awareness Antiretroviral therapy coverage Condom use Coverage of HIV prevention programmes Avoidance of health care because of stigma and discrimination **Expenditures in US\$**

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [– %]		
Final vertical transmission rate including during breastfeeding	%	%		

breastfeeding	[%]	[%]
Early infant diagnosis	%	%

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	12 [6–20]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.7%
Knowledge of HIV prevention among young people aged 15–24 years (2014)	
— Women	2.8%
— Men	5.8%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	
— Men	
Women aged 15–49 years who have their	
demand for family planning satisfied by	

modern methods	
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	85
Harm reduction	

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy


— Naloxone available (2021)

— Safe injection rooms available (2021)

BARBADOS

KEY POPULATION	S				
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population				•••	
HIV prevalence	0%	2.8%			
HIV testing and status awareness					
Antiretroviral therapy coverage		35.3%			
Condom use					
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	0 [0–0]
People living with HIV who started TB preventive therapy (2018)	0%
Women who tested positive for HIV among those screened for cervical cancer (programme data) (2018)	1.9%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	0%

HIV PREVENTION

Adults aged	15+ y	ears with	unsuppressed	
viral load				

Knowledge of HIV prevention among young people aged 15–24 years (2014)

— Women	47.6%
— Men	44.8%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2017)

— Women	19.7%
— Men	42.1%

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable	
Voluntary medical male circumcisions performed according to national standards	Not applicable	
People who received PrEP at least once during the reporting period (2020)	78	

Harm reduction

_	Use of sterile injecting equipment at	
	last injection	

 Needles and syringes distributed per person who injects

Coverage of opioid substitution therapy

Naloxone available (2021)
Safe injection rooms available (2021)
No

...

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2013		US\$ 5 478 563	US\$ 235 742		US\$ 10 256 837	US\$ 15 971 143

COUNTRY DATA

LAWS AND POLICIES		STIGMA AND DISCRIMINATION	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No	Percentage of women aged 15–49 years who report discriminatory attitudes towards	2018
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work	people living with HIV	46.4
Criminalization of same-sex sexual acts	No specific legislation	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence	Percentage of people living with HIV who reported a health-care professional told	
Criminalization of transgender people	Neither criminalized nor prosecuted	others about their HIV status without their consent	
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE	
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years	Proportion of ever-married or partnered women aged 15–49 years who experienced	
Spousal consent for married women to access sexual and reproductive health services	No	physical or sexual violence from a male intimate partner in the past 12 months	
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No		

BELIZE

KEY POPULATION	S				
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence					5.8%
HIV testing and status awareness	62.2%	44.3%			
Antiretroviral therapy coverage					
Condom use	84.8%	81.4%			
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	37 [26–50]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	100%

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	1%
Knowledge of HIV prevention among young people aged 15–24 years (2016)	
— Women	41.4%
— Men	45%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49

-49 years	
— Women	
— Men	

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised		Not applicable	
	untary medical male circumcisions formed according to national standards	Not applicable	
	ple who received PrEP at least once ing the reporting period		
Ца	me weeks at		

Harm reduction

Use of sterile injecting equipment at last injection	
 Needles and syringes distributed per person who injects 	
 Coverage of opioid substitution therapy 	

- Safe injection rooms available (2021)

— Naloxone available (2021)


EXPENDITURES								
Financing sources								
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total		
Last available report: 2012	US\$ 118 050	US\$ 832 345	US\$ 555 482	US\$ 517 357	US\$ 640 356	115\$ 2 836 772		

COUNTRY DATA

LAWS AND POLICIES		STIGMA AND DISCRIMINATION	ON	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes	Percentage of women and men aged 15–49 years who report discriminatory attitudes	2011	2016
Criminalization of sex work among consenting adults		towards people living with HIV (2016 refers to women only)	32	36.9
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		2013 6.6
Drug use or possession for personal use is an offence		Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their		2013
Criminalization of transgender people		consent		9.2
Laws or policies restricting the entry, stay and residence of people living with HIV	Yes	VIOLENCE		
Parental consent for adolescents to access HIV testing		Proportion of ever-married or partnered women aged 15–49 years who experienced		
Spousal consent for married women to access sexual and reproductive health services		physical or sexual violence from a male intimate partner in the past 12 months		
Mandatory HIV testing for marriage, work or residence permits or for certain groups				

CUBA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	2100	2100	2000
	[1900–2300]	[1800–2400]	[1700–2300]
lew HIV infections (0–14)	<100	<100	<100
	[<100- <100]	[<100– <100]	[<100- <100]
lew HIV infections (women, 15+)	920	940	890
	[820–1000]	[800–1100]	[760–1000]
New HIV infections (men, 15+)	1100	1100	1100
	[940–1300]	[910–1400]	[830–1400]
HIV incidence per 1000 population	0.18 [0.17–0.2]	0.19 [0.16–0.21]	0.18 [0.15–0.2]
AIDS-related deaths			
AIDS-related deaths (all ages)	<500	<500	<500
	[<500-<500]	[<500–<500]	[<500–580]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100– <100]	[<100- <100]	[<100– <100]
IDS-related deaths (women, 15+)	<500	<500	<500
	[<200– <500]	[<500–<500]	[<500–<500]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100-<100]	[<100– <200]	[<100- <200]
eople living with HIV			
eople living with HIV (all ages)	17 000	26 000	33 000
	[16 000–19 000]	[23 000–28 000]	[29 000–36 000]
eople living with HIV (0–14)	<200	<200	<200
	[<200– <200]	[<200– <500]	[<200– <500]
eople living with HIV (women, 15+)	7500	11 000	13 000
	[6800–8100]	[9700–11 000]	[12 000–14 000]
eople living with HIV (men, 15+)	9800	15 000	20 000
	[8300–11 000]	[13 000–17 000]	[16 000–23 000]
HIV prevalence (15–49)	0.2 [0.2–0.3]	0.3 [0.3–0.4]	0.4 [0.4–0.5]




^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2013		US\$ 63 807 290		US\$ 5 927 082		US\$ 69 734 372

COUNTRY DATA

HIV TESTING AND TREATMENT CASCADE




		24 863	
Children (0-14)	19% [16–21%]	18% [15–20%] 32	% [%]
Women (15+)	44% [39–47%]	40% [36–43%] 5318	% [%]
Men (15+)	113% [94–130%]	99% [82–114%] 19 513	% [%]

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	57% [51–63%]	100% [100–100%]		
Final vertical transmission rate including during breastfeeding	30% [28.1–31.5%]	11.8% [10.3–13.8%]		
Early infant diagnosis	62.9% [45.2- >95%]	>95% [>95 >95%]		

DOMINICA

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population						
HIV prevalence	0.4%					
HIV testing and status awareness						
Antiretroviral therapy coverage						
Condom use	42.3%					
Coverage of HIV prevention programmes	42.3%	8.4%				
Avoidance of health care because of stigma and discrimination						
Expenditures in US\$						

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2018)	0%

HIV PREVENTION

Adults aged	15+	years	with	unsuppressed	
viral load					

Knowledge of HIV prevention among young people aged 15-24 years (2010)

— Women	56.2%
Mon	47.0%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49 years

7	ears
	Women

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	applicable	
Voluntary medical male circumcisions performed according to national standards	Not applicable	
People who received PrEP at least once during the reporting period		

Harm reduction

— Men

— Use of sterile injecting equipment a	ıt
last injection	

_	Needles and syringes distributed per
	person who injects

_	Coverage of opioid substitution
	therapy

— Naloxone available (2021)	
-----------------------------	--

- Safe injection rooms available (2021)

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2019	US\$ 108 111	US\$ 2 013 000				US\$ 2 157 887

COUNTRY DATA

LAWS AND POLICIES		STIGMA AND DISCRIMINATION	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No	Percentage of women and men aged 15–49 years who report discriminatory attitudes	
Criminalization of sex work among consenting adults	Sex work is not subject to punitive regulations or is not criminalized	towards people living with HIV	
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Drug use or possession for personal use is an offence		Percentage of people living with HIV who reported a health-care professional told	
Criminalization of transgender people	Neither criminalized nor prosecuted	others about their HIV status without their consent	
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE	
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years	Proportion of ever-married or partnered women aged 15–49 years who experienced	
Spousal consent for married women to access sexual and reproductive health services	No	physical or sexual violence from a male intimate partner in the past 12 months	
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes		

DOMINICAN REPUBLIC

COUNTRY DATA

	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	3500	3500	3400
	[2400–4900]	[2200–4800]	[1900–5100]
New HIV infections (0–14)	<200	<200	<200
	[<100- <500]	[<100-<500]	[<100-<500]
New HIV infections (women, 15+)	1500	1600	1600
	[1100–2200]	[1000–2200]	[890–2400]
New HIV infections (men, 15+)	1800	1800	1700
	[1300–2600]	[1100–2500]	[920–2500]
HIV incidence per 1000 population	0.37 [0.25–0.51]	0.34 [0.22–0.47]	0.32 [0.17–0.47]
AIDS-related deaths			
AIDS-related deaths (all ages)	4200	2700	1900
	[2600–6400]	[1600–4200]	[1200–2900]
AIDS-related deaths (0–14)	<200	<100	<100
	[<100-<500]	[<100-<200]	[<100-<100]
AIDS-related deaths (women, 15+)	1700	1100	880
	[1000–2600]	[660–1800]	[560–1400]
AIDS-related deaths (men, 15+)	2400	1500	930
	[1500–3600]	[920–2400]	[590–1400]
People living with HIV			
People living with HIV (all ages)	74 000	72 000	75 000
	[56 000–100 000]	[58 000–93 000]	[61 000–93 000]
People living with HIV (0-14)	2000	1600	1400
	[1400–2900]	[1000–2400]	[880–2000]
People living with HIV (women, 15+)	35 000	36 000	38 000
	[26 000–46 000]	[29 000–46 000]	[31 000–47 000]
People living with HIV (men, 15+)	37 000	35 000	36 000
	[28 000–51 000]	[28 000–44 000]	[29 000–45 000]
HIV prevalence (15–49)	1.2 [0.9–1.6]	1 [0.8–1.3]	0.9 [0.7–1.1]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	Yes
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	Yes

residence permits or for certain groups

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	•••	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		•••
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their		


VIOLENCE

consent

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2019	US\$ 25 027 710	US\$ 40 931 323	US\$ 20 558 584	US\$ 9 897 659	US\$ 25 948	US\$ 97 118 277


EPIDEMIC TRANSITION METRICS



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS Men who People who Transgender Sex workers have sex Prisoners inject drugs people with men Estimated size of population ... 29 000 **HIV** prevalence 4.2% 4% 27.7% 4.8% HIV testing and status 90.8% 63.3% 83.3% awareness 30.8% 31.5% 14 4% Antiretroviral therapy coverage 83 7% 42% Condom use 20.2% Coverage of HIV prevention 16.8% 30.4% 37.1% programmes Avoidance of health care because of stigma and 1.9% 65.1% discrimination Expenditures in US\$ (2019) 750 021 2885 169 699

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION 2010 2020 Percentage of pregnant women living with HIV 65% 74% accessing antiretroviral medicines [49–92%] [55–97%]

Final vertical transmission rate including during breastfeeding	14.3% [10.1–18.1%]	17.3% [11.6–21.5%]
Early infant diagnosis	9.3% [6.9–11.4%]	36.6% [27.9–49.1%]

	IDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	1200 [920–1500]
People living with HIV who started TB preventive therapy (2018)	28.4%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed
viral load

Knowledge of HIV prevention among young people aged 15–24 years (2014)

— Women	46.4%
— Men	

0.5%

2

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2013)

— Women	44.7%
— Men	71%

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged	15-49 years who are circumcised	Not
(2013)		applicable

Voluntary medical male circumcisions	Not
performed according to national standards	applicable


People who received PrEP at least once	1464
during the reporting period (2020)	1404

Harm reduction

- Use of sterile injecting equipment at last injection ...
- Needles and syringes distributed per person who injects (2015)
- Coverage of opioid substitution therapy ...Naloxone available (2021) No
 - Safe injection rooms available (2021) No

GUYANA

	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<500	<500	<500
	[<500–560]	[<500–510]	[<500–<500]
lew HIV infections (0–14)	<100	<100	<100
	[<100- <100]	[<100– <100]	[<100–<100]
lew HIV infections (women, 15+)	<200	<200	<200
	[<200-<500]	[<200–<500]	[<200–<500]
New HIV infections (men, 15+)	<500	<500	<200
	[<500-<500]	[<200– <500]	[<200-<500]
HIV incidence per 1000 population	0.62 [0.54–0.72]	0.51 [0.43–0.63]	0.43 [0.33–0.54]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<200
	[<100– <200]	[<100– <200]	[<100- <200]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100– <100]	[<100- <100]	[<100- <100]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100– <100]	[<100- <100]	[<100– <100]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100-<100]	[<100- <100]	[<100- <100]
People living with HIV			
People living with HIV (all ages)	7100	8200	9000
	[6400–7800]	[7500–9000]	[8100–10 000]
People living with HIV (0–14)	<500	<500	<500
	[<500– <500]	[<500-<500]	[<500-<500]
eople living with HIV (women, 15+)	3600	4000	4400
	[3200–4000]	[3600–4300]	[4000–4900]
People living with HIV (men, 15+)	3200	3900	4300
	[2800–3600]	[3500–4400]	[3800–4900]
HIV prevalence (15–49)	1.4 [1.3–1.5]	1.4 [1.3–1.6]	1.3 [1.2–1.5]




^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2012	US\$ 1 142 925	US\$ 3 347 064				US\$ 21 921 471

COUNTRY DATA

HIV TESTING AND TREATMENT CASCADE



All ages	94% [86–105%]	66% [59–73%] 5889	57% [52–64%]
Children (0-14)	38% [33–44%]	38% [33–44%] 97	18% [16–21%]
Women (15+)	92% [84–102%]	73% [67–81%] 3202	63% [57–69%]
Men (15+)	100% [88–113%]	60% [53–68%] 2590	54% [48–62%]

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	52% [46–59%]	84% [74–97%]		
Final vertical transmission rate including during breastfeeding	17.5% [16.2–18.6%]	11.3% [9.3–13.3%]		
Early infant diagnosis	16.6% [14.3–19.1%]	85.9% [74.5- >95%]		

HAITI COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	8900	7200	5000
	[7400–11 000]	[5600–8900]	[3300–6900]
New HIV infections (0–14)	1600	1100	960
	[1300–1900]	[680–1300]	[590–1300]
New HIV infections (women, 15+)	3900	3500	2500
	[3100–4700]	[2700–4400]	[1600–3300]
New HIV infections (men, 15+)	3400	2600	1600
	[2700–4300]	[2000–3400]	[1000–2400]
HIV incidence per 1000 population	0.91 [0.76–1.1]	0.69 [0.53–0.85]	0.45 [0.3–0.62]
AIDS-related deaths			
AIDS-related deaths (all ages)	5900	4000	2200
	[4700–7700]	[3100–5100]	[1700–2800]
AIDS-related deaths (0–14)	1100	640	550
	[910–1300]	[<500–830]	[<500–740]
AIDS-related deaths (women, 15+)	2400	1400	750
	[1800–3200]	[1100–1900]	[560–980]
AIDS-related deaths (men, 15+)	2400	2000	880
	[1900–3500]	[1500–2800]	[640–1200]
People living with HIV			
People living with HIV (all ages)	140 000	150 000	150 000
	[120 000–160 000]	[130 000–160 000]	[140 000–170 000]
People living with HIV (0–14)	12 000	9700	8000
	[11 000–14 000]	[8000–11 000]	[6200–9400]
People living with HIV (women, 15+)	71 000	78 000	86 000
	[64 000–79 000]	[71 000–86 000]	[75 000–96 000]
People living with HIV (men, 15+)	56 000	58 000	59 000
	[50 000–65 000]	[52 000–66 000]	[53 000–68 000]
HIV prevalence (15–49)	2.2 [2–2.3]	2 [1.8–2.2]	1.9 [1.6–2.1]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Sex work is not subject to punitive regulations or is not criminalized
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No


Percentage of women and men aged 15–49 years who report discriminatory attitudes	2012	2017
towards people living with HIV (2017 refers to women only)	57.7	71.7
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male	2012	2017
intimate partner in the past 12 months	14.9	13.9

STIGMA AND DISCRIMINATION

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

... US\$ 111 563 836 Last available report: 2016 ... US\$ 3 968 260 ...

EPIDEMIC TRANSITION METRICS




^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••		***	•••	11 600
HIV prevalence	4.3%	4.5%			3.4%
HIV testing and status awareness		100%**			
Antiretroviral therapy coverage					100%
Condom use		75.1%			
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

^{**} Programme data—not representative; includes people with negative results.

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	39% [32–44%]	71% [57–82%]
Final vertical transmission rate including during breastfeeding	25.4% [23.8–26.9%]	16.5% [12.6–19.4%]
Early infant diagnosis	% [–%]	44.5% [38.5–55.4%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	2900 [2300 –3700]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	0.6%
Knowledge of HIV prevention among young people aged 15–24 years (2017)	
— Women	38.3%
— Men	36.2%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2016)	
— Women	49.7%
— Men	70.2%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2017)	45.4%
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	4108

Harm reduction

 Use of sterile injecting equipment at 	
last injection	

 Needles and syringes d 	istributed per
person who injects	

 Coverage of opioid substitution
therapy
- Nalovone available (2021)

— Naioxone available (2021)	
— Safe injection rooms available (2021)	No

JAMAICA

COUNTRY DATA

	2040	0045	2000
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	1900	1800	1500
tew inv infections (an ages)	[1400–2900]	[1300–2700]	[1100–2400]
New HIV infections (0–14)	<100	<100	<100
1644 1114 11116C00113 (0-1-4)	[<100-<200]	[<100-<200]	[<100-<200]
New HIV infections (women, 15+)	880	830	690
iew my injections (women, 13+)	[650–1300]	[630–1300]	[510–1100]
Alexander (Control of the Control of	920	870	740
New HIV infections (men, 15+)	[680–1400]	[620–1300]	[<500–1200]
HIV incidence per 1000 population	0.68 [0.5–1.03]	0.62 [0.45–0.95]	0.53 [0.38–0.87]
AIDS-related deaths			
AIDS-related deaths (all ages)	1000	970	800
AID3-related deaths (all ages)	[730–1600]	[640–1600]	[560–1400]
AIDS-related deaths (0-14)	<100	<100	<100
	[<100-<200]	[<100-<200]	[<100-<100]
AIDS-related deaths (women, 15+)	<500	<500	<500
	[<500–780]	[<500–690]	[<500–550]
AIDC let ellet ette (e.e. 451)	<500	550	<500
AIDS-related deaths (men, 15+)	[<500–780]	[<500–910]	[<500–760]
People living with HIV			
People living with HIV (all ages)	27 000	30 000	32 000
	[22 000–38 000]	[25 000–42 000]	[26 000–45 000]
People living with HIV (0-14)	790	670	520
	[620–1100]	[510–1000]	[<500–820]
People living with HIV (women, 15+)	13 000	15 000	16 000
	[11 000–19 000]	[12 000–21 000]	[13 000–23 000]
People living with HIV (men, 15+)	13 000	15 000	15 000
eopie iiviiig with the (men, 13+)	[10 000–19 000]	[12 000–20 000]	[12 000–21 000]
IIV prevalence (15–49)	1.5 [1.2–2.1]	1.4 [1.2–2.1]	1.4 [1.1–2]
· · · · · · · · · · · · · · · · · · ·			


LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No, but prosecutions exist based on general criminal laws
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

STIGMA AND DISCRIMINATION	NC	
Percentage of women aged 15–49 years who report discriminatory attitudes towards		2017
people living with HIV		66.8
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their		2019
consent		14.9
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced	2012	2016
physical or sexual violence from a male intimate partner in the past 12 months	9.89	8.52


EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2016	US\$ 1 456 785	US\$ 2 750 285	US\$ 3 119 936	US\$ 11 301 865	US\$ 858 868	US\$ 19 487 739

EPIDEMIC TRANSITION METRICS


since 2010



since 2010



4.64



* The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

ratio


KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••	42 400	***	3800	
HIV prevalence	2%	29.8%		51%	6.9%
HIV testing and status awareness	92.8%	88.2%			
Antiretroviral therapy coverage					
Condom use	95%	68.8%			
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2016)	138	606		16	

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	20 [11–31]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

mortality ratio*

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION

Adults	aged	15+	vears	with	unsuppressed
	_		<i>y</i> - a		
viral lo	ad				

0.9%

Knowledge of HIV prevention among young people aged 15–24 years (2012)

— vvomen	42.8%
— Men	35.6%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

— Women

— Men

...

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once	

FLIMINATION OF MOTHER-TO-CHILD TRANSMISSION

ELIMINATION OF MOTTER-TO-CITED TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	57% [45–81%]	64% [52–90%]		
Final vertical transmission rate including during breastfeeding	14.1% [11.5–17.4%]	14% [11.3–17.6%]		
Early infant diagnosis	% [–%]	21.3% [15.2–26.2%]		

Harm reduction

— Use of sterile injecting equipment at
last injection

— Ne	edles and syri	inges o	distributed	per
ре	rson who injed	cts		

 Coverage of opioid substitution 	١
therapy	


— Naloxone available (2021)

- Safe injection rooms available (2021)

SAINT LUCIA

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population		3000		•••	500	
HIV prevalence					1.6%	
HIV testing and status awareness						
Antiretroviral therapy coverage						
Condom use						
Coverage of HIV prevention programmes						
Avoidance of health care because of stigma and discrimination						
Expenditures in US\$						

HIV TESTING AND TREATMENT CASCADE



HIV			

Estimated number of incident tuberculosis cases among people living with HIV (2018)	1 [0–4]
People living with HIV who started TB preventive therapy (2018)	0%
Cervical cancer screening of women living with HIV (2017)	5.8%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2018)	0%

HIV PREVENTION

Adult	s aged	15+	years	with	unsuppressed
viral I	oad				

Knowledge of HIV prevention among young people aged 15-24 years (2012)

— Women	62.2%
— Men	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49

	-	-	_		_
.9	years				
_	Womer	า			

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2017)	1

Not

Harm reduction

— Men

— Use of sterile injecting equipment at
last injection

_	Needles and syringes distributed per
	person who injects

— Coverage of opioid substitution	
therapy	

_	Naloxone available (2021)	

- Safe injection rooms available (2021)

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020		US\$ 516 407				US\$ 516 407

COUNTRY DATA

LAWS AND POLICIES		STIGMA AND DISCRIMINATION		
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes	Percentage of women and men aged 15–49 years who report discriminatory attitudes		
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work	towards people living with HIV		
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Drug use or possession for personal use is an offence		reported a health-care professional told	···	
Criminalization of transgender people	Neither criminalized nor prosecuted	others about their HIV status without their consent		
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE		
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years	Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months		
Spousal consent for married women to access sexual and reproductive health services	No			
Mandatory HIV testing for marriage, work or residence permits or for certain groups				

SURINAME

COUNTRY DATA

	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<500	<500	<200
	[<500–<500]	[<200–<500]	[<100-<500]
New HIV infections (0–14)	<100	<100	<100
	[<100–<100]	[<100–<100]	[<100-<100]
New HIV infections (women, 15+)	<200	<100	<100
	[<100- <200]	[<100–<200]	[<100-<200]
New HIV infections (men, 15+)	<200	<200	<100
	[<200-<500]	[<100–<200]	[<100–<200]
HIV incidence per 1000 population	0.59 [0.42–0.81]	0.38 [0.24–0.6]	0.3 [0.15–0.51]
AIDS-related deaths			
AIDS-related deaths (all ages)	<200	<200	<200
	[<200-<500]	[<100-<200]	[<100-<200]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100-<100]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100– <100]	[<100–<100]	[<100-<100]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100-<200]	[<100- <200]	[<100–<200]
People living with HIV			
People living with HIV (all ages)	4700	5100	5200
	[4100–5600]	[4300–6100]	[4300–6600]
People living with HIV (0–14)	<200	<200	<100
	[<200-<200]	[<200–<200]	[<100- <200]
People living with HIV (women, 15+)	1900	2200	2400
	[1600–2200]	[1900–2600]	[2000–3000]
People living with HIV (men, 15+)	2600	2800	2700
	[2200–3200]	[2300–3400]	[2200–3500]
HIV prevalence (15–49)	1.4 [1.2–1.6]	1.3 [1.1–1.5]	1.1 [0.9–1.4]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	Yes

residence permits or for certain groups

Last available report: 2011

	D DISCI	3 I B A I B I	
		211/1/11/11/	


Percentage of women aged 15–49 years who report discriminatory attitudes towards	 2018
people living with HIV	 66.4
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent	


VIOLENCE


Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2011	US\$ 81 800	US\$ 2 249 605		US\$ 1 009 894	US\$ 1 265 510	US\$ 4 674 508

EPIDEMIC TRANSITION METRICS









Change in new
HIV infections = -44%
since 2010

Change in AIDS-related deaths = -22% since 2010

Incidence:
prevalence = 3.25
ratio

Incidence: mortality ratio*


* The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••		•••	•••	
HIV prevalence	10.3%	16.6%			
HIV testing and status awareness	51.0%	97.5%			
Antiretroviral therapy coverage					
Condom use	90.8%	63.8%			
Coverage of HIV prevention programmes	64.1%				
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	32 [19–49]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION

A	dults	aged	15+	years	with	unsuppressed
vi	ral lo	ad				

0.8%

Knowledge of HIV prevention among young people aged 15–24 years (2010)

— Women	41.9%
— Men	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

— Women

— Men

...

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

Harm reduction


- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	67% [55–81%]	100% [80–100%]
Final vertical transmission rate including during breastfeeding	14.9% [12.1–17.6%]	5.5% [3–9.7%]
Early infant diagnosis	6.9% [5.7–8.7%]	% [–%]

TRINIDAD AND TOBAGO

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	<500	<200	<200	
	[<500–590]	[<200-<500]	[<100-<200]	
New HIV infections (0–14)				
	[]	[]	[]	
lew HIV infections (women, 15+)	<500	<100	<100	
	[<200- <500]	[<100- <200]	[<100- <100]	
New HIV infections (men, 15+)	<500	<100	<100	
	[<200-<500]	[<100– <200]	[<100–<200]	
HIV incidence per 1000 population	0.35 [0.27–0.44]	0.14 [0.09–0.21]	0.07 [0.03–0.13]	
AIDS-related deaths				
AIDS-related deaths (all ages)	<500	<500	<200	
	[<500-<500]	[<200-<500]	[<200-<500]	
AIDS-related deaths (0–14)				
	[]	[]	[]	
AIDS-related deaths (women, 15+)	<200	<200	<200	
	[<200-<200]	[<100- <200]	[<100- <200]	
AIDS-related deaths (men, 15+)	<200	<200	<100	
	[<200-<500]	[<100-<200]	[<100-<100]	
People living with HIV				
People living with HIV (all ages)	12 000	11 000	10 000	
	[11 000–13 000]	[10 000–12 000]	[9200–12 000]	
eople living with HIV (0–14)				
	[]	[]	[]	
People living with HIV (women, 15+)	5800	5700	5300	
	[5300–6300]	[5200–6300]	[4700–5900]	
People living with HIV (men, 15+)	5400	5300	4900	
	[4800–6100]	[4700–5900]	[4200–5500]	
HIV prevalence (15–49)	1.2 [1.1–1.3]	1 [0.9–1.1]	0.7 [0.6–0.8]	



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2009	US\$ 277 991	US\$ 11 415 268			US\$ 1 408 776	US\$ 13 810 965

COUNTRY DATA

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION					
	2010	2020			
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]			
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]			
Early infant diagnosis	% [–%]	% [–%]			

3684

MIDDLE EAST AND NORTH AFRICA



he Middle East and North Africa has a long road ahead in fully addressing its AIDS epidemic. New HIV infections rose by 7% between 2010 and 2020—making it one of only two regions in the world where new HIV infections are still on the rise. 95% percent of new adult infections in 2020 occurred among key populations and their sexual partners. AIDS-related deaths have declined by 17% since 2010, but that fall is much faster among women (24%) than men (12%).

Recent years have seen significant advances in the region's HIV response, including the emergence of community-led networks representing people living with HIV and key populations, and legal reforms in a number of countries. Several countries, among them Algeria and Morocco, have made notable progress in expanding access to HIV services, while others—including Somalia and Sudan—have encountered significant challenges.

As a whole, the region is lagging in attaining the 2020 Fast-Track Targets: only 61% of people living with HIV were aware of their HIV status in 2020, 43% of people living with HIV were on treatment and 37% of people living with HIV were virally suppressed. Coverage of services to prevent vertical transmission is also off-track, and only 47% of children (aged 0 to 14 years) with HIV were on treatment in 2020. The Middle East and North Africa is also far behind in fully integrating HIV counselling and testing with sexual and reproductive health services.


The current gaps in HIV services across the Middle East and North Africa reflect long-standing challenges, including restrictive sociocultural norms that are mirrored in proscriptive laws and policies, and widespread stigma and discrimination. Modest political leadership on HIV is reflected in the low financial investment in the AIDS response. Matters are not helped by widespread humanitarian crises, including protracted conflicts and other forms of political instability, that make the Middle East and North Africa home to the world's largest migrant, refugee and internally displaced populations.

Progress towards the 2030 goals will depend on opening space for civil society and community-led organizations, and on linking the HIV response to efforts to achieve universal health coverage, expand social protection systems and enhance access to sexual and reproductive health and rights. None of this will be possible without stronger commitment from governments, including greater domestic funding and social contracting, and without a wider recognition of the connections between HIV and the other Sustainable Development Goals to which countries are committed.

PRIORITY ACTIONS FOR ENDING AIDS


- Scale up access to high-quality, combination HIV prevention, testing and treatment, with a focus on key populations and other priority groups.
- Collect and employ timely, accurate and disaggregated data to achieve transformative results.
- Strengthen, empower and resource communities, including people living with HIV and key populations, to lead the HIV response.
- Ground the response in human rights and gender equality.
- Ensure preparedness for comprehensive and integrated HIV service delivery during humanitarian emergencies and pandemics.

NUMBER OF PEOPLE TESTED FOR HIV, BY POPULATION GROUP, SELECTED COUNTRIES, MIDDLE EAST AND NORTH AFRICA, 2018 AND 2020



Source: HIV case reporting in eastern Mediterranean region (EMR), 2019. Tehran: HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance. Data for 2020 provided by WHO EMR office.

PERCENTAGE OF PEOPLE LIVING WITH HIV RECEIVING MULTIMONTH DISPENSING OF ANTIRETROVIRAL THERAPY, SIX COUNTRIES IN THE MIDDLE EAST AND NORTH AFRICA, 2020



■ More than three months routine dispensing


More than one month, but less that three months routine dispensing

One month or less routine dispensing

Source: UNAIDS special policy analysis, 2021.


STATE OF THE PANDEMIC

NUMBER OF NEW HIV INFECTIONS AND AIDS-RELATED DEATHS, MIDDLE EAST AND NORTH AFRICA, 2000–2020




Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).

DISTRIBUTION OF NEW HIV INFECTIONS BY POPULATION GROUP AND SEX (AGED 15–49 YEARS), MIDDLE EAST AND NORTH AFRICA, 2020



Source: UNAIDS special analysis, 2021 (see methods annex).


HIV PREVALENCE AMONG KEY POPULATIONS, REPORTING COUNTRIES IN MIDDLE EAST AND NORTH AFRICA, 2016–2020



- Sex workers (n = 8)
- Gay men and other men who have sex with men (n = 7)
- People who inject drugs (n = 7)
- Transgender people (n = 0)
- Prisoners (n = 8)

Source: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/). Note: (n = number of countries). Total number of reporting countries = 21.

How to read this chart



REPORTED ESTIMATED SIZE OF KEY POPULATIONS, MIDDLE EAST AND NORTH AFRICA, 2018–2020

	National adult population (aged 15–49 years) in 2020 or relevant year	Sex workers	Sex workers as per cent of adult population (aged 15-49 years)	Gay men and other men who have sex with men	Gay men and other men who have sex with men as per cent of adult population (aged 15–49 years)	People who inject drugs	People who inject drugs as per cent of adult population (aged 15–49 years)	Transgender people	Transgender people as per cent of adult population (aged 15–49 years)	Prisoners	Prisoners as per cent of adult population (aged 15–49 years)
Iran (Islamic Republic of)	46 200 000	138 000	0.30%			90 000	0.20%			148 000	0.32%
Kuwait	700 000									5100	0.74%
Lebanon	3 300 000			17 000	0.50%						
Morocco	19 000 000									85 000	0.45%
Oman	1 400 000										
Tunisia	6 100 000									22 000	0.36%
Estimated regional proportion as per cadult population (aged 15–49 years)	ent of		0.59%		0.51%		0.03%		-		-


Sources: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/); Spectrum Demproj module, 2021.

^a Quick Start Guide for Spectrum, 2020. Geneva: UNAIDS; 2020 (https://www.unaids.org/sites/default/files/media_asset/QuickStartGuide_ Spectrum_en.pdf).

^b Technical brief: recommended population size estimates of men who have sex with men. Geneva: WHO, UNAIDS; 2020. Note 1: Estimates shown are government-provided estimates reported for 2018–2020. Additional and alternative estimates may be available from different sources, including the Key Populations Atlas (https://kpatlas.unaids.org/), academic publications or institutional documents. Note 2: The reported values for gay men and other men who have sex with men are presented as a per cent of the adult population (aged 15–49 years) for consistency across key populations. The percentage of this population out of the adult male population (aged 15-49 years) will be approximately twice the values shown.

HIV SERVICES

PEOPLE LIVING WITH HIV, PEOPLE NEWLY INFECTED IN THE PAST SIX MONTHS, AND HIV TESTING AND TREATMENT CASCADE, ADULTS (AGED 15+ YEARS), MIDDLE EAST AND NORTH AFRICA, 2016–2020




Source: UNAIDS special analysis, 2021.


Number of children

HIV TESTING AND TREATMENT CASCADE, CHILDREN (AGED 0-14 YEARS) COMPARED TO ADULTS (AGED 15 YEARS AND OLDER), MIDDLE EAST AND NORTH AFRICA, 2020

Children (aged 0-14 years) living with HIV





Adults (aged 15 years and older) living with HIV




Source: UNAIDS special analysis, 2021.

HIV TESTING AND TREATMENT CASCADE, WOMEN (AGED 15+ YEARS) COMPARED TO MEN (AGED 15+ YEARS), MIDDLE EAST AND NORTH AFRICA, 2020





Men (aged 15+ years) living with HIV



Source: UNAIDS special analysis, 2021.

LAWS AND POLICIES

PUNITIVE AND DISCRIMINATORY LAWS, MIDDLE EAST AND NORTH AFRICA, 2021

POLICIES	Criminalization of transgender people	Criminalization of sex work	Criminalization of same-sex sexual acts	Law allows for possession of a certain limited amount of drugs for personal use	Parental consent for adolescents to access HIV testing	Laws criminalizing the transmission of, non-disclosure of or exposure to HIV transmission	Laws or policies restricting the entry, stay and residence of people living with HIV	Mandatory HIV testing for marriage, work or residence permits or for certain groups
Algeria	3	4	10		11	3		11
Bahrain		5	10			13		17
Djibouti		6	10			14		
Egypt	2		2		2	2		1
Iran (Islamic Republic of)	1		1	1		1		1
Iraq			10			14		
Jordan			1	1				18
Kuwait	3		10		11	3		11
Lebanon		19	10	20				
Libya	1							1
Morocco	1		21			1		1
Oman	2		1	1				2
Qatar			10			15		2
Saudi Arabia	2		10					2
Somalia				1		14		
Sudan		9	10			3		3
Syrian Arab Republic	3		10			2		3
Tunisia	2	2	2		2	2		2
United Arab Emirates	3		10					3
Yemen			10					

Criminalization of transgender people

- Criminalized and/or prosecuted
- Neither criminalized nor prosecuted
- Data not available

Criminalization of sex work

- Any criminalization or punitive regulation of sex work
- Sex work is not subject to punitive regulations or is not criminalized
- Issue is determined/differs at the subnational level
- Data not available

Criminalization of same-sex sexual acts

- Death penalty
- Imprisonment (14 years–life, up to 14 years) or no penalty specified
- Laws penalizing same-sex sexual acts have been decriminalized or never existed, or no specific legislation
- Data not available

Law allows for possession of a certain limited amount $% \left\{ 1,2,...,4\right\}$ of drugs for personal use

- No
- Yes
- Data not available

Parental consent for adolescents to access HIV testing

- Yes, for adolescents younger than 18
- Yes, for adolescents younger than 14 or 16
- Yes, for adolescents younger than 12
- No
- Data not available

Laws criminalizing the transmission of, non-disclosure of or exposure to HIV transmission

- No, but prosecutions exist based on general criminal laws
- Data not available

Laws or policies restricting the entry, stay and residence of people living with HIV

- Deport, prohibit short and/or long stay and require HIV testing or disclosure for some permits
- Prohibit short and/or long stay and require HIV testing or disclosure for some permits
- Require HIV testing or disclosure for some permits
- No restrictions
- Data not available

Mandatory HIV testing for marriage, work or residence permits or for certain groups

- Yes
- No
- Data not available


Sources:

- 1. UNAIDS National Commitments and Policy Instrument, 2021 (see http://lawsandpolicies.unaids.org/).
- 2. UNAIDS National Commitments and Policy Instrument, 2019 (see http://lawsandpolicies.unaids.org/).
- 3. UNAIDS National Commitments and Policy Instrument, 2017 (see http://lawsandpolicies.unaids.org/).
- 4. Algeria. Code Penal. Article 343 (https://www.wipo.int/edocs/lexdocs/laws/fr/dz/dz020fr.pdf).
- Bahrain. Bahrain Penal Code, 1976. Article 326 (https://www.unodc.org/res/cld/document/bhr/1976/ bahrain_penal_code_ html/Bahrain_Penal_Code_1976.pdf).
- 6. Djibouti. Penal Code of Djibouti, 1995 (https://acjr.org.za/resource-centre/penal-code-ofdjibouti-1995/view).
- 7. Iraq. Combating Prostitution Law No. 8 of 1988. Article 2 (gjpi.org/2010/02/20/combating-prostitutionlaw-no-8-of-1988/).
- 8. Overview of trafficking and prostitution laws in the Middle East and Africa. London: Thomson Reuters Foundation; 2012 (https://www.trust.org/contentAsset/raw-data/1035fde5-b945-49ed-8cd4- 166bc1ec156b/file).
- 9. Sudan. The Penal Code, 1991 (https://www.ecoi.net/en/file/local/1219135/1329_1202725629_sb106- sud-criminalact1991.pdf).
- 10. Mendos LR. State-sponsored homophobia, 2020. Geneva: International Lesbian, Gay, Bisexual, Trans and Intersex Association; December 2020 (https://ilga.org/downloads/ILGA_State_Sponsored_Homophobia_2019_light.pdf).
- 11. UNAIDS National Commitments and Policy Instrument, 2018 (see http://lawsandpolicies.unaids.org/).
- 12. Republic of Djibouti. Décret N° 2008-0182/PR/MS portant Institution des Normes et Directives en Matière de Conseil Dépistage Volontaire du VIH/SIDA en République de Djibouti. Article 19 (http://www.ilo.org/wcmsp5/groups/public/---ed_protect/--protrav/---ilo_aids/documents/legaldocument/wcms_126992.pdf).
- 13. Bahrain. 2017 law on the protection of society against HIV.
- 14. Global HIV Criminalisation Database [database]. Amsterdam: HIV Justice Network (https://www.hivjustice.net/global-hiv-criminalisation-database/).
- 15. Bernard EJ, Cameron S. Advancing HIV justice 2. Building momentum in global advocacy against HIV criminalisation. Brighton and Amsterdam: HIV Justice Network, GNP+; 2016 (https://www.scribd.com/doc/312008825/Advancing-HIV-Justice-2-Building-momentum-inglobal-advocacy-against-HIVcriminalisation).
- 16. Still not welcome: HIV-related travel restrictions. Geneva: UNAIDS, UNDP; 2019 (https://www.unaids.org/sites/default/files/media_asset/hiv-related-travel-restrictions-explainer_en.pdf).
- 17. UNGASS country progress report: Kingdom of Bahrain. Reporting period: January 2012–December 2013. Kingdom of Bahrain; 2014 (http://www.unaids.org/sites/default/files/country/documents/BHR_narrative_report_2014.pdf).
- 18. Jordan. Law on Residency, No. 24 (https://www.refworld.org/docid/3ae6b4ed4c.html); The Jordanian Constitution (https://www.refworld.org/pdfid/3ae6b53310.pdf); Civil Servant Policy, No 82 (https://www.ilo.org/dyn/natlex/natlex4. detail?p_lang=en&p_isn=95849&p_country=JOR&p_count=1); Work Law, No 8 (https://www.ilo.org/dyn/natlex/docs/WEB-TEXT/45676/65048/E96JOR01.htm).
- 19. Lebanon. Penal Code. Article 523 (https://sherloc.unodc.org/cld/legislation/lbn/lebanon_penal_code/_/article_523-524/article_523-524.html?lnq=en).
- 20. Lebanon. Lebanese Law on Drug Violations (https://www.aub.edu.lb/faid/Documents/LEBANESE%20SANCTIONS%20ON%20 DRUG%20LAW%20VIOLATION.pdf).
- 21. Morocco. Penal Code (1963). Article 489 (https://wipolex.wipo.int/en/text/568119).

Notes: A country is considered to have criminalized transgender persons if it uses the law to punish transgender individuals. Such a law may, for example, explicitly criminalize impersonation of the other gender, including cross-dressing. A country is considered to have any criminalization or punitive regulation of sex work if selling and/or buying sexual services is criminalized, ancillary activities associated with selling and/or buying sexual services are criminalized, profiting from organizing and/or managing sexual services is criminalized, and/or there are other punitive and/or administrative regulations of sex work.

SOCIETAL ENABLERS

EVER-MARRIED OR PARTNERED WOMEN (AGED 15–49 YEARS) WHO EXPERIENCED PHYSICAL AND/OR SEXUAL VIOLENCE BY AN INTIMATE PARTNER IN THEIR LIFETIME, COUNTRIES WITH AVAILABLE DATA, MIDDLE EAST AND NORTH AFRICA, 2018



Source: Violence against women prevalence estimates, 2018: global, regional and national prevalence estimates for intimate partner violence against women and global and regional prevalence estimates for non-partner sexual violence against women. Geneva: World Health Organization; 2021.

The COVID-19 pandemic and extended lockdowns have disrupted HIV services across the Middle East and North Africa, especially in settings affected by humanitarian emergencies and particularly for key populations. That being said, COVID-19 has also spurred innovations in service delivery. Multimonth dispensing of antiretroviral medicines in the Middle East and North Africa, once a rarity, has risen significantly in a number of countries across the region, thanks in large part to the efforts of civil society organizations, which have helped fill gaps in public and private health care provision caused by the COVID-19 pandemic.

COVID-19 has also shone a bright light on gender inequalities across the region. Gender-based violence, already a growing problem across the region, has been exacerbated by lockdowns and other pandemic-related drivers (1). The pandemic has increased the burden of unpaid care on women and girls, further undermined their prospects of employment (which were already modest in many countries), put their educational gains at risk and heightened the prevalence of harmful practices such as child marriage and female genital mutilation. All of these risks are intertwined and are part of the complex fabric of vulnerabilities to HIV experienced by women and girls.


^{1.} Violence against women and girls and COVID-19 in the Arab region. United Nations Economic and Social Commission for Western Asia, UN Women; 2020 (https://www2.unwomen.org/-/media/field%20office%20arab%20states/attachments/publications/2020/12/covid_and_vawg_un_brief_final.pdf?la=en&vs=5344).

INVESTING TO END AIDS

Resource availability from both domestic and external sources in the Middle East and North Africa has fluctuated over the past decade. One constant feature has been the large gap between what is available and what is needed: the resources available in 2020 were less than 20% of what is required to scale up HIV programmes and achieve the 2025 targets.

The COVID-19 pandemic and the accompanying economic downturn is making a difficult funding environment even more challenging. Increasing domestic investments in HIV responses will require formulating well-prioritized and fully costed national strategic plans and investment cases. It will also necessitate positioning HIV within broader efforts to reach the Sustainable Development Goals, including integration of HIV into social protection schemes and universal health coverage. A regional HIV response with community-led action at its heart will also benefit from forging partnerships with new regional donors, the private sector and philanthropic foundations, as well as innovative financing models, such as social contracting.


RESOURCE AVAILABILITY FOR HIV, MIDDLE EAST AND NORTH AFRICA, 2010–2020, AND ESTIMATED RESOURCE NEEDS FOR HIV BY 2025



Source: UNAIDS financial estimates and projections, 2021 (http://hivfinancial.unaids.org/hivfinancialdashboards.html).

Note: The resource estimates are presented in constant 2019 US dollars.


YEAR-TO-YEAR CHANGE IN RESOURCE AVAILABILITY FOR HIV, MIDDLE EAST AND NORTH AFRICA, 2009– 2010 TO 2019–2020



Source: UNAIDS financial estimates, 2021 (http://hivfinancial.unaids.org/hivfinancialdashboards.html).

ALGERIA

	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	720	1700	1700
	[620–820]	[1500–1900]	[1400–1900]
New HIV infections (0–14)	<100	<200	<200
	[<100-<100]	[<200-<200]	[<200–<200]
New HIV infections (women, 15+)	<500	690	670
	[<500– <500]	[590–790]	[590–760]
New HIV infections (men, 15+)	<500	840	820
	[<500–<500]	[700–1000]	[690–980]
HIV incidence per 1000 population	0.02 [0.02–0.02]	0.04 [0.04–0.05]	0.04 [0.03–0.04]
AIDS-related deaths			
AIDS-related deaths (all ages)	<200	<200	<200
	[<200–<200]	[<200-<200]	[<200-<500]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100-<100]	[<100- <100]	[<100-<100]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100– <100]	[<100– <100]	[<100-<100]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100- <100]	[<100–<100]	[<100-<200]
People living with HIV			
People living with HIV (all ages)	5800	11 000	18 000
	[5300–6200]	[10 000–12 000]	[17 000–20 000]
People living with HIV (0–14)	<200	<500	850
	[<200– <500]	[<500-<500]	[780–920]
People living with HIV (women, 15+)	2500	4700	8000
	[2300–2600]	[4400–5200]	[7300–8600]
People living with HIV (men, 15+)	3200	5800	9500
	[2800–3500]	[5100–6500]	[8500–11 000]
HIV prevalence (15–49)	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]






COUNTRY DATA

HIV TESTING AND TREATMENT CASCADE

91% [82–103%]

Men (15+)



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION					
	2010	2020			
Percentage of pregnant women living with HIV accessing antiretroviral medicines	58% [53–65%]	34% [32–37%]			
Final vertical transmission rate including during breastfeeding	21.5% [20.1–22.7%]	21.5% [20.1–23.2%]			
Early infant diagnosis	% [–%]	22.1% [20.6–23.8%]			

80% [72–91%]

7626

...% [...-...%]

DJIBOUTI

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<500	<200	<200
	[<500–560]	[<100-<500]	[<100-<500]
New HIV infections (0–14)	<200	<100	<100
	[<100- <200]	[<100–<200]	[<100-<100]
lew HIV infections (women, 15+)	<200	<100	<100
	[<100- <500]	[<100–<200]	[<100-<100]
New HIV infections (men, 15+)	<200	<100	<100
	[<100-<200]	[<100-<200]	[<100-<100]
HIV incidence per 1000 population	0.44 [0.24–0.69]	0.22 [0.1–0.37]	0.13 [0.05–0.22]
AIDS-related deaths			
AIDS-related deaths (all ages)	870	630	<500
	[610–1100]	[<500–880]	[<200–530]
NIDS-related deaths (0–14)	<200	<100	<100
	[<100- <200]	[<100–<200]	[<100-<100]
NIDS-related deaths (women, 15+)	<500	<500	<200
	[<500–540]	[<200–<500]	[<100-<500]
NIDS-related deaths (men, 15+)	<500	<500	<200
	[<500-<500]	[<200-<500]	[<100-<500]
eople living with HIV			
eople living with HIV (all ages)	11 000	8300	6800
	[8200–14 000]	[6000–11 000]	[5000–9000]
eople living with HIV (0-14)	1600	1100	600
	[1200–2100]	[730–1500]	[<500–880]
eople living with HIV (women, 15+)	5300	4100	3500
	[3900–6900]	[3000–5400]	[2600–4600]
eople living with HIV (men, 15+)	4200	3200	2700
	[3000–5500]	[2300–4300]	[2000–3600]
HIV prevalence (15–49)	1.8 [1.3–2.4]	1.2 [0.8–1.6]	0.8 [0.6–1.1]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	
Mandatory HIV testing for marriage, work or	

residence permits or for certain groups

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	•••	
	•••	•••
Percentage of people living with HIV denied health services because of their HIV status in		•••
the last 12 months		

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent


VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

Last available report: 2014 US\$ 274 426 US\$ 1 563 399 US\$ 1 045 940 US\$ 2 883 765


EPIDEMIC TRANSITION METRICS



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS Men who People who Transgender Sex workers Prisoners have sex inject drugs people with men Estimated size of population ... **HIV** prevalence 9.3% 14.2% HIV testing and status 58.1%** 66.3%** awareness Antiretroviral therapy coverage Condom use Coverage of HIV prevention programmes Avoidance of health care because of stigma and discrimination **Expenditures in US\$**

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	11% [7–16%]	44% [27-65%]
Final vertical transmission rate including during breastfeeding	40.2% [38–42.5%]	32.3% [24.8–36.1%]
Early infant diagnosis	% [–%]	% [–%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	90 [62 –1 20]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	0.7%
Knowledge of HIV prevention among young people aged 15–24 years (2011)	
— Women	9.1%
— Men	13%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	
— Men	•••
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction — Use of sterile injecting equipment at	

 Use of sterile injecting equipment at 	
last injection	

— Needles and syringes distributed	per
person who injects	

 Coverage of opioid substitution
therapy

Naloxone available (2021)Safe injection rooms available (2021)

^{**} Programme data—not representative; includes people with negative results.

EGYPT

COUNTRY DATA

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	980	2000	3300	
	[830–1100]	[1800–2200]	[2800–3800]	
New HIV infections (0–14)	<100	<100	<200	
	[<100–<100]	[<100–<100]	[<100-<200]	
New HIV infections (women, 15+)	<200	<500	690	
	[<200– <500]	[<500-<500]	[600–810]	
New HIV infections (men, 15+)	770	1500	2500	
	[650–900]	[1300–1700]	[2000–2900]	
HIV incidence per 1000 population	0.01 [0.01–0.01]	0.02 [0.02–0.02]	0.03 [0.03–0.04]	
AIDS-related deaths				
AIDS-related deaths (all ages)	<200	<500	<500	
	[<100- <200]	[<200-<500]	[<500-<500]	
AIDS-related deaths (0–14)	<100	<100	<100	
	[<100–<100]	[<100- <100]	[<100- <100]	
AIDS-related deaths (women, 15+)	<100	<100	<100	
	[<100– <100]	[<100- <100]	[<100- <100]	
AIDS-related deaths (men, 15+)	<200	<200	<500	
	[<100- <200]	[<200–<500]	[<200–<500]	
People living with HIV				
People living with HIV (all ages)	5400	12 000	24 000	
	[4400–6400]	[10 000–13 000]	[21 000–26 000]	
People living with HIV (0–14)	<100	<200	<500	
	[<100– <100]	[<200– <500]	[<500–<500]	
People living with HIV (women, 15+)	960	2300	5000	
	[800–1100]	[2100–2600]	[4600–5400]	
People living with HIV (men, 15+)	4300	9300	18 000	
	[3500–5200]	[8000–10 000]	[16 000–20 000]	
HIV prevalence (15–49)	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No, but prosecutions exist based on general criminal laws
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	Yes
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	.,

residence permits or for certain groups

STIGMA AND DISCRIMINATION


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	•••	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told		•••


others about their HIV status without their consent


VIOLENCE


Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2008	US\$ 113 715	US\$ 3 793 463		US\$ 1 338 706	US\$ 1 432 081	US\$ 7 652 152









Change in new
HIV infections = 234%
since 2010

Change in AIDSrelated deaths = since 2010 106% Incidence: prevalence ratio

prevalence = 13.83


Incidence: mortality ratio*

^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population				•••	
HIV prevalence		6.7%	2.5%		
HIV testing and status awareness		96.7%**	95.4%**		
Antiretroviral therapy coverage					
Condom use					
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

^{**} Programme data—not representative; includes people with negative results.

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION 2010 2020

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	18% [15–22%]	27% [24–29%]
Final vertical transmission rate including during breastfeeding	42.1% [39.4–45%]	33.4% [31.4–35.7%]
Early infant diagnosis	7.7% [4.6–10.8%]	19.9% [18.1–22.1%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	100 [49 –1 70]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

6
6

demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised applicable

Voluntary medical male circumcisions	Not
performed according to national standards	applicable
People who received PrEP at least once during the reporting period	

Harm reduction

- Use of sterile injecting equipment at last injection (2015)
 Needles and syringes distributed per
- Needles and syringes distributed per person who injects

 Coverage of opioid substitution
- therapy

 Naloxone available (2021)
- Safe injection rooms available (2021)

IRAN (ISLAMIC REPUBLIC OF)

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	4900	2700	2400
	[2800–9500]	[1400–11 000]	[1000–11 000]
New HIV infections (0–14)	<200	<200	<100
	[<100- <200]	[<100-<500]	[<100–<500]
New HIV infections (women, 15+)	990	940	940
	[560–1900]	[<500–3700]	[<500–4400]
New HIV infections (men, 15+)	3800	1700	1400
	[2200–7300]	[870–6700]	[580–6300]
HIV incidence per 1000 population	0.07 [0.04–0.13]	0.03 [0.02–0.14]	0.03 [0.01–0.13]
AIDS-related deaths			
AIDS-related deaths (all ages)	3600	4200	3200
	[2800–5800]	[3200–7100]	[2000–7100]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100– <200]	[<100-<200]	[<100–<200]
AIDS-related deaths (women, 15+)	560	570	<500
	[<500–1000]	[<500–970]	[<500–1300]
AIDS-related deaths (men, 15+)	3000	3600	2600
	[2300–4700]	[2800–5900]	[1800–5600]
People living with HIV			
People living with HIV (all ages)	70 000	62 000	54 000
	[55 000–100 000]	[46 000–110 000]	[39 000–130 000]
People living with HIV (0-14)	610	680	740
	[<500–1000]	[<500–1200]	[<500–2000]
People living with HIV (women, 15+)	11 000	12 000	15 000
	[8300–16 000]	[8600–23 000]	[9700–39 000]
People living with HIV (men, 15+)	59 000	48 000	39 000
	[46 000–87 000]	[37 000–86 000]	[29 000–86 000]
HIV prevalence (15–49)	0.1 [0.1–0.2]	0.1 [<0.1–0.2]	<0.1 [<0.1–0.2]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, death penalty
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a non-criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	No

residence permits or for certain groups

STIGMA AND DISCRIMINATION


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	•••	
	•••	•••
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		


VIOLENCE


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES						
Financing sources International: International: International:						
	Domestic private	Domestic public	PEPFAR	Global Fund	all others	Total

Last available report: 2012 US\$ 2 093 938 US\$ 69 420 049 US\$ 74 486 120









Change in new
HIV infections
since 2010

-51%

Change in AIDSrelated deaths = -12% since 2010

Incidence: prevalence = 4.44

Incidence: mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	137 600				148 500
HIV prevalence	1.6%		3.1%		0.8%
HIV testing and status awareness	67.1%		52.9%		
Antiretroviral therapy coverage			16.7%		66.1%
Condom use	60.5%		35.4%	42.5%	
Coverage of HIV prevention programmes	35.1%		25.6%		
Avoidance of health care because of stigma and discrimination	27.8%				
Expenditures in US\$					

	HIV (CO	MO	RBI	DITI	ES
--	-------	----	----	-----	------	----

Estimated number of incident tuberculosis cases among people living with HIV (2018)	380 [290–500]
People living with HIV who started TB preventive therapy (2018)	8.5%
Women who tested positive for HIV among those screened for cervical cancer (programme data) (2019)	40.7%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	36.1%

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load

Knowledge of HIV prevention among young people aged 15–24 years (2012)

— Women	16.21%
— Men	20.63%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

— Women

— Men

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION


	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	20% [15–29%]	53% [32–100%]
Final vertical transmission rate including during breastfeeding	40.7% [35.9–48.5%]	29% [18–42.4%]
Early infant diagnosis	14.1% [10.1–20.4%]	23.5% [7.4–39.1%]

Harm reduction

 Use of sterile injecting equipment at last injection (2019) 	73.4%
 Needles and syringes distributed per person who injects (2020) 	76
 Coverage of opioid substitution therapy (2020) 	15.3%
— Naloxone available (2021)	No
— Safe injection rooms available (2021)	No

JORDAN

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100–<100]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)	<100	<100	<100
	[<100–<100]	[<100-<100]	[<100–<100]
New HIV infections (men, 15+)	<100	<100	<100
	[<100–<100]	[<100-<100]	[<100–<100]
HIV incidence per 1000 population	<0.01 [<0.01–<0.01]	<0.01 [<0.01-<0.01]	<0.01 [<0.01–<0.01]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<100
	[<100- <100]	[<100- <100]	[<100- <100]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100–<100]	[<100-<100]	[<100– <100]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100–<100]	[<100-<100]	[<100-<100]
People living with HIV			
People living with HIV (all ages)	<500	680	930
	[<500-<500]	[630–750]	[840–1000]
People living with HIV (0-14)			
	[]	[]	[]
People living with HIV (women, 15+)	<200	<500	<500
	[<200–<200]	[<200–<500]	[<500–<500]
People living with HIV (men, 15+)	<500	<500	640
	[<500-<500]	[<500–510]	[570–710]
HIV prevalence (15–49)	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2013		US\$ 1 000 000		US\$ 79 616		US\$ 1 079 616

COUNTRY DATA

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION			
	2010	2020	
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]	
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]	
Early infant diagnosis	% [–%]	% [–%]	

283

LEBANON

COUNTRY DATA

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	<200	<200	<200	
	[<200- <200]	[<200- <500]	[<200- <500]	
New HIV infections (0–14)				
	[]	[]	[]	
New HIV infections (women, 15+)	<100	<100	<100	
	[<100-<100]	[<100–<100]	[<100– <100]	
New HIV infections (men, 15+)	<200	<200	<200	
	[<100- <200]	[<200–<200]	[<200–<200]	
HIV incidence per 1000 population	0.03 [0.03–0.03]	0.03 [0.03–0.04]	0.03 [0.02–0.03]	
AIDS-related deaths				
AIDS-related deaths (all ages)	<100	<100	<100	
	[<100- <100]	[<100–<100]	[<100-<100]	
AIDS-related deaths (0–14)				
	[]	[]	[]	
AIDS-related deaths (women, 15+)	<100	<100	<100	
	[<100-<100]	[<100–<100]	[<100– <100]	
AIDS-related deaths (men, 15+)	<100	<100	<100	
	[<100- <100]	[<100–<100]	[<100-<100]	
People living with HIV				
People living with HIV (all ages)	1400	2200	2700	
	[1200–1500]	[2000–2400]	[2400–3100]	
People living with HIV (0–14)				
	[–]	[]	[]	
People living with HIV (women, 15+)	<500	<500	<500	
	[<500-<500]	[<500-<500]	[<500–<500]	
People living with HIV (men, 15+)	1100	1800	2300	
	[960–1200]	[1600–2100]	[2000–2700]	
HIV prevalence (15–49)	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	

) PO	

Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	
Criminalization of transgender people	
Laws or policies restricting the entry, stay and residence of people living with HIV	Require HIV testing or disclosure for some permits
Parental consent for adolescents to access HIV testing	
Spousal consent for married women to access sexual and reproductive health services	
Mandatory HIV testing for marriage, work or	

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49 years who report discriminatory attitudes

•••

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent


VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

residence permits or for certain groups

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 135 080 US\$ 6 829 080 Last available report: 2019 US\$ 6 620 000



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••	16 500		•••	
HIV prevalence	0%	12%			0.1%
HIV testing and status awareness		92.3%			
Antiretroviral therapy coverage					
Condom use	79.2%	52.2%			
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION					
	2010	2020			
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [– %]			
Final vertical transmission rate including during	%	%			

1678

breastfeeding [...-..%] [...-..%] ...% ...% Early infant diagnosis [...-..%] [...-..%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	8 [2–16]
People living with HIV who started TB preventive therapy (2018)	2.1%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2017)	100%

HIV PREVENTION

- Men

— Men

Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged

15-49 years - Women

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable	
Voluntary medical male circumcisions performed according to national standards	Not applicable	
People who received PrEP at least once during the reporting period (2020)	360	

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution 49.7% therapy (2015)
- Naloxone available (2021)
- Safe injection rooms available (2021)

LIBYA

COUNTRY DATA

	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<500	<500	<500
	[<500–540]	[<500– <500]	[<500–<500]
New HIV infections (0–14)	<100	<100	<100
	[<100-<100]	[<100– <100]	[<100-<100]
New HIV infections (women, 15+)	<100	<100	<100
	[<100- <200]	[<100– <100]	[<100-<200]
New HIV infections (men, 15+)	<500	<200	<500
	[<200-<500]	[<200– <200]	[<200-<500]
HIV incidence per 1000 population	0.06 [0.04–0.09]	0.04 [0.03–0.05]	0.05 [0.04–0.07]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<100
	[<100– <100]	[<100– <200]	[<100– <100]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100–<100]	[<100- <100]	[<100-<100]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100– <100]	[<100– <100]	[<100-<100]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100-<100]	[<100- <100]	[<100- <100]
People living with HIV			
People living with HIV (all ages)	5600	5700	6700
	[5100–5900]	[5300–6100]	[6100–7400]
People living with HIV (0–14)	<200	<500	<500
	[<200-<200]	[<200– <500]	[<200-<500]
People living with HIV (women, 15+)	1500	1600	1900
	[1400–1600]	[1500–1700]	[1800–2100]
People living with HIV (men, 15+)	3900	3900	4500
	[3600–4200]	[3500–4200]	[4100–5100]
HIV prevalence (15–49)	0.1 [0.1–0.1]	0.1 [0.1–0.1]	0.1 [0.1–0.1]

LAV			

Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Both criminalized and prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49

years who report discriminatory attitudes towards people living with HIV	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	•••
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their	•••

VIOLENCE

consent


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES


residence permits or for certain groups


EXPENDITORES						
Financing sources						
Domestic private	Domestic public	International:	International:	International:	Total	
Domestic private	Domestic public	PEPFAR	Global Fund	all others	lotai	

Last available report:









Change in new
HIV infections = 1%
since 2010

Change in AIDS-related deaths = -15% since 2010

Incidence:
prevalence = 5.20
ratio

Incidence: mortality ratio*

* The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence					
HIV testing and status awareness					
Antiretroviral therapy coverage					
Condom use					
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	33 [16–55]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2017)	100%

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years	

ople aged 15–24 years

— Women

— Men

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

— Women

— Men

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised Applicable

Voluntary medical male circumcisions performed according to national standards Applicable

People who received PrEP at least once during the reporting period

FLIMINATION OF MOTHER-TO-CHILD TRANSMISSION

ELIMINATION OF MOTTER-TO-CITED TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	0% [0–0%]	94% [84–100%]		
Final vertical transmission rate including during breastfeeding	47.2% [44.7–51.2%]	23.8% [21.2–27.7%]		
Early infant diagnosis	% [–%]	53.7% [48–60%]		

Harm reduction

— Use of sterile injecting equipment at
last injection
— Needles and syringes distributed per

 Needles and syringes distributed per
person who injects
- Coverage of opioid substitution

 Coverage of 	ropioid substitution
therapy	
N. I	:1 1 1 (0004)

Naioxone available (2021)	
— Safe injection rooms available (2021)	No

MOROCCO

COUNTRY DATA

New HIV infections (all ages)	EPIDEMIC ESTIMATES			
New HIV infections (all ages) 1500 1100 720		2010	2015	2020
New HIV infections (all ages) [1300-1800] [990-1400] [580-910] [200	New HIV infections			
New HIV infections (0-14)	New HIV infections (all ages)			
New HIV infections (women, 15+) [520-720] [<500-<500] [<200-<200] [<200-<200] [<400-<200] [640-920] [530-790] [<500-660] [<500-660] [<500-660] [<500-660] [<500-660] [<500-660] [<500-660] [<500-660] [<500-660] [<500-660] [<500-660] [<500-660] [<500-660] [<500-660] [<500-660] [<500-660] [<500-660] [<500-660] [<500-60] [<500-600] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<500-60] [<5	New HIV infections (0–14)			
	New HIV infections (women, 15+)			
AIDS-related deaths AIDS-related deaths (all ages) AIDS-related deaths (all ages) AIDS-related deaths (0-14) AIDS-related deaths (0-14) AIDS-related deaths (women, 15+) AIDS-related deaths (women, 15+) AIDS-related deaths (women, 15+) AIDS-related deaths (man, 15+) AIDS-related	New HIV infections (men, 15+)			
AIDS-related deaths (all ages) AIDS-related deaths (0-14) AIDS-related deaths (0-14) AIDS-related deaths (0-14) AIDS-related deaths (women, 15+) AIDS-related deaths (men, 15+)	HIV incidence per 1000 population	0.05 [0.04–0.06]	0.03 [0.03–0.04]	0.02 [0.02–0.02]
AIDS-related deaths (all ages) [700–1000] [520–840] [<500–530] AIDS-related deaths (0–14) 2000 (100 (100 (100 (100 (100 (100 (100	AIDS-related deaths			
AIDS-related deaths (0–14) [<100 – <200] [<100 – <100] [<100 – <100] [<100 – <100] [<100 – <100] [<100 – <100] [<100 – <100] AIDS-related deaths (women, 15+) [<500 – <500] [<500 – <500] [<500 – <500] [<500 – <500] [<200 – <500] [<200 – <500] [<200 – <500] [<200 – <500] People living with HIV People living with HIV (all ages) [18 000	AIDS-related deaths (all ages)			
AIDS-related deaths (women, 15+) [<500 - <500] [<200 - <500] [<100 - <200] AIDS-related deaths (men, 15+) [<500 - <500] [<500 - <500] [<500 - <500] [<200 - <500] [<200 - <500] People living with HIV People living with HIV (all ages) [18 000	AIDS-related deaths (0–14)			
Companies Comp	AIDS-related deaths (women, 15+)			
18 000 20 000 22 000 22 000 22 000 23 000 25 000 2	AIDS-related deaths (men, 15+)			
People living with HIV (all ages) [16 000–20 000] [18 000–23 000] [19 000–24 000] People living with HIV (0–14) 780 860 860 [690–880] [780–950] [770–960] People living with HIV (women, 15+) 8100 8900 9300 [7200–9100] [8000–9800] [8400–10 000] People living with HIV (men, 15+) 9100 11 000 12 000 [8000–10 000] [9300–12 000] [10 000–13 000]	People living with HIV			
People living with HIV (0-14) [690-880] [780-950] [770-960] People living with HIV (women, 15+) 8100 8900 9300 [7200-9100] [8000-9800] [8400-10 000] People living with HIV (men, 15+) 9100 11 000 12 000 [8000-10 000] [9300-12 000] [10 000-13 000]	People living with HIV (all ages)			
People living with HIV (women, 15+) [7200–9100] [8000–9800] [8400–10 000] People living with HIV (men, 15+) 9100 11 000 12 000 [8000–10 000] [9300–12 000] [10 000–13 000]	People living with HIV (0–14)			
People living with HIV (men, 15+) [8000–10 000] [9300–12 000] [10 000–13 000]	People living with HIV (women, 15+)			
HIV prevalence (15–49) <0.1 [<0.1–<0.1] <0.1 [<0.1–<0.1] <0.1 [<0.1–<0.1]	People living with HIV (men, 15+)			
	HIV prevalence (15–49)	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	

residence permits or for certain groups

STIGMA AND DISCRIMINATION


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	•••	
Percentage of people living with HIV denied		2017
the last 12 months		41.2
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their		2017
consent		15.5

VIOLENCE

Proportion of ever-married or partnered	2019
women aged 15–49 years who experienced	
physical or sexual violence from a male	
intimate partner in the past 12 months	22.2

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

Last available report: 2017 US\$ 1 493 732 US\$ 18 244 377 US\$ 39 062 783



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population				•••	85 000
HIV prevalence	1.7%	4.9%	7.1%		0.4%
HIV testing and status awareness	44.4%	54.9%	36.1%		
Antiretroviral therapy coverage					
Condom use	61.1%	57.7%	44.6%		
Coverage of HIV prevention programmes	54.9%	53.3%	45.4%		
Avoidance of health care because of stigma and discrimination	23.4%	7.6%	29.9%		
Expenditures in US\$ (2016)	1 003 725	1 013 117	948 275		

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	23% [20–26%]	54% [49–60%]		
Final vertical transmission rate including during breastfeeding	28.2% [27–29.4%]	18% [16–19.6%]		

Early infant diagnosis

17.7%

[13.9-22.8%]

8008

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	500 [150–1100]
People living with HIV who started TB preventive therapy (2018)	14.3%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	<0.1%

Knowledge of HIV prevention among young people aged 15–24 years (2013)

— Women	19.82%
— Men	24.66%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

— Women

therapy (2020)

— Naloxone available (2021)

...%

[...-..%]

Safe injection rooms available (2021)

— Men

Women aged 15–49 years who have their demand for family planning satisfied by

modern methods		
Men aged 15–49 years who are circumcised	Not applicable	
Voluntary medical male circumcisions performed according to national standards	Not applicable	
People who received PrEP at least once during the reporting period (2020)	631	
Harm reduction		
 Use of sterile injecting equipment at last injection (2017) 	92.1%	
 Needles and syringes distributed per person who injects (2020) 	100	
— Coverage of opioid substitution	33.4%	


Yes

No

OMAN

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population						
HIV prevalence					0.2%	
HIV testing and status awareness						
Antiretroviral therapy coverage						
Condom use						
Coverage of HIV prevention programmes						
Avoidance of health care because of stigma and discrimination						
Expenditures in US\$						

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	7 [2–14]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	25%

HIV PREVENTION

- Women

— Men

Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2014)	

9.8%

...

— Men

Condom use at last sex with a non-marital,

non-cohabiting partner among people aged 15–49 years — Women

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised applicable

Voluntary medical male circumcisions performed according to national standards

People who received PrEP at least once during the reporting period

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2014		US\$ 4 313 471		•••	US\$ 11 390	US\$ 4 324 861

COUNTRY DATA

LAWS AND POLICIES		STIGMA AND DISCRIMINATION	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No, but prosecutions exist based on general criminal laws	Percentage of women and men aged 15–49 years who report discriminatory attitudes	
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work	towards people living with HIV	
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Drug use or possession for personal use is an offence		Percentage of people living with HIV who reported a health-care professional told	
Criminalization of transgender people	Criminalized	others about their HIV status without their consent	
Laws or policies restricting the entry, stay and residence of people living with HIV	Deport, prohibit short- and/or long-stay and require HIV testing or disclosure for some permits	VIOLENCE	
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 12 years	Proportion of ever-married or partnered women aged 15–49 years who experienced	
Spousal consent for married women to access sexual and reproductive health services	No	physical or sexual violence from a male intimate partner in the past 12 months	
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes		

SAUDI ARABIA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<500	750	1000
	[<500–<500]	[640–920]	[750–1500]
New HIV infections (0–14)	<100	<100	<100
	[<100–<100]	[<100–<100]	[<100-<100]
New HIV infections (women, 15+)	<100	<200	<200
	[<100-<100]	[<200– <200]	[<200-<500]
New HIV infections (men, 15+)	<500	590	800
	[<500-<500]	[510–730]	[590–1200]
HIV incidence per 1000 population	0.02 [0.02–0.03]	0.04 [0.03–0.04]	0.05 [0.03–0.07]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<200
	[<100–<100]	[<100-<100]	[<100-<200]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100–<100]	[<100-<100]	[<100-<100]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100– <100]	[<100-<100]	[<100-<100]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100–<200]
People living with HIV			
People living with HIV (all ages)	4800	7500	12 000
	[4400–5300]	[6700–8200]	[10 000–14 000]
People living with HIV (0–14)	<200	<200	<200
	[<200–<200]	[<200–<200]	[<200–<200]
People living with HIV (women, 15+)	1100	1600	2400
	[990–1200]	[1400–1800]	[2100–2800]
People living with HIV (men, 15+)	3600	5700	9100
	[3300–3900]	[5100–6300]	[7800–11 000]
HIV prevalence (15–49)	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]

MIC		DΡ	\sim 1 1	
W	Δ			

residence permits or for certain groups

LAVVS AND FOLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, death penalty
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Criminalized
Laws or policies restricting the entry, stay and residence of people living with HIV	Yes
Parental consent for adolescents to access HIV testing	No
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	Yes

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49 years who report discriminatory attitudes


towards people living with HIV	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent	


VIOLENCE


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 19 331 648 Last available report: 2009 US\$ 19 389 141









Change in new **HIV** infections since 2010

Change in AIDS-110% related deaths since 2010

Incidence: 8.68 prevalence ratio


mortality ratio*

* The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••				
HIV prevalence			0%		0.2%
HIV testing and status awareness			100%**		
Antiretroviral therapy coverage					91.7%
Condom use					
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

^{**} Programme data—not representative; includes people with negative results.

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	0% [0–0%]	37% [31–44%]
Final vertical transmission rate including during breastfeeding	33.7% [31–36.2%]	28.3% [24.8–32.6%]
Early infant diagnosis	% [–%]	% [–%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	49 [33–67]
People living with HIV who started TB preventive therapy (2018)	1.5%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2018)	100%

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	
Condom use at last sex with a non-marital,	

non-cohabiting partner among people aged 15-49 years

— Women

— Men

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

SOMALIA

COUNTRY DATA

New HIV infections 710 <500	
Sew HIV infections (all ages) Seminorary	
New HIV infections (0-14)	
Color Colo	
Company Comp	
AIDS-related deaths AIDS-related deaths (all ages) AIDS-related deaths (all ages) AIDS-related deaths (0-14) AIDS-related deaths (0-14) AIDS-related deaths (women, 15+) AIDS-related deaths (women, 15+) AIDS-related deaths (men, 15+)	
AIDS-related deaths (all ages) 1000 [860–1100] [860–890] [500–560] AIDS-related deaths (0–14) [200–500] [200–200] [400–4100] [500–4100] [400–4100] [500–500] [500–500] [200–500] [200–500] [200–500] [200–500] [200–500] [200–500]	3]
AIDS-related deaths (all ages) [860–1100] [630–890] [<500–560] AIDS-related deaths (0–14) (<500	
AIDS-related deaths (0-14) [<200-<500]	
AIDS-related deaths (women, 15+) [<500 < <500] [<200 < <500] [<200 < <200] <500 < 500 < 500 < 500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500 < <500 <500	
AIDS-related deaths (men, 15+) [<500–520] [<500–<500] [<200–<500]	
People living with HIV	
People living with HIV (all ages) 14 000 11 000 8700 [12 000-15 000] [9400-12 000] [7700-9800]	
People living with HIV (0–14) 1600 1400 1000 [1400–1800] [1200–1600] [880–1200]	
People living with HIV (women, 15+) 5600 4400 3900 [3900-5000] [4900-6300] [3900-5000]	
People living with HIV (men, 15+) 6500 4800 3800 [5700-7400] [4100-5500] [3300-4300]	
HIV prevalence (15–49) 0.2 [0.2–0.2] 0.1 [0.1–0.1] <0.1 [<0.1–<0.1]	

LAW	NID	\mathbf{D}	
$\mathbf{L} \Delta \mathbf{W}$			

LAWS AND I OLICILS	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	
Criminalization of same-sex sexual acts	Yes, death penalty
Drug use or possession for personal use is an offence	
Criminalization of transgender people	
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	
Spousal consent for married women to access sexual and reproductive health services	
Mandatory HIV testing for marriage, work or	

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49 years who report discriminatory attitudes towards people living with HIV

Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their	

VIOLENCE


consent

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

residence permits or for certain groups

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


US\$ 6 467 638 US\$ 6 467 638 Last available report: 2019



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••		***	•••	
HIV prevalence	3.4%				0.4%
HIV testing and status awareness					
Antiretroviral therapy coverage					
Condom use	41.5%				
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	0% [0–0%]	33% [29–39%]
Final vertical transmission rate including during breastfeeding	37.5% [35.9–39%]	31% [29.1–32.9%]
Early infant diagnosis	% [–%]	% [%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	470 [290–690]
People living with HIV who started TB preventive therapy (2018)	20.1%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	
— Men	***
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not applicable

modern methods	
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction	

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapyNaloxone available (2021)
- Safe injection rooms available (2021)

SUDAN

COUNTRY DATA

	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	3600	3700	3800
	[3000–4800]	[3000–4700]	[2900–4900]
New HIV infections (0–14)	710	670	660
	[540–890]	[510–830]	[510–810]
New HIV infections (women, 15+)	1400	1400	1400
	[1200–1900]	[1100–1800]	[1000–1900]
New HIV infections (men, 15+)	1400	1600	1800
	[1200–2100]	[1200–2200]	[1300–2400]
HIV incidence per 1000 population	0.11 [0.09–0.14]	0.1 [0.08–0.12]	0.09 [0.07–0.12]
AIDS-related deaths			
AIDS-related deaths (all ages)	2400	2900	2300
	[1600–3200]	[2400–3500]	[1900–3000]
AIDS-related deaths (0–14)	<500	<500	<500
	[<500–600]	[<500–580]	[<500–560]
AIDS-related deaths (women, 15+)	950	1200	960
	[570–1200]	[970–1400]	[810–1200]
AIDS-related deaths (men, 15+)	980	1200	860
	[560–1400]	[1000–1600]	[670–1300]
People living with HIV			
People living with HIV (all ages)	42 000	44 000	49 000
	[37 000–51 000]	[39 000–53 000]	[42 000–57 000]
People living with HIV (0–14)	3900	4100	4100
	[3100–4800]	[3300–5000]	[3200–4800]
People living with HIV (women, 15+)	19 000	20 000	21 000
	[16 000–22 000]	[17 000–23 000]	[18 000–25 000]
People living with HIV (men, 15+)	19 000	20 000	23 000
	[16 000–24 000]	[18 000–25 000]	[20 000–28 000]
HIV prevalence (15–49)	0.2 [0.2–0.2]	0.2 [0.2–0.2]	0.2 [0.2–0.2]

	V/G	A RI	D C	EC.
LAV	$\mathbf{v} \rightarrow \mathbf{v}$	_ N N I		

Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, death penalty
Drug use or possession for personal use is an offence	
Criminalization of transgender people	
Laws or policies restricting the entry, stay and residence of people living with HIV	Deport, prohibit short- and/or long-stay and require HIV testing or disclosure for some permits
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	Yes

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49

towards people living with HIV	
	 •••
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their	•••

VIOLENCE

consent


Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES

residence permits or for certain groups

	Finar	ncing sources			
Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 42 553 US\$ 1 070 800 US\$ 8 170 054 Last available report: 2013 US\$ 3 717 832 US\$ 13 840 875




^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).



^{**} Programme data—not representative; includes people with negative results.

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	4% [3–6%]	3% [3–4%]
Final vertical transmission rate including during breastfeeding	35.9% [33.5–38.3%]	36.8% [35–39.1%]
Early infant diagnosis	% [–%]	% [–%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	970 [300–2000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2014)	
— Women	8.5%
— Men	
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable	
Voluntary medical male circumcisions performed according to national standards	Not applicable	
People who received PrEP at least once		

Harm reduction

- Men

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

SYRIAN ARAB REPUBLIC

COUNTRY DATA

PIDEMIC ESTIMATES			
	2010	2015	2020
ew HIV infections			
lew HIV infections (all ages)	<100	<100	<100
	[<100- <100]	[<100– <200]	[<100- <100]
ew HIV infections (0-14)			
	[]	[]	[=]
lew HIV infections (women, 15+)	<100	<100	<100
	[<100– <100]	[<100-<100]	[<100– <100]
lew HIV infections (men, 15+)	<100	<100	<100
	[<100- <100]	[<100- <100]	[<100–<100]
IV incidence per 1000 population	<0.01 [<0.01–<0.01]	<0.01 [<0.01–<0.01]	<0.01 [<0.01-<0.01]
IDS-related deaths			
IDS-related deaths (all ages)	<100	<100	<100
	[<100- <100]	[<100–<100]	[<100–<100]
IDS-related deaths (0-14)			
	[]	[]	[]
IDS-related deaths (women, 15+)	<100	<100	<100
	[<100–<100]	[<100–<100]	[<100-<100]
IDS-related deaths (men, 15+)	<100	<100	<100
	[<100-<100]	[<100- <100]	[<100–<100]
eople living with HIV			
eople living with HIV (all ages)	510	660	840
	[<500–560]	[570–780]	[700–980]
eople living with HIV (0–14)			
	[]	[]	[]
eople living with HIV (women, 15+)	<200	<200	<500
	[<200-<200]	[<200–<500]	[<200-<500]
eople living with HIV (men, 15+)	<500	<500	580
	[<500-<500]	[<500–540]	[<500–700]
IV prevalence (15–49)	<0.1 [<0.1– <0.1]	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	Deport, prohibit short- and/or long-stay and require HIV testing or disclosure for some permits
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49

years who report discriminatory attitudes towards people living with HIV	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Percentage of people living with HIV who	


reported a health-care professional told others about their HIV status without their consent

VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


US\$ 809 850 Last available report: 2011 US\$ 620 000



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS Men who People who Transgender Sex workers Prisoners have sex inject drugs people with men Estimated size of population ... **HIV** prevalence 0% HIV testing and status awareness Antiretroviral therapy coverage Condom use Coverage of HIV prevention programmes Avoidance of health care because of stigma and $\ discrimination$ **Expenditures in US\$**

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTTER-TO-CITED TRANSMISSION		
	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]
Early infant diagnosis	% [–%]	% [–%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	3 [2–5]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	
— Men	
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not applicable

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction	
 Use of sterile injecting equipment at 	

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy

— Naloxone available (2021)

— Safe injection rooms available (2021)

TUNISIA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<500	<500	<500
	[<500-<500]	[<500-<500]	[<500– <500]
New HIV infections (0–14)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100–<100]
New HIV infections (women, 15+)	<100	<200	<200
	[<100– <100]	[<100-<200]	[<200–<200]
New HIV infections (men, 15+)	<200	<200	<500
	[<200-<200]	[<200– <500]	[<200– <500]
HIV incidence per 1000 population	0.02 [0.02–0.03]	0.03 [0.02–0.04]	0.03 [0.02–0.04]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<200	<200
	[<100–<200]	[<200–<200]	[<200–<200]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100–<100]	[<100-<100]	[<100-<100]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100– <100]	[<100– <100]	[<100- <100]
AIDS-related deaths (men, 15+)	<100	<200	<100
	[<100-<100]	[<100- <200]	[<100- <200]
People living with HIV			
People living with HIV (all ages)	2700	3400	4500
	[2400–2900]	[3100–3700]	[3900–5200]
People living with HIV (0-14)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100–<100]
People living with HIV (women, 15+)	830	1200	1700
	[760–880]	[1100–1300]	[1500–1900]
People living with HIV (men, 15+)	1800	2200	2700
	[1600–2000]	[1900–2400]	[2300–3200]
HIV prevalence (15–49)	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Criminalized
Laws or policies restricting the entry, stay and residence of people living with HIV	Prohibit short- and/or long-stay and require HIV testing or disclosure for some permits
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

Last available report: 2011

STIGMA AND DISCRIMINATION


Percentage of women aged 15–49 years who report discriminatory attitudes towards	•••	2018
people living with HIV		65.3
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their		•••


VIOLENCE


consent


Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2011		US\$ 117 400		US\$ 2 615 149	US\$ 10 000	US\$ 2 742 549









Change in new **HIV** infections since 2010

Change in AIDS-45% related deaths since 2010

Incidence: prevalence 8.77 ratio

mortality ratio*

^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••		•••	•••	22 000
HIV prevalence	1.2%		6%		
HIV testing and status awareness	7.7%		28.6%		
Antiretroviral therapy coverage					
Condom use	58.3%	34.8%	46.7%	56.7%	
Coverage of HIV prevention programmes	7.9%				
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV	COM	10R	BII	ITIC	ES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	38 [23–57]
People living with HIV who started TB preventive therapy (2018)	85.5%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2018)	100%

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years (2012)	
— Women	19.7%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49 years

— Women

- Men

— Men

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	23% [20–26%]	54% [44–64%]		
Final vertical transmission rate including during breastfeeding	33.2% [31.3–34.9%]	27.6% [24.7–29.9%]		
Early infant diagnosis	% [–%]	19.6% [16.4–23.9%]		

Harm reduction

Use of sterile injecting equipment at last injection (2017)	90.9%
 Needles and syringes distributed per person who injects (2019) 	49
 Coverage of opioid substitution therapy 	

— Naloxone available (2021)

- Safe injection rooms available (2021)

— Use of sterile injecting equipment at

UNITED ARAB EMIRATES

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population			•••	•••	•••
HIV prevalence					0.5%
HIV testing and status awareness					
Antiretroviral therapy coverage					
Condom use					
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE

Last available report: 2020



HIV COMORBIDITIES	
Estimated number of incident tuberculosis cases among people living with HIV (2018)	3 [0–9]
People living with HIV who started TB preventive therapy (2018)	1.5%
Cervical cancer screening of women living with HIV	

50%

HIV PREVENTION

People coinfected with HIV and hepatitis C

virus starting hepatitis C treatment (2019)

Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-

–49 years				
— Wome	en			
— Men				

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Hama vaduation	

arm reduction	
 Use of sterile injecting equipment at last injection 	
 Needles and syringes distributed per person who injects 	
 Coverage of opioid substitution therapy 	
— Naloxone available (2021)	

US\$ 9 689 766

- Safe injection rooms available (2021)

EXPENDITURES								
Financing sources								
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total		


US\$ 9 689 766

COUNTRY DATA

LAWS AND POLICIES		STIGMA AND DISCRIMINATION	J
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission		Percentage of women and men aged 15–49 years who report discriminatory attitudes	
Criminalization of sex work among consenting adults		towards people living with HIV	
Criminalization of same-sex sexual acts	Yes, death penalty	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Drug use or possession for personal use is an offence		Percentage of people living with HIV who reported a health-care professional told	•••
Criminalization of transgender people	consent		
Laws or policies restricting the entry, stay and residence of people living with HIV	Yes	VIOLENCE	
Parental consent for adolescents to access HIV testing		Proportion of ever-married or partnered women aged 15–49 years who experienced	
Spousal consent for married women to access sexual and reproductive health services		physical or sexual violence from a male intimate partner in the past 12 months	
Mandatory HIV testing for marriage, work or residence permits or for certain groups			

YEMEN

	2010	2015	2020
	2010	2013	2020
New HIV infections			
New HIV infections (all ages)	630	840	1100
	[590–680]	[790–900]	[1000–1100]
New HIV infections (0-14)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100-<100]
New HIV infections (women, 15+)	<500	<500	<500
	[<200-<500]	[<500-<500]	[<500-<500]
New HIV infections (men, 15+)	<500	<500	640
,,	[<500-<500]	[<500–540]	[580–690]
HIV incidence per 1000 population	0.03 [0.03-0.03]	0.03 [0.03–0.03]	0.04 [0.03–0.04]
AIDS-related deaths			
NIDS valated deaths (all ares)	<500	<500	<500
AIDS-related deaths (all ages)	[<200-<500]	[<500-<500]	[<500-<500]
AIDS-related deaths (0-14)	<100	<100	<100
AIDS-related deaths (0-14)	[<100-<100]	[<100-<100]	[<100-<100]
AIDS-related deaths (women, 15+)	<100	<100	<100
AID5-related deaths (women, 15+)	[<100-<100]	[<100-<100]	[<100-<200]
AIDS TO THE STATE OF	<200	<200	<200
AIDS-related deaths (men, 15+)	[<100-<200]	[<200–<200]	[<200–<500]
eople living with HIV			
People living with HIV (all ages)	5000	7400	11 000
copie iiviiig with thiv (an ages)	[4600–5200]	[7000–7800]	[9900–11 000]
People living with HIV (0-14)	<500	<500	510
	[<500-<500]	[<500-<500]	[<500–540]
People living with HIV (women, 15+)	1800	2700	3700
	[1700–1900]	[2500–2800]	[3500–3900]
People living with HIV (men, 15+)	2900	4400	6300
eopie namy with the (men, 131)	[2600–3100]	[4000–4700]	[5800–6700]
IIV prevalence (15–49)	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]
-			




^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2011		US\$ 467 395		US\$ 351 385	US\$ 333 504	US\$ 1 613 920

COUNTRY DATA

HIV TESTING AND TREATMENT CASCADE



	, (6, 16,6)	2927	
Children (0-14)	27% [26–29%]	27% [26–29%] 139	% [%]
Women (15+)	55% [52–58%]	28% [26–29%] 1039	% [%]
Men (15+)	34% [32–37%]	28% [26–30%] 1749	% [%]

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION								
	2010	2020						
Percentage of pregnant women living with HIV accessing antiretroviral medicines	9% [8–10%]	3% [3–4%]						
Final vertical transmission rate including during breastfeeding	38.9% [37–40.8%]	39.1% [37.4–40.6%]						
Early infant diagnosis	7.4% [5.1–10.6%]	% [–%]						

EASTERN EUROPE AND CENTRAL ASIA

Europe and central Asia is failing to control its HIV epidemic, with new HIV infections and AIDS-related deaths both continuing to rise. The annual number of new HIV infections increased by an estimated 43% from 2010 to 2020, making this the fastest growing HIV epidemic in the world. Key populations and their sex partners account for virtually all new infections in the region, with an estimated 43% of new adult HIV infections occurring among people who inject drugs. Criminal laws are still being applied too broadly, including unintentional HIV transmission, non-disclosure of HIV status or exposure to HIV where HIV was not actually transmitted.

AIDS-related deaths rose by 32% between 2010 and 2020 in the context of poorly performing testing and treatment programmes in most countries in the region. Overall, 70% of people living with HIV knew their HIV status, 53% were receiving antiretroviral therapy, and 50% were virally suppressed. Diagnosing people living with HIV and linking them to treatment and care are the biggest gaps in the region's treatment efforts. Bridging those gaps will be exceedingly difficult as long as key populations are subject to punitive laws, aggressive policing and social stigma.

The withdrawal or reduction of external donor financing for HIV programmes in the region has challenged efforts to preserve and expand access to essential HIV services. Services provided by civil society organizations are key to enhancing the region's HIV response, but in several countries, these organizations operate in restrictive environments, limiting their contributions to the HIV response. Administrative and financial barriers, including restrictions on foreign funding and complicated registration procedures, are among the impediments they face.

After being hard-hit by the COVID-19 pandemic, a combination of resilient health-care systems, multimonth dispensing of antiretroviral medicines, the use of Internet-based and social media platforms, and the exceptional work of nongovernmental organizations have ensured that many people living with HIV

PRIORITY ACTIONS FOR ENDING AIDS

- Urgently
 expand access
 to combination
 HIV prevention,
 including pre exposure
 prophylaxis (PrEP)
 and harm reduction.
- Close gaps in the testing and treatment cascade by fully rolling out a treat all approach, including improving testing strategies and expanding access to affordable and quality-assured antiretroviral medicines.
- Institutionalize community-led services within national health-care and HIV prevention systems.
- Build human rightsbased responses by transforming harmful gender norms, reducing genderbased violence, and removing discriminatory and punitive laws, policies, and other structural and social barriers.




An HIV community centre in Moscow, Russian Federation, receives donations of hand sanitizer during the COVID-19 pandemic.

Credit: Center-Plus


STATE OF THE PANDEMIC

NUMBER OF NEW HIV INFECTIONS AND AIDS-RELATED DEATHS, EASTERN EUROPE AND CENTRAL ASIA, 2000–2020




Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).

DISTRIBUTION OF NEW HIV INFECTIONS BY POPULATION GROUP AND SEX (AGED 15–49 YEARS), EASTERN EUROPE AND CENTRAL ASIA, 2020



Source: UNAIDS special analysis, 2021 (see methods annex).


HIV PREVALENCE AMONG KEY POPULATIONS, REPORTING COUNTRIES IN EASTERN EUROPE AND CENTRAL ASIA, 2016–2020



- Sex workers (n = 13)
- Gay men and other men who have sex with men (n = 13)
- People who inject drugs (n = 15)
- Transgender people (n = 2)
- Prisoners (n = 12)

Source: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/). Note: (n = number of countries). Total number of reporting countries = 16.

How to read this chart



REPORTED ESTIMATED SIZE OF KEY POPULATIONS, EASTERN EUROPE AND CENTRAL ASIA, 2018–2020

	National adult population (aged 15–49 years) in 2020 or relevant year	Sex workers	Sex workers as per cent of adult population (aged 15–49 years)	Gay men and other men who have sex with men	Gay men and other men who have sex with men as per cent of adult population (aged 15–49 years)	People who inject drugs	People who inject drugs as per cent of adult population (aged 15–49 years)	Transgender people	Transgender people as per cent of adult population (aged 15–49 years)	Prisoners	Prisoners as per cent of adult population (aged 15–49 years)
Albania	1 400 000									2300	0.16%
Armenia	1 500 000	4600	0.31%	16 000	1.07%	9000	0.60%				
Azerbaijan	5 500 000	32 000	0.58%			60 000	1.10%				
Belarus	4 400 000	18 600	0.42%		0.73%	80 000	1.82%				
Georgia	1 800 000			19 000	0.97%					9100	0.01%
Kazakhstan	9 200 000	21 000	0.22%			94 600	1.03%				
North Macedonia	1 100 000					6800	0.61%			2300	0.20%
Republic of Moldova	1 300 000	15 800	1.22%	14 600	1.12%	27 500	2.12%				
Tajikistan	4 800 000	18 000	0.36%								
Ukraine	20 700 000	87 000	0.41%	180 000	0.85%	350 000	1.66%	8200	0.04%	48 700	0.24%
Estimated regional proportion as per cadult population (aged 15–49 years)	cent of		0.34%		1.06%		1.09%		-		-

National population size estimate

Local population size estimate

Insufficient data

No data

Sources: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/); Spectrum Demproj module, 2021.


Note 1: Estimates shown are government-provided estimates reported for 2018–2020. Additional and alternative estimates may be available from different sources, including the Key Populations Atlas (https://kpatlas.unaids.org/), academic publications or institutional documents. Note 2: The reported values for gay men and other men who have sex with men are presented as a per cent of the adult population (aged 15–49 years) for consistency across key populations. The percentage of this population out of the adult male population (aged 15-49 years) will be approximately twice the values shown.

^a Quick Start Guide for Spectrum, 2020. Geneva: UNAIDS; 2020 (https://www.unaids.org/sites/default/files/media_asset/QuickStartGuide_ Spectrum_en.pdf).

^b Technical brief: recommended population size estimates of men who have sex with men. Geneva: WHO, UNAIDS; 2020.


HIV SERVICES


PEOPLE LIVING WITH HIV, PEOPLE NEWLY INFECTED IN THE PAST SIX MONTHS, AND HIV TESTING AND TREATMENT CASCADE, ADULTS (AGED 15+ YEARS), EASTERN EUROPE AND CENTRAL ASIA, 2016–2020




Source: UNAIDS special analysis, 2021.

HIV TESTING AND TREATMENT CASCADE, WOMEN (AGED 15+ YEARS) COMPARED TO MEN (AGED 15+ YEARS), EASTERN EUROPE AND CENTRAL ASIA, 2020





Men (aged 15+ years) living with HIV




Source: UNAIDS special analysis, 2021.

INVESTING TO END AIDS

The resources available for HIV responses in the region in 2020 were less than half (45%) of what is required to reach the region's resource targets for 2025. An average of US\$ 976 per person living with HIV was estimated to be available in 2020. A 2.2-fold increase in annual resources by 2025 is needed to expand HIV services sustainably and get on track to ending AIDS by 2030. The increase in needed resources is steeper in some countries in the region, which have lagged behind in specific areas of the response. In 2020, 90% of the total HIV resources were from domestic sources. There was a 46% growth in domestic resources between 2010 and 2020, with most of that growth happening between 2013 and 2018. It has since been followed by a flattening of HIV resources over the last few years. Given the current high HIV incidence rates (compared to 2025 targets), there is a need to bring down the unit prices of antiretroviral medicines and to strengthen spending on prevention programmes that are focused on key populations at higher risk of HIV infection.


RESOURCE AVAILABILITY FOR HIV, EASTERN EUROPE AND CENTRAL ASIA, 2010–2020, AND ESTIMATED RESOURCE NEEDS FOR HIV BY 2025



Source: UNAIDS financial estimates and projections, 2021 (http://hivfinancial.unaids.org/hivfinancialdashboards.html).

Note: The resource estimates are presented in constant 2019 US dollars.

YEAR-TO-YEAR CHANGE IN RESOURCE AVAILABILITY FOR HIV, EASTERN EUROPE AND CENTRAL ASIA, 2010– 2011 TO 2019–2020



Source: UNAIDS financial estimates, 2021 (http://hivfinancial.unaids.org/hivfinancialdashboards.html).

LAWS AND DOI ICIEC

PUNITIVE AND DISCRIMINATORY LAWS, EASTERN EUROPE AND CENTRAL ASIA, 2021

POLICIES	Criminalization of transgender people	Criminalization of sex work	Criminalization of same-sex sexual acts	Law allows for possession of a certain limited amount of drugs for personal use	Parental consent for adolescents to access HIV testing	Laws criminalizing the transmission of, non-disclosure of or exposure to HIV transmission	Laws or policies restricting the entry, stay and residence of people living with HIV	Mandatory HIV testing for marriage, work or residence permits or for certain groups
Albania	1	1	1	1	1	1		1
Armenia	1		1	1		1		1
Azerbaijan	2		2	2				1
Belarus	1		1					1
Bosnia and Herzegovina		5	9			10		
Georgia	1		1	1				1
Kazakhstan	1	6	1			1		1
Kyrgyzstan	1		1	1				1
Montenegro	2		2	2		10		2
Republic of Moldova	1		1	1				1
Russian Federation	2		9			10		2
Tajikistan	1		1	1				1
North Macedonia		8	9			10		
Turkmenistan	3		9			10		
Ukraine	1	1	1			1		1
Uzbekistan	2		9		1			1

Criminalization of transgender people

- Criminalized and/or prosecuted
- Neither criminalized nor prosecuted
- Data not available

Criminalization of sex work

- Any criminalization or punitive regulation of sex work
- Sex work is not subject to punitive regulations or is not criminalized
- Issue is determined/differs at the subnational level
- Data not available

Criminalization of same-sex sexual acts

- Death penalty
- Imprisonment (14 years–life, up to 14 years) or no penalty specified
- Laws penalizing same-sex sexual acts have been decriminalized or never existed, or no specific legislation
- Data not available

Law allows for possession of a certain limited amount of drugs for personal use

- No
- Yes
- Data not available

Parental consent for adolescents to access HIV testing

- Yes, for adolescents younger than 18
- Yes, for adolescents younger than 14 or 16
- Yes, for adolescents younger than 12
- No
- Data not available

Laws criminalizing the transmission of,

non-disclosure of or exposure to HIV transmission

- No, but prosecutions exist based on general criminal laws
- No
- Data not available

Laws or policies restricting the entry, stay and residence of people living with HIV

- Deport, prohibit short and/or long stay and require HIV testing or disclosure for some permits
- Prohibit short and/or long stay and require HIV testing or disclosure for some permits
- Require HIV testing or disclosure for some permits
- No restrictions
- Data not available

Mandatory HIV testing for marriage, work or residence permits or for certain groups

- Yes
- No
- Data not available

Sources

- 1. UNAIDS National Commitments and Policy Instrument, 2021 (see http://lawsandpolicies.unaids.org/).
- 2. UNAIDS National Commitments and Policy Instrument, 2019 (see http://lawsandpolicies.unaids.org/).
- 3. Chiam Z, Duffy S, González Gil M, Goodwin L, Mpemba Patel NT. Trans legal mapping report 2019: recognition before the law. Geneva: ILGA World; 2020.
- 4. Azerbaijan. Code of the Azerbaijan Republic on Administrative Violations, 2000 (https://www.legislationline.org/download/id/3439/file/Azerbaijan_Code%20on%20Administrative%20offences_2000_eng.pdf).
- 5. Bosnia and Herzegovina. The Criminal Code of Bosnia and Herzegovina (https://www.legislationline.org/download/id/8499/file/CC_BiH_am2018_eng.pdf).
- Kazkhstan. Criminal Code. Article 309 (https://www.legislationline.org/download/id/8260/file/Kazakhstan_CC_2014_2016_ en.pdf).
- 7. The Russian Federation. The Criminal Code of the Russian Federation. No. 63–Fz of 13 June 1996. Article 241 (http://www.wipo.int/edocs/lexdocs/laws/en/ru/ru080en.pdf).
- 8. North Macedonia. Law on Misdemeanors against the Public Order. Article 19 (https://www.refworld.org/pdfid/5aa126e07.pdf).
- 9. Mendos LR. State-sponsored homophobia, 2020. Geneva: International Lesbian, Gay, Bisexual, Trans and Intersex Association; December 2020 (https://ilga.org/downloads/ILGA_State_Sponsored_Homophobia_2019_light.pdf).
- 10. Global HIV Criminalisation Database [database]. Amsterdam: HIV Justice Network (https://www.hivjustice.net/global-hiv-criminalisation-database/).
- 11. Still not welcome: HIV-related travel restrictions. Geneva: UNAIDS, UNDP; 2019 (https://www.unaids.org/sites/default/files/media_asset/hiv-related-travel-restrictions-explainer_en.pdf).

Notes: A country is considered to have criminalized transgender persons if it uses the law to punish transgender individuals. Such a law may, for example, explicitly criminalize impersonation of the other gender, including cross-dressing. A country is considered to have any criminalization or punitive regulation of sex work if selling and/or buying sexual services is criminalized, ancillary activities associated with selling and/or buying sexual services are criminalized, profiting from organizing and/or managing sexual services is criminalized, and/or there are other punitive and/or administrative regulations of sex work.

ALBANIA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<200	<200	<100
	[<100- <200]	[<100-<200]	[<100- <200]
New HIV infections (0–14)			
	[]	[]	[–]
New HIV infections (women, 15+)	<100	<100	<100
	[<100– <100]	[<100–<100]	[<100–<100]
New HIV infections (men, 15+)	<100	<100	<100
	[<100-<100]	[<100- <200]	[<100-<100]
HIV incidence per 1000 population	0.04 [0.03–0.04]	0.04 [0.03–0.05]	0.03 [0.02–0.04]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100- <100]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100– <100]	[<100-<100]	[<100– <100]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100- <100]	[<100–<100]	[<100-<100]
People living with HIV			
People living with HIV (all ages)	630	1100	1400
	[540–740]	[920–1200]	[1200–1700]
People living with HIV (0-14)			
	[]	[]	[]
People living with HIV (women, 15+)	<200	<500	<500
	[<200- <200]	[<500-<500]	[<500–<500]
People living with HIV (men, 15+)	<500	790	1000
	[<500–560]	[630–940]	[830–1200]
HIV prevalence (15–49)	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No, but prosecutions exist based on general criminal laws
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	No
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	No

STIGMA AND DISCRIMINATION

Percentage of women aged 15–49 years who report discriminatory attitudes towards	 2018
people living with HIV	 68.5
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Percentage of people living with HIV who reported a health-care professional told	•••

others about their HIV status without their consent

VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EX	ЮΗ	\sim		ID	150
$ \sim$			1	иπ	

residence permits or for certain groups

EXI ENDITORES						
		Finar	ncing sources			
Dome	estic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 1 212 308 US\$ 5 614 403 Last available report: 2018 US\$ 146 666 US\$ 4 145 254

< 0.1%

35.1%

20.1%

18.1%

58%

6.3%

Not

Not

...

75.4%


42


11.2%


Yes


No

EPIDEMIC TRANSITION METRICS









Change in new **HIV** infections since 2010

Change in AIDS-255% related deaths since 2010

Incidence: 6.28 prevalence ratio

mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					2300
HIV prevalence	0.7%	2%	1.4%		0.5%
HIV testing and status awareness	30.6%	39.3%	50.8%		
Antiretroviral therapy coverage					
Condom use	86.7%	74%	54.5%		
Coverage of HIV prevention programmes		28.9%	77.9%		
Avoidance of health care because of stigma and discrimination	6%	9.4%	11.6%		
Expenditures in US\$ (2018)	34 470	51 159	339 788		37 357

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	8 [5–13]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION Adults aged 15+ years with unsuppressed viral load Knowledge of HIV prevention among young people aged 15-24 years (2017) — Women - Men Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49 years (2017) - Women — Men Women aged 15-49 years who have their demand for family planning satisfied by modern methods (2018) Men aged 15-49 years who are circumcised applicable Voluntary medical male circumcisions performed according to national standards applicable People who received PrEP at least once during the reporting period Harm reduction — Use of sterile injecting equipment at

last injection (2019)

therapy (2019) — Naloxone available (2021)

person who injects (2019)

— Coverage of opioid substitution

- Needles and syringes distributed per

- Safe injection rooms available (2021)

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION 2010 2020 ...% ...% Percentage of pregnant women living with HIV

461

45% [36-54%]

37% [30-44%]

accessing antiretroviral medicines	[%]	[%]
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]
Early infant diagnosis	% [–%]	% [–%]

76% [62-92%]

Men (15+)

ARMENIA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
lew HIV infections			
New HIV infections (all ages)	<500	<500	<500
	[<500-<500]	[<500-<500]	[<500–<500]
New HIV infections (0–14)	<100	<100	<100
	[<100–<100]	[<100-<100]	[<100–<100]
New HIV infections (women, 15+)	<100	<100	<200
	[<100– <200]	[<100-<200]	[<100-<200]
New HIV infections (men, 15+)	<200	<200	<500
	[<200-<500]	[<200–<200]	[<200–<500]
IIV incidence per 1000 population	0.1 [0.08–0.12]	0.09 [0.07–0.1]	0.11 [0.08–0.14]
AIDS-related deaths			
AIDS-related deaths (all ages)	<200	<200	<100
	[<200– <500]	[<200-<500]	[<100–<100]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100–<100]	[<100–<100]	[<100–<100]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100– <200]	[<100– <100]	[<100–<100]
AIDS-related deaths (men, 15+)	<200	<200	<100
	[<100-<200]	[<100-<200]	[<100-<100]
People living with HIV			
eople living with HIV (all ages)	3900	4000	4800
	[3300–4800]	[3500–4600]	[4200–5600]
eople living with HIV (0–14)	<100	<100	<100
	[<100–<100]	[<100-<100]	[<100–<100]
People living with HIV (women, 15+)	1400	1400	1700
	[1100–1600]	[1200–1600]	[1500–1900]
People living with HIV (men, 15+)	2500	2500	3000
	[2200–3100]	[2300–3000]	[2700–3600]
HIV prevalence (15–49)	0.2 [0.2–0.3]	0.2 [0.2–0.2]	0.2 [0.2–0.3]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes


Percentage of women and men aged 15–49 years who report discriminatory attitudes	2010	2016
towards people living with HIV (2016 refers to women only)	73	62.1
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		


STIGMA AND DISCRIMINATION


VIOLENCE


Proportion of ever-married or partnered	2016
women aged 15-49 years who experienced	
physical or sexual violence from a male	
intimate partner in the past 12 months	3.5

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020		US\$ 1 532 499		US\$ 1 297 074	US\$ 76 319	US\$ 3 391 340









Change in new
HIV infections = 17%
since 2010

Change in AIDSrelated deaths = since 2010 Incidence:
prevalence = 6.73
ratio

Incidence: mortality ratio*

* The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

.68%

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population	4600	16 100	9000			
HIV prevalence	0.6%	1.9%	1.9%	2%	0.3%	
HIV testing and status awareness	78.7%	74.3%	58.3%			
Antiretroviral therapy coverage						
Condom use	99.1%	69.7%	41.4%			
Coverage of HIV prevention programmes	96.9%		38.1%			
Avoidance of health care because of stigma and discrimination	9.3%	5.8%	36.4%			
Expenditures in US\$ (2020)	131 375	321 359	338 045	4117	21 932	

with HIV

Adults aged 15+ years with unsuppressed viral load

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)

People living with HIV who started TB

Cervical cancer screening of women living

People coinfected with HIV and hepatitis C

virus starting hepatitis C treatment (2019)

preventive therapy (2018)

HIV PREVENTION

0.1%

95

[66-130]

3%

0%

Knowledge of HIV prevention among young people aged 15–24 years (2016)

— Women	20.2%
— Men	12.5%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2016)

— Women	54.1%
— Men	82%

Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2016)

40.6%

14


No

Voluntary medical male circumcisions	Not
performed according to national standards	applicable

during the reporting period (2020)

Harm reduction


People who received PrEP at least once



person who injects (2020)	137
 Coverage of opioid substitution therapy (2020) 	7.8%
— Naloxone available (2021)	No

— Safe injection rooms available (2021)

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	28% [22–35%]	90% [74–100%]
Final vertical transmission rate including during breastfeeding	18.4% [16.6–20%]	8.8% [6.2–10.5%]
Early infant diagnosis	% [–%]	78.4% [64.5- >95%]

AZERBAIJAN

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	690	560	<500
	[<500–930]	[<500–720]	[<500–620]
New HIV infections (0–14)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100–<100]
New HIV infections (women, 15+)	<500	<200	<200
	[<200-<500]	[<200–<500]	[<100–<500]
New HIV infections (men, 15+)	<500	<500	<500
	[<500–590]	[<500-<500]	[<200–<500]
HIV incidence per 1000 population	0.08 [0.05–0.1]	0.06 [0.03–0.07]	0.04 [0.02–0.06]
AIDS-related deaths			
AIDS-related deaths (all ages)	<500	<500	<200
	[<500–760]	[<200–680]	[<100-<200]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100–<100]	[<100–<100]	[<100- <100]
AIDS-related deaths (women, 15+)	<200	<200	<100
	[<200-<500]	[<100-<500]	[<100-<100]
AIDS-related deaths (men, 15+)	<500	<200	<100
	[<200– <500]	[<100-<500]	[<100- <200]
People living with HIV			
People living with HIV (all ages)	8600	9100	9900
	[6200–12 000]	[7000–13 000]	[7600–13 000]
People living with HIV (0–14)	<200	<200	<200
	[<100-<500]	[<100-<200]	[<100- <200]
eople living with HIV (women, 15+)	3200	3300	3600
	[2200–4300]	[2400–4300]	[2600–4400]
eople living with HIV (men, 15+)	5200	5700	6200
	[4000–7700]	[4400–8100]	[4900–8400]
HIV prevalence (15–49)	0.1 [<0.1–0.2]	0.1 [0.1–0.2]	0.1 [<0.1–0.2]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	Require HIV testing or disclosure for some permits
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	•••	
and the second s	•••	•••
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		•••


Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent


VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 14 215 892 US\$ 6 177 985 US\$ 233 483 US\$ 20 627 360 Last available report: 2014









Change in new **HIV** infections since 2010

Change in AIDSrelated deaths since 2010

Incidence: 4.11 prevalence ratio

mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	31 900		60 300		
HIV prevalence	3.5%	1.1%	6.9%		1.9%
HIV testing and status awareness	16.0%	43.6%	18.6%		
Antiretroviral therapy coverage					91.8%
Condom use	53.5%	68.8%	11.2%		
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	85 [57 –1 20]
People living with HIV who started TB preventive therapy (2018)	65.1%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	<0.1%
K. I. I (110V	

Knowledge of HIV prevention among young people aged 15-24 years (2011)

— Women	14.9%
— Men	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49 year

47 years	
— Women	
— Men	

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

Not

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION			
	2010	2020	
Percentage of pregnant women living with HIV accessing antiretroviral medicines	12% [8–18%]	97% [63–100%]	
Final vertical transmission rate including during breastfeeding	32.1% [29.8–33.8%]	13.9% [10.6–19.6%]	
Early infant diagnosis	15.5% [11.4–21.9%]	% [–%]	

Harm reduction

 Use of sterile injecting equipment at last injection (2018) 	80.6%
 Needles and syringes distributed per person who injects (2020) 	57
 Coverage of opioid substitution 	1.00/

— Use of sterile injecting equipment at

- Safe injection rooms available (2021)

 Coverage of opioid substitution therapy (2020) 	1.2%
— Naloxone available (2021)	

BELARUS

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	2100	2100	1300
	[1500–2700]	[1500–2900]	[770–2000]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)	650	650	<500
	[<500–840]	[<500–850]	[<500–590]
New HIV infections (men, 15+)	1500	1500	850
	[1100–1900]	[1000–1900]	[510–1400]
HIV incidence per 1000 population	0.22 [0.16–0.29]	0.23 [0.16–0.3]	0.13 [0.08–0.21]
AIDS-related deaths			
AIDS-related deaths (all ages)	<200	<500	<200
	[<200-<500]	[<200–540]	[<200-<500]
AIDS-related deaths (0-14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100-<100]	[<100– <100]	[<100-<100]
AIDS-related deaths (men, 15+)	<200	<500	<200
	[<100-<500]	[<200-<500]	[<100-<200]
People living with HIV			
People living with HIV (all ages)	14 000	23 000	28 000
	[11 000–18 000]	[18 000–29 000]	[22 000–37 000]
People living with HIV (0-14)			
	[]	[]	[]
People living with HIV (women, 15+)	4400	7400	9500
	[3400–5500]	[5800–9500]	[7200–13 000]
People living with HIV (men, 15+)	9600	15 000	19 000
	[7600–12 000]	[12 000–20 000]	[15 000–25 000]
HIV prevalence (15–49)	0.2 [0.2–0.3]	0.4 [0.3–0.5]	0.5 [0.4–0.6]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	Yes

residence permits or for certain groups

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49


years who report discriminatory attitudes towards people living with HIV	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their	•••


VIOLENCE


consent


Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2017		US\$ 16 302 125		US\$ 4 656 596	US\$ 41 526	US\$ 21 000 247









Change in new HIV infections since 2010

Change in AIDSrelated deaths since 2010

Incidence: 4.48 prevalence ratio

mortality ratio*


* The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	18 600	32 000	80 000		
HIV prevalence	9.7%	5.8%	22.7%		8.5%
HIV testing and status awareness	83.1%	76.2%	78.5%		
Antiretroviral therapy coverage			40.5%		84.4%
Condom use	88.6%	76.8%	46.2%		
Coverage of HIV prevention programmes	73.5%	51.7%	67.1%		
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2017)	398 774	287 004	1 239 188		106 287

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	230 [170–300]
People living with HIV who started TB preventive therapy (2018)	0%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2018)	89.1%

HIV TESTING AND TREATMENT CASCADE



	their status	treatment	virally suppressed
All ages	81% [63–107%]	66% [52–88%] 18 765	59% [47–79%]
Children (0-14)	% [%]	% [%] 	% [%]
Women (15+)	102% [78–135%]	81% [62–107%] 7657	79% [60–104%]
Men (15+)	70% [56–93%]	59% [47–78%] 10 928	49% [39–65%]

Estimated number of incident tuberculosis cases among people living with HIV (2018)	230 [170–300]
People living with HIV who started TB preventive therapy (2018)	0%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2018)	89.1%

Women (15+	-)	102% [7	8–135%]	819 765	% [62–′ 57	107%]	79%	[60–10	4%]	
Children (0-	14)	% [%]	%		%]	% [–%]	
All ages		81% [63	–107%]		% [52–8 765	38%]	59%	[47–79	%]	
0		ing with HIV their status	/ who know s		iving with reatment		People livi viral	ng with H ly suppre		0%
Number of 10 000										25%
MH 25 000 with a 20 000 look with 15 000 look with 5 000 look			2000			first and second 90: 4200			reaching all three 90s: 3900	50%
20 000			reaching the first 90: 2600		_	Gap to reaching the			Gap to	75%
≩ 25 000			Gap to							

HIV PREVENTION

THE TREVEITHOR	
Adults aged 15+ years with unsuppressed viral load	0.1%
Knowledge of HIV prevention among young people aged 15–24 years (2012)	
— Women	56.1%
— Men	50.9%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

— Men

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]
Early infant diagnosis	48.8% [39.9–62.8%]	% [–%]

 Use of sterile injecting equipment at last injection (2017) 	87.9%
 Needles and syringes distributed per person who injects (2020) 	43
 Coverage of opioid substitution therapy (2019) 	3.7%

— Naloxone available (2021)	Yes
— Safe injection rooms available (2021)	No

GEORGIA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	520	630	680
	[<500–570]	[540–720]	[<500 <u>–</u> 850]
New HIV infections (0–14)	<100	<100	<100
	[<100-<100]	[<100– <100]	[<100–<100]
New HIV infections (women, 15+)	<200	<200	<500
	[<200–<200]	[<200–<500]	[<200–<500]
New HIV infections (men, 15+)	<500	<500	<500
	[<500-<500]	[<500–<500]	[<500–590]
HIV incidence per 1000 population	0.13 [0.12–0.14]	0.16 [0.13–0.18]	0.17 [0.12–0.21]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100-<100]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100– <100]	[<100-<100]	[<100-<100]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100–<100]	[<100– <100]	[<100–<100]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100-<100]	[<100- <100]	[<100-<100]
People living with HIV			
People living with HIV (all ages)	3100	5700	8400
	[2800–3400]	[5300–6200]	[7300–9300]
People living with HIV (0-14)	<100	<100	<100
	[<100-<100]	[<100– <100]	[<100–<200]
eople living with HIV (women, 15+)	950	1800	2600
	[860–1000]	[1600–1900]	[2300–2900]
People living with HIV (men, 15+)	2100	3900	5600
	[1900–2300]	[3600–4200]	[4900–6300]
HIV prevalence (15–49)	0.1 [0.1–0.1]	0.2 [0.2–0.3]	0.3 [0.3–0.4]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a non-criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No

US\$ 136 306

Mandatory HIV testing for marriage, work or residence permits or for certain groups

Last available report: 2020

STIGMA AND DISCRIMINATION

Percentage of women aged 15–49 years who report discriminatory attitudes towards	•••	2018
people living with HIV		58.5
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their		

US\$ 255 854

US\$ 15 920 176

VIOLENCE


consent


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


US\$ 2 813 114


EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 12 313 129









Change in new
HIV infections = 30%
since 2010

Change in AIDSrelated deaths since 2010

353%

prevalence = 8.12
ratio

Incidence: mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••	18 500		•••	9100
HIV prevalence	0.9%	16.2%	2.3%		0.4%
HIV testing and status awareness		55.5%			
Antiretroviral therapy coverage					
Condom use	93.4%	72.5%	36.5%		
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2020)	456 300	223 113	4 788 417	5606	40 197

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	66 [46–90]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2018)	28.6%

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	

— Men

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

— Women

therapy (2018)

— Naloxone available (2021)

- Safe injection rooms available (2021)

— Men

Women aged 15–49 years who have their demand for family planning satisfied by

demand for family planning satisfied by modern methods		
Men aged 15–49 years who are circumcised	Not applicable	
Voluntary medical male circumcisions performed according to national standards	Not applicable	
People who received PrEP at least once during the reporting period (2020)	216	
Harm reduction		
 Use of sterile injecting equipment at last injection (2017) 	90.4%	
 Needles and syringes distributed per person who injects (2020) 	70	
— Coverage of opioid substitution	48.7%	

Yes

No

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

3773

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	53% [47–60%]	53% [47–59%]
Final vertical transmission rate including during breastfeeding	18.3% [16.9–19.4%]	19.2% [17–20.8%]
Early infant diagnosis	%	59.2% [53.6–66.2%]

KAZAKHSTAN


COUNTRY DATA


EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	2100	2400	3700
	[1300–2800]	[1500–3300]	[2200–4900]
New HIV infections (0–14)	<100	<100	<100
	[<100–<100]	[<100- <100]	[<100–<200]
New HIV infections (women, 15+)	630	730	1100
	[<500–830]	[<500–970]	[700–1500]
New HIV infections (men, 15+)	1400	1700	2500
	[880–1900]	[1000–2200]	[1500–3300]
HIV incidence per 1000 population	0.13 [0.08–0.17]	0.14 [0.08–0.19]	0.19 [0.12–0.26]
AIDS-related deaths			
AIDS-related deaths (all ages)	560	<500	<500
	[<500–820]	[<200–660]	[<200–<500]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100– <100]	[<100-<100]	[<100–<100]
AIDS-related deaths (women, 15+)	<200	<100	<100
	[<100- <500]	[<100– <200]	[<100-<100]
AIDS-related deaths (men, 15+)	<500	<500	<200
	[<500–530]	[<200–<500]	[<100-<500]
People living with HIV			
People living with HIV (all ages)	15 000	22 000	35 000
	[9500–20 000]	[14 000–28 000]	[23 000–46 000]
People living with HIV (0–14)	<500	<500	550
	[<500– <500]	[<500–540]	[<500–740]
People living with HIV (women, 15+)	4600	6800	11 000
	[2900–6100]	[4500–9000]	[7200–15 000]
People living with HIV (men, 15+)	10 000	14 000	23 000
	[6400–13 000]	[9500–19 000]	[15 000–30 000]
HIV prevalence (15–49)	0.1 [<0.1–0.2]	0.2 [0.1–0.3]	0.3 [0.2–0.4]


LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	Require HIV testing or disclosure for some permits
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No


STIGMA AND DISCRIMINATION	NC	
Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV (2015 refers to women only)	2011 64.8	2015 71.9
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		2015 17.6
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		2015 22.9
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months		•••

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020		US\$ 35 350 963	US\$ 84 296	US\$ 1 418 307	US\$ 837 123	US\$ 37 690 689









Change in new
HIV infections = 73%

Change in AIDSrelated deaths = -62% since 2010 Incidence:
prevalence = 10.38
ratio

Incidence: mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population	21 500					
HIV prevalence	1.4%	6.5%	8.3%		4.1%	
HIV testing and status awareness	98.7%	99.0%	77.9%			
Antiretroviral therapy coverage			49.5%			
Condom use	93.5%	80.4%	57.2%			
Coverage of HIV prevention programmes	89.6%		63.1%			
Avoidance of health care because of stigma and discrimination						
Expenditures in US\$ (2020)	1 184 720	597 578	1 915 728		4214	

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	730 [470–1000]
People living with HIV who started TB preventive therapy (2018)	53.1%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	38%

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION

Adults	aged	15+	years	with	unsuppressed
viral lo	ad				

0.1%

Knowledge of HIV prevention among young people aged 15–24 years (2015)

_	Women	26.7%
_	Men	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

— Women

— Men

...

Not

No

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]
Final vertical transmission rate including during breastfeeding	24% [23.1–31.8%]	10.6% [7–13.8%]
Early infant diagnosis	93.8% [77.2– >95%]	% [%]

Harm reduction

 Use of sterile injecting equipment at last injection (2020) 	62.2%
 Needles and syringes distributed per person who injects (2020) 	132
 Coverage of opioid substitution therapy (2020) 	0.38%
— Naloxone available (2021)	No

- Safe injection rooms available (2021)

KYRGYZSTAN


COUNTRY DATA


EPIDEMIC ESTIMATES			
	2010	2015	2020
lew HIV infections			
New HIV infections (all ages)	640	680	710
	[580–700]	[600–750]	[630–800]
lew HIV infections (0–14)	<100	<100	<100
	[<100-<100]	[<100- <100]	[<100-<100]
lew HIV infections (women, 15+)	<200	<200	<500
	[<200- <500]	[<200– <500]	[<200-<500]
New HIV infections (men, 15+)	<500	<500	<500
	[<500-<500]	[<500–520]	[<500–550]
IIV incidence per 1000 population	0.12 [0.11–0.13]	0.11 [0.1–0.13]	0.11 [0.1–0.12]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100–<200]
NDS-related deaths (0–14)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100–<100]
NIDS-related deaths (women, 15+)	<100	<100	<100
	[<100–<100]	[<100–<100]	[<100– <100]
NIDS-related deaths (men, 15+)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100-<100]
eople living with HIV			
People living with HIV (all ages)	3800	6400	9200
	[3500–4000]	[6000–6900]	[8400–9900]
eople living with HIV (0-14)	<200	<500	<500
	[<200–<200]	[<500-<500]	[<500-<500]
eople living with HIV (women, 15+)	1100	1900	2800
	[960–1100]	[1800–2000]	[2600–3100]
eople living with HIV (men, 15+)	2600	4300	6100
	[2400–2800]	[4000–4600]	[5500–6600]
HV prevalence (15–49)	0.1 [0.1–0.1]	0.2 [0.2–0.2]	0.2 [0.2–0.2]


LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	The law allows possession of a certain amount of drugs
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	Prohibit short- and/or long-stay and require HIV testing or disclosure for some permits
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No


Percentage of women and men aged 15–49 years who report discriminatory attitudes	2014	2018
towards people living with HIV (2018 refers to women only)	73.7	67
Percentage of people living with HIV denied		2015
the last 12 months		9.1
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their		2020
consent		19.5
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months		•••

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020		US\$ 2 131 199	US\$ 1 965 110	US\$ 5 446 870	US\$ 1 208 083	US\$ 10 751 263









Change in new **HIV** infections since 2010

Change in AIDS-4% related deaths since 2010

Incidence: 7.69 prevalence ratio

mortality ratio*

^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population	•••			•••		
HIV prevalence	2%	6.6%	14.3%		11.3%	
HIV testing and status awareness	57.5%					
Antiretroviral therapy coverage						
Condom use	97.2%		58.8%			
Coverage of HIV prevention programmes		37.8%	40.4%			
Avoidance of health care because of stigma and discrimination						
Expenditures in US\$ (2020)	185 393	455 285	1 059 630	16 980	88 377	

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	220 [170–260]
People living with HIV who started TB preventive therapy (2018)	80.2%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	25%

HIV TESTING AND TREATMENT CASCADE



	their status	treatment	virally suppressed
All ages	76% [70–82%]	48% [44–52%] 4442	43% [39–46%]
Children (0-14)	128% [120–135%]	113% [107–120%] 320	103% [98–110%]
Women (15+)	96% [88–105%]	67% [61–73%] 1901	60% [55–66%]
Men (15+)	65% [59–70%]	36% [33–39%] 2221	32% [29–35%]

viral load

virus starting nepatitis & treatment (2017)	
HIV PREVENTION	
Adults aged 15+ years with unsuppressed	0.1%

0.1%

No

Knowledge of HIV prevention among young people aged 15-24 years (2014)

— Women	19.8%
— Men	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49 years (2012)

— Women	28.4%
— Men	78.3%

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised (2012)	Not applicable
Voluntary medical male circumcisions	Not applicable

performed according to national standards	applicable
People who received PrEP at least once during the reporting period (2020)	27

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	79% [69–88%]	94% [84–100%]
Final vertical transmission rate including during breastfeeding	33.6% [32–35.6%]	7.4% [6.3–8.6%]
Early infant diagnosis	% [–%]	91% [81.8– >95%]

Harm reduction

 Use of sterile injecting equipment at last injection (2017) 	80.9%
 Needles and syringes distributed per person who injects (2020) 	176
 Coverage of opioid substitution therapy (2018) 	4.4%
— Naloxone available (2021)	Yes

- Safe injection rooms available (2021)

MONTENEGRO


COUNTRY DATA


EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<100	<100	<100
	[–]	[-]	[-]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)	<100	<100	<100
	[–]	[–]	[–]
New HIV infections (men, 15+)	<100	<100	<100
	[–]	[–]	[–]
HIV incidence per 1000 population	0.04 [0.01–0.09]	0.04 [0.01–0.08]	0.04 [<0.01–0.12]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<100
	[–]	[–]	[–]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[–]	[–]	[–]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[–]	[–]	[–]
People living with HIV			
People living with HIV (all ages)	<200	<500	<500
	[–0]	[–0]	[–0]
People living with HIV (0–14)			
	[]	[]	[]
People living with HIV (women, 15+)	<100	<100	<100
	[0–0]	[0–0]	[0–0]
People living with HIV (men, 15+)	<200	<500	<500
	[0–0]	[0–0]	[0–0]
HIV prevalence (15–49)	<0.1 []	<0.1 [–]	<0.1 []


LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes


Percentage of women and men aged 15–49 years who report discriminatory attitudes	2013	2018
towards people living with HIV (2018 refers to women only)	52	52.3
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		•••
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months		

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2009				US\$ 830 121		US\$ 830 121









Change in new 4% **HIV** infections since 2010

Change in AIDS-0% related deaths since 2010

Incidence: 6.38 prevalence ratio

mortality ratio*


* The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••				
HIV prevalence			0.5%		
HIV testing and status awareness			24.1%		
Antiretroviral therapy coverage					
Condom use			33.3%		
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination			30.8%		
Expenditures in US\$					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	1 [0–3]
People living with HIV who started TB preventive therapy (2018)	0%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	100%

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years (2013)	
— Women	47.7%
— Men	36.9%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable	
Voluntary medical male circumcisions performed according to national standards	Not applicable	
People who received PrEP at least once during the reporting period		
Harm reduction		

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

2010 2020				
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [%]		
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]		
Early infant diagnosis	% [–%]	% [–%]		

- Men

Use of sterile injecting equipment at last injection (2020)	93.8%
 Needles and syringes distributed per person who injects (2020) 	74
— Coverage of opioid substitution	

 Coverage of opioid substitution
therapy
— Naloxone available (2021)


- Safe injection rooms available (2021)

— Use of sterile injecting equipment at

THE REPUBLIC OF NORTH MACEDONIA

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					2300
HIV prevalence	0%	5.4%	0%		0%
HIV testing and status awareness	49.1%		37.4%		
Antiretroviral therapy coverage					
Condom use	90%	51.3%	39.8%		
Coverage of HIV prevention programmes	80.9%	52.3%	67%		
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2019)	121 789	100 929	1 159 915		

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	
People living with HIV who started TB preventive therapy (2018)	0%
Women who tested positive for HIV among those screened for cervical cancer (programme data) (2019)	100%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	0%

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	

49 years

— Women

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

— Naloxone available (2021)

- Safe injection rooms available (2021)

— Men

modern methods	
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction	
 Use of sterile injecting equipment at last injection (2017) 	94.6%
 Needles and syringes distributed per person who injects (2019) 	66
 Coverage of opioid substitution therapy (2019) 	30.6%

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2019		US\$ 2 177 200		US\$ 109 812		US\$ 2 287 012

•••

COUNTRY DATA

LAWS AND POLICIES		STIGMA AND DISCRIMINATION	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission		Percentage of women and men aged 15–49 years who report discriminatory attitudes	
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work	towards people living with HIV	
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Drug use or possession for personal use is an offence		Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their	
Criminalization of transgender people		consent	
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE	
Parental consent for adolescents to access HIV testing		Proportion of ever-married or partnered women aged 15–49 years who experienced	
Spousal consent for married women to access sexual and reproductive health services		physical or sexual violence from a male intimate partner in the past 12 months	
Mandatory HIV testing for marriage, work or residence permits or for certain groups			

REPUBLIC OF MOLDOVA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	1400	1000	740
	[990–2000]	[700–1400]	[510–1000]
New HIV infections (0–14)	<100	<100	<100
	[<100–<100]	[<100- <100]	[<100-<100]
New HIV infections (women, 15+)	<500	<500	<500
	[<500–620]	[<500–<500]	[<200-<500]
New HIV infections (men, 15+)	980	680	<500
	[680–1400]	[<500–940]	[<500–680]
HIV incidence per 1000 population	0.4 [0.27–0.55]	0.31 [0.21–0.42]	0.24 [0.16–0.33]
AIDS-related deaths			
AIDS-related deaths (all ages)	620	590	<500
	[<500–900]	[<500–870]	[<500–570]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100–<100]	[<100-<100]	[<100-<100]
AIDS-related deaths (women, 15+)	<200	<200	<100
	[<200–<500]	[<100–<200]	[<100-<200]
AIDS-related deaths (men, 15+)	<500	<500	<500
	[<500 <u></u> -600]	[<500–670]	[<500–<500]
People living with HIV			
People living with HIV (all ages)	13 000	14 000	14 000
	[11 000–16 000]	[12 000–17 000]	[12 000–18 000]
People living with HIV (0–14)	<200	<200	<200
	[<100-<200]	[<200–<200]	[<200-<200]
People living with HIV (women, 15+)	4300	4900	5300
	[3600–5000]	[4100–5800]	[4400–6300]
eople living with HIV (men, 15+)	8900	9300	9000
	[7700 –1 1 000]	[8100–11 000]	[7800–11 000]
HIV prevalence (15–49)	0.6 [0.5–0.7]	0.7 [0.6–0.8]	0.8 [0.6–0.9]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	The law allows possession of a certain amount of drugs
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	No

residence permits or for certain groups

Last available report: 2019


STIGMA AND DISCRIMINATION


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV		
	•••	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		•••


VIOLENCE


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2019		US\$ 5 129 168		US\$ 2 929 515	US\$ 289 919	US\$ 8 709 970









Change in new **HIV** infections since 2010

Change in AIDSrelated deaths since 2010

Incidence: 5.08 prevalence ratio

Incidence: mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	15 800	14 600	27 500		
HIV prevalence	2.7%	11.4%	11.4%		3.8%
HIV testing and status awareness	63.5%	47.9%	49.7%		
Antiretroviral therapy coverage			70.3%		
Condom use	95.6%	59.7%	40.6%		
Coverage of HIV prevention programmes	60.7%	63.2%	36.5%		
Avoidance of health care because of stigma and discrimination	5.1%	17.3%	18.8%		
Expenditures in US\$ (2019)	358 699	216 652	1 194 391		117 590

HIV			

Estimated number of incident tuberculosis cases among people living with HIV (2018)	300 [240–360]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	
HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.3%
Knowledge of HIV prevention among young people aged 15–24 years (2012)	

36%

28.1%

Yes

No

— Men Condom use at last sex with a non-marital,

non-cohabiting partner among people aged 15-49 years

— Women

— Women

— Men

— Naloxone available (2021)

- Safe injection rooms available (2021)

Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	192
Harm reduction	
 Use of sterile injecting equipment at last injection (2020) 	94.7%
 Needles and syringes distributed per person who injects (2020) 	82
 Coverage of opioid substitution therapy (2020) 	5.5%

3478 **ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION**

	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	100% [79–100%]	87% [68–100%]		
Final vertical transmission rate including during breastfeeding	12.4% [9–15.3%]	12.3% [8.7–14.7%]		
Early infant diagnosis	70.6% [59.9–82.5%]	89.9% [74.7- >95%]		

RUSSIAN FEDERATION

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population			•••	•••	
HIV prevalence			26%		
HIV testing and status awareness					
Antiretroviral therapy coverage					
Condom use					
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2017)	230 355	196 265	881 820	17 440	

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES	
Estimated number of incident tuberculosis cases among people living with HIV (2018)	16 000 [10 000 –22 000]
People living with HIV who started TB preventive therapy (2018)	96.9%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49

49 years	
— Women	
— Men	

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction	

	reduction
_	- Use of sterile injecting equipment a
	last injection

— Nee	dles and syrii	nges distri	buted per
pers	on who injec	ts	

—	Coverage of opioid substitution
	therapy

— Naloxone available (2021)	
— Safe injection rooms available (2021)	

EXPENDITURES						
		Finar	cing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2017	US\$ 7 966 202	US\$ 694 996 044				US\$ 703 043 888

•••

COUNTRY DATA

LAWS AND POLICIES		STIGMA AND DISCRIMINATION
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes	Percentage of women and men aged 15–49 years who report discriminatory attitudes
Criminalization of sex work among consenting adults		towards people living with HIV
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months
Drug use or possession for personal use is an offence		Percentage of people living with HIV who reported a health-care professional told
Criminalization of transgender people	Neither criminalized nor prosecuted	others about their HIV status without their consent
Laws or policies restricting the entry, stay and residence of people living with HIV	Yes	VIOLENCE
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years	Proportion of ever-married or partnered women aged 15–49 years who experienced
Spousal consent for married women to access sexual and reproductive health services	No	physical or sexual violence from a male intimate partner in the past 12 months
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes	

TAJIKISTAN

COUNTRY DATA


EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	1400	1300	810	
	[1300–1600]	[1100–1500]	[560–1100]	
New HIV infections (0–14)	<200	<200	<200	
	[<200-<200]	[<200–<500]	[<200-<500]	
New HIV infections (women, 15+)	<500	<500	<500	
	[<500–540]	[<500–500]	[<200– <500]	
New HIV infections (men, 15+)	780	680	<500	
	[700–900]	[590–800]	[<500–520]	
HIV incidence per 1000 population	0.19 [0.17–0.21]	0.15 [0.14–0.18]	0.09 [0.06–0.11]	
AIDS-related deaths				
AIDS-related deaths (all ages)	<200	<500	<500	
	[<100-<200]	[<500-<500]	[<500-<500]	
AIDS-related deaths (0–14)	<100	<200	<200	
	[<100-<100]	[<100-<200]	[<200–<200]	
AIDS-related deaths (women, 15+)	<100	<100	<100	
	[<100-<100]	[<100-<100]	[<100–<100]	
AIDS-related deaths (men, 15+)	<100	<200	<200	
	[<100-<100]	[<100-<200]	[<100-<200]	
People living with HIV				
People living with HIV (all ages)	5200	11 000	14 000	
	[4600–5700]	[10 000–12 000]	[13 000–16 000]	
People living with HIV (0-14)	<500	620	1100	
	[<200-<500]	[570–650]	[960–1200]	
People living with HIV (women, 15+)	1900	3900	5300	
	[1700–2000]	[3700–4200]	[4800–5900]	
People living with HIV (men, 15+)	3200	6300	7900	
	[2800–3500]	[5800–6800]	[7200–9000]	
HIV prevalence (15–49)	0.1 [0.1–0.1]	0.2 [0.2–0.2]	0.2 [0.2–0.3]	


LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	The law allows possession of a certain amount of drugs
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No


STIGMA AND DISCRIMINATION	ON	
Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	2017	2020
(2020 refers to women only)	75.3	47
Percentage of people living with HIV denied health services because of their HIV status in		2015
the last 12 months		21.1
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their		2015
consent		20.1
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male	2012	2017
intimate partner in the past 12 months	15.2	19


EXPENDITURES						
Financing sources						
Domestic private Domestic public International: International: International: Total PEPFAR Global Fund all others						

US\$ 574 157 US\$ 2 860 680 US\$ 11 969 103 Last available report: 2020









Change in new HIV infections since 2010

Change in AIDS-148% related deaths since 2010

Incidence: 5.70 prevalence ratio

mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population	17 500					
HIV prevalence	2.9%	2.3%	12.1%		3.1%	
HIV testing and status awareness	98.8%					
Antiretroviral therapy coverage	81.5%		64.2%		97.4%	
Condom use	76.6%	78.5%	36.6%	80.5%		
Coverage of HIV prevention programmes	47.3%		67.2%			
Avoidance of health care because of stigma and discrimination						
Expenditures in US\$						

HIV	MO	RBI	113

Estimated number of incident tuberculosis cases among people living with HIV (2018)	310 [230–400]
People living with HIV who started TB preventive therapy (2018)	5.7%
Cervical cancer screening of women living with HIV (2017)	40.9%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	0%

HIV TESTING AND TREATMENT CASCADE



2 2 000				0%
0	People living with HIV who know their status	People living with HIV on treatment	People living with HIV who are virally suppressed	0 /0
All ages	66% [60–75%]	56% [51–63%] 7960	48% [44–54%]	
Children (0-1	4) 85% [77–96%]	83% [75–93%] 876	72% [65–80%]	
Women (15+)	68% [62–77%]	62% [55–69%] 3242	54% [49–61%]	
Men (15+)	63% [56–71%]	49% [44–55%] 3842	41% [37–47%]	

Estimated number of incident tuberculosis cases among people living with HIV (2018)	310 [230–400]
People living with HIV who started TB preventive therapy (2018)	5.7%
Cervical cancer screening of women living with HIV (2017)	40.9%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	0%

Women ((15+)	68% [62–77%]	62% [55– 3242	69%]	54%	[49–61%	6]	
Children	(0–14)	85% [77–96%]	83% [75– 876	93%]	72%	[65–80%	[6]	
All ages		66% [60–75%]	56% [51– 7960	63%]	48%	[44–54%	[5]	
	-	ple living with HIV who know their status	People living wit treatmer		People livii viral	ng with HIV ly suppress		070
≥ 20	000							0%
Number of people living with HIV	000							25%
f people	000			second 90: 3600			three 90s: 3500	50%
ivin 8 (000	first 90: 3400		reaching th first and	е		Gap to reaching all	50%
₹ 10 (000	Gap to reaching t	he	Gap to				75%
≥ 120	000		_					

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	0.1%
Knowledge of HIV prevention among young people aged 15–24 years (2017)	
— Women	13.8%
— Men	
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2017)	
147	40 (0)

Men aged 15-49 years who are circumcised

— Women	42.6%
— Men	

Women aged 15-49 years who have their demand for family planning satisfied by 52.2% modern methods (2017)

	аррисаріе
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	10

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION			
	2010	2020	
Percentage of pregnant women living with HIV accessing antiretroviral medicines	17% [15–19%]	33% [27–39%]	
Final vertical transmission rate including during breastfeeding	61.4% [57.2–65.9%]	25.7% [23.9–27.7%]	
Early infant diagnosis	8% [6.1–10.4%]	27.6% [22.9–33.1%]	

Harm reduction

Use of sterile injecting equipment at last injection (2018)	55.6%
 Needles and syringes distributed per person who injects (2018) 	200
 Coverage of opioid substitution therapy (2018) 	2.7%
— Naloxone available (2021)	Yes

No

— Safe injection rooms available (2021)

UKRAINE

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	12 000	11 000	9300
	[8500–16 000]	[8500–16 000]	[6500–14 000]
New HIV infections (0–14)	<500	<500	<200
	[<500–960]	[<500–690]	[<100- <500]
New HIV infections (women, 15+)	5200	4800	3900
	[3700–7200]	[3600–6700]	[2800–5800]
New HIV infections (men, 15+)	6200	6400	5200
	[4500–8400]	[4600–8700]	[3600–8100]
HIV incidence per 1000 population	0.26 [0.19–0.35]	0.25 [0.19–0.36]	0.21 [0.15–0.32]
AIDS-related deaths			
AIDS-related deaths (all ages)	13 000	7400	3100
	[10 000–17 000]	[4800–11 000]	[2100–4600]
AIDS-related deaths (0–14)	<500	<500	<100
	[<500–640]	[<200-<500]	[<100-<500]
AIDS-related deaths (women, 15+)	5700	3200	1300
	[4400–7300]	[2000–4800]	[850–2000]
AIDS-related deaths (men, 15+)	6900	3900	1700
	[5500–8900]	[2600–5700]	[1100–2500]
People living with HIV			
People living with HIV (all ages)	230 000	230 000	260 000
	[180 000–280 000]	[190 000–290 000]	[210 000–330 000]
People living with HIV (0–14)	3800	3400	2900
	[2800–5500]	[2400–5600]	[2000–5100]
People living with HIV (women, 15+)	100 000	110 000	120 000
	[85 000 –1 30 000]	[88 000 –1 30 000]	[98 000 –1 50 000]
People living with HIV (men, 15+)	120 000	120 000	130 000
	[96 000 –1 50 000]	[98 000–150 000]	[110 000–170 000]
HIV prevalence (15–49)	0.9 [0.7–1.1]	0.9 [0.7–1.1]	1 [0.8–1.3]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	Prohibit short- and/or long-stay and require HIV testing or disclosure for some permits
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	

residence permits or for certain groups

66.6
2013
11
2020
17.3

STIGMA AND DISCRIMINATION


VIOLENCE


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES	
	Financing sources


	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
1	LIC¢ 247 400	LIC¢ 42 172 0/0	LIC\$ 17 704 F/7	LIC¢ 27 27/ 770	LIC¢ 2 247 402	LIC¢ 100 000 0/2

Last available report: 2019 US\$ 347 498 US\$ 42 172 060 US\$ 16 704 566 US\$ 37 276 770 US\$ 2 246 403 US\$ 100 008 963









Change in new
HIV infections = -21%
since 2010

Change in AIDS-related deaths = -76% since 2010

Incidence:
prevalence = 3.60
ratio


Incidence: mortality ratio*

^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	86 600	179 400	350 300	8200	48 700
HIV prevalence	5.2%	7.5%	20.9%	1.7%	7.2%
HIV testing and status awareness	58.2%	39.2%	51.0%	52.7%	
Antiretroviral therapy coverage	29%	46.3%	37.9%		87.4%
Condom use	93.9%	77.7%	43.4%	79.4%	
Coverage of HIV prevention programmes				22.8%	
Avoidance of health care because of stigma and discrimination	16.3%	9.7%	10.3%	8.4%	
Expenditures in US\$ (2019)	807 267	989 887	7 408 451	69 229	933 295

HIV COMORBIDITIES	
Estimated number of incident tuberculosis cases among people living with HIV (2018)	8200 [5300 –12 000]
People living with HIV who started TB preventive therapy (2018)	60.6%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C	4.4%

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.3%
Knowledge of HIV prevention among young people aged 15–24 years (2014)	
— Women	21%
— Men	25%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2017)	
— Women	
— Men	82.9%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
	Not

	their status	treatment	virally suppressed
All ages	69% [56–87%]	57% [46–72%] 146 488	53% [43–67%]
Children (0-14)	99% [71–175%]	92% [65–162%] 2655	84% [59–147%]
Women (15+)	67% [55–84%]	57% [46–71%] 67 993	54% [44–67%]
Men (15+)	70% [57–87%]	56% [46–71%] 75 840	52% [43–66%]

Men aged 15–49 years who are circumcised	applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	2258
Harm reduction	
 Use of sterile injecting equipment at last injection (2017) 	96.6%
 Needles and syringes distributed per person who injects (2020) 	65

5.3%

Yes

— Coverage of opioid substitution

- Safe injection rooms available (2021)

therapy (2020)

— Naloxone available (2021)

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION							
	2010	2020					
Percentage of pregnant women living with HIV accessing antiretroviral medicines	79% [58–100%]	95% [75–100%]					
Final vertical transmission rate including during breastfeeding	10.2% [9.2–16.3%]	5.8% [4.6 –1 3%]					
Early infant diagnosis	68.4% [57.1–81.9%]	72.9% [56.2–92.8%]					

UZBEKISTAN

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	4900	5000	2700
	[4300–5400]	[4400–6200]	[1800–4100]
New HIV infections (0–14)	810	860	<100
	[780–840]	[810–920]	[<100- <200]
New HIV infections (women, 15+)	1400	1400	890
	[1200–1600]	[1200–1800]	[600–1300]
New HIV infections (men, 15+)	2700	2700	1700
	[2300–3000]	[2300–3500]	[1200–2600]
HIV incidence per 1000 population	0.17 [0.15–0.19]	0.16 [0.14–0.2]	0.08 [0.06–0.12]
AIDS-related deaths			
AIDS-related deaths (all ages)	800	1400	610
	[710–910]	[1200–1600]	[<500–800]
AIDS-related deaths (0–14)	600	720	<100
	[580–610]	[690–740]	[<100–<100]
AIDS-related deaths (women, 15+)	<100	<200	<100
	[<100–<100]	[<100–<200]	[<100–<100]
AIDS-related deaths (men, 15+)	<200	610	510
	[<200–<500]	[<500–730]	[<500–690]
People living with HIV			
People living with HIV (all ages)	24 000	43 000	58 000
	[21 000–28 000]	[38 000–47 000]	[52 000–69 000]
People living with HIV (0-14)	2000	2900	4100
	[1900–2100]	[2800–3000]	[3900–4400]
People living with HIV (women, 15+)	7900	15 000	20 000
	[6700–9000]	[13 000–16 000]	[18 000–24 000]
People living with HIV (men, 15+)	15 000	26 000	34 000
	[12 000–17 000]	[22 000–28 000]	[30 000–41 000]
HIV prevalence (15–49)	0.1 [0.1–0.1]	0.2 [0.2–0.2]	0.2 [0.2–0.3]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

residence permits or for certain groups

STIGMA AND DISCRIMINATION

years who report discriminatory attitudes towards people living with HIV	•••	
		•••
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their		•••


VIOLENCE


consent


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES							
Financing sources							
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total	

US\$ 4 976 056 Last available report: 2020 US\$ 3 658 922









Change in new HIV infections = -45% since 2010

Change in AIDS-related deaths = -24% since 2010

Incidence:
prevalence = 4.67
ratio

Incidence: mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS								
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners			
Estimated size of population			•••	•••				
HIV prevalence	3.2%	3.7%	5.1%		0.5%			
HIV testing and status awareness								
Antiretroviral therapy coverage								
Condom use								
Coverage of HIV prevention programmes								
Avoidance of health care because of stigma and discrimination								
Expenditures in US\$ (2020)	79 780		91 934					

	\sim	$\mathbf{N}\mathbf{A}\mathbf{C}$	ιвв	חו	100	т.
HIV (UU		ΙKD	וטו		

Estimated number of incident tuberculosis cases among people living with HIV (2018)	1000 [700–1400]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	
HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.1%
Knowledge of HIV prevention among young	

— Women
— Men

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

— Women

— Men

Women aged 15–49 years who have their demand for family planning satisfied by

modern methods

Men aged 15–49 years who are circumcised Not applicable

Voluntary medical male circumcisions Not applicable

People who received PrEP at least once during the reporting period

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	15% [11–18%]	89% [77–100%]		
Final vertical transmission rate including during breastfeeding	265.3% [223.8–337.7%]	12% [9.6–15.3%]		
Early infant diagnosis	12.8% [11.2–14.8%]	77% [61.4–89.5%]		

Harm reduction

Use of sterile injecting equipment at last injection (2015)	85.1%
 Needles and syringes distributed per person who injects (2018) 	105
— Coverage of opioid substitution	

Coverage of opioid substitution therapy

Naloxone available (2021)Safe injection rooms available (2021)



WESTERN AND CENTRAL EUROPE AND NORTH AMERICA

s a region, western and central Europe and North America has achieved the 90–90–90 targets, and continuing declines in annual HIV infections and deaths suggest that most of the epidemics of the region are being controlled. However, these regional averages obscure differences, both among and within countries. In the United States of America, for example, 34.5% of people living with diagnosed HIV infection (aged 13 years and older) were not virally suppressed (1).


Service access in western and central Europe and North America tends to be lower among migrant populations and racial and ethnic minority groups. These disparities are linked to structural discrimination, administrative and linguistic barriers to accessing health insurance and services, and stigma at the community level. In the United States, for example, health insurance coverage is lower among people living with HIV in black and Hispanic communities, and people living with HIV who do not have health insurance are less likely to be virally suppressed than those with private or government-provided health insurance (2). People living with HIV who do not have health insurance in the United States, however, can access affordable HIV treatment through the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act.

The increased provision of pre-exposure prophylaxis (PrEP) is contributing to reductions in the incidence of HIV infections in the United Kingdom of Great Britain and Northern Ireland and parts of the United States. Other proven prevention methods, such as harm reduction services, continue to hold the HIV epidemics in check in countries such as Italy, the Netherlands, Portugal, Spain and Switzerland, and they should be implemented more widely in countries where injecting drug use is a major driver of HIV and viral hepatitis infections.

PRIORITY ACTIONS FOR ENDING AIDS

- Improve testing strategies, including for viral load.
- Overcome stigma and discrimination in health-care settings, and integrate care for co-infections and comorbidities.
- Ensure that key populations, migrants and people in closed settings have access to HIV services, regardless of their legal or insurance status.
- Remove laws and policies that punish and discriminate against LGBTI communities, sex workers, people who use drugs, people living with HIV and migrants.
- Increase investments in HIV research, with particular attention to long-acting antiretrovirals, HIV vaccines and a cure.

INSURANCE COVERAGE AMONG ADULTS LIVING WITH HIV, BY RACE/ETHNICITY, UNITED STATES OF AMERICA, 2018




WhiteBlackHispanic

Source: Dawson L, Kates J. Insurance coverage and viral suppression among people with HIV, 2018. In: KFF.org [Internet]. 24 September 2020. San Francisco (CA): Kaiser Family Foundation; c2021 (https://www.kff.org/hivaids/issue-brief/insurance-coverage-and-viral-suppression-among-people-with-hiv-2018/).

 a Coverage significantly different (p < .001) reference group is white. The remaining percentage is other public coverage.

SUSTAINED VIRAL SUPPRESSION AMONG ADULTS WITH HIV, BY INSURANCE COVERAGE MODALITY, UNITED STATES OF AMERICA, 2018



Source: Dawson L, Kates J. Insurance coverage and viral suppression among people with HIV, 2018. In: KFF.org [Internet]. 24 September 2020. San Francisco (CA): Kaiser Family Foundation; c2021 (https://www.kff.org/hivaids/issue-brief/insurance-coverage-and-viral-suppression-among-people-with-hiv-2018/).


Note: Sustained viral suppression is defined as having an undetectable viral load over all tests in the preceding 12 months. Medicaid includes those covered by both Medicaid and Medicare.

 $^{^{\}circ}$ Viral suppression rate greater than that of the uninsured p < .001.

 $^{^{\}rm b}$ Viral suppression rate greater than that of the uninsured p < .05.


STATE OF THE PANDEMIC

NUMBER OF NEW HIV INFECTIONS AND AIDS-RELATED DEATHS, WESTERN AND CENTRAL EUROPE AND NORTH AMERICA, 2000–2020




Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).

DISTRIBUTION OF NEW HIV INFECTIONS BY POPULATION GROUP AND SEX (AGED 15–49 YEARS), WESTERN AND CENTRAL EUROPE AND NORTH AMERICA, 2020



Source: UNAIDS special analysis, 2021 (see methods annex).


HIV PREVALENCE AMONG KEY POPULATIONS, REPORTING COUNTRIES IN WESTERN AND CENTRAL EUROPE AND NORTH AMERICA, 2016–2020



- Sex workers (n = 3)
 Gay men and other men who have sex with men (n = 9)
 People who inject drugs (n = 15)
- Transgender people (n = 1)
- Prisoners (n = 7)

Source: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/). Note: (n = number of countries). Total number of reporting countries = 40. Additional countries have reported after the release of the Global Report. Their results, not included in this figure, are shown in the specific country sheets

How to read this chart



Local population size estimate

REPORTED ESTIMATED SIZE OF KEY POPULATIONS, WESTERN AND CENTRAL EUROPE AND NORTH AMERICA, 2018-2020

	National adult population (aged 15–49 years) in 2020 or relevant year	Sex workers	Sex workers as per cent of adult population (aged 15–49 years)	Gay men and other men who have sex with men	Gay men and other men who have sex with men as per cent of adult population (aged 15–49 years)	People who inject drugs	People who inject drugs as per cent of adult population (aged 15-49 years)	Transgender people	Transgender people as per cent of adult population (aged 15–49 years)	Prisoners	Prisoners as per cent of adult population (aged 15–49 years)
Canada	16 500 000							75 000	0.45%	14 000	0.09%
Czechia	4 800 000					40 800	0.85%			21 600	0.45%
Estonia	560 000									2300	0.42%
Germany	35 800 000									57 600	0.16%
Israel	4 100 000										
Serbia	4 000 000										
United States of America	148 000 000							1 000 000	0.68%		
Estimated global more proportion as per cadult population (aged 15–49 years)	ent of		0.34%		0.82%		0.06%		0.06%		-

Sources: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/); Spectrum Demproj module, 2021.

No data

Note 1: Estimates shown are government-provided estimates reported for 2018–2020. Additional and alternative estimates may be available from different sources, including the Key Populations Atlas (https://kpatlas.unaids.org/), academic publications or institutional documents. Note 2: The reported values for gay men and other men who have sex with men are presented as a per cent of the adult population (aged 15–49 years) for consistency across key populations. The percentage of this population out of the adult male population (aged 15-49 years) will be approximately twice the values shown.

^a Quick Start Guide for Spectrum, 2020. Geneva: UNAIDS; 2020 (https://www.unaids.org/sites/default/files/media_asset/QuickStartGuide_

^b Technical brief: recommended population size estimates of men who have sex with men. Geneva: WHO, UNAIDS; 2020.

CHANGE IN NEW HIV INFECTIONS BETWEEN 2010 AND 2020, WESTERN AND CENTRAL EUROPEAN COUNTRIES

	Estimates approved by country	Estimates not finalized by the time of publication
Countries with declines in new HIV infections of greater than 20%	Denmark Estonia Italy Netherlands Norway Portugal	Austria Belgium Switzerland United Kingdom of Great Britain and Northern Ireland
Countries with declines in HIV infections of 0% to less than 20%	Greece Spain	Finland Israel Lithuania
Countries with increasing new HIV infections	Ireland Serbia	Bulgaria Cyprus Czechia Hungary Latvia Poland Slovakia Sweden Turkey


Source: UNAIDS epidemiological estimates 2021; European Centre for Disease Prevention and Control, WHO Regional Office for Europe. HIV/AIDS Surveillance in Europe 2020: 2019 data. Copenhagen: WHO Regional Office for Europe; 2020.

Notes: Countries were omitted if there was a discrepancy between the estimated number of new infections for 2010–2020 and new diagnoses for 2010–2019 (Croatia, France, Germany, and Romania). Countries with <50 new HIV infections were omitted.

In western and central Europe, 11 countries have seen HIV infections decline by more than 20% since 2010, and 16 countries experienced increases or had limited declines in new HIV infections. HIV responses in several countries within central Europe are being held back by limited political commitment, harassment and other rights violations against lesbian, gay, bisexual, transgender and intersex (LGBTI) people and other key populations, and by insufficient steps to reach key populations with evidence-informed combinations of HIV prevention, testing and treatment services.

HIV SERVICES

PEOPLE LIVING WITH HIV, PEOPLE NEWLY INFECTED IN THE PAST SIX MONTHS, AND HIV TESTING AND TREATMENT CASCADE, ADULTS (AGED 15+ YEARS), WESTERN AND CENTRAL EUROPE AND NORTH AMERICA, 2016–2020





Source: UNAIDS special analysis, 2021.

References


- 1. US Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2019. HIV Surveillance Supplemental Report. 2021;26(No. 2) (http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html).
- 2. Dawson L, Kates J. Insurance coverage and viral suppression among people with HIV, 2018. In: KFF.org [Internet]. 24 September 2020. San Francisco: Kaiser Family Foundation; c2021 (https://www.kff.org/hivaids/issue-brief/insurance-coverage-and-viral-suppression-among-people-with-hiv-2018/).

HIV TESTING AND TREATMENT CASCADE, WOMEN (AGED 15+ YEARS) COMPARED TO MEN (AGED 15+ YEARS), WESTERN AND CENTRAL EUROPE AND NORTH AMERICA, 2020





Men (aged 15+ years) living with HIV




Source: UNAIDS special analysis, 2021.

BULGARIA

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence	0.3%	3.7%	1.7%		1.7%
HIV testing and status awareness	99.6%	98.5%	100%		
Antiretroviral therapy coverage					0.2%
Condom use	92%	80.5%	34.3%		
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2015)	358 976	199 337	473 372		

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	19 [6–40]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged viral load	15+ years	with	unsuppressed	

Knowledge of HIV prevention among young people aged 15-24 years (2016)

— Women	19.9%
— Men	17.6%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49

9	years		
	- Women		

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

— Men

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction — Use of sterile injecting equipment at	72 9%

last injection (2016)	72.9%
 Needles and syringes distributed per person who injects (2017) 	52
 Coverage of opioid substitution therapy (2016) 	26%
— Naloxone available (2021)	

- Safe injection rooms available (2021)

72.9%

EXPENDITURES

	Fina	ncing sources			
Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

Last available report: 2017 US\$ 20 128 659

LAWS AND POLICIES		STIGMA AN
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission		Percentage of wom-
Criminalization of sex work among consenting adults		towards people livir
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed	Percentage of peop health services beca the last 12 months
Drug use or possession for personal use is an offence		Percentage of peop
Criminalization of transgender people		others about their I consent
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE
Parental consent for adolescents to access HIV testing		Proportion of ever- women aged 15–49
Spousal consent for married women to access sexual and reproductive health services		physical or sexual vi intimate partner in t

Mandatory HIV testing for marriage, work or residence permits or for certain groups

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49 years who report discriminatory attitudes owards people living with HIV Percentage of people living with HIV denied nealth services because of their HIV status in

Percentage of people living with HIV who eported a health-care professional told others about their HIV status without their


/IOLENCE

Proportion of ever-married or partnered vomen aged 15-49 years who experienced physical or sexual violence from a male ntimate partner in the past 12 months

CANADA

KEY POPULATION	S				
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					14 000
HIV prevalence			10.3%		1%
HIV testing and status awareness		8.9%	58.2%		
Antiretroviral therapy coverage		90.3%			97.8%
Condom use		17.2%			
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination			45.5%		
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	86 [28 –1 80]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

— Women

modern methods

Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	
Condom use at last sex with a non-marital,	

non-cohabiting partner among people aged 15–49 years

— Men	
Women aged 15–49 years who have their	
demand for family planning satisfied by	

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction	

 Use of sterile injecting equipment at last injection (2019) 	92.3%
 Needles and syringes distributed per person who injects 	
 Coverage of opioid substitution therapy 	
— Naloxone available (2021)	Yes

Yes

- Safe injection rooms available (2021)

EXPENDITURES


	Finar	ncing sources			
Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

Last available report:

LAWS AND POLICIES		STIGMA AND DISCRIMINATION		
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No, but prosecutions exist based on general criminal laws	Percentage of women and men aged 15–49 years who report discriminatory attitudes		
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work	towards people living with HIV		
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Drug use or possession for personal use is an offence	No	Percentage of people living with HIV who reported a health-care professional told		
Criminalization of transgender people	Neither criminalized nor prosecuted	others about their HIV status without their consent		
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE		
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent	Proportion of ever-married or partnered women aged 15–49 years who experienced		
Spousal consent for married women to access sexual and reproductive health services	No	physical or sexual violence from a male intimate partner in the past 12 months		
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes			

CROATIA

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	<100	<100	<100	
	[<100-<100]	[<100–<200]	[<100-<200]	
New HIV infections (0–14)				
	[]	[]	[–]	
New HIV infections (women, 15+)	<100	<100	<100	
	[<100–<100]	[<100-<100]	[<100-<100]	
New HIV infections (men, 15+)	<100	<100	<100	
	[<100-<100]	[<100–<100]	[<100–<100]	
HIV incidence per 1000 population	0.02 [0.01–0.02]	0.02 [0.01–0.02]	0.02 [0.01–0.03]	
AIDS-related deaths				
AIDS-related deaths (all ages)	<100	<100	<100	
	[<100-<100]	[<100–<100]	[<100-<100]	
AIDS-related deaths (0–14)				
	[]	[]	[]	
AIDS-related deaths (women, 15+)	<100	<100	<100	
	[<100–<100]	[<100–<100]	[<100–<100]	
AIDS-related deaths (men, 15+)	<100	<100	<100	
	[<100-<100]	[<100–<100]	[<100-<100]	
People living with HIV				
People living with HIV (all ages)	1100	1400	1700	
	[880–1200]	[1100–1600]	[1400–2000]	
People living with HIV (0-14)				
	[]	[]	[–]	
People living with HIV (women, 15+)	<200	<200	<200	
	[<100- <200]	[<200-<200]	[<200–<200]	
People living with HIV (men, 15+)	950	1200	1500	
	[770–1100]	[1000–1500]	[1200–1800]	
HIV prevalence (15–49)	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	




^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
Financing sources						
International: International: International: Total Domestic private Domestic public PEPFAR Global Fund all others						Total

US\$ 14 362 023 US\$ 14 363 785 Last available report: 2013

HIV TESTING AND TREATMENT CASCADE



All ages	84% [69–100%]	75% [61–89%] 1265	73% [60–87%]
Children (0-14)	% [–%]	% [%] 	% [%]
Women (15+)	80% [69–92%]	73% [63–84%] 122	72% [62–82%]
Men (15+)	85% [68–102%]	75% [60–90%]	73% [59–89%]


ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION					
	2010	2020			
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]			
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]			
Early infant diagnosis	% [–%]	% [–%]			

CZECHIA

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population				•••	21 600
HIV prevalence	0%		0.1%		
HIV testing and status awareness	100%**	87.7%	71.0%		
Antiretroviral therapy coverage		97.9%			
Condom use		43%	24.6%		
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

 $[\]hbox{** Programme data} \\ - \hbox{not representative; includes people with negative results.}$

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	6 [3–9]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	
— Men	***
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	

modern methods	
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	495
Harm reduction	
 Use of sterile injecting equipment at last injection (2016) 	47.8%
 Needles and syringes distributed per person who injects (2020) 	183
 Coverage of opioid substitution therapy (2018) 	38.2%
— Naloxone available (2021)	No
— Safe injection rooms available (2021)	No


EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2009	US\$ 836 737	US\$ 66 970 753			US\$ 2 340 368	US\$ 70 147 859

LAWS AND POLICIES		STIGMA AND DISCRIMINATION			
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes	Percentage of women and men aged 15–49 years who report discriminatory attitudes			
Criminalization of sex work among consenting adults	Sex work is not subject to punitive regulations or is not criminalized	towards people living with HIV			
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months			
Drug use or possession for personal use is an offence	Possession of drugs for personal use is specified as a non-criminal offence	Percentage of people living with HIV who reported a health-care professional told			
Criminalization of transgender people	Neither criminalized nor prosecuted	others about their HIV status without their consent			
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE			
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years	Proportion of ever-married or partnered women aged 15–49 years who experienced			
Spousal consent for married women to access sexual and reproductive health services	No	physical or sexual violence from a male intimate partner in the past 12 months			
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No				

DENMARK

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	<500	<200	<200	
	[<200- <500]	[<200– <500]	[<100-<500]	
New HIV infections (0–14)				
	[]	[]	[]	
New HIV infections (women, 15+)	<100	<100	<100	
	[<100–<100]	[<100- <100]	[<100-<100]	
New HIV infections (men, 15+)	<200	<200	<100	
	[<200-<500]	[<200–<500]	[<100- <500]	
HIV incidence per 1000 population	0.04 [0.03–0.05]	0.03 [0.02–0.04]	0.02 [<0.01–0.04]	
AIDS-related deaths				
AIDS-related deaths (all ages)	<100	<100	<100	
	[<100-<100]	[<100- <100]	[<100-<100]	
AIDS-related deaths (0–14)				
	[]	[]	[]	
AIDS-related deaths (women, 15+)	<100	<100	<100	
	[<100–<100]	[<100- <100]	[<100-<100]	
AIDS-related deaths (men, 15+)	<100	<100	<100	
	[<100-<100]	[<100- <100]	[<100–<100]	
People living with HIV				
People living with HIV (all ages)	5400	6200	6700	
	[4400–6300]	[5000–7300]	[5400–7900]	
People living with HIV (0–14)				
	[]	[]	[]	
People living with HIV (women, 15+)	1400	1600	1700	
	[1100–1600]	[1200–1800]	[1300–1900]	
People living with HIV (men, 15+)	4000	4700	5000	
	[3200–4900]	[3700–5700]	[3900–6200]	
HIV prevalence (15–49)	0.1 [0.1–0.2]	0.1 [0.1–0.1]	0.1 [<0.1–0.1]	








Last available report:

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION			
	2010	2020	
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]	
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]	
Early infant diagnosis	% [–%]	% [–%]	

ESTONIA

COUNTRY DATA

	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<500	<500	<500
	[<500-<500]	[<200-<500]	[<200- <500]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)	<200	<100	<100
	[<100- <200]	[<100– <200]	[<100- <100]
New HIV infections (men, 15+)	<200	<200	<200
	[<200-<500]	[<200-<200]	[<100- <200]
HIV incidence per 1000 population	0.24 [0.2–0.28]	0.18 [0.14–0.23]	0.16 [0.12–0.22]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<100
	[<100-<100]	[<100–<100]	[<100-<100]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100- <100]	[<100–<100]	[<100- <100]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100-<100]
People living with HIV			
People living with HIV (all ages)	5600	6500	7100
	[4900–6300]	[5700–7100]	[6200–7900]
People living with HIV (0-14)			
	[]	[]	[–]
People living with HIV (women, 15+)	2200	2500	2800
	[1900–2400]	[2200–2800]	[2500–3100]
People living with HIV (men, 15+)	3400	3900	4300
	[2800–4000]	[3300–4600]	[3700–5000]
HIV prevalence (15-49)	0.7 [0.7–0.8]	0.8 [0.7–0.9]	0.8 [0.7–0.8]

LAWS AND POLICIES

Laws criminalizing the transmission of, nondisclosure of or exposure to HIV transmission Criminalization of sex work among consenting adults Laws penalizing same-sex sexual Criminalization of same-sex sexual acts acts have been decriminalized or never existed Drug use or possession for personal use is an offence Criminalization of transgender people Laws or policies restricting the entry, stay and residence of people living with HIV Parental consent for adolescents to access HIV Spousal consent for married women to access sexual and reproductive health services

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV

Percentage of people living with HIV denied health services because of their HIV status in the last 12 months

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent

VIOLENCE

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

residence permits or for certain groups

Mandatory HIV testing for marriage, work or

EXPENDITURES						
Financing sources						
Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total	

Last available report: 2010 ... US\$ 16 353 142 US\$ 16 353 142

Number of people

1 500

1 000

500

mortality ratio*


2000 2005 2010 2015 2020 New HIV infections

All-cause deaths among

the HIV population

EPIDEMIC TRANSITION METRICS


since 2010




since 2010



ratio



HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION			
	2010	2020	
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]	
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]	
Early infant diagnosis	% [–%]	% [–%]	

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	15 [7–25]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.3%
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	•••
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	
— Men	
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction — Use of sterile injecting equipment at	97.4%

last injection (2018)

therapy (2018) — Naloxone available (2021)

person who injects (2018) — Coverage of opioid substitution

- Needles and syringes distributed per

- Safe injection rooms available (2021)


195

13.1%

FRANCE

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••		•••	•••	•••
HIV prevalence					
HIV testing and status awareness		64.0%	6.0%		
Antiretroviral therapy coverage		78%	90.9%		
Condom use		44.5%			
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	360 [280–450]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

— Women	
— Men	
Women aged 15–49 years who have their	

demand	for	family	planning	satisfied	by
modern	met	thods			

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction — Use of sterile injecting equipment at	

last injection	•••
— Needles and syringes distributed per	115
parson who injects (2015)	113

person who injects (2015)
Coverage of opioid substitution therapy (2015)

— Naloxone available (2021)	
 Safe injection rooms available (2021) 	

80%

	Sale injection rooms available (2021)

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report:						

LAWS AND POLICIES Laws criminalizing the transmission of, nondisclosure of or exposure to HIV transmission Criminalization of sex work among consenting Laws penalizing same-sex sexual Criminalization of same-sex sexual acts acts have been decriminalized or never existed Drug use or possession for personal use is an offence Criminalization of transgender people Laws or policies restricting the entry, stay and residence of people living with HIV Parental consent for adolescents to access HIV testing Spousal consent for married women to access sexual and reproductive health services

Mandatory HIV testing for marriage, work or residence permits or for certain groups

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49 years who report discriminatory attitudes towards people living with HIV

Percentage of people living with HIV denied health services because of their HIV status in the last 12 months

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent

VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

GERMANY

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	2900	2800	2600
	[2100–3600]	[2100–3700]	[1900–3500]
New HIV infections (0–14)			
	[]	[]	[–]
New HIV infections (women, 15+)	<500	<500	<500
	[<500–610]	[<500–610]	[<500–570]
New HIV infections (men, 15+)	2400	2300	2100
	[1700–3100]	[1600–3100]	[1500–2900]
HIV incidence per 1000 population	0.03 [0.03–0.04]	0.03 [0.02–0.04]	0.03 [0.02–0.04]
AIDS-related deaths			
AIDS-related deaths (all ages)	<500	<500	<500
	[<500 <u>–</u> 610]	[<500–570]	[<500 <u>–</u> 650]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100-<100]	[<100– <100]	[<100-<100]
AIDS-related deaths (men, 15+)	<500	<500	<500
	[<500–530]	[<500-<500]	[<500–550]
People living with HIV			
People living with HIV (all ages)	70 000	82 000	93 000
	[55 000–82 000]	[64 000–96 000]	[72 000–110 000]
People living with HIV (0-14)			
	[]	[]	[]
People living with HIV (women, 15+)	14 000	16 000	18 000
	[11 000–16 000]	[13 000–19 000]	[15 000–21 000]
People living with HIV (men, 15+)	56 000	66 000	75 000
	[44 000–67 000]	[51 000–79 000]	[57 000–90 000]
HIV prevalence (15–49)	0.1 [<0.1–0.1]	0.1 [<0.1–0.1]	0.1 [<0.1–0.1]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No, but prosecutions exist based on general criminal laws
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a non-criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49

years who report discriminatory attitudes towards people living with HIV	
Percentage of people living with HIV denied	2013
health services because of their HIV status in the last 12 months	17.5
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their	2013

19.4

VIOLENCE

consent


Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


residence permits or for certain groups


EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


Last available report:

EPIDEMIC TRANSITION METRICS









Change in new **HIV** infections since 2010

-9%

Change in AIDS--1% related deaths since 2010

Incidence: 2.79 prevalence ratio

mortality ratio

2.5

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					57 600
HIV prevalence		6%			
HIV testing and status awareness		51.6%	98.8%		
Antiretroviral therapy coverage		82.3%			
Condom use		50.1%			
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION			
	2010	2020	
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]	
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]	
Farly infant diagnosis	%	%	

[...-..%]

[...-..%]

Early infant diagnosis

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	150 [79–230]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	
— Men	

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49 years

— Women

therapy (2015) — Naloxone available (2021)

- Safe injection rooms available (2021)

— Men

Women aged 15-49 years who have their

demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2017)	2000
Harm reduction — Use of sterile injecting equipment at last injection (2015)	90.2%
 Needles and syringes distributed per person who injects 	
— Coverage of opioid substitution	45.2%

Yes

Yes

GREECE

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	1200	520	980
	[1100–1200]	[<500–580]	[770–1200]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)	<200	<100	<200
	[<200–<200]	[<100-<100]	[<200–<200]
New HIV infections (men, 15+)	990	<500	830
	[940–1000]	[<500-<500]	[660–990]
HIV incidence per 1000 population	0.1 [0.1–0.11]	0.05 [0.04–0.05]	0.09 [0.07–0.11]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100-<100]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100–<100]	[<100-<100]	[<100-<100]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100-<100]
People living with HIV			
People living with HIV (all ages)	11 000	14 000	17 000
	[9800–11 000]	[13 000–15 000]	[15 000–18 000]
People living with HIV (0-14)			
	[]	[]	[=]
People living with HIV (women, 15+)	1700	2300	2700
	[1500–1800]	[2100–2400]	[2400–2900]
People living with HIV (men, 15+)	8800	12 000	14 000
	[8200–9500]	[11 000–13 000]	[13 000–15 000]
HIV prevalence (15–49)	0.1 [0.1–0.2]	0.2 [0.1–0.2]	0.2 [0.2–0.2]

LAW	111		

LAWS AND I OLICILS	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	
Criminalization of sex work among consenting adults	
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	
Spousal consent for married women to access sexual and reproductive health services	

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49
years who report discriminatory attitudes
towards people living with HIV

Percentage of people living with HIV denied

health services because of their HIV status in the last 12 months	11
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their	2017
consent	15

2017

VIOLENCE

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


-	/ 6	14.	VI		П	D	н	c


Mandatory HIV testing for marriage, work or residence permits or for certain groups


EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


Last available report: 2008 US\$ 96 058 435 US\$ 96 058 435

EPIDEMIC TRANSITION METRICS









Change in new
HIV infections = -16%
since 2010

Change in AIDS-related deaths = -25% since 2010

Incidence:
prevalence = 5.88
ratio

Incidence: mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••			•••	
HIV prevalence					
HIV testing and status awareness					
Antiretroviral therapy coverage					
Condom use		73%	40%	66%	
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	16 [9–26]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



HIV DDEVENTION

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young	

people aged 15–24 years

— Women

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

— Women

— Men

— Men nen aged 15–49 years who have their

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2017)	75
Harm reduction — Use of sterile injecting equipment at	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [%]
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]
Early infant diagnosis	% [–%]	% [–%]

last injection (2015)	
— Needles and syringes distributed per	

 Needles and syringes distributed per person who injects (2016)

Coverage of opioid substitution therapy (2016)
Naloxone available (2021)
...


86%

80

— Safe injection rooms available (2021)

ICELAND


EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<100	<100	<100
	[<100- <100]	[<100- <100]	[<100–<100]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)	<100	<100	<100
	[<100-<100]	[<100- <100]	[<100–<100]
New HIV infections (men, 15+)	<100	<100	<100
	[<100-<100]	[<100- <100]	[<100–<100]
HIV incidence per 1000 population	0.04 [0.03–0.05]	0.04 [0.03–0.05]	0.04 [0.03–0.05]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<100
	[<100-<100]	[<100- <100]	[<100-<100]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100-<100]	[<100- <100]	[<100-<100]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100-<100]	[<100- <100]	[<100-<100]
People living with HIV			
People living with HIV (all ages)	<500	<500	<500
	[<200-<500]	[<500–<500]	[<500-<500]
People living with HIV (0-14)			
	[]	[]	[]
People living with HIV (women, 15+)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100–<200]
People living with HIV (men, 15+)	<200	<500	<500
	[<200-<500]	[<200–<500]	[<200-<500]
HIV prevalence (15–49)	0.1 [<0.1–0.1]	0.1 [<0.1–0.1]	0.1 [0.1–0.1]





Last available report:


HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]		
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]		
Early infant diagnosis	%	% [–%]		


IRELAND

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<500	<500	<500
	[<500-<500]	[<500–<500]	[<500–600]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)			
	[]	[]	[]
New HIV infections (men, 15+)			
	[]	[]	[]
HIV incidence per 1000 population	0.07 [0.06–0.09]	0.08 [0.06–0.11]	0.08 [0.05–0.12]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<100
	[<100-<100]	[<100- <100]	[<100-<100]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100- <100]	[<100– <100]	[<100–<100]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100-<100]	[<100–<100]	[<100–<100]
People living with HIV			
People living with HIV (all ages)	4600	6100	7800
	[4000–5100]	[5200–7100]	[6300–9800]
People living with HIV (0–14)			
	[]	[]	[]
People living with HIV (women, 15+)	1600	1900	2300
	[1400–1800]	[1700–2100]	[1900–2600]
People living with HIV (men, 15+)	3000	4200	5600
	[2500–3500]	[3400–5100]	[4300–7300]
HIV prevalence (15–49)	0.1 [0.1–0.2]	0.2 [0.2–0.2]	0.2 [0.2–0.3]






HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]		
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]		
Early infant diagnosis	% [–%]	% [–%]		


ITALY

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	4800	4100	2500
	[3900–5500]	[3300–4900]	[2000–3100]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)	1200	1100	740
	[1100–1500]	[880–1200]	[600–880]
New HIV infections (men, 15+)	3500	3000	1800
	[2600–4300]	[2200–3800]	[1300–2400]
HIV incidence per 1000 population	0.08 [0.07–0.09]	0.07 [0.06–0.08]	0.04 [0.03–0.05]
AIDS-related deaths			
AIDS-related deaths (all ages)			
	[]	[]	[]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)			
	[]	[]	[]
AIDS-related deaths (men, 15+)			
	[]	[–]	[]
People living with HIV			
People living with HIV (all ages)	110 000	130 000	140 000
	[95 000–120 000]	[110 000–140 000]	[120 000–150 000]
People living with HIV (0–14)			
	[]	[]	[]
People living with HIV (women, 15+)	31 000	36 000	39 000
	[27 000–34 000]	[31 000–39 000]	[33 000–44 000]
eople living with HIV (men, 15+)	79 000	91 000	98 000
	[66 000–92 000]	[75 000–110 000]	[80 000–120 000]
HIV prevalence (15–49)	0.3 [0.2–0.3]	0.3 [0.2–0.3]	0.2 [0.2–0.3]





HIV TESTING AND TREATMENT CASCADE




ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]		
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]		
Early infant diagnosis	% [%]	% [–%]		

LITHUANIA

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••			•••	•••
HIV prevalence	11.1%	4.7%	4.7%		4.5%
HIV testing and status awareness			28.0%		
Antiretroviral therapy coverage		65.5%	21.8%		30.7%
Condom use			32%		
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	39 [26–55]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged	15+ years	with	unsuppressed
viral load			

Knowledge of HIV prevention among young people aged 15-24 years (2014)

— Women	67.5%
— Men	71.6%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49

<i>y</i>	ears			
- '	Women			

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once	

Harm reduction

during the reporting period

— Men

 Use of sterile injecting equipment at last injection (2016) 	65.9%
 Needles and syringes distributed per person who injects (2017) 	28

— Coverage of opioid substitution therapy (2017)

— Naloxone available (2021)

22.2%

- Safe injection rooms available (2021)

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2012		US\$ 2 496 551				US\$ 2 496 551

LAWS AND POLICIES		STIGMA A
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission		Percentage of w
Criminalization of sex work among consenting adults		towards people
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed	Percentage of per health services be the last 12 month
Drug use or possession for personal use is an offence		Percentage of perceported a health
Criminalization of transgender people		others about the consent
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENC
Parental consent for adolescents to access HIV testing	sent for adolescents to access HIV	
Spousal consent for married women to access sexual and reproductive health services		women aged 15- physical or sexua intimate partner
Mandatory HIV testing for marriage, work or		

residence permits or for certain groups

AND DISCRIMINATION

vomen and men aged 15–49 rt discriminatory attitudes living with HIV

eople living with HIV denied because of their HIV status in ths

...


eople living with HIV who th-care professional told eir HIV status without their

Έ

ver-married or partnered i–49 years who experienced al violence from a male r in the past 12 months


NETHERLANDS

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	980	650	<500	
	[930–1000]	[580–710]	[<200- <500]	
New HIV infections (0–14)				
	[]	[]	[]	
lew HIV infections (women, 15+)	<200	<200	<100	
	[<200-<200]	[<200– <200]	[<100- <100]	
New HIV infections (men, 15+)	780	520	<500	
	[750–820]	[<500–560]	[<200–<500]	
HIV incidence per 1000 population	0.06 [0.06–0.06]	0.04 [0.03–0.04]	0.02 [<0.01–0.02]	
AIDS-related deaths				
AIDS-related deaths (all ages)	<100	<100	<100	
	[<100-<200]	[<100- <200]	[<100– <200]	
AIDS-related deaths (0–14)				
	[]	[]	[]	
AIDS-related deaths (women, 15+)	<100	<100	<100	
	[<100-<100]	[<100– <100]	[<100– <100]	
AIDS-related deaths (men, 15+)	<100	<100	<100	
	[<100-<100]	[<100- <100]	[<100-<200]	
People living with HIV				
People living with HIV (all ages)	20 000	23 000	24 000	
	[17 000–22 000]	[20 000–25 000]	[21 000–27 000]	
eople living with HIV (0–14)				
	[]	[]	[]	
People living with HIV (women, 15+)	3500	4100	4300	
	[3100–3800]	[3700–4500]	[3800–4900]	
People living with HIV (men, 15+)	16 000	19 000	19 000	
	[14 000–18 000]	[16 000–21 000]	[17 000–22 000]	
HIV prevalence (15–49)	0.2 [0.1–0.2]	0.2 [0.1–0.2]	0.2 [0.1–0.2]	






HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]		
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]		
Early infant diagnosis	% [–%]	% [–%]		

NORWAY


EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<500	<200	<100
	[<200-<500]	[<200–<200]	[<100- <200]
New HIV infections (0–14)			
	[]	[]	[]
lew HIV infections (women, 15+)	<100	<100	<100
	[<100- <100]	[<100- <100]	[<100- <100]
New HIV infections (men, 15+)	<200	<200	<100
	[<200–<200]	[<100- <200]	[<100- <100]
HIV incidence per 1000 population	0.04 [0.04–0.05]	0.03 [0.02–0.03]	0.01 [<0.01–0.02]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<100
	[<100-<100]	[<100- <100]	[<100- <100]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100-<100]	[<100- <100]	[<100-<100]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100-<100]	[<100- <100]	[<100-<100]
People living with HIV			
People living with HIV (all ages)			
	[]	[]	[–]
eople living with HIV (0–14)			
	[]	[]	[–]
People living with HIV (women, 15+)			
	[]	[]	[]
People living with HIV (men, 15+)			
	[]	[]	[]
HIV prevalence (15–49)	[]	[]	[]



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report:	···					

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]		
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]		
Early infant diagnosis	% [–%]	% [%]		

PORTUGAL

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	1600	1200	670
	[1400–1900]	[970–1300]	[<500–850]
New HIV infections (0–14)	<100	<100	<100
	[<100–<100]	[<100– <100]	[<100–<100]
New HIV infections (women, 15+)	<500	<500	<200
	[<500–500]	[<500–<500]	[<200–<500]
New HIV infections (men, 15+)	1200	850	<500
	[950–1400]	[650–1000]	[<500 <u>–</u> 660]
HIV incidence per 1000 population	0.16 [0.13–0.18]	0.11 [0.09–0.13]	0.07 [0.05–0.08]
AIDS-related deaths			
AIDS-related deaths (all ages)	800	<500	<500
	[610–1000]	[<500–590]	[<500–<500]
AIDS-related deaths (0–14)	<100	<100	<100
	[<100- <100]	[<100–<100]	[<100- <100]
AIDS-related deaths (women, 15+)	<500	<200	<100
	[<200-<500]	[<100- <200]	[<100-<100]
AIDS-related deaths (men, 15+)	590	<500	<500
	[<500–780]	[<500–<500]	[<200–<500]
People living with HIV			
People living with HIV (all ages)	38 000	40 000	42 000
	[34 000–42 000]	[36 000–44 000]	[37 000–45 000]
People living with HIV (0–14)	<100	<100	<100
	[<100–<100]	[<100–<100]	[<100–<100]
People living with HIV (women, 15+)	11 000	12 000	12 000
	[9900–12 000]	[11 000–13 000]	[11 000–13 000]
People living with HIV (men, 15+)	27 000	29 000	29 000
	[24 000–31 000]	[25 000–32 000]	[25 000–33 000]
HIV prevalence (15–49)	0.5 [0.5–0.6]	0.5 [0.5–0.6]	0.5 [0.4–0.5]

	IS I	A B I	\neg	 ~1	
A 1 1 1 1		A W L 7			

residence permits or for certain groups

EATTS AITS I SEIGIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	
Criminalization of sex work among consenting adults	
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	
Spousal consent for married women to access sexual and reproductive health services	
Mandatory HIV testing for marriage, work or	

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	
	 •••
Percentage of people living with HIV denied	2013
the last 12 months	7.5
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent	

VIOLENCE

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
	Financing sources					
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 274 577 668 Last available report: 2013 US\$ 274 577 668

EPIDEMIC TRANSITION METRICS 3 000 2 500 3 000 a 2 500 a 2 000 b 1 500 Number of people Number of people 2 000 1 500 1 500 2 1 000 1 000 500 500 1 000 500 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 2000 2005 2010 2015 2020 New HIV infections Incidence:prevalence ratio New HIV infections AIDS-related deaths All-cause deaths among • • • • • Target the HIV population

-61%

Incidence:

prevalence

ratio

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••		•••	•••	
HIV prevalence			21.3%		
HIV testing and status awareness	46.0%**	57.0%		58.0%	
Antiretroviral therapy coverage					
Condom use	68.2%	50.1%			
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination			9%		
Expenditures in US\$					

Change in AIDS-

related deaths

since 2010


-59%

Change in new

HIV infections

since 2010

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-	-CHILD TRA	NSMISSION
	2010	2020

Percentage of pregnant women living with HIV accessing antiretroviral medicines	100% [90–100%]	100% [89–100%]
Final vertical transmission rate including during breastfeeding	2.9% [2.6–3.2%]	1% [0.8–1.3%]
Early infant diagnosis	% [–%]	% [–%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	210 [74–430]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

mortality ratio

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years	
— Women	•••
— Men	•••
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years	
— Women	
— Men	
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction	
 Use of sterile injecting equipment at last injection 	
 Needles and syringes distributed per person who injects 	

— Coverage of opioid substitution

- Safe injection rooms available (2021)

therapy (2015)

— Naloxone available (2021)

60%

^{**} Programme data—not representative; includes people with negative results.

ROMANIA

COUNTRY DATA

	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	860	810	770
	[<500–1200]	[<500–1200]	[<500–1100]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)	<500	<500	<200
	[<500-<500]	[<200– <500]	[<200-<500]
New HIV infections (men, 15+)	510	580	580
	[<500–760]	[<500–860]	[<500–870]
HIV incidence per 1000 population	0.04 [0.02–0.06]	0.04 [0.02–0.06]	0.04 [0.02–0.06]
AIDS-related deaths			
AIDS-related deaths (all ages)	<200	<500	<500
	[<100-<500]	[<200-<500]	[<200–<500]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<100	<200	<200
	[<100–<100]	[<100- <500]	[<100-<500]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100-<100]	[<100–<200]	[<100– <200]
People living with HIV			
People living with HIV (all ages)	15 000	17 000	19 000
	[8900–19 000]	[10 000–22 000]	[12 000–25 000]
People living with HIV (0-14)			
	[]	[]	[]
People living with HIV (women, 15+)	6700	7300	7500
	[4000–8900]	[4700–9200]	[5000–9200]
People living with HIV (men, 15+)	7300	9700	12 000
	[4200–10 000]	[5600–13 000]	[6800–16 000]
HIV prevalence (15–49)	0.1 [<0.1–0.1]	0.1 [<0.1–0.2]	0.1 [<0.1–0.2]

LAWS		

Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	
Spousal consent for married women to access sexual and reproductive health services	
Mandatory HIV testing for marriage, work or	

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49
years who report discriminatory attitudes
towards people living with HIV

Percentage of people living with HIV denied health services because of their HIV status in the last 12 months

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent

VIOLENCE


Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


residence permits or for certain groups


EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


Last available report: 2017 US\$ 70 977 789

EPIDEMIC TRANSITION METRICS









Change in new
HIV infections
since 2010

Change in AIDS-related deaths = 104% since 2010

Incidence:
prevalence = 3.96
ratio

Incidence: mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••			•••	
HIV prevalence					
HIV testing and status awareness			54.0%		
Antiretroviral therapy coverage			32%		66.8%
Condom use			26%		
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	320 [260–380]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young	

people aged 15–24 years

— Women

Men

Condom use at last sex with a non-marital,

popular and popular and

non-cohabiting partner among people aged 15–49 years

— Women

— Men

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]		
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]		
Early infant diagnosis	>95% [>95 >95%]	% [–%]		

Harm reduction

last injection (2016)	86.2%
 Needles and syringes distributed per person who injects (2016) 	75
 Coverage of opioid substitution therapy (2016) 	15%

86.2%

— Use of sterile injecting equipment at

- Safe injection rooms available (2021)

— Naloxone available (2021)

People living with HIV (men, 15+)

residence permits or for certain groups

HIV prevalence (15-49)

SERBIA

EPIDEMIC ESTIMATES					
	2010	2015	2020		
New HIV infections					
New HIV infections (all ages)	<200	<200	<500		
	[<200– <200]	[<200- <500]	[<200–<500]		
New HIV infections (0–14)					
	[]	[]	[]		
New HIV infections (women, 15+)	<100	<100	<100		
	[<100- <100]	[<100-<100]	[<100-<100]		
New HIV infections (men, 15+)	<200	<200	<200		
	[<200– <200]	[<200- <500]	[<100- <500]		
HIV incidence per 1000 population	0.02 [0.02–0.02]	0.02 [0.02–0.03]	0.02 [0.01–0.04]		
AIDS-related deaths					
AIDS-related deaths (all ages)	<100	<100	<100		
	[<100-<100]	[<100-<100]	[<100–<100]		
AIDS-related deaths (0-14)					
	[]	[]	[]		
AIDS-related deaths (women, 15+)	<100	<100	<100		
	[<100- <100]	[<100- <100]	[<100- <100]		
AIDS-related deaths (men, 15+)	<100	<100	<100		
	[<100-<100]	[<100-<100]	[<100–<100]		
People living with HIV					
People living with HIV (all ages)	1800	2600	3300		
	[1500–2000]	[2200–2900]	[2600–4100]		
People living with HIV (0-14)					
	[]	[]	[]		
People living with HIV (women, 15+)	<500	<500	<500		
	[<500- <500]	[<500–510]	[<500–570]		
People living with HIV (men. 15+)	1400	2100	2800		

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	Yes

[1200-1600]

<0.1 [<0.1-<0.1]

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15-49

•••	

[2200-3500]

<0.1 [<0.1-<0.1]

COUNTRY DATA

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent

VIOLENCE


[1800-2400]


<0.1 [<0.1–<0.1]


Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2013	US\$ 595	US\$ 11 468 548		US\$ 4 813 976	US\$ 1845	US\$ 16 333 869

EPIDEMIC TRANSITION METRICS









Change in new **HIV** infections since 2010

Change in AIDS-211% related deaths since 2010

Incidence: 6.11 prevalence ratio

mortality ratio*


^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population	•••		•••	•••		
HIV prevalence						
HIV testing and status awareness	64.2%	53.5%	98.8%			
Antiretroviral therapy coverage						
Condom use						
Coverage of HIV prevention programmes						
Avoidance of health care because of stigma and discrimination	8.4%	19%				
Expenditures in US\$						

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	5 [3–8]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV TESTING AND TREATMENT CASCADE



HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young	

people aged 15-24 years (2010) - Women

- Men 47.6%

54.1%

...

2

28.3%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49 years

- Women

— Men

modern methods

Women aged 15-49 years who have their demand for family planning satisfied by

Not Men aged 15-49 years who are circumcised applicable Voluntary medical male circumcisions Not performed according to national standards applicable

People who received PrEP at least once during the reporting period

Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects (2018)
- Coverage of opioid substitution therapy (2018)
- Naloxone available (2021) - Safe injection rooms available (2021)

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]
Early infant diagnosis	% [–%]	% [–%]

SLOVENIA

COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100- <100]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)	<100	<100	<100
	[<100- <100]	[<100-<100]	[<100-<100]
New HIV infections (men, 15+)	<100	<100	<100
	[<100-<100]	[<100-<100]	[<100–<100]
HIV incidence per 1000 population	0.02 [0.01–0.03]	0.01 [<0.01–0.02]	<0.01 [<0.01–<0.01]
AIDS-related deaths			
AIDS-related deaths (all ages)			
	[]	[]	[]
AIDS-related deaths (0–14)			
	[]	[=]	[]
AIDS-related deaths (women, 15+)			
	[]	[]	[]
AIDS-related deaths (men, 15+)			
	[]	[]	[]
People living with HIV			
People living with HIV (all ages)	640	770	810
	[<500–830]	[<500–980]	[520–1100]
People living with HIV (0-14)			
	[]	[]	[]
People living with HIV (women, 15+)	<100	<100	<100
	[<100- <200]	[<100-<200]	[<100-<200]
People living with HIV (men, 15+)	550	670	720
	[<500–720]	[<500–870]	[<500–940]
HIV prevalence (15–49)	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]	<0.1 [<0.1–<0.1]

	IS I	A B I	\neg	 ~1	
A 1 7 A 7		A W L 7			

LAWS AND I SEISIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	
Criminalization of sex work among consenting adults	
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	
Spousal consent for married women to access sexual and reproductive health services	
Mandatory HIV testing for marriage, work or	

STIGMA AND DISCRIMINATION

Percentage of women and men aged 15–49
years who report discriminatory attitudes
towards people living with HIV

Percentage of people living with HIV denied health services because of their HIV status in the last 12 months

Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent

VIOLENCE

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months


EXPENIITHES


residence permits or for certain groups


EXPENDITORES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


Last available report:

EPIDEMIC TRANSITION METRICS









Change in new **HIV** infections since 2010

-71%


Change in AIDSrelated deaths since 2010

Incidence: 1.72 prevalence ratio

mortality ratio

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence		5.8%			
HIV testing and status awareness					
Antiretroviral therapy coverage					
Condom use		54%			
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV TESTING AND TREATMENT CASCADE



All ages	90% [58–117%]	87% [56–113%] 709	83% [54–108%]
Children (0-14)	% [%]	% [%]	% [%]
Women (15+)	% [%]	% [%] 	% [%]
Men (15+)	% [–%]	% [%]	% [–%]

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]
Early infant diagnosis	% [–%]	% [–%]

HIV COMORBIDITIES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	1 [0–3]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION

Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years	

— Women - Men

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49 years

— Women — Men

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2017)	2

Harm reduction

— Use of sterile injecting equipment at	
last injection	

_	Needles and syringes distributed per
	person who injects (2016)


 Coverage of opioid substitution 	17 10/
therapy (2016)	17.1%

117

— Naloxone available (2021) - Safe injection rooms available (2021)

SPAIN

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	4100	4200	3500	
	[3400–4800]	[3400–5200]	[2300–4800]	
New HIV infections (0–14)				
	[]	[]	[]	
New HIV infections (women, 15+)	560	600	500	
	[<500–650]	[<500–700]	[<500–720]	
New HIV infections (men, 15+)	3500	3600	3000	
	[2900–4200]	[2800–4600]	[1900–4100]	
HIV incidence per 1000 population	0.09 [0.07–0.1]	0.09 [0.07–0.11]	0.08 [0.05–0.1]	
AIDS-related deaths				
AIDS-related deaths (all ages)	1000	720	740	
	[790–1200]	[560–860]	[580–920]	
AIDS-related deaths (0–14)				
	[]	[]	[]	
AIDS-related deaths (women, 15+)	<200	<200	<200	
	[<100- <200]	[<100-<200]	[<100– <200]	
AIDS-related deaths (men, 15+)	880	610	630	
	[670–1100]	[<500–740]	[<500–790]	
People living with HIV				
People living with HIV (all ages)	130 000	140 000	150 000	
	[110 000–140 000]	[120 000–160 000]	[130 000–170 000]	
People living with HIV (0–14)				
	[]	[]	[]	
People living with HIV (women, 15+)	23 000	25 000	27 000	
	[21 000–25 000]	[22 000–28 000]	[23 000–30 000]	
People living with HIV (men, 15+)	110 000	110 000	130 000	
	[92 000 –1 20 000]	[99 000 –1 30 000]	[110 000–140 000]	
HIV prevalence (15–49)	0.4 [0.3–0.4]	0.4 [0.3–0.4]	0.4 [0.3–0.4]	




Financing sources				EXPENDITURES	
International International International	Financing sources				
Domestic private Domestic public PEPFAR Global Fund all others	iternational: International: Total PEPFAR Global Fund all others	Domestic public	Domestic private		

US\$ 918 865 056 US\$ 919 488 342 Last available report: 2013

COUNTRY DATA


HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]		
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]		
Early infant diagnosis	% [–%]	% [%]		

SWITZERLAND

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	<500	<500	
	[<500–500]	[<500-<500]	[]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)	<200	<100	
	[<200-<200]	[<100- <200]	[]
New HIV infections (men, 15+)	<500	<500	
	[<500–<500]	[<500–<500]	[]
HIV incidence per 1000 population	0.06 [0.05–0.07]	0.05 [0.04–0.05]	[]
AIDS-related deaths			
AIDS-related deaths (all ages)	<200	<200	<200
	[<200-<500]	[<200-<500]	[<200-<200]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100–<100]	[<100- <100]	[<100-<100]
AIDS-related deaths (men, 15+)	<200	<200	<200
	[<100-<200]	[<200–<200]	[<100-<200]
People living with HIV			
People living with HIV (all ages)	15 000	17 000	17 000
	[13 000–17 000]	[14 000–19 000]	[14 000–20 000]
People living with HIV (0-14)			
	[]	[]	[]
People living with HIV (women, 15+)	4100	4500	4700
	[3600–4600]	[3900–5200]	[3900–5500]
People living with HIV (men, 15+)	11 000	12 000	12 000
	[9400–13 000]	[10 000–14 000]	[10 000–15 000]
HIV prevalence (15–49)	0.2 [0.2–0.3]	0.2 [0.2–0.3]	0.2 [0.1–0.2]




^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2016		US\$ 7 179 990				US\$ 7 179 990

COUNTRY DATA


HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]		
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]		
Early infant diagnosis	% [–%]	% [–%]		

UNITED STATES OF AMERICA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	40 000	38 000	
	[34 000–45 000]	[33 000–43 000]	[]
New HIV infections (0–14)			
	[]	[]	[]
New HIV infections (women, 15+)	6800	6800	
	[5700–8000]	[5700–8000]	[]
New HIV infections (men, 15+)	33 000	31 000	
	[28 000–37 000]	[27 000–36 000]	[]
HIV incidence per 1000 population	0.13 [0.11–0.15]	0.12 [0.1–0.14]	[]
AIDS-related deaths			
AIDS-related deaths (all ages)			
	[]	[–]	[]
AIDS-related deaths (0–14)			
	[]	[–]	[]
AIDS-related deaths (women, 15+)			
	[]	[–]	[]
AIDS-related deaths (men, 15+)			
	[]	[]	[]
People living with HIV			
People living with HIV (all ages)	960 000	1 100 000	
	[820 000–1 100 000]	[940 000 –1 200 000]	[]
People living with HIV (0-14)			
	[]	[]	[]
People living with HIV (women, 15+)	230 000	250 000	
	[190 000–260 000]	[210 000–280 000]	[]
People living with HIV (men, 15+)	730 000	840 000	
	[630 000–840 000]	[720 000–960 000]	[]
HIV prevalence (15–49)	0.5 [0.4–0.6]	0.5 [0.3–0.6]	[]




^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report:						

COUNTRY DATA

HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION						
	2010	2020				
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]				
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]				
Early infant diagnosis	%	%				

ANNEX ON METHODS



METHODS FOR DERIVING UNAIDS HIV ESTIMATES

Introduction

UNAIDS annually provides revised global, regional and country-specific modelled estimates using the best available epidemiological and programmatic data to track the HIV epidemic. Modelled estimates are required because it is impossible to count the exact number of people living with HIV, people who are newly infected with HIV or people who have died from AIDS-related causes in any country: doing so would require regularly testing every person for HIV and investigating all deaths, which is logistically impossible and ethically problematic. Modelled estimates—and the lower and upper bounds around these estimates—provide a scientifically appropriate way of describing HIV epidemic levels and trends.

Partnerships in developing methods for UNAIDS estimates

Country teams use UNAIDS-supported software to develop estimates annually. The country teams are primarily comprised of monitoring and evaluation specialists, programme officers, epidemiologists, demographers and others from the national ministry of health, national AIDS bodies and technical partners.

The software used to produce the estimates is Spectrum (developed by Avenir Health), with additional models that interact with Spectrum to estimate HIV incidence. 1 The UNAIDS Reference Group on Estimates, Modelling and Projections provides technical guidance on the development of the HIV component of the software.²

A brief description of methods used by UNAIDS to create estimates³

For countries where HIV transmission is high enough to sustain an epidemic in the general population, available epidemiological data typically consist of HIV prevalence results from pregnant women attending antenatal clinics and from nationally representative populationbased surveys. Many countries have historically conducted HIV sentinel surveillance among women attending antenatal clinics, which requires collecting data from a selection of clinics for a few months every few years. More recently, a number of countries have stopped conducting sentinel surveillance among pregnant women and are now using the data from the routine HIV tests conducted when pregnant women attend antenatal clinics and are tested for HIV. These data avoid the need to conduct a separate surveillance effort, and they provide a complete set of data from all clinics across the country instead of samples from specific sites.

¹ More information on Avenir Health can be found at www.avenirhealth.org.

² For more on the UNAIDS Reference Group on Estimates, Modelling and Projections, please visit www.epidem.org.

³ A set of articles describing the methods is available in a 2019 supplement (Volume 33, Supplement 3) of the journal AIDS: https://journals.lww.com/aidsonline/toc/2019/12153. A supplement on the latest methods will be released in 2021from the Journal of the International AIDS Society.

The trends from pregnant women at antenatal clinics, whether done through surveillance or routine data, can be used to inform estimates of national prevalence trends, whereas data from population-based surveys—which are conducted less frequently but have broader geographical coverage and also include men—are more useful for informing estimates of national HIV prevalence levels. Data from these surveys also contribute to estimating age- and sex-specific HIV prevalence and incidence levels and trends. For a few countries in sub-Saharan Africa that have not conducted population-based surveys, HIV prevalence levels are adjusted based on comparisons of antenatal clinic surveillance and population-based survey data from other countries in the region. HIV prevalence trends and numbers of people on antiretroviral therapy are then used to derive an estimate of HIV incidence trends.

In the remaining countries, where HIV transmission occurs largely among key populations at higher risk of HIV and the epidemic can be described as low-level, the estimates are derived from either surveillance among key populations and the general, lowrisk population, or from HIV case reporting data, depending on which data are most reliable in a particular country. In countries with high-quality HIV surveillance data among key populations, the data from repeated HIV prevalence studies that are focused on key populations are used to derive national estimates and trends. Estimates of the size of key populations are increasingly derived empirically in each country; when studies are not available, they are derived based on regional values and consensus among experts. Other data sources—including HIV case reporting data, population-based surveys and surveillance among pregnant women—are used to estimate the HIV prevalence in the general, low-risk population. The HIV prevalence curves and numbers of people on antiretroviral therapy are then used to derive national HIV incidence trends.

For most countries in western and central Europe and North America—and many countries in Latin America, the Caribbean, and the Middle East and North Africa that have insufficient HIV surveillance or survey data, but that have robust disease reporting systems—HIV case reporting and AIDS-related mortality data from vital registration systems are used to inform trends and levels in national HIV prevalence and incidence. These methods also allow countries to take into account evidence of under-reporting or reporting delays in HIV case report data, as well as the misclassification of deaths from AIDS-related causes.

In all countries where UNAIDS supports the development of estimates, assumptions about the effectiveness of HIV programme scale-up and patterns of HIV transmission and disease progression are used to obtain age- and sexspecific estimates of people living with HIV, people newly infected with HIV, people dying from AIDS-related illness and other important indicators (including treatment programme coverage statistics). These assumptions are based on systematic literature reviews and analyses of raw study data by scientific experts. Demographic population data, including fertility estimates, are derived from the United Nations Population Division's World population prospects 2019 data files or recent census data.

Selected inputs into the model—including the number of people on antiretroviral therapy and the number of women accessing services to prevent the vertical transmission of HIV—are reviewed and validated in partnership with the United Nations Children's Fund (UNICEF), the World Health Organization (WHO), the United States President's Emergency Plan for AIDS Relief (PEPFAR) and its agencies, the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), and other partners.

Final country-submitted files containing the modelled outputs are reviewed at UNAIDS to ensure that the results are comparable across regions and countries, and over time.

In 2021, subnational estimates were created and used by 39 countries in sub-Saharan Africa. The methods for creating these subnational estimates are provided in Part 4 of this annex.

Uncertainty bounds around UNAIDS estimates

The estimation software calculates uncertainty bounds around each estimate. These bounds define the range within which the true value lies (if it can be measured). Narrow bounds indicate that an estimate is precise, while wide bounds indicate greater uncertainty regarding the estimate.

In countries using HIV surveillance data, the quantity and source of the available data partly determine the precision of the estimates: countries with more HIV surveillance data have smaller ranges than countries with less surveillance data or smaller sample sizes. Countries in which a national population-based survey has been conducted generally have smaller ranges around estimates than countries where such surveys have not been conducted. Countries producing subnational estimates at the provincial level have wider ranges. In countries using HIV case reporting and AIDSrelated mortality data, the number of years of data and the magnitude of the cases reported or AIDS-related deaths observed will contribute to determining the precision of the estimate.

The assumptions required to arrive at the estimate also contribute to the extent of the ranges around the estimates: in brief, the more assumptions, the wider the uncertainty range, since each assumption introduces additional uncertainties. For example, the ranges around the estimates of adult HIV prevalence are smaller than those around the estimates of HIV incidence among children, which require additional data on prevalence among pregnant women and the probability of mother-to-child HIV transmission that have their own additional uncertainty.

UNAIDS is confident that the actual numbers of people living with HIV, people who are newly infected with HIV or people who have died from AIDS-related causes lie within the reported ranges. Over time, more and better data from countries will steadily reduce uncertainty.

Improvements included in the 2021 **UNAIDS** estimates model

Country teams create new Spectrum files every year. The files may differ from one year to the next for two reasons. First, new surveillance and programme data are entered into the model: this can change HIV prevalence and incidence trends over time or antiretroviral therapy coverage rates, including for past years. Second, improvements are incorporated into the model based on the latest available science and statistical methods. which leads to the creation of more accurate trends in HIV incidence. Occasionally, countries will also change the incidence modeling option within Spectrum, based on improvements in the data available in the country.

Due to these improvements to the model and the addition of new data to create the estimates, the results from previous years cannot be compared with the results from this year. A full historical set of estimates are created each year, however, enabling a description of trends over time.

Between the 2020 and 2021 estimates, the following changes were applied to the model under the guidance of the UNAIDS Reference Group on Estimates, Modelling and Projections, and based on the latest scientific evidence.

Antiretroviral therapy data and COVID-19 disruptions

In the 2021 software, teams chose whether to enter antiretroviral therapy data for 2020 by year or by month. Entering data by month captures disruptions due to COVID-19 mitigation efforts. Countries were encouraged to enter "Loss to follow-up" data (that is, people living with HIV who are alive and who had been previously enrolled on antiretroviral therapy, but who were no longer retained in care) in order to avoid underestimating the disruption effects if numbers on antiretroviral therapy decrease but retention on treatment is assumed to be perfect.

Effect: Increased estimates of AIDS-related deaths due to antiretroviral therapy interruptions.

Adult natural history model

Using Population-based HIV Impact Assessment (PHIA) survey data on untreated people living with HIV, the UNAIDS Reference Group determined that Spectrum was overestimating CD4 cell counts among persons off of antiretroviral therapy. To adjust for this, several inputs were updated to better fit the PHIA data:

- The estimated distribution of CD4 cell counts at initial infection with HIV.
- Disease progression rates among people not on treatment.
- AIDS-related mortality rates off antiretroviral therapy.
- The relative weight that the model places on allocating antiretroviral therapy to people with lower CD4 cell counts or to anyone eligible for treatment, regardless of their CD4 count.

As a result of these changes, people living with HIV who were not receiving antiretroviral therapy reach low CD4 cell counts sooner but survive longer at low CD4 cell counts.

Effect: Increased estimates of AIDS-related deaths globally.

Sex ratio of incidence

Spectrum uses an incidence rate ratio to disaggregate adult incidence by sex. Most countries with generalized epidemics use a default pattern to describe the trend in this ratio, with higher incidence in women than men, and which is set at a fixed value from about 20 years into the epidemic onward.

A review of mechanistic HIV transmission models suggested that antiretroviral therapy and voluntary medical male circumcision (VMMC) scale-up may reduce incidence in men more than in women. To account for this, Spectrum now increases the female-to-male incidence ratio by 0.05 per year during 2010–2020.

Effect: This directly increases new infections among females (about 10%) and indirectly raises new infections and AIDS-related deaths overall (~1%) via more mother-to-child transmission and shifts in adult antiretroviral therapy coverage.

Reduction in transmission on antiretroviral therapy

Spectrum previously assumed that antiretroviral therapy reduces HIV incidence by 0.7% per percentage point increase in treatment coverage. This parameter value is now increased from 0.7% to 0.8% based on a review of recent HIV epidemic calibrations of mechanistic HIV transmission models and evidence from Universal Test and Treat trials.

Effect: HIV incidence will be lower as antiretroviral therapy coverage increases. The effect of this change may be larger in countries—and in years—without strong HIV prevalence data.

Treatment interruption

Previously in the model, people who interrupted antiretroviral therapy returned to their baseline CD4 count category when they dropped off treatment. Based on a review of treatment interruption literature, Spectrum now assumes that people are one CD4 category higher after treatment interruption than their pre-treatment category. This only applies to patients who were on antiretroviral therapy for more than 12 months before interruption.

Effect: The impact of this change will depend on whether the country team has entered loss to follow-up information. Countries that assume 100% annual retention will see no change. Countries that reported lower retention may see fewer deaths with this change compared to their 2020 estimates.

Paediatric mortality on antiretroviral therapy

Assumptions about mortality rates among children on antiretroviral therapy are based on data from the IeDEA network of treatment sites. A recent review of their data on mortality among children on treatment has provided updated data for sub-Saharan Africa, Latin America, the Caribbean and Asia and the Pacific. The analysis considers age, CD4 at initiation, duration on treatment and region. The updated analysis suggests that among children on antiretroviral therapy, mortality has decreased over time: a child on antiretroviral therapy in 2010 was more likely to die than a child on treatment in 2018. Mortality rates for a given CD4 count and duration of time on antiretroviral therapy are lower than in previous versions of Spectrum, but these lower rates are offset by higher relative mortality in earlier years compared to the 2020 Spectrum inputs.

Effect: Little change in paediatric HIV deaths.

Fertility among women living with HIV

Assumptions about how HIV impacts fertility have been updated. These updates reflect changes in the estimated CD4 levels of all women, based on the changes in the adult natural history model (discussed above). In addition to revised natural history assumptions, HIV-related fertility effect estimates have been updated to include new household survey data that have become available since the last analysis in 2018.

Effect: New child infections may increase, especially in countries without routine antenatal care testing data that are used to adjust HIV prevalence among pregnant women.

Breastfeeding practices

Spectrum's model of breastfeeding duration in sub-Saharan Africa has been updated with the addition of three new surveys. In addition, data from all PHIA surveys were removed, except for the 2015 surveys from Malawi, Zambia and Zimbabwe. The PHIA surveys conducted after these first three surveys underestimated breastfeeding duration due to a change in the questionnaire.

Effect: Small changes in new child infections overall, but some countries in eastern Africa may see estimates of new child infections increase by 10–15%.

Changes for countries that use case surveillance data in their models

There were two methodological changes in the Case Surveillance and Vital Registration model. The likelihood specification for the distribution of the number of new HIV infections and AIDS-related deaths was changed from an inverse gaussian to a gamma distribution.

Effect: Narrower uncertainty bounds.

The incidence rate ratios fitter has been adjusted to allow time-varying sex and age ratios. The incidence and the rate ratios are now estimated simultaneously.

Effect: The model will be more flexible, but fitting procedures will be slower when incidence rate ratio fitting is enabled.



Credit: UNAIDS

AIDS Epidemic Model

The AIDS Epidemic Model (AEM) is, among other things, a model that estimates trends in incidence in countries with high-quality data on key populations. While it has been used to calculate adult incidence that is subsequently used in Spectrum, it was not capturing some of the complex calculations (e.g., by age, sex and CD4 count stratum) taking place in Spectrum, resulting in inconsistencies. To bring the two models in line, seven important updates have been made to AEM:


- Built in time-varying age, sex and CD4 mortality, progression and distribution by CD4 of new infections in order to align with Spectrum assumptions.
- Used the background all-cause mortality generated by Spectrum in AEM.
- Added other Spectrum changes in mortality to AEM code.


- Declining off-antiretroviral therapy mortality as antiretroviral therapy coverage increases.
- On-antiretroviral therapy mortality multipliers were added that reflect changes in the effectiveness of antiretroviral therapy over time.
- Antiretroviral therapy is allocated to people based on a weighted probability of death and eligibility for treatment.
- Refined AEM to do all mortality calculations by sex.


Effect: These modifications will eliminate the need to modify the assumptions and data in the Spectrum files to match AEM results.

Figure below presents the impact of all of the above changes on the estimates. At the global level, trends in new HIV infections, AIDS-related deaths and people living with HIV are similar to the 2020 round, although there are shifts within regions.

COMPARISON OF 2020 TO 2021 UNAIDS ESTIMATES: NEW HIV INFECTIONS, AIDS-RELATED DEATHS AND PEOPLE LIVING WITH HIV, GLOBAL, 2000–2019







Source: UNAIDS epidemiological estimates, 2020 and 2021.

Publication of country-specific estimates

UNAIDS aims to publish estimates for all countries with populations of 250 000 or more (according to the United Nations Population Division World population prospects 2019). For the countries with populations of 250 000 or more that did not submit estimates, UNAIDS developed estimates using the Spectrum software, based on published or otherwise available information. These estimates contributed to regional and global totals, but they were not published as country-specific estimates.

In countries with low-level epidemics, the number of pregnant women living with HIV is difficult to estimate. Many women living with HIV in these countries are sex workers or people who use drugs—or they are the sexual partners of people who use drugs or gay men and other men who have sex with men or sex workers—making them likely to have different fertility levels than the general population. UNAIDS does not present estimates of mother-to-child HIV transmission, including estimates related to children in some countries that have concentrated epidemics, unless adequate data are available to validate these estimates. UNAIDS also does not publish

estimates related to children for countries where the estimated number of pregnant women living with HIV is less than 50.

With regard to reporting incidence trends, if there are not enough historical data to state with confidence whether a decline in incidence has occurred, UNAIDS will only publish data for the most recent year. This is done to prevent users from making inaccurate inferences about trends. Specifically, incidence trends are not published if there are fewer than four data points for the key population, or if there have been no data for the past four years for countries using repeated survey or routine testing data. Trends prior to 2000 are not published for countries using case surveillance models if there are no early case surveillance or mortality data available.

Finally, UNAIDS does not publish country estimates when further data or analyses are needed to produce justifiable estimates. More information on the UNAIDS estimates and the individual Spectrum files for most countries can be found on the UNAIDS website (www.UNAIDS.org). Data from the estimates can be found in the AIDSinfo section of the UNAIDS website (http://aidsinfo.unaids.org).

METHODS FOR DERIVING THE 90-90-90 TARGETS

Introduction

Since 2015, UNAIDS has reported estimates of global, regional and country-specific progress against the 90-90-90 targets. Progress toward these targets is monitored using three basic indicators:

- Indicator 1 (the first 90): The percentage of people living with HIV who know their HIV status.
- Indicator 2 (the second 90): The percentage of people living with HIV who know their status and are accessing treatment.
- Indicator 3 (the third 90): The percentage of people living with HIV on treatment who have suppressed viral loads.

Indicators 2 and 3 can also be expressed as a percentage of all people living with HIV. When numbers or coverage of the treatment target are expressed relative to the total number of people living with HIV, this is called "the HIV testing and treatment cascade." Annual estimates of antiretroviral therapy coverage among people living with HIV are available from the time when treatment was first introduced in countries.

Data sources for constructing country measures

Country-level progress against the 90–90–90 targets was constructed using reported data from Spectrum and the Global AIDS Monitoring tool. Estimates are published for all people and separately for children (0 to 14 years) and adults (15 years and older, by sex). Upper and lower ranges of uncertainty for country-level estimates were calculated from the range of estimated numbers of people living with HIV. This range may not fully capture uncertainty in the reported estimates.

A description of the target-related indicators that countries report against is provided in the UNAIDS 2021 Global AIDS Monitoring guidelines (1). Data sources are also briefly described. A summary of the number of countries that are publicly reporting on each measure is provided in Table on the right, organized by region.

DATA AVAILABILITY FOR CONSTRUCTING UNAIDS MEASURES OF PROGRESS AGAINST THE 90–90–90 TARGETS, 2015–2020

Number		Asia and the Pacific	Caribbean	Eastern and southern Africa	Eastern Europe and central Asia	Latin America	Middle East and North Africa	Western and central Africa	Western and central Europe and North America	Global
Countries	2020	38	16	21	16	17	20	25	39	193
Countries in UNAIDS global estimates	2020	28	10	20	16	17	20	25	36	172
Countries with publicly available data on estimates of people living with HIV	2020	21	9	20	12	17	16	25	15	133
Countries with publicly available	2015	8	6	18	9	5	7	22	15	90
data on knowledge of HIV status	2016	10	6	19	9	7	7	22	19	90
OI HIV Status	2017	11	6	19	9	8	7	22	23	105
	2018	11	6	19	10	9	8	22	19	104
	2019	11	6	20	10	10	7	23	6	93
	2020	18	8	20	12	13	14	25	6	116
Countries with publicly available	2015	22	9	20	15	17	17	24	20	144
data on treatment	2016	22	9	20	13	17	17	24	19	141
	2017	23	9	20	14	17	18	24	17	142
	2018	21	9	20	13	16	16	24	14	133
	2019	18	7	20	12	15	13	24	9	118
	2020	26	10	20	15	17	20	25	16	150
Countries with publicly available data on people with suppressed viral load	2015	6	2	3	6	4	3	1	4	29
	2016	6	4	8	6	8	4	2	8	46
	2017	7	6	6	9	10	6	3	7	54
	2018	8	8	14	9	9	7	7	8	70
	2019	9	7	18	12	7	6	6	5	70
	2020	11	8	15	11	10	5	7	6	73

Source: UNAIDS epidemiological estimates, 2016–2021.

The final set of country measures of progress against the 90–90–90 targets for 2015 through 2020 are available at http://aidsinfo.unaids.org. Not all countries were able to report against all three prongs of the 90–90–90 targets: complete treatment cascades are published for 60 countries, the same as in the previous round.

Estimates of people living with HIV

All progress measures in this report are based on UNAIDS global, regional and country-specific modelled estimates from Spectrum of the numbers of people living with HIV. Estimates of people living with HIV are developed for all countries with populations above 250 000. More details about how UNAIDS derives estimates and uncertainty bounds around the number of people living with HIV can be found in Part 1 of this annex.

Estimates of people living with HIV in 2020 were available for 172 of 194 countries and territories, and they were published for 133. Published country estimates of people living with HIV (available at http://aidsinfo.unaids.org) represent 88% of the total global estimated number of people living with HIV in 2020.

Knowledge of HIV status among people living with HIV

Estimates of the number of people living with HIV who know their status were derived using the most recent HIV surveillance, programme data and nationally representative population-based survey data. Where data were available separately for children (aged 0 to 14 years) and adults (aged 15 years and older, by sex), the age- and sexspecific measures were first calculated and then aggregated to produce a national measure.

For countries outside of eastern and southern Africa and western and central Africa, published estimates of the number of people living with HIV who knew their HIV status are based on HIV surveillance case notification data, programme registers or modelled estimates derived from case surveillance data. If the estimate from these sources was lower than the number of people accessing antiretroviral therapy, the reported value was excluded. For countries using HIV surveillance or programme data, a country should have included this measure only if the HIV surveillance system had been functioning since at least 2015 and people who have died, emigrated or have otherwise been lost to follow-up are removed.

Although HIV surveillance systems, including those based on programme registers, can be

a reasonably robust source of data to estimate the number of people living with HIV who know their status, biases in the reported numbers may still exist. For example, a country's measure of the knowledge of status may be underestimated if not all people diagnosed are reported to the surveillance system in a timely manner. The measure also may be overestimated if people are reported to the system or included on a register more than once and these duplicates are not detected. Similarly, if people die or emigrate but are not removed from the system, the number of people living with HIV who are reported to know their HIV status also will be overstated.

For most countries in eastern and southern Africa and western and central Africa, estimates of the numbers of people living with HIV who knew their status were derived using Shiny90, a UNAIDS-supported mathematical model. This model uses population-based survey and HIV testing service programme data—together with country-specific HIV epidemic parameters from the standard UNAIDS Spectrum model—to produce outputs of knowledge of HIV status for adults, by sex. More details on the modelling approach are available elsewhere (2).

Knowledge of HIV status from the Shiny90 model for eastern and southern Africa and western and central Africa has a number of strengths compared with other approaches that rely directly on population survey data and programme treatment coverage data. Most importantly, the Shiny90 model uses population survey data to estimate the proportion of people living with HIV who report ever having an HIV test who are aware of their HIV status, and those who likely seroconverted after their last HIV-negative test. This distinction is informed by the national incidence trend calculated in Spectrum and is consistent with national published estimates of HIV prevalence and reported antiretroviral therapy coverage. The Shiny90 tool also uses assumptions from Spectrum and the population survey data to estimate knowledge of status by sex and age, assuming male-to-female testing ratios have remained relatively constant over time. Estimates of knowledge of status are also available since 2010.

An important model limitation, similar to other estimation approaches, is that caution should be



Credit: UNAIDS

used in interpreting results in instances when the last population-based survey was conducted more than five years ago, or if there are concerns about the accuracy of self-reported testing history in the survey (3). Countries can include HIV testing data from HIV programmes to improve trends in years where the population survey data are not available. Another limitation is that model results are only for those aged 15 years and older. UNAIDS continues to recommend that countries conservatively estimate knowledge of status among children as the proportion of children living with HIV on treatment (unless other information from case surveillance data are available).

People accessing antiretroviral therapy

Global and regional measures of antiretroviral therapy numbers are abstracted from country-reported programme data through the UNAIDS-supported Spectrum software and the Global AIDS Monitoring reporting tool. In the 2021 round, 148 countries publicly reported treatment numbers, and between 2015 and 2020, 150 countries had at least one publicly available estimate of the number of people on treatment (representing 95% of all

people on treatment). For the small number of countries where reported numbers of people on treatment are not available in selected years—primarily in western and central Europe and North America, and in Japan and the Republic of Korea—estimates of the number of people on treatment are developed either in consultation with the public health agency responsible for monitoring the national treatment programme or based on published and unpublished sources.

In partnership with UNICEF, WHO, PEPFAR and its agencies, the Global Fund, and other partners that support treatment service delivery in countries, UNAIDS annually reviews and validates treatment numbers that countries have reported to UNAIDS through Global AIDS Monitoring and Spectrum. UNAIDS staff also provide technical assistance and training to country public health and clinical officers to ensure the quality of the treatment data reported. Nevertheless, this measure may overestimate the number of people on treatment if people who transfer from one facility to another are reported by both facilities. Similarly, coverage may be overestimated if people who have died, disengaged from care or emigrated are not

identified and removed from treatment registries. Treatment numbers also may be underestimated if not all clinics report the numbers on treatment completely or in a timely manner.

Since early 2017, UNAIDS and other international partners have supported countries, primarily in sub-Saharan Africa, to verify that the number of people reported to be currently on treatment is accurate. This activity, however, has not been conducted during the COVID-19 pandemic.

People who have achieved viral suppression

Progress towards the viral suppression target among people on treatment and as a proportion of all people living with HIV was derived from data reported in Spectrum and through the online Global AIDS Monitoring reporting tool. For the purposes of reporting, the threshold for suppression is a viral load of less than 1000 copies per ml. Some countries may set lower thresholds or require persons to achieve an undetectable viral load, and where these lower thresholds are reported by a country, an estimate of the number of people who would have been suppressed at 1000 copies per ml is added to the number reported to be suppressed at the lower threshold. The Global AIDS Monitoring guidance describes this adjustment in more detail. This guidance also specifies that only a person's last test result from the reporting year should be submitted, so the reported number suppressed among those tested should represent people and not tests performed.4

The UNAIDS Global AIDS Monitoring guidelines were revised in 2019 to clarify that countries should report viral load suppression outcomes, regardless of testing coverage. However, viral load testing results will only be published in countries where access to testing is assessed to be nationally representative of all people on treatment (typically 50% or higher testing coverage). The Table above (page 453) shows the number of countries able to report on viral load suppression compared to previous years. For 2015, only 29 countries had reliable estimates; 107 countries were able to

report data for 2020. Some countries had lower viral load testing coverage for 2020 compared to 2019, presumably due to the COVID-19 pandemic and the related mitigation effects. In some countries, there is a longer than usual reporting delay on viral suppression tests.

For countries with nationally representative but not universal access to viral suppression testing, the estimate of viral suppression among those tested (i.e., the third 90) was multiplied by the number of people on treatment to obtain overall viral suppression levels in the country.

A number of challenges exist in using country-reported data to monitor the viral load suppression target. First, routine viral load testing may not be offered at all treatment facilities, and those facilities that do offer it may not be representative of the care available at facilities without viral load testing. Since it is not possible to know suppression in the untested population with certainty, we assume that the percentage of people suppressed among those accessing viral load testing is representative of all people on treatment.

Another challenge in measuring the accuracy of viral load suppression estimates is that UNAIDS guidance requests routine annual viral load testing results only for people who are on treatment and eligible for testing. If people newly initiated on treatment achieve viral suppression but have not yet been offered viral load testing, they will be incorrectly counted as not suppressed, and the resulting viral suppression estimate will be understated. UNAIDS also requests countries to only report results from routine viral load testing: if countries report test results primarily performed because of suspected treatment failure, the number of people virally suppressed in these countries will be underestimated. UNAIDS validates country submissions for quality, but it is not always possible to identify cases where both routine and other types of testing are occurring.

Finally, UNAIDS guidance recommends reporting viral load test results only for people

⁴ The 2020 UNAIDS guidance *Global AIDS Monitoring 2021: indicators for monitoring the 2016 Political Declaration on Ending AIDS* is available at https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf

on antiretroviral therapy; persons who are not on treatment and who naturally suppress the virus will not be included in this measure.

Methods for constructing the 90–90–90 treatment target at the regional and global levels

All programme data submitted to UNAIDS were validated by UNAIDS and its partners prior to publication. Country-submitted data that did not meet the required validation checks for quality, either at the indicator level or across the treatment cascade, were not included in the composite regional or global measures.

To estimate regional and global progress against the 90–90–90 targets, UNAIDS imputed missing country data for the first and third 90 targets using a Bayesian hierarchical model based on regional trends (or when regional trends are sparse, global trends), sex differences and country-specific data for those countries reporting data for some but not all years. The Bayesian model also provides uncertainty bounds. Estimates are available by sex for adults 15 years and older from 2015 to 2020. As in previous years, results of global and regional progress towards the 90–90–90 targets presented in this report supersede all previously published estimates. Additional details on the modelling approach are available elsewhere (4).

The proportion of estimates of knowledge of status and viral load suppression imputed by region from 2015 to 2020 in order to account for countries with missing data are shown in Table below. Due to large differences in the proportion of virally suppressed people in western and central Europe and the United States of America for the years in which data were available, subregional estimates were separately calculated for North America and western and central Europe, and then were combined to estimate the western and central Europe and North America regional results at large. Upper and lower ranges of uncertainty around the global and regional estimates of the HIV testing and treatment cascade are provided that reflect uncertainty in the number of people living with HIV and uncertainty (from missing country data) in the

number of people who know their HIV status and the number of people who are virally suppressed. Based on reports from data quality reviews through 2019, uncertainty from possible over-reporting or under-reporting of treatment numbers was added to the bounds of treatment coverage among people living with HIV and the second and third 90s. Upper and lower ranges of uncertainty for the 90s do not capture uncertainty in the reported or missing programme data on the numbers of people who know their HIV status or the number of people on treatment who are virally suppressed.

In this year's report, UNAIDS has used a new way of presenting the situation across the cascade in stacked bars. Out of the 100% of adult people living with HIV, the proportions under each of the following categories had been added in stacked bars:

- The lowest part are those who are virally suppressed on treatment.
- The next part are those who are not virally suppressed but are on treatment, calculated as the product of the number of people living with HIV and the difference between the proportion virally suppressed and proportion on treatment.
- The next part are those who know their status but are not on treatment, calculated as the product of the total number of people living with HIV and the difference between proportion knowing their status and those on treatment.
- At the top are those people living with HIV who have acquired the infection in the past six months, calculated as the number of new HIV infections among adults divided by two.
- The proportion immediately under it are those who have been infected for more than six months age and still not aware of their status. This proportion is calculated as the difference between people living with HIV who know their status, the product of the number of people living with HIV and one minus proportion knowing their status, and the number infected in the past six months.

PROPORTION OF IMPUTED DATA OF THE NUMBER OF PEOPLE LIVING WITH HIV WHO KNOW THEIR STATUS AND THE NUMBER OF PEOPLE LIVING WITH HIV ON TREATMENT WHO ARE VIRALLY SUPPRESSED, 2015–2020

		Asia and the Pacific	Caribbean	Eastern and southern Africa	Eastern Europe and central Asia	Latin America	Middle East and North Africa	Western and central Africa	Western and central Europe and North America	Global
Estimates of people living	2015	84	15	0	8	27	29	0	30	17
with HIV where knowledge	2016	83	15	0	8	23	30	0	13	16
of status is	2017	23	15	0	7	19	31	0	29	7
imputed (%)	2018	49	15	0	6	13	27	0	39	11
	2019	79	16	0	2	58	34	0	97	21
	2020	11	5	0	3	59	17	0	98	11

Source: UNAIDS epidemiological estimates, 2016–2021.

One primary limitation that arises from incomplete availability of country estimates is that it is difficult to quantify the extent to which progress in countries that reported data to UNAIDS is similar to that of countries in the region that do not have data. This is particularly true for viral load suppression estimates, where reported data in some regions—especially in 2015 and 2016—are

limited. For example, viral load testing coverage in western and central Africa was especially low between 2015 and 2017, with most estimates derived from countries reporting data in 2018 and 2019. In Asia and the Pacific, national-level estimates of viral load suppression are not available in any year for India and not prior to 2018 for China.

DATA ON KEY POPULATIONS

Distribution of new HIV infections by subpopulation

The distribution of new HIV infections among subpopulations globally and by region was estimated based on data for 175 countries using four data sources.

The underlying number of new infections for each country is estimated with Spectrum. New infections among men and women aged 15 to 49 years are used.

For countries that model their HIV epidemic based on data from subpopulations, including key populations, the numbers of new infections were extracted from Spectrum 2020 files. This source provided data for sex workers from 51 countries, for people who inject drugs from 36 countries, for gay men and other men who have sex with men from 64 countries, and for transgender people from 25 countries (all of which were located in Latin America, the Caribbean, western and central Europe and North America, and Asia and the Pacific).

Incidence Pattern Model reports were available for 15 countries (Botswana, Cameroon, Eswatini, Ethiopia, Ghana, Haiti, Kenya, Lesotho, Malawi, Mozambique, Namibia, the United Republic of Tanzania, Uganda, Zambia and Zimbabwe) and provided information on distributions of new infections for their respective regions.

New HIV infections for western and central European countries were derived from the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe HIV/AIDS surveillance in Europe 2020 (2019 data) report (5). The proportions of new diagnoses for each region in Europe (western, central and eastern) were applied to UNAIDS estimates of new infections in each country for people who inject drugs, gay men and other men who have sex with men, and transgender people. Data for sex workers

were not available from the ECDC report. New HIV infections in China, India, the Russian Federation and the United States were taken from the most recent available national reports of new diagnoses or other published sources.

New HIV infections among countries without a direct data source were calculated from regional benchmarks. The benchmarks were set by the median proportion of new infections in the specific subpopulation in all available countries in the same region. The majority of these countries were located in sub-Saharan Africa. There were 56 countries that used benchmark values for the sex worker estimate, 85 countries for the people who inject drugs estimate, 56 countries for the gay men and other men who have sex with men estimate, and 144 countries for the transgender people estimate.

New infections among sex partners of key populations were estimated using the number of sex partners and transmission probabilities from the literature. These include non-injecting sex partners of people who inject drugs, female sex partners of gay men and other men who have sex with men, spouses/steady sexual partners of sex workers, clients of sex workers and the spouses/steady sex partners of clients.

Quality of population size estimates

Population size estimates are used to calculate the relative risks presented in this report. The Global AIDS Monitoring system collects population size estimates. Some of the submitted size estimates are considered subnational, and UNAIDS uses regional medians of the population proportions of submitted size estimates to fill in missing information or extrapolate from subnational estimates.

The regional sections of this report include tables on the estimated size of key populations. These data are based on values reported through Global AIDS Monitoring in 2019, 2020 and 2021. A comprehensive review of the data was conducted during these reporting rounds, and estimates therefore should not be compared with data presented in previous UNAIDS reports. As a result of this process, the estimates reported can be categorized as follows:

- "National population size estimate" refers to estimates that are empirically derived using one of the following methods: multiplier, capture–recapture, mapping/enumeration, network scale-up method (NSUM) or population-based survey, or respondent-driven sampling-successive sampling (RDS-SS). Estimates had to be national or from a combination of multiple sites with a clear approach to extrapolating to a national estimate.
- "Local population size estimate" refers to estimates that are empirically derived using one of the previously mentioned methods, but only for a subnational group of sites that are insufficient for national extrapolation.
- "Insufficient data" refers either to estimates derived from expert opinions, Delphi, wisdom of crowds, programmatic results or registry, regional benchmarks or unknown methods, or estimates derived prior to 2016. Estimates may or may not be national.

SUBNATIONAL HIV ESTIMATES FOR SUB-SAHARAN AFRICA

Subnational HIV estimates were generated for 38 countries in sub-Saharan Africa and Haiti in the Caribbean using the Naomi model (Figure on page 18). The indicator displayed on page 18 is HIV incidence among females aged 15 to 24 years by subnational level.

estimation to jointly model uses small area estimation to jointly model HIV prevalence and people living with HIV, antiretroviral therapy coverage and HIV incidence. The model combines subnational-level data about multiple outcomes from several sources in a Bayesian statistical model. It uses national population-based survey data and antiretroviral therapy and antenatal clinic testing service provision data to provide robust indicators of subnational HIV burden. It provides estimates and uncertainty ranges for a number of indicators (including HIV prevalence, people living with HIV, antiretroviral therapy coverage, HIV incidence and new infections) by sex, five-year age groups and subnational level.

The model produces estimates at three time points: the year of the most recent population-based survey, the year of the last round of HIV national estimates (2020), and short-term, one-year projections for HIV programme planning purposes. Subnational population estimates by sex and age group are sourced from consensus sources in each country and adjusted to match the populations used within Spectrum by sex and age group.

Cross-sectional estimates for HIV prevalence, antiretroviral therapy coverage and HIV incidence are produced at the midpoint of the most recent nationally representative household survey. For HIV prevalence, the model is calibrated to survey data on HIV prevalence by subnational level, sex and five-year age group from the most recent population-based survey (Demographic and Health Survey or PHIA). Since the survey sample size in each subnational area is relatively small, routinely reported data about HIV prevalence among

pregnant women attending their first antenatal care visit, extracted from the national health information system, are used to improve estimates of the spatial pattern of HIV.

Antiretroviral therapy coverage by subnational area, age and sex is estimated from population-based survey data about the presence of antiretroviral biomarkers in HIV-positive survey respondents. Routinely reported antiretroviral therapy coverage among pregnant women prior to their first antenatal care visit is used as a covariate for the spatial pattern of antiretroviral therapy coverage. The antiretroviral therapy coverage and HIV prevalence are also calibrated so that the total number on antiretroviral therapy matches that report in the Spectrum national file.

A challenge for estimating treatment coverage for subnational areas is that persons may access antiretroviral therapy services in a different district than their residence (for instance, if facilities are closer or felt to provide better services). The model allows for a probability that resident people living with HIV access antiretroviral therapy in a neighbouring subnational area. The prior assumption is that the large majority of people living with HIV will access antiretroviral therapy in their area of residence, but this probability can vary based on subnational area data about the number of people receiving antiretroviral therapy compared to HIV prevalence, antiretroviral therapy coverage and population.

Direct estimates of HIV incidence are not available at the subnational level. While some recent household surveys have measured HIV incidence at the national level based on biomarker measures for recent HIV infections, too few recent infections are observed in any district to make a robust estimate. Therefore, to estimate HIV incidence at the subnational level, the HIV transmission rate from Spectrum estimates is calculated and applied to small area estimates of HIV prevalence and

antiretroviral therapy coverage in each subnational area. The sex and age distribution in each subnational area is based on HIV incidence rate ratios from Spectrum, applied to the population structure in each area.

The model projects from the most recent household survey to the current period by creating a one-step projection of the population to 2020. Population estimates are updated with official population estimates. The number of people living with HIV is projected forward based on survival estimates by province, sex and age group from Spectrum over the same period (which accounts for HIV disease progression and the effects of antiretroviral therapy scale-up on reducing AIDS mortality). Antiretroviral therapy coverage is updated based on the number on treatment in 2020 from service provision data.

The incidence rate among young women aged 15 to 24 years was calculated as follows:

New infections among females aged 15 to 24 years in 2020 / (population of females aged 15 to 24 years – HIV-positive females aged 15 to 24 years) in 2020 * 1000

COUNTRIES USING THE NAOMI MODEL TO GENERATE SUBNATIONAL ESTIMATES

No	Country
1	Angola
2	Benin
3	Botswana
4	Burkina Faso
5	Burundi
6	Cameroon
7	Central African Republic
8	Chad
9	Congo
10	Côte d'Ivoire
11	Democratic Republic of the Congo
12	Equatorial Guinea
13	Eswatini
14	Ethiopia
15	Gabon
16	Gambia
17	Ghana
18	Guinea
19	Guinea-Bissau
20	Haiti
21	Kenya
22	Lesotho
23	Liberia
24	Malawi
25	Mali
26	Mozambique
27	Namibia
28	Niger
29	Nigeria
30	Rwanda
31	Sao Tome and Principe
32	Senegal
33	Sierra Leone
34	South Africa
35	United Republic of Tanzania
36	Togo
37	Uganda
38	Zambia
39	Zimbabwe

LAWS AND POLICIES SCORECARDS

The regional laws and policies scorecards were constructed based on data reported by countries through the 2017, 2018, 2019, 2020 and 2021 National Commitments and Policy Instrument, a component of Global AIDS Monitoring (1).

Data submitted by countries through the National Commitments and Policy Instrument are reviewed by UNAIDS. During this review process, UNAIDS liaises with national Global AIDS Monitoring focal points to request clarification or to revise data submitted through the tool.

Data reported through the National Commitments and Policy Instrument have been complemented with data available from other sources, including global databases and primary sources.



Credit: UNAIDS

References

- 1. AIDS monitoring 2021: indicators for monitoring the 2016 United Nations Political Declaration on HIV and AIDS. Geneva: UNAIDS; 2020 (https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf).
- 2. Maheu-Giroux M, Marsh K, Doyle C, Godin A, Delauney CL, Johnson LF et al. National HIV testing and diagnosis coverage in sub-Saharan Africa. AIDS: 2019;33:S255-S269.
- 3. Johnston LG, Sabin ML, Prybylski D, Sabin K, McFarland W, Baral S et al. Policy and practice: the importance of assessing self-reported HIV status in bio-behavioural surveys. Bull World Health Organ. 2016;94:605-12.
- 4. Marsh K, Eaton JW, Mahy M, Sabin K, Autenrieth CS, Wanyeki I et al. Global, regional and country-level 90–90–90 estimates for 2018. AIDS;33:S213-S226.
- 5. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2020 2019 data. Stockholm: ECDC; 2020 (https://www.ecdc.europa.eu/sites/default/files/documents/hiv-surveillance-report-2020.pdf).



© Joint United Nations Programme on HIV/AIDS (UNAIDS), 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo/).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that UNAIDS endorses any specific organization, products or services. The use of the UNAIDS logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by UNAIDS. UNAIDS is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules).

Suggested citation. [Title]. Geneva: Joint United Nations Programme on HIV/AIDS; [Year]. Licence: CC BY-NC-SA 3.0 IGO.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of UNAIDS concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by UNAIDS in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by UNAIDS to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall UNAIDS be liable for damages arising from its use.

UNAIDS/JC3032E



UNAIDS Joint United Nations Programme on HIV/AIDS

20 Avenue Appia 1211 Geneva 27 Switzerland

+41 22 791 3666

unaids.org